Name,Drug,Description
clobazam,DB00734,"Clobazam, with the DrugBank identifier DB00734 and SMILES notation Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2, is a 1,5-benzodiazepine characterized by a fused benzene and diazepine ring structure, with a fluorophenyl group and an additional oxygen-nitrogen-containing heterocycle attached to the diazepine ring. It falls under the chemical category of benzodiazepines, sharing a chemical scaffold with similar anxiolytic and anticonvulsant drugs such as diazepam and lorazepam. Clobazam's pharmacokinetic profile indicates that it is well-absorbed orally, widely distributed throughout the body, primarily metabolized in the liver by the cytochrome P450 enzyme CYP3A4, and its metabolites are excreted mainly through the urine. The drug has a reasonable safety profile but can be associated with toxicity, particularly involving the central nervous system, leading to symptoms such as sedation, drowsiness, and respiratory depression when overdosed. Clobazam's primary protein target is the GABA_A receptor, where it acts as an allosteric modulator to potentiate the inhibitory effects of GABA, thereby stabilizing neuronal firing. It is indicated for use in the treatment of anxiety and various seizure disorders, including adjunctive therapy for epilepsy. The side effects of clobazam are consistent with those of other benzodiazepines and may include dizziness, fatigue, ataxia, and decreased alertness. Clinically, it is prescribed for its anxiolytic and anticonvulsant effects, being particularly effective in conditions such as Lennox-Gastaut syndrome, a severe form of childhood-onset epilepsy."
vinorelbine,DB00987,"Vinorelbine, with DrugBank ID DB00987 and SMILES notation Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1, is a semi-synthetic vinca alkaloid derivative chemically characterized by its catharanthine-lower dimerization structure modified by a nitro group at the R3' position of the vindoline moiety. It falls under the chemical category of alkaloids and shares the vinca alkaloid chemical scaffold. Vinorelbine is closely related to other vinca alkaloids used in chemotherapy, such as vincristine and vinblastine. Pharmacokinetically, vinorelbine exhibits moderate absorption upon intravenous administration, with extensive tissue distribution and primary metabolism in the liver through CYP3A4/5 enzymes. Subsequently, it is excreted mostly via feces with a lesser extent in urine. Its toxicity profile includes bone marrow suppression, characterized by neutropenia, and neurotoxicity, similar to other microtubule inhibitor drugs. Vinorelbine targets tubulin proteins, inhibiting tubulin polymerization, leading to mitotic arrest and apoptosis in rapidly proliferating cells. Clinically, vinorelbine is indicated for the treatment of non-small cell lung cancer and advanced breast cancer, often as part of combination chemotherapy. Common side effects of vinorelbine involve neutropenia, constipation, and peripheral neuropathy. In clinical practice, it is used in both single-agent and combination regimens depending on the patient's specific disease state and treatment plan, demonstrating its utility in progressive oncologic therapeutics."
carvedilol,DB00812,"Carvedilol, with DrugBank ID DB00812 and the SMILES notation CCCCC1C(=O)N(c2ccccc2)N(c2ccccc2)C1=O, is a nonselective β-adrenergic blocking agent with α1-blocking activity. Its chemical structure is characterized by a biphenyl moiety linked to a carbazole system through an amine linkage, bearing an oxyacetyl side chain. This compound falls within the chemical category of carbazoles, a class known for its wide-ranging biological activities. As a scaffold, the carbazole ring system is pivotal for the drug's adrenergic receptor blocking properties and is shared by similar drugs like labetalol. Carvedilol undergoes extensive hepatic metabolism primarily via the cytochrome P450 enzymes CYP2D6 and CYP2C9, potentially leading to variable pharmacokinetics among individuals with different genetic CYP polymorphisms. After oral administration, carvedilol is well-absorbed, highly protein-bound (~98%), and widely distributed with an average elimination half-life of 7-10 hours. It is predominantly excreted in the bile and feces. The primary toxicity concerns of carvedilol include cardiogenic shock and severe bradycardia. Carvedilol targets multiple adrenergic receptors, namely β1, β2, and α1, resulting in its wide therapeutic indications such as treatment for hypertension, heart failure, and left ventricular dysfunction post-myocardial infarction. Side effects could range from dizziness, hypotension, and bradycardia to gastrointestinal disturbances and fatigue. Clinically, carvedilol has found its niche not only in managing cardiovascular diseases due to its vasodilatory and cardioprotective effects but also as a part of chronic heart failure treatment regimens, attesting to its efficacy in improving survival rates and reducing hospitalization."
benazepril,DB00211,"Benazepril, with the DrugBank identifier DB00211, is an angiotensin-converting enzyme (ACE) inhibitor characterized by its SMILES notation 'COc1ccc(OC)c(C(O)CNC(=O)CN)c1', denoting a molecular structure that includes a benzene ring with methoxy substituents, a carboxyl group coneected to a tetrahedral carbon atom bearing a hydroxyl group, and a secondary amine linked to the carboxyl group via an ethyl chain, signifying its chemical category as a carboxylic acid derivative with functionalities pertinent to antihypertensive agents. Its chemical scaffold is based on a phenethylamine core, shared by similar drugs such as enalapril and lisinopril, underscoring a common mechanism of action within the ACE inhibitor class. Pharmacokinetically, benazepril is absorbed orally, with a bioavailability affected by the presence of food, distributed widely across tissues, metabolized hepatically to benazeprilat via cleavage of the ester group, which is then primarily excreted by the kidneys. Its toxicity profile is generally low; however, side effects of hypotension, and rare instances of angioedema, are of concern. Benazepril targets angiotensin-converting enzyme, thus disrupting the conversion of angiotensin I to the vasoconstrictive angiotensin II, leading to its primary indication for the management of hypertension and symptomatic heart failure. Adverse effects may entail cough, fatigue, dizziness, and hyperkalemia, which are typically manageable. Clinically, benazepril is often prescribed as a first-line treatment for hypertension alone or in combination with other antihypertensive agents, and in cases of heart failure, it is used to reduce the symptoms and prevent hospitalization."
leflunomide,DB00915,"Leflunomide is a synthetic isoxazole derivative with a chemical structure defined by the SMILES notation NC12CC3CC(CC(C3)C1)C2, which constructs a bicyclic ring system containing an isoxazole ring fused to a cyclohexyl ring, resulting in the chemical scaffold known as an isoxazole-cyclohexyl conjugation. It belongs to the chemical category of disease-modifying antirheumatic drugs (DMARDs), sharing a mechanism of action similar to that of teriflunomide, its active metabolite. The pharmacokinetics of leflunomide involve its rapid and almost complete absorption after oral administration, followed by conversion into its active metabolite by the action of gastrointestinal and hepatic enzymes. Leflunomide is widely distributed in the body and has a long elimination half-life, primarily because it undergoes enterohepatic recycling. Metabolism occurs through the cytochrome P450 system, particularly CYP1A2 and CYP2C19 isoenzymes, and it is excreted in urine and feces. Toxicity profiles for leflunomide have highlighted an increased risk for liver damage, bone marrow suppression, and teratogenic effects. The primary molecular target of leflunomide is dihydroorotate dehydrogenase (DHODH), an enzyme involved in the de novo synthesis of pyrimidines, which is critical for lymphocyte proliferation. Leflunomide is indicated for the treatment of active rheumatoid arthritis and psoriatic arthritis, aiming to reduce the signs and symptoms of the diseases, achieving an improvement in physical function. The side effects observed with leflunomide use can be diverse, ranging from mild—such as diarrhea, alopecia, and hypertension—to severe, including serious infections, peripheral neuropathy, and interstitial lung disease. Clinically, leflunomide is generally reserved for patients who have had an inadequate response to or are intolerant of first-line therapies such as methotrexate, and it can be used either as monotherapy or in combination with other drugs, demonstrating efficacy in slowing disease"
lamotrigine,DB00877,"Lamotrigine, with DrugBank ID DB00877, is a phenyltriazine derivative that structurally consists of a triazine ring bonded to a phenyl group and an amino group, with additional substituents that contribute to its biological activity as reflected in its SMILES notation. Belonging to the chemical category of anticonvulsants, lamotrigine's chemical scaffold underpins its mechanism of action and relates it to other drugs in its class, like carbamazepine and phenytoin, which are used to manage epileptic seizures. Lamotrigine exhibits a complex pharmacokinetics profile characterized by good oral absorption, extensive distribution with a volume of distribution around 0.9 to 1.3 L/kg, hepatic metabolism primarily through glucuronic acid conjugation, and renal excretion with a half-life of approximately 24 to 35 hours in adults. Although generally well-tolerated, lamotrigine's toxicity can manifest as skin rashes, including the potentially life-threatening Stevens-Johnson syndrome. Lamotrigine primarily targets voltage-sensitive sodium channels, stabilizing neuronal membranes and inhibiting glutamate release, which explains its utility in controlling seizures and mood disturbances. It is approved for the treatment of epilepsy and bipolar disorder, efficiently managing conditions such as partial seizures, generalized tonic-clonic seizures, and the prevention of mood episodes in bipolar patients. Common side effects of lamotrigine may include dizziness, ataxia, blurred vision, nausea, and vomiting. Clinically, lamotrigine is employed both as monotherapy and as an adjunctive treatment for epilepsy and as a mood stabilizer for maintenance therapy in bipolar disorder, demonstrating its versatile application in neurological and psychiatric conditions. Despite its therapeutic benefits, careful dosage titration and monitoring for adverse effects are essential to optimize its clinical efficacy and safety."
nefazodone,DB00627,"Nefazodone, identified by DrugBank ID DB00627, is a synthetic phenylpiperazine antidepressant with a chemical structure distinguished by the SMILES notation 'O=C(O)c1cccnc1', indicating the presence of a carboxamide group attached to a benzene ring with an adjacent nitrogen-containing five-membered heterocycle. As a member of the phenylpiperazine class of compounds, its chemical scaffold is characterized by a piperazine ring linked to a phenyl group, a motif shared with similar antidepressant drugs such as trazodone. The pharmacokinetics of nefazodone involves its absorption which is relatively slow, with its bioavailability affected by food intake, extensive distribution throughout the body, and metabolism primarily in the liver through the cytochrome P450 enzyme system, particularly CYP3A4, leading to the formation of active metabolites. Its excretion is predominantly via urine and feces. Touted as having fewer cardiovascular side effects, nefazodone's toxicity concerns have included rare but serious liver failure. It targets multiple proteins, including serotonin receptors (5-HT2) and the serotonin reuptake transporter, thus modulating neurotransmitter levels in the brain. It is indicated for the treatment of major depressive disorder with clinical utilization in cases presenting symptoms such as pervasive melancholy, anhedonia, and anxiety. Despite its therapeutic efficacy, nefazodone's use has been marred by side effects ranging from mild, like dizziness and nausea, to severe, including hepatotoxicity and life-threatening drug interactions. Owing to its risk profile, the clinical usage of nefazodone has been considerably limited, with healthcare professionals prescribing it cautiously, often when patients have not responded well to other antidepressants."
trandolapril,DB00316,"Trandolapril, associated with DrugBank ID DB00316 and represented by the SMILES notation CC(=O)Nc1ccc(O)cc1, is a small molecule that features a proline-derived structure with a carboxy group (CC(=O)) and an aromatic phenyl ring substituted with a hydroxyl group (c1ccc(O)cc1). This compound belongs to the chemical category of angiotensin-converting enzyme (ACE) inhibitors and structurally falls within the peptide-like scaffold inherent to this class. In terms of chemical kinship, trandolapril is closely related to other ACE inhibitors such as enalapril and ramipril, sharing a similar mechanism of action. Pharmacokinetically, trandolapril is characterized by bioactivation through ester hydrolysis to its active metabolite, trandolaprilat, with absorption from the gastrointestinal tract, wide distribution including into tissues, hepatic metabolism primarily by esterases, and renal excretion. Potential toxicity of trandolapril, akin to other ACE inhibitors, includes hypotension and, rarely, angioedema, underscored by its action on the renin-angiotensin system. Trandolapril's primary target protein is the angiotensin-converting enzyme, which it inhibits, thereby reducing the production of angiotensin II and attenuating vasoconstriction and water retention. Trandolapril is indicated for the treatment of hypertension and to stave off the symptomatic heart failure or post-myocardial infarction complications. Side effects associated with trandolapril include cough, dizziness, and headache, amongst others. Clinically, trandolapril is prescribed both as a standalone therapy and in combination with other antihypertensive agents to achieve management of blood pressure and mitigate the risks associated with chronic heart failure."
clopidogrel,DB00977,"Clopidogrel, with the DrugBank identifier DB00977, is a thienopyridine class antiplatelet agent that inhibits blood clots by irreversibly modifying the platelet ADP receptor, P2Y12. Its SMILES notation, C#C[C@]1(O)CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@@]21C, reflects a complex chemical structure featuring a bicyclic thiophene-pyridine fused ring system with stereochemistry encoded by the '@' symbols, indicating enantiomerically active centers within its scaffold. Similar drugs include prasugrel and ticagrelor, both of which also target platelet aggregation pathways. Clopidogrel's pharmacokinetics are characterized by rapid absorption, with peak plasma concentrations occurring approximately one hour post-administration; however, it must be metabolized by hepatic enzymes, notably CYP2C19, to form its active metabolite. Distribution is wide, but the drug binds reversibly to plasma proteins, and it is primarily excreted through the urine and feces as both metabolites and unchanged drug. Toxicity is relatively low but can include bleeding risks and, rarely, thrombotic thrombocytopenic purpura. The primary target of clopidogrel is the P2Y12 receptor on the surface of platelets, which mediates platelet aggregation.

Clopidogrel is indicated for the prevention of thrombotic events in patients with a history of myocardial infarction, peripheral arterial disease, ischemic stroke, or acute coronary syndrome. Common side effects include bleeding, including gastrointestinal bleeding and bruising, while severe neutropenia is a rare but significant risk. Clinically, clopidogrel's antiplatelet activity is exploited to maintain vascular patency in patients at risk for thrombosis, often in conjunction with other anticoagulants like aspirin, in dual antiplatelet therapy to prevent stent thrombosis following percutaneous coronary interventions. The drug's interplay between its pharmacokinetic profile, clinical efficacy in reducing atherothrombotic events"
gemcitabine,DB00554,"Gemcitabine, bearing the DrugBank identifier DB00554, has a complex chemical structure epitomized by its SMILES notation 'CN1C(C(=O)Nc2ccccn2)=C(O)c2ccccc2S1(=O)=O'. This structure features a nucleoside analog framework wherein a pyrimidine ring is conjoined with a 2',2'-difluorodeoxycytidine scaffold, establishing it within the antimetabolite chemical category. Due to its structural resemblance to nucleosides, gemcitabine is similar to other chemotherapeutic agents such as cytarabine. In terms of pharmacokinetics, after intravenous administration, gemcitabine is rapidly distributed, with a plasma half-life of approximately 42 to 94 minutes; it is metabolized predominantly by cytidine deaminase in the liver, kidneys, and blood to an inactive uracil metabolite, and it is excreted primarily through urine. The toxicity profile of gemcitabine includes myelosuppression, exemplified by neutropenia, anemia, and thrombocytopenia; hepatic, pulmonary, and renal toxicity are also observed. Gemcitabine's mechanisms of action involve the inhibition of DNA synthesis by targeting ribonucleotide reductase and incorporating into DNA, thereby terminating DNA strand elongation. This drug is indicated primarily for the treatment of pancreatic cancer, non-small cell lung cancer, breast cancer, and ovarian cancer. Common side effects include flu-like symptoms, alopecia, nausea, and vomiting. Clinically, gemcitabine is utilized as a first-line treatment or in combination with other chemotherapeutic agents, depending on the specific cancer type and stage, reflecting its role in oncology therapy regimens tailored to inhibit cancer cell proliferation."
troglitazone,DB00661,"Troglitazone (DB00661), with the SMILES notation 'COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC', is a thiazolidinedione with a complex chemical structure featuring a central thiazolidinedione nucleus linked to a chlorophenyl group and a methoxyethoxyphenyl moiety, reflecting its classification within the chemical category of thiazolidinediones (TZDs). It shares a similar chemical scaffold with other TZDs such as rosiglitazone and pioglitazone, which also act as insulin sensitizers. The pharmacokinetics of troglitazone involve reasonable oral absorption, extensive plasma protein binding, and metabolism primarily in the liver by cytochrome P450 enzymes, chiefly CYP3A4, leading to various metabolites, some of which retain pharmacological activity. It is excreted mainly in bile and feces, with a minor portion eliminated via urine. Troglitazone's toxicity, which led to its withdrawal from the market, is most notably hepatotoxicity, with some patients experiencing severe liver injury including hepatic failure. The drug's primary target protein is peroxisome proliferator-activated receptor-gamma (PPARγ), a nuclear receptor that regulates gene expression involved in glucose and lipid metabolism. Troglitazone was indicated as an antidiabetic agent, particularly for the management of type 2 diabetes mellitus, to improve glycemic control. However, its side effects, besides hepatotoxicity, included mild anemia, and weight gain. Clinically, troglitazone's use was in the context of a combination therapy with other antidiabetic agents like metformin or sulfonylureas for a synergistic effect in lowering blood glucose levels before the emergence of safety concerns led to its market withdrawal."
pioglitazone,DB01142,"Pioglitazone, with the DrugBank identifier DB01142 and SMILES notation 'CN(C)CCC=C1c2ccccc2COc2ccccc21', is a synthetic compound featuring a thiazolidinedione structural moiety with an attached substituted aromatic ring and a side chain containing a tertiary amine. Belonging to the class of thiazolidinediones, pioglitazone acts as an insulin sensitizer through activation of the peroxisome proliferator-activated receptor gamma (PPARγ). This chemical domain is also shared by similar antidiabetic drugs like rosiglitazone. Pioglitazone's pharmacokinetic profile entails oral absorption with a peak plasma concentration achieved in 2 hours post-dose, extensive plasma protein binding (mostly to albumin), and it is primarily metabolized by cytochrome P450 enzymes 2C8 and 3A4 in the liver to both active and inactive metabolites. Its elimination is through biliary excretion, with a half-life of 3-7 hours. While generally well-tolerated, pioglitazone toxicity may manifest as hepatotoxicity, though serious adverse events are rare. The drug's main therapeutic target is PPARγ, a nuclear receptor that influences glucose and lipid metabolism. Clinically, pioglitazone is indicated for the management of type 2 diabetes mellitus, often as an adjunct to diet and exercise to improve glycemic control. The side effects associated with pioglitazone include weight gain, edema, and an increased risk of heart failure in certain populations. Nonetheless, pioglitazone is used in the clinical setting due to its effectiveness in lowering blood glucose levels when used in combination with other antidiabetic medications or insulin, but it must be done with conscientious monitoring for adverse effects."
zafirlukast,DB00215,"Zafirlukast, identified by DrugBank ID DB00215, is a synthetic, fluorinated methoxyphenyl quinoline derivative with its chemical structure encoded by the SMILES notation 'CN(C)CCCC1(c2ccc(F)cc2)OCc2cc(C#N)ccc21'. Analyzing its chemical structure reveals a methoxy derivative fused to a phenyl quinoline, carrying a fluoro substituent and a cyano group, which classifies it under the chemical category of leukotriene receptor antagonists. This drug is structurally related to the therapeutic agent montelukast, bearing the similar strategic quinoline scaffold pivotal for anti-leukotriene activity. Zafirlukast exhibits a complex pharmacokinetic profile with oral absorption, extensive hepatic metabolism chiefly via the cytochrome P450 system, particularly CYP2C9 and CYP3A4, and subsequent renal and fecal excretion. Its therapeutic index presents a margin of safety, with reported toxicities reflecting dose-dependent effects, such as hepatic dysfunction and eosinophilia. The primary target proteins for zafirlukast are leukotriene receptors, specifically the CysLT1 receptor subtype, which play a crucial role in the pathophysiology of asthma. Zafirlukast is indicated primarily for the prophylaxis and chronic treatment of asthma, tackling symptoms like bronchoconstriction. Common side effects encompassing the clinical profile of zafirlukast range from mild, such as headache and nausea, to more severe cases including Churg-Strauss syndrome. In clinical practice, zafirlukast serves as a maintenance therapy for asthma, emphasizing its role in reducing the frequency and severity of asthma attacks through leukotriene pathway modulation, although it is not intended for acute bronchospasm relief."
mycophenolate mofetil,DB01193,"Mycophenolate mofetil, identified by DrugBank with the ID DB01193, is a prodrug that is structurally characterized by its SMILES notation 'CCCC(=O)Nc1ccc(OCC(O)CNC(C)C)c(C(C)=O)c1'. Its chemical structure suggests an ester derivative of mycophenolic acid linked through a morpholinoethyl group, indicating its prodrug nature designed for improved pharmacokinetics. Classified under the category of immunosuppressant drugs, this chemical entity was engineered based on the parent compound mycophenolic acid, intended to improve drug delivery properties. Structurally similar immunosuppresants include azathioprine and ciclosporin, which also target the immune system to prevent organ rejection post-transplantation. Upon administration, mycophenolate mofetil is rapidly absorbed and then de-esterified in the liver to its active form, mycophenolic acid. The drug distributes widely in the body, with a volume of distribution suggestive of extensive tissue binding. It undergoes glucuronidation and the glucuronide metabolites, along with the parent compound, are primarily excreted in the urine. The principal toxicity of the drug stems from its profound immunosuppressive effects, which can predispose patients to infections and hematological abnormalities. Mycophenolate mofetil targets the inosine monophosphate dehydrogenase (IMPDH), a key enzyme in the de novo pathway of purine synthesis important for lymphocyte proliferation. Indications for this drug include preventing graft rejection in renal, hepatic, and cardiac transplantation patients, as well as treating autoimmune conditions like lupus nephritis. Side effects may include, but are not limited to, gastrointestinal disturbances, increased susceptibility to infections, and potential development of lymphoma. Clinically, mycophenolate mofetil is part of a broader immunosuppressive regimen, commonly administered alongside steroids and calcineurin inhibitors to bolster its therapeutic efficacy in both transplant medicine and select autoimmune disorders."
fluvastatin,DB01026,"Fluvastatin, designated by DrugBank ID DB01026 and represented by the SMILES notation CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1, is a synthetic cholesterol-lowering agent that structurally belongs to the class of statins, which are characterized by their lactone or hydroxy acid forms. The molecule's chemical structure features a hexahydronaphthalene scaffold, distinguishing it from other statins like simvastatin or atorvastatin, which are based on different core structures. Fluvastatin's pharmacokinetic profile demonstrates significant hepatic uptake, where it is absorbed moderately and subject to extensive first-pass metabolism mainly through the cytochrome P450 2C9 isoenzyme, leading to multiple inactive metabolites; it is ultimately excreted predominantly in the bile and to a lesser extent in the urine. As for toxicity, fluvastatin exhibits a relatively low incidence of severe side effects, but like other statins, can occasionally cause rhabdomyolysis or hepatotoxicity. The drug specifically targets the HMG-CoA reductase enzyme, which plays a pivotal role in cholesterol biosynthesis. Clinically, fluvastatin is indicated for the treatment of hypercholesterolemia and prevention of cardiovascular disease, including conditions such as familial hypercholesterolemia and mixed dyslipidemia. Noteworthy side effects may include myalgia, abdominal pain, and headache, though it tends to be well-tolerated in most patients. In practice, fluvastatin is administered to manage cholesterol levels, reducing the risk of atherosclerosis and subsequent cardiovascular events in patients at increased risk."
meloxicam,DB00440,"Meloxicam, with DrugBank ID DB00440 and SMILES notation COc1cc(Cc2cnc(N)nc2N)cc(OC)c1OC, is a nonsteroidal anti-inflammatory drug (NSAID) that exhibits an oxicam chemical structure characterized by a heterocyclic enolic acid scaffold. This scaffold is integral to the drug's anti-inflammatory properties and is shared among oxicam derivatives, setting it apart from other NSAID subfamilies, such as salicylates or propionic acid derivatives; similar drugs within the oxicam group include piroxicam and tenoxicam. Meloxicam's pharmacokinetics reveal that it is well-absorbed from the gastrointestinal tract, with a high plasma protein binding rate and a steady-state volume of distribution indicating significant tissue distribution. The drug is predominantly metabolized in the liver, primarily through cytochrome P450 2C9 and to a lesser extent CYP3A4, before being excreted in urine and feces; the elimination half-life allows for once-daily dosing. Meloxicam's potential for toxicity includes gastrointestinal disturbances, renal impairment, and cardiovascular risks, which are generally risks associated with the NSAID drug class. Its therapeutic mechanism involves the inhibition of cyclooxygenase-1 and -2 (COX-1 and COX-2), the target proteins responsible for converting arachidonic acid to prostaglandins, which are mediators of inflammation and pain. Indicated for the treatment of osteoarthritis, rheumatoid arthritis, and other inflammatory conditions, meloxicam aids in reducing the signs and symptoms of these diseases, such as joint pain and swelling. Side effects can range from mild, such as dyspepsia and headache, to severe, such as peptic ulceration or asthma exacerbation in susceptible individuals. In clinical practice, meloxicam is valued for its efficacy in managing chronic pain and inflammation with a lower incidence of gastrointestinal side effects compared to other NSAIDs, which can be attributed to its preferential inhibition of COX-2 over COX-1."
docetaxel,DB01124,"Docetaxel, with the DrugBank identifier DB01124 and SMILES notation 'CCCCNC(=O)NS(=O)(=O)c1ccc(C)cc1', is a chemotherapeutic agent classified as a taxane antineoplastic drug, characterized by its complex structure that includes a tetracyclic diterpenoid core coupled with a side chain at the C-13 position. It is chemically categorized as a taxoid and shares its core taxane scaffold with drugs like paclitaxel. Docetaxel is structurally similar to paclitaxel (Taxol), another prominent member of the taxane class, but it harbors synthetic modifications that impart distinct pharmacokinetic properties.

Pharmacokinetically, docetaxel presents with a biphasic plasma elimination pattern, indicating complex absorption and distribution, with a substantial volume of distribution suggesting extensive tissue binding. It is extensively metabolized in the liver by the cytochrome P450 enzyme CYP3A4 to multiple hydroxylated metabolites, with subsequent biliary and fecal excretion, whereas renal clearance plays a minor role.

The toxicity profile of docetaxel includes dose-limiting side effects such as neutropenia, which can lead to fatal infections if not monitored and managed properly. It exerts its cytotoxic effects primarily by binding to and stabilizing microtubule structures, thereby inhibiting depolymerization, which leads to cell cycle arrest and apoptosis in rapidly dividing cells. The key target proteins are beta-tubulin isotypes within the microtubules.

Indicated principally for the treatment of a wide array of cancers, including breast cancer, non-small cell lung cancer, prostate cancer, and gastric adenocarcinoma, docetaxel demonstrates efficacy by interfering with cellular mitosis. The side effects of docetaxel span from mild reactions like alopecia and nausea to severe conditions such as peripheral neuropathy and fluid retention.

Clinically, docetaxel is often used in various therapeutic regimens, either as a monotherapy or in combination with other cytotoxic or targeted therapies. Examples include its use in combination with prednisone for androgen"
olanzapine,DB00437,"Olanzapine, with the DrugBank ID DB00437, is an atypical antipsychotic characterized by its thienobenzodiazepine structure, identifiable through its SMILES notation 'Oc1ncnc2[nH]ncc12'. This structure comprises a fusion of a thiophene and a benzodiazepine ring, thus classifying it under the thienobenzodiazepine chemical category and standing on a unique dibenzo[b,f][1,4]thiazepine scaffold. Olanzapine shares this chemical structure with members of its drug class, such as clozapine and quetiapine which are also used to treat psychiatric conditions. Olanzapine's pharmacokinetic profile reveals oral bioavailability with rapid absorption, extensive distribution evidenced by its high volume of distribution, metabolism predominantly occurring in the liver via the cytochrome P450 system (specifically CYP1A2 and CYP2D6), and renal and fecal excretion of its metabolites. The toxicity spectrum of olanzapine includes but is not limited to, risk of weight gain, diabetes, and dyslipidemia as illustrated by postmarketing surveillance data. It primarily targets neurotransmitter receptors in the brain, such as dopamine D2, serotonin 5-HT2A/2C, 5-HT3, muscarinic M1-5, histamine H1, and adrenergic α1 receptors, contributing to its antipsychotic and mood-stabilizing effects. Olanzapine is indicated for the treatment of psychiatric conditions such as schizophrenia and bipolar disorder, addressing symptoms ranging from hallucinations to mood swings. Concerning side effects, patients may experience somnolence, extrapyramidal symptoms, and akathisia, as well as metabolic effects that warrant monitoring. Clinically, olanzapine is utilized in both acute and maintenance treatment phases, playing a vital role in managing psychotic episodes and preventing their recurrence, supporting its established use as a cornerstone in the pharmacotherapy of severe mental illnesses."
candesartan,DB00468,"Candesartan, with the DrugBank identifier DB00468, is an angiotensin receptor blocker (ARB) distinguished by its chemical structure, represented by the SMILES notation C=C[C@H]1C[N@@]2CC[C@H]1C[C@H]2[C@H](O)c1ccnc2ccc(OC)cc12, which highlights its distinctive biphenyl tetrazole molecular scaffold. Chemically, it belongs to the class of tetrazoles and is characterized by a tetrazole ring fused to a biphenyl moiety and substituted with an additional benzimidazole group, conferring specificity to its action. Candesartan is chemically similar to other ARBs like losartan and valsartan. In terms of pharmacokinetics, candesartan exhibits favorable absorption, reaching peak plasma concentrations in a few hours; its distribution is characterized by moderate protein binding and volume of distribution; it is metabolized by O-deethylation, primarily via the cytochrome P450 enzyme CYP2C9; and its excretion is mainly renal and also through bile. Its toxicity profile indicates that it is generally well-tolerated, but potential side effects such as hypotension, renal impairment, and hyperkalemia may occur at higher doses or in susceptible individuals. Candesartan acts primarily on the angiotensin II receptor type 1 (AT1), contributing to vasodilation and reduction in blood pressure. This makes it an effective treatment for hypertension and heart failure, where it is indicated to lower blood pressure and decrease the cardiovascular complications associated with these conditions. Common side effects include dizziness, headache, and back pain; however, it is often selected for its relatively lower incidence of cough when compared to ACE inhibitors. Clinically, candesartan is utilized as an antihypertensive agent and for heart failure management, either as monotherapy or in conjunction with other agents like diuretics, and has shown to improve outcomes in patients with left ventricular dysfunction following myocardial infarction."
telmisartan,DB00836,"Telmisartan, with DrugBank ID DB00836, is an angiotensin II receptor blocker (ARB) characterized by its unique biphenylmethyl structure with a tetrazole group, as embodied in its SMILES notation 'CN(C)C(=O)C(CCN1CCC(O)(c2ccc(Cl)cc2)CC1)(c1ccccc1)c1ccccc1', indicating the presence of a benzimidazole ring substituted with a carboxyl group and a long hydrophobic side chain. It falls within the chemical category of biphenyltetrazoles, sharing a similar scaffold with other ARBs like losartan and valsartan, distinguished by variations in their side chains which impact their pharmacokinetic profiles. In the context of pharmacokinetics, telmisartan is known for its high oral bioavailability, owing to its lipophilic nature, facilitating absorption. It is widely distributed in the body and binds extensively to plasma proteins, mainly albumin and alpha-1 acid glycoprotein. Metabolism of telmisartan is minimal as it is mainly excreted unchanged in feces via biliary elimination, and to a lesser extent in urine. As for toxicity, telmisartan is generally considered safe, but can induce hypotension or renal impairment if administered in high dosages. The primary known target protein is the angiotensin II type 1 (AT1) receptor, which it antagonizes to inhibit the vasoconstrictor and aldosterone-secreting effects of angiotensin II. Telmisartan is indicated for the treatment of hypertension, reducing the risk of cardiovascular events in patients, and for the prevention of renal failure progression in patients with type 2 diabetes, manifesting as diabetic nephropathy. Common side effects include dizziness, fatigue, and gastrointestinal disturbances, potentially affecting patient compliance. Clinically, telmisartan is used both as monotherapy and in combination with other antihypertensives like diuretics, providing an efficacious treatment option with once-daily dosing for patients with high blood pressure and those requiring cardiovascular risk management."
bosentan,DB00796,"Bosentan, identified by DrugBank ID 'DB00796', is a dual endothelin receptor antagonist (ERA) with the SMILES notation 'CCOc1nc2cccc(C(=O)OC(C)OC(=O)OC3CCCCC3)c2n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1'. Its complex chemical structure includes two aromatic rings connected by a sulfamide group, a tert-butyl group, and an ether linkage to a methoxyethyl side chain. As an ERA, it belongs to the chemical category of heterocyclic compounds and is structured around a biphenyl tetrazole chemical scaffold which is a common feature in this drug class. Similar drugs include ambrisentan and macitentan, which share the tetrazole motif and act as selective endothelin receptor blockers. Bosentan exhibits pharmacokinetics with rapid oral absorption, wide tissue distribution, extensive hepatic metabolism primarily through the cytochrome P450 system (particularly CYP3A4 and CYP2C9 isoenzymes), and is largely excreted in feces, with a minor fraction in urine. Despite its therapeutic benefits, bosentan's toxicity includes the potential for hepatotoxicity, evidenced by elevated liver aminotransferases, and teratogenic effects, necessitating regular liver function monitoring. It acts by targeting and antagonizing endothelin receptors (ET_A and ET_B), reducing vasoconstriction and preventing pathological remodeling. Clinically, bosentan is indicated for the treatment of pulmonary arterial hypertension (PAH) to improve exercise ability and delay clinical worsening. Adverse effects often seen with bosentan use include, but are not limited to, headache, flushing, and edema. In a clinical setting, its prescription is carefully managed to balance the therapeutic control of PAH symptoms against its side-effect profile and potential for drug-drug interactions, particularly with substrates of CYP3A4 or CYP2C9."
cerivastatin,DB01586,"Cerivastatin, with DrugBank ID 'DB01586' and SMILES notation 'C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@@]21C,' is a synthetic lipophilic statin, characterized by a complex cyclohexane hexahydronaphthalene polyhydroxy structure with several chiral centers, indicative of its specific three-dimensional conformation and designated stereochemistry. It belongs to the chemical category of statins, sharing the HMG-CoA reductase inhibitor scaffolding common to this class, with related drugs including atorvastatin, simvastatin, and lovastatin. Cerivastatin is well absorbed orally, with extensive hepatic first-pass metabolism primarily mediated by the cytochrome P450 3A4 (CYP3A4) enzyme, leading to various metabolites before being excreted predominantly in the bile and feces. Its toxicity, which led to its voluntary withdrawal from the market, was characterized by rare but severe cases of rhabdomyolysis, often when used in combination with gemfibrozil. This drug was designed to inhibit the target protein HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis. It was primarily indicated for the treatment of hypercholesterolemia to reduce the risk of coronary heart disease and associated atherosclerotic events. Side effects of cerivastatin included mild symptoms such as headache and gastrointestinal disturbance, with the aforementioned risk of rhabdomyolysis being a severe adverse effect. Clinically, cerivastatin was used in varying doses depending on the severity of dyslipidemia, aiming to lower low-density lipoprotein (LDL) cholesterol as part of a broader strategy including diet and lifestyle modification. However, due to safety concerns, cerivastatin was discontinued and is no longer in use."
rosiglitazone,DB00140,"Rosiglitazone, bearing the DrugBank identifier DB00140 and represented by the SMILES notation 'Cc1cc2nc3c(=O)[nH]c(=O)nc-3n(C[C@H](O)[C@H](O)[C@H](O)CO)c2cc1C', is a thiazolidinedione (TZD) categorized as an antidiabetic agent. Its structure is characterized by a thiazolidine core bearing a 2,4-thiazolidinedione moiety, which is essential for its biological activity, together with a substituted aromatic group that adds to the molecule's chemical complexity and specificity. Rosiglitazone is chemically related to other TZDs, such as pioglitazone, sharing a similar mechanism of action. Pharmacokinetically, rosiglitazone is well-absorbed after oral administration, extensively bound to plasma proteins, and metabolized by the cytochrome P450 system in the liver, primarily by CYP2C8, with subsequent renal and fecal excretion. The drug displays a notable risk profile including cardiotoxicity, as evidenced by an increased risk of myocardial infarction, and hepatotoxicity, which led to its restricted usage in various regions. Rosiglitazone targets the peroxisome proliferator-activated receptor gamma (PPARγ), a nuclear receptor playing a pivotal role in the regulation of glucose and lipid metabolism. The drug is indicated for the treatment of type 2 diabetes mellitus, aiming to improve glycemic control by increasing insulin sensitivity. Side effects associated with rosiglitazone include, but are not limited to, weight gain, edema, and an increased risk of fractures. Clinically, its use has become limited due to the safety concerns, with a shift towards alternative medications with safer profiles for managing type 2 diabetes; nevertheless, its role in understanding PPARγ-mediated pathways remains significant."
fexofenadine,DB00755,"Fexofenadine, with DrugBank ID DB00755, is denoted by the SMILES (Simplified Molecular Input Line Entry System) notation 'CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)C(C)(C)CCC1', highlighting its detailed chemical structure which includes a diphenylmethane skeleton modified by carboxylic acid and hydrophobic isopropyl side chains, thus classifying it as a piperidine derivative and a member of the third-generation antihistamine chemical category. Its chemical scaffold shares similarities with certain other non-sedating antihistamines such as loratadine, from which fexofenadine is derived as an active metabolite. The pharmacokinetics of fexofenadine is characterized by its rapid absorption, high oral bioavailability, negligible metabolism (as it does not undergo significant hepatic biotransformation), and primarily renal excretion, which contribute to its favorable safety profile and low toxicity. The target proteins for fexofenadine are histamine H1 receptors, where it functions as a selective antagonist, reducing allergic reactions. Fexofenadine is indicated for the treatment and relief of symptoms associated with allergic conditions such as seasonal allergic rhinitis and chronic idiopathic urticaria. Possible side effects included with fexofenadine use, although rare, can range from mild gastrointestinal discomfort and headache to dizziness and sleep disturbances. Clinically, fexofenadine is utilized for its non-sedating properties in managing allergic symptoms without significant central nervous system depression, broadening its therapeutic use, especially in situations where cognitive impairment must be minimized, such as when operating machinery or driving."
montelukast,DB00802,"Montelukast, with DrugBank identifier DB00802, is a leukotriene receptor antagonist that embodies a quinoline backbone as its chemical scaffold and portrays a comprehensive molecular structure highlighted by the SMILES notation 'CCC(=O)N(c1ccccc1)C1(COC)CCN(CCn2nnn(CC)c2=O)CC1'. It falls under the chemical category of anti-asthmatics and anti-allergic agents, and is structurally related to leukotriene inhibitors like zafirlukast. As for its pharmacokinetic profile, montelukast is well-absorbed orally, exhibiting peak plasma concentrations after 3 to 4 hours. Its distribution is extensive — it displays a high volume of distribution and is highly protein-bound. The metabolism of montelukast predominantly occurs via the CYP3A4 and CYP2C9 pathways within the liver, resulting in the formation of inactive metabolites. The drug and its metabolites are excreted primarily in the bile and feces. In terms of toxicity, montelukast is generally well-tolerated; however, it has been associated with rare cases of Churg-Strauss syndrome and hepatic eosinophilic infiltration. The primary target proteins for montelukast are the cysteinyl leukotriene receptors CysLT1, on which it exerts an antagonistic effect to impede the action of cysteinyl leukotrienes. Therapeutically, montelukast is indicated for the management of asthma and for the relief of symptoms of allergic rhinitis (such as hay fever). While the drug is often well-received by patients, some may experience side effects, including but not limited to upper respiratory infection, fever, headache, pharyngitis, cough, abdominal pain, diarrhea, and otitis media. In the clinical setting, montelukast is habitually prescribed for long-term control of asthma symptoms and to prevent exercise-induced bronchoconstriction; it's also used prophylactically to ameliorate seasonal and perennial allergic rhinitis symptoms. This singular, multifaceted paragraph encapsulates the intricate essence of mont"
alitretinoin,DB01580,"Alitretinoin, registered with DrugBank ID 'DB01580' and delineated by its SMILES notation 'C=CCOc1ccccc1OCC(O)CNC(C)C,' is a retinoid structurally characterized by a conjugated double bond linked to an ether that is fused with a phenyl ring, alongside a side chain containing a hydroxyl group, a carboxylic ester, and an amide. As a member of the retinoid chemical category, it shares a polyene hydrocarbon scaffold with other retinoids such as isotretinoin and acitretin. Alitretinoin's pharmacokinetics is notable, characterized by oral absorption that varies due to its lipophilicity, wide tissue distribution that includes the skin, an extensive metabolism primarily via cytochrome P450 enzymes in the liver, and excretion predominantly through biliary mechanisms. Toxicity is a concern with this drug; for example, teratogenic effects have been observed, leading to strict regulations on its prescription to women of childbearing potential. This drug targets a variety of retinoic acid receptors (RARs) and retinoid X receptors (RXRs) modulating gene expression and influencing cell differentiation and proliferation. Alitretinoin is indicated mainly for chronic hand eczema unresponsive to potent topical steroids and has seen use in conditions like Kaposi's sarcoma due to its anti-angiogenic properties. Adverse effects accompanying alitretinoin treatment include instances of cheilitis, dry skin, and elevated blood lipid levels. Clinically, alitretinoin has been beneficial for patients with severe skin diseases, exemplified by its efficacy in treating refractory cases of eczema, thus representing a significant therapeutic option when other treatments fail."
rofecoxib,DB00332,"Rofecoxib, with DrugBank ID DB00332 and SMILES notation CC(C)[N+]1(C)[C@H]2CC[C@@H]1C[C@H](OC(=O)C(CO)c1ccccc1)C2, is a synthetic chemical compound classified as a nonsteroidal anti-inflammatory drug (NSAID) that is structurally characterized by its methyl sulfone moiety - a hallmark feature of its chemical scaffold. Belonging to the subclass of cyclooxygenase-2 (COX-2) inhibitors, it shares therapeutic properties with similar drugs like celecoxib. Pharmacokinetically, rofecoxib is efficiently absorbed after oral administration, achieving peak plasma concentrations, with its distribution characterized by a moderate volume of distribution and a high binding affinity to plasma proteins. Biologically transformed through metabolism primarily by the cytochrome P450 system, its metabolites are subsequently eliminated predominantly via renal excretion in the urine. Rofecoxib's therapeutic action arises from selective inhibition of target protein COX-2, reducing the synthesis of inflammatory prostaglandins, thus effectively managing symptoms of osteoarthritis and acute pain, while its use for reducing the risk of colonic polyps has been observed. Adverse drug reactions include increased risk for cardiovascular events such as myocardial infarctions and strokes, prompting consideration in patient populations with cardiovascular risk factors. Notably, its clinical application once embraced the management of chronic conditions like rheumatoid arthritis before being withdrawn globally due to concerns over its associated toxicity profile. Although rofecoxib was voluntarily removed from the market, its pharmacological insights continue to inform the development and monitoring of COX-2 inhibitors within the scope of analgesic and anti-inflammatory agents."
desloratadine,DB00242,"Desloratadine, identified by DrugBank ID DB00242, is a long-acting tricyclic antihistamine with selective H1-receptor antagonist activity which belongs to the chemical category of histamine H1 antagonists. Its chemical structure is denoted by the SMILES notation Nc1nc(Cl)nc2c1ncn2[C@H]1C[C@H](O)[C@@H](CO)O1, which describes a chlorinated benzoxazinone moiety linked to a dehydrogenated piperidine derivative, indicating a similar scaffold to that of loratadine, its parent compound, and other antihistamines like cetirizine. Pharmacokinetically, desloratadine is well absorbed after oral administration, achieving peak plasma concentrations within 3 hours, widely distributed with a low volume of distribution, extensively metabolized primarily through hydroxylation and dealkylation via cytochrome P450 enzymes (notably CYP3A4 and CYP2D6), and excreted mainly in the urine as metabolites. The toxicity of desloratadine is characterized by low acute toxicity, with side effects including, but not limited to, fatigue, headache, and dry mouth reported at elevated doses. Its primary target proteins are the histamine H1 receptors, which it blocks to mitigate allergic reactions. Indicated for the relief of symptoms associated with allergic rhinitis and urticaria, desloratadine alleviates sneezing, runny nose, itchy/watery eyes, and skin rash. Side effects are typically mild to moderate and can include dizziness, somnolence, and gastrointestinal disturbances. Clinically, desloratadine is administered to patients as a once-daily treatment, often preferred due to its non-sedating properties, for chronic allergic conditions and is suitable for use in both adults and children."
gefitinib,DB00741,"Gefitinib, with the DrugBank identifier DB00741, is a small molecule anticancer agent that falls under the category of kinase inhibitors, specifically inhibiting the epidermal growth factor receptor (EGFR) tyrosine kinase. Its SMILES notation is not provided accurately, but gefitinib is characterized by the presence of a quinazoline ring and an anilino-substituent, contributing to its selectivity against EGFR. As a chemical scaffold, it shares this quinazoline core with other EGFR inhibitors such as erlotinib and lapatinib. Gefitinib is absorbed orally with bioavailability of around 60%, and once in circulation, it is extensively distributed across body tissues. Its metabolism primarily occurs in the liver via cytochrome P450 enzymes, primarily CYP3A4, resulting in several metabolites that are less active than the parent compound. Excretion of gefitinib and its metabolites is mainly through feces, with a small percentage eliminated in urine. The toxicity profile includes interstitial lung disease as a severe adverse effect, alongside liver toxicity in some patients.

The primary pharmacological target of gefitinib is the EGFR, which, when overexpressed or mutated, can lead to uncontrolled cellular proliferation and cancer. Therefore, gefitinib is indicated for the treatment of non-small cell lung cancer (NSCLC), particularly in patients harboring EGFR mutations. Common side effects of gefitinib include skin rash, diarrhea, and nausea; these are typically manageable, but can significantly impact a patient's quality of life. Clinically, gefitinib is utilized as a first-line treatment in selected NSCLC patients and is administered as a once-daily oral tablet. Continual research and trials are directed at further refining its usage, expanding its indications, and managing its side effects for optimal patient outcomes."
sorafenib,DB00813,"Sorafenib, bearing the DrugBank ID DB00813, is a small-molecule kinase inhibitor with a complex molecular structure encapsulated by the SMILES notation ""CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1"". Its chemical structure features a biphenyl urea moiety with an adjacent cyclohexane-fused diethylamine group, signifying its categorization within the multi-kinase inhibitor chemical class. The core scaffold of sorafenib is attributed to its biphenyl urea structure, similar to drugs like sunitinib, another tyrosine kinase inhibitor. Regarding pharmacokinetics, sorafenib exhibits rapid absorption with a bioavailability affected by high-fat meals, extensive hepatic metabolism primarily via CYP3A4 and CYP3A5 enzymes, and elimination predominantly in the feces. Its toxicity profile includes dermatological and gastrointestinal manifestations, such as hand-foot skin reactions and diarrhea, respectively. Sorafenib targets various protein kinases, including VEGFR, PDGFR, and RAF kinases, which are implicated in tumor growth and angiogenesis. Clinically, sorafenib is indicated for the treatment of advanced renal cell carcinoma and unresectable hepatocellular carcinoma, showcasing therapeutic utility in specifically controlling disease progression and symptomatic management. However, patients may experience side effects including hypertension, fatigue, and cardiotoxicity in rare cases. The clinical usage of sorafenib has expanded over the years encompassing trials in thyroid carcinoma and other advanced solid tumors, where it often serves as a palliative option to improve quality of life and prolong survival."
sunitinib,DB00927,"Sunitinib, with the DrugBank identifier DB00927, is characterized by a SMILES notation NC(N)=Nc1nc(CSCCC(N)=NS(N)(=O)=O)cs1, representing its intricate molecular structure that features a substituted indoline scaffold harboring a nitrile group, a thiophene ring, and a sulfonylurea moiety. It falls under the chemical category of kinase inhibitors, specifically serving as a multi-targeted receptor tyrosine kinase (RTK) inhibitor. Its structure and mode of action are akin to similar multi-kinase inhibitors, such as sorafenib and pazopanib, which share the same therapeutic class and traits. Sunitinib's pharmacokinetics profile reveals that after oral administration, it is rapidly absorbed with peak plasma concentrations occurring between 6 to 12 hours post-dose, whereas its distribution is characterized by extensive plasma protein binding with a relatively large volume of distribution. The drug is metabolized primarily by the cytochrome P450 enzyme CYP3A4 to its active N-desethyl metabolite, with subsequent excretion predominantly in the feces, and to a lesser extent, in the urine. Sunitinib's toxicity includes its potential to induce heart and liver problems, with cases showing cardiotoxicity and hepatotoxicity among patients, demanding close monitoring of cardiovascular and liver function during treatment. It operates by targeting multiple RTKs, notably VEGFR and PDGFR, which play critical roles in tumor angiogenesis and cell proliferation, and is further indicated for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). However, use of this drug may precipitate a range of side effects, from fatigue and diarrhea to more severe conditions like neutropenia and thrombocytopenia. Clinically, sunitinib is exploited as a therapeutic agent in advanced RCC and progressive, well-differentiated pancreatic neuroendocrine tumors, where it extends survival and offers a palliative benefit by inhibiting tumor growth and angiogenesis."
celecoxib,DB00295,"Celecoxib, with the DrugBank ID DB00295, is a nonsteroidal anti-inflammatory drug (NSAID) that exhibits selective inhibition of the enzyme cyclooxygenase-2 (COX-2). It is characterized by its unique SMILES notation 'CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5', highlighting its chemical structure which comprises a diaryl-substituted pyrazole ring, rendering it part of the selective COX-2 inhibitor category within NSAIDs. This chemical scaffold differentiates it from non-selective NSAIDs like ibuprofen and naproxen, while likening it to similar drugs such as rofecoxib and valdecoxib, which share the same target but differ in structure and potency. Celecoxib's pharmacokinetic profile includes rapid oral absorption, peak plasma concentrations reached within 3 hours, a distribution volume affected by its high protein binding (approximately 97%), metabolism primarily by hepatic cytochrome P450 2C9, with sulfoxide metabolites excreted mainly in the urine and feces. The drug's toxicity is relatively low compared to other NSAIDs, but it can increase the risk of serious cardiovascular thrombotic events, gastrointestinal ulcers, and renal damage at high doses or in vulnerable populations. Celecoxib targets COX-2 enzymes, reducing the production of pro-inflammatory prostaglandins. Clinically, it is indicated for the relief of osteoarthritis, rheumatoid arthritis symptoms, acute pain, and dysmenorrhea, and has been used in familial adenomatous polyposis as an adjunct to standard care. While generally well-tolerated, side effects can include dyspepsia, diarrhea, and peripheral edema. Despite its adverse events, celecoxib's clinical usage persists due to its efficacy in reducing inflammation and pain with a lower incidence of gastrointestinal irritation compared to its non-selective counterparts."
sildenafil citrate,DB00917,"Sildenafil citrate, with the DrugBank identifier DB00917, possesses a complex chemical structure, as represented by its SMILES notation ""CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1C/C=C\CCCC(=O)O."" This structure describes a cyclopentanoperhydrophenanthrene skeletal framework with a methyl group and a carboxylic acid moiety, highlighting that sildenafil is classified chemically as a cGMP-specific phosphodiesterase type 5 (PDE5) inhibitor. This classification places it in the same category as other similar vasodilator agents like tadalafil (Cialis) and vardenafil (Levitra). Pharmacokinetically, sildenafil is well-absorbed orally with peak plasma concentrations occurring within 30 to 120 minutes. Its distribution is widespread, with a protein binding rate of about 96%, and it is primarily metabolized via hepatic enzymes CYP3A4 and CYP2C9. Sildenafil is excreted predominantly as metabolites in the feces and to a lesser extent in the urine. Regarding toxicity, sildenafil's safety profile is relatively solid, though there have been reports of cardiovascular events among predisposed individuals. The drug's primary target proteins are PDE5 enzymes located in the vascular smooth muscle cells, which it inhibits to produce vasodilation. Sildenafil citrate is indicated primarily for the treatment of erectile dysfunction and also for managing pulmonary arterial hypertension (PAH) by relaxing blood vessels in the chest to improve blood flow. Side effects commonly associated with sildenafil include headaches, flushing, dyspepsia, and dizziness. In clinical practice, sildenafil has revolutionized the management of erectile dysfunction and improved the quality of life for patients with PAH, being often recognized under the trade name Viagra for erectile dysfunction and Revatio for PAH treatment."
rosuvastatin calcium,DB00519,"Rosuvastatin calcium (DrugBank ID: DB00519), with its SMILES notation CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@H]2CCCC[C@@H]21, is a synthetic lipid-lowering agent exhibiting a complex chemical structure characterized by an asymmetric, hydrophilic pyrimidine scaffold that is substituted with a series of non-polar and polar groups, conferring it both lipophilic and hydrophilic properties. Classified under the category of statins, this compound shares a common HMG-CoA reductase inhibitory activity with similar drugs, such as atorvastatin and simvastatin. The pharmacokinetics of rosuvastatin in the body involves rapid absorption with a bioavailability of approximately 20%, extensive distribution preferentially to the liver, the primary site of cholesterol synthesis, and biotransformation primarily via CYP2C9, along with minimal involvement of CYP3A4, contrasting sharply with other statins. It is excreted in both feces and urine, predominantly in its metabolized form. Rosuvastatin's safety profile indicates a low potential for severe toxicity; however, it may cause myopathy and, in rare cases, rhabdomyolysis when overdosed or interacted with other medications. The drug targets HMG-CoA reductase, a key enzyme in the cholesterol biosynthesis pathway, effectively reducing the production of mevalonate, a cholesterol precursor. Rosuvastatin is used primarily for the treatment of hypercholesterolemia and mixed dyslipidemia, to lower elevated levels of total cholesterol, LDL-cholesterol, and triglycerides, and to increase HDL-cholesterol in the prevention of cardiovascular events. Side effects range from mild, such as headache and nausea, to more serious muscle-related symptoms like myalgia and arthralgia. In clinical practice, rosuvastatin is utilized in varying doses, tailored to patient-specific cardiovascular risk profiles, and is often a drug of choice for"
valsartan,DB00349,"Valsartan, bearing the DrugBank identifier DB00349, is an angiotensin II receptor blocker (ARB) characterized by its chemical structure delineated by the SMILES notation CN1C(=O)CC(=O)N(c2ccccc2)c2cc(Cl)ccc21, which depicts a benzimidazole fused to a tetrazole ring with a biphenyl moiety possessing a chloro substituent. It belongs to the chemical category of synthetic tetrazole derivatives and shares its chemical scaffold with similar drugs like losartan and irbesartan, which are also ARBs used in the management of hypertension and cardiovascular diseases. Valsartan demonstrates favorable pharmacokinetics with rapid absorption, achieving peak plasma concentrations within 2 to 4 hours post-oral administration. It exhibits a moderate volume of distribution and is largely bound to plasma proteins. Metabolism is minimal as it does not undergo significant first-pass metabolism, and it predominantly undergoes renal excretion unchanged. Regarding toxicity, valsartan is generally well-tolerated; however, it is contraindicated in patients with known hypersensitivity to the drug and should be used cautiously in those with renal impairment. Valsartan's primary target protein is the angiotensin II type 1 (AT1) receptor, which it blocks to impede the vasoconstrictive and aldosterone-secreting effects of angiotensin II. Clinically, it is indicated for the treatment of hypertension to reduce the risks associated with high blood pressure, heart failure (NYHA class II-IV), and is employed as a therapy post-myocardial infarction. Side effects of valsartan can include dizziness, hyperkalemia, and renal impairment, although serious adverse effects are infrequent. As part of the standard clinical practice for managing the aforementioned conditions, valsartan is often combined with other cardiovascular agents to achieve a more comprehensive therapeutic effect."
imatinib mesylate,DB00831,"Imatinib mesylate (DrugBank ID: DB00831) is a small molecule tyrosine kinase inhibitor, characterized by its SMILES notation 'CN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1', which describes its complex structure that includes a pyrimidine derivative fused with a benzene ring, substituents like a methylpiperazine group, and a trifluoromethyl group attached to another benzene ring via a sulfur atom, conferring it unique pharmacological properties. As a 2-phenylaminopyrimidine derivative, it represents a class of selective inhibitors targeting specific tyrosine kinases. Imatinib shares its chemical scaffold with other drugs such as dasatinib and nilotinib, indicating they belong to a similar class of tyrosine kinase inhibitors used for certain cancers. Pharmacokinetically, imatinib is well-absorbed orally, exhibits extensive tissue distribution, undergoes hepatic metabolism primarily by the CYP3A4 enzyme, and is excreted predominantly via the feces in the form of metabolites. Its toxicity profile includes risks such as hepatotoxicity and cardiotoxicity, which necessitates regular monitoring of liver enzymes and cardiac function. Imatinib has a specific affinity to target proteins including BCR-ABL tyrosine kinase, found in chronic myeloid leukemia (CML) cells, c-KIT, and PDGF receptors, which play pivotal roles in the pathophysiology of the diseases it treats. Clinically, imatinib is indicated for the treatment of CML, gastrointestinal stromal tumors (GISTs), and other malignancies driven by dysregulated tyrosine kinase activity. Side effects associated with imatinib can range from mild to severe and include edema, nausea, muscle cramps, and hematological abnormalities such as neutropenia and thrombocytopenia. In clinical practice, imatinib has significantly improved the prognosis of CML and GIST patients, demonstrating transformative impacts on the natural history of these diseases, with continual long-term monitoring for adverse reactions and resistance to therapy being a critical component of patient"
sitagliptin phosphate,DB01327,"Sitagliptin phosphate (DrugBank ID: DB01327) is characterized by its comprehensive chemical structure, signified by the SMILES notation 'Cc1nnc(SCC2=C(C(=O)O)N3C(=O)[C@@H](NC(=O)Cn4cnnn4)[C@H]3SC2)s1', which identifies it as a small heterocyclic amine. As a member of the dipeptidyl peptidase-4 (DPP-4) inhibitor class, it shares a chemical scaffold – a beta-amino acid-like structure with a fused triazolopyrazine system – with other antidiabetic drugs in the same category, such as saxagliptin and vildagliptin. Sitagliptin’s pharmacokinetics are characterized by high oral absorption, a protein binding rate of approximately 38%, extensive metabolic processing primarily by the cytochrome P450 3A4 and 2C8 isoenzymes, and renal excretion with a half-life of about 12 hours. Its toxicity profile is generally low, yet some reported examples include acute pancreatitis and hypersensitivity reactions. Sitagliptin’s primary target protein is the DPP-4 enzyme, which it inhibits to potentiate incretin hormones, thereby moderating blood glucose levels. Its indication is in the management of type 2 diabetes mellitus, specifically to improve glycemic control in conjunction with diet and exercise. Common side effects include nasopharyngeal infection, headache, and joint pain; although rare, there have been reports of angioedema and acute renal failure. Clinically, sitagliptin is often used either as monotherapy or combined with other antidiabetic medications like metformin, and its use exemplifies a strategic approach in diabetes management to reduce the risk of developing complications associated with chronic hyperglycemia."
atorvastatin calcium,DB00819,"Atorvastatin calcium, with the DrugBank ID DB00819, is encapsulated by the SMILES notation ""CC(=O)Nc1nnc(S(N)(=O)=O)s1,"" representing a detailed description of its chemical structure which includes a lactone ring, a fluorophenyl group, and a thiazole moiety containing a sulfonylurea-linked nitrophenyl group. Classified as a statin, atorvastatin is part of the broader chemical category of HMG-CoA reductase inhibitors, which utilize the mevalonate pathway scaffold for cholesterol synthesis inhibition. Statins such as simvastatin and pravastatin share this pharmacological profile. In terms of pharmacokinetics, atorvastatin is well-absorbed with a bioavailability of approximately 12%, undergoes extensive first-pass metabolism primarily by the liver via the cytochrome P450 3A4 enzyme, has a mean plasma elimination half-life of 14 hours, and is excreted in bile following hepatic and extrahepatic metabolism. The drug's toxicity is commonly evident in a dose-dependent increase in hepatic transaminases and, rarely, rhabdomyolysis. Atorvastatin specifically targets and inhibits the HMG-CoA reductase enzyme, the rate-controlling enzyme of cholesterol biosynthesis. Indicated for the treatment of hypercholesterolemia and the prevention of cardiovascular disease, it is prescribed to lower LDL cholesterol and triglycerides in the blood, as well as to modestly raise HDL cholesterol, thereby managing conditions such as familial hypercholesterolemia and reducing the risk of heart attack and stroke. Common side effects include myalgia, diarrhea, and headache, whereas more serious adverse events may involve myopathy and liver enzyme abnormalities. Clinically, atorvastatin is commonly dispatched in a once-daily oral dosage form, which can be prescribed as an adjunct to diet for the reduction of elevated LDL cholesterol - a regimen detailed in various guidelines for the management of dyslipidemia and the primary and secondary prevention of cardiovascular disease."
erlotinib hydrochloride,DB00255,"Erlotinib hydrochloride, with the DrugBank identifier DB00255 and the SMILES notation CC/C(=C(/CC)c1ccc(O)cc1)c1ccc(O)cc1, is a small molecule tyrosine kinase inhibitor primarily characterized by its quinazoline framework and anilino-quinazoline scaffold. This compound houses a biphenyl moiety ortho-substituted with hydroxyl groups, crucial for its activity, and falls within the chemical category of synthetic quinazoline derivatives. Like its counterparts gefitinib and afatinib, erlotinib is among a class of similar agents used in targeted cancer therapies. Pharmacokinetically, erlotinib is well absorbed orally, exhibits high plasma protein binding, undergoes extensive hepatic metabolism predominantly by CYP3A4 and, to a lesser extent, CYP1A2, with its metabolites and parent drug excreted via feces and urine. The toxicity profile of erlotinib includes potential hepatotoxicity and interstitial lung disease, evidenced by elevated liver enzymes and pulmonary symptoms in some patients. Erlotinib's therapeutic action is exerted through selective inhibition of the epidermal growth factor receptor (EGFR) tyrosine kinase domain, thereby impeding downstream signaling and proliferative processes in EGFR-expressing tumor cells found in non-small cell lung cancer and pancreatic cancer, for which it is indicated. Side effects commonly seen with erlotinib encompass rash, diarrhea, and fatigue, which require careful management to maintain patient quality of life and continuation of therapy. In clinical practice, erlotinib has been predominantly utilized for the treatment of locally advanced or metastatic non-small cell lung cancer, especially in patients with EGFR mutations, as well as in combination with gemcitabine for pancreatic cancer, highlighting its role as a targeted therapeutic agent in the burgeoning field of precision oncology."
quetiapine fumarate,DB00501,"Quetiapine fumarate, with the DrugBank identifier DB00501, is an atypical antipsychotic drug distinguished by its chemical structure, represented by the SMILES notation 'CN/C(=N/C#N)NCCSCc1nc[nH]c1C'. This notation denotes a molecular framework that includes a dibenzothiazepine scaffold characterized by a thiazepine ring fused to two benzene rings, with a side chain containing nitrogen and sulfur elements. Its chemical categorization places it alongside other dibenzothiazepine antipsychotics, while its pharmacological profile shares similarities with related atypical antipsychotics such as clozapine and olanzapine, primarily due to the presence of the dibenzothiazepine core and the mechanism of action targeting multiple neurotransmitter systems. Quetiapine’s pharmacokinetics involves rapid absorption with a bioavailability affected by food intake, wide distribution with a volume of distribution indicating extensive tissue binding, hepatic metabolism primarily through cytochrome P450 (CYP) 3A4 isoenzymes, and excretion with a half-life conducive to twice-daily dosing. The drug's toxicity profile includes the risk of metabolic alterations like weight gain and dyslipidemia, QT interval prolongation, and extrapyramidal symptoms, among others, though it is generally considered to have a lower risk of extrapyramidal side effects compared to typical antipsychotics. The molecular targets for quetiapine include a variety of neurotransmitter receptors, notably serotonin (5-HT2A) and dopamine (D2) receptors, leading to its antipsychotic and mood-stabilizing effects. Clinically, quetiapine is indicated for the treatment of a range of psychiatric conditions such as schizophrenia, bipolar disorder, and as an adjunctive for major depressive disorder, helping to alleviate symptoms like hallucinations, delusions, mood swings, and depression. However, its use is not without side effects; quetiapine can cause somnolence, orthostatic hypotension, and potential aggravation of suicidal ideation, particularly in younger patients. In practice, quetiapine is"
ezetimibe,DB00959,"Ezetimibe, with the DrugBank ID of DB00959 and SMILES notation 'C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12', is a synthetic lipid-lowering agent that distinctively inhibits the intestinal absorption of cholesterol. Structurally, ezetimibe is characterized by a phenoilidine chemical scaffold, a condensed polycyclic molecule comprising phenolic and azetidine moieties. It can be chemically categorized as an azetidinone and is distinct from statins, such as atorvastatin or simvastatin, which reduce cholesterol biosynthesis. Pharmacokinetically, ezetimibe is orally absorbed, glucuronidated in the small intestine and liver, enterohepatically circulated, and predominantly excreted in the feces. Despite its effective cholesterol-lowering action, concerns regarding its toxicity, particularly rare cases of myopathy and liver enzyme elevations, have been reported. Ezetimibe targets the Niemann-Pick C1-Like 1 (NPC1L1) protein in the jejunal brush border, inhibiting cholesterol uptake. Its primary indication is for the treatment of hypercholesterolemia and is employed in conditions such as familial hypercholesterolemia and sitosterolemia. Common side effects may include upper respiratory tract infections, diarrhea, and arthralgia. Clinically, ezetimibe is administered either as monotherapy or in combination with statins to synergistically reduce plasma cholesterol levels, with a view towards preventing cardiovascular events in patients at risk of atherosclerosis-related diseases."
dasatinib,DB00712,"Dasatinib, bearing the DrugBank identifier DB00712, is a synthetic small-molecule inhibitor possessing a distinctive chemical structure, as highlighted by its SMILES notation 'CC(C(=O)O)c1ccc(-c2ccccc2)c(F)c1', which describes a benzene ring ortho-substituted with a fluorine atom and a phenyl group linked to a tertiary butyl ester moiety. This agent falls under the chemical category of kinase inhibitors and shares its thiazole chemical scaffold with similar drugs such as imatinib and nilotinib, both of which are also used in the treatment of chronic myeloid leukemia (CML). Dasatinib is characterized by rapid oral absorption, and its pharmacokinetics reveals extensive distribution throughout the body, metabolized predominantly via the cytochrome P450 enzyme CYP3A4, with the resulting metabolites excreted primarily in the feces. Its toxicity profile includes, but is not limited to, myelosuppression, leading to neutropenia and thrombocytopenia. The drug targets multiple tyrosine kinases, prominently including BCR-ABL1, which is the aberrant protein driving CML, and the SRC-family kinases. Clinically, dasatinib is indicated for the treatment of all phases of CML and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) when patients are resistant or intolerant to prior therapy. Side effects are diverse, ranging from fluid retention and pleural effusion to gastrointestinal disturbances and rash. In a clinical context, dasatinib is administered as a highly potent second-generation tyrosine kinase inhibitor for the management of specific hematological malignancies, where it may be used as a front-line therapy or as a subsequent treatment following the failure of other tyrosine kinase inhibitors due to its ability to overcome certain BCR-ABL kinase domain mutations."
venlafaxine hydrochloride,DB01254,"Venlafaxine hydrochloride, cataloged under DrugBank ID DB01254, has a complex chemical structure represented by the SMILES notation ""Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1"". It is an arylalkanolamine serotonin-norepinephrine reuptake inhibitor (SNRI) and chemically relates to other antidepressants such as desvenlafaxine and duloxetine in its biphenyl scaffold. Venlafaxine undergoes extensive metabolism, primarily via CYP2D6-mediated O-demethylation into its active metabolite, O-desmethylvenlafaxine, and it's further processed by CYP3A4 and CYP2C19 enzymes. The hydrochloride salt formulation enhances its water solubility, facilitating oral absorption, and it is widely distributed in the body, crossing the blood-brain barrier with a volume of distribution around 7.5 L/kg. Venlafaxine and its metabolites are primarily excreted by the kidneys, with drug clearance depending on both renal function and genetic factors that affect CYP2D6 enzyme activity. Its toxicity profile includes dose-dependent hypertension, the serotonin syndrome when interacted with serotonergic agents, and potential increase in suicidal ideation in adolescents and young adults.

Venlafaxine's mechanism of action involves targeting and inhibiting the protein transporters for serotonin and norepinephrine, namely SERT and NET, thereby increasing the concentration of these neurotransmitters in the synaptic cleft and resulting in antidepressant effects. Indications for venlafaxine include major depressive disorder, general anxiety disorder, social anxiety disorder, and panic disorder, exemplifying its role in the treatment of diverse affective conditions. Common side effects of venlafaxine can range from mild gastrointestinal disturbances (nausea, constipation) to more severe neurological symptoms (headaches, dizziness), somnolence, and sexual dysfunction. In clinical practice, venlafaxine is often selected for its dual-action on both serotonin and norepine"
acebutolol,DB00533,"Acebutolol, with DrugBank ID DB00533 and SMILES notation CS(=O)(=O)c1ccc(C2=C(c3ccccc3)C(=O)OC2)cc1, is a beta-adrenergic receptor antagonist characterized by a substituted phenoxypropanolamine structure that features a sulfonamide moiety and an aromatic ring with an ether linkage to a secondary alcohol. Classified as a beta-blocker within the aryloxypropanolamine chemical category, acebutolol's chemical scaffold is shared with similar drugs like propranolol and atenolol, which also contain aromatic rings linked to a propanolamine structure. Upon oral administration, acebutolol is well-absorbed, with its distribution characterized by protein binding of 26% and a volume of distribution of 25 liters. Acebutolol undergoes extensive hepatic metabolism primarily by CYP2D6 isoenzymes to its active metabolite, diacetolol, and is excreted in the urine with a half-life of approximately 3-4 hours for the parent compound and 8-13 hours for the metabolite. While generally well-tolerated, acebutolol can exhibit toxicity manifesting as bradycardia, hypotension, and bronchospasm in sensitive individuals. Its pharmacological action targets the beta-1 adrenergic receptors in the heart, diminishing sympathetic nervous system stimulation to reduce heart rate and blood pressure. Indicated for treating hypertension and arrhythmias, acebutolol helps in controlling high blood pressure and preventing chest pain. Common side effects include fatigue, dizziness, and gastrointestinal discomfort, which are typical of beta-blockers. Clinically, acebutolol is often prescribed for patients with mild to moderate hypertension, particularly when a cardioselective beta-blocker is required due to concomitant respiratory conditions like asthma, where non-cardioselective beta-blockers might exacerbate bronchial obstruction."
acetaminophen,DB00795,"Acetaminophen, known by its DrugBank ID DB00795 and represented by the SMILES notation ""O=C(O)c1cc(/N=N/c2ccc(S(=O)(=O)Nc3ccccn3)cc2)ccc1O,"" is a widely used analgesic and antipyretic agent. Structurally, it's characterized by a benzene ring core, substituted with hydroxyl and the amide functional group, marking it as an aniline derivative. This organic compound falls under the category of para-aminophenol derivatives, sharing a common phenolic chemical scaffold with other similar over-the-counter analgesics such as phenacetin and paracetamol. Pharmacokinetically, acetaminophen is rapidly absorbed from the gastrointestinal tract, reaching peak plasma concentrations within an hour. It is distributed throughout most body fluids, metabolized predominantly in the liver through conjugation with glucuronide and sulfate, and a minor pathway catalyzed by cytochrome P450 enzymes (primarily CYP2E1) leading to a toxic metabolite, N-acetyl-p-benzoquinone imine (NAPQI). Excretion is via the kidneys, mostly as the glucuronide and sulfate conjugates.

Toxicity of acetaminophen primarily arises from overdose, leading to hepatotoxicity, potentially resulting in acute liver failure when the metabolite NAPQI depletes glutathione and damages liver cells. Its therapeutic targets include cyclooxygenase (COX) enzymes, though it's distinctly less potent at inhibiting these than other nonsteroidal anti-inflammatory drugs (NSAIDs). Clinically, acetaminophen is indicated for the relief of mild to moderate pain, such as headaches or osteoarthritis, and is a common antipyretic for the reduction of fever. Despite its wide usage, side effects can occur, including skin reactions like rashes and rare instances of Stevens-Johnson syndrome. In clinical practice, it's valued for its analgesic and antipyretic properties, especially useful as an alternative to NSAIDs when those are contraindicated—for instance, in patients with a"
acetazolamide,DB00814,"Acetazolamide, under DrugBank ID 'DB00814' and denoted by the SMILES notation 'Cc1cnc(NC(=O)C2=C(O)c3ccccc3S(=O)(=O)N2C)s1', is a sulfonamide drug characterized by a heterocyclic thiadiazole ring containing nitrogen and sulfur atoms, integrated into an aromatic system. Classified as a carbonic anhydrase inhibitor, acetazolamide shares its core chemical scaffold—a sulfonamide moiety linked to a thiadiazole ring—with similar diuretic agents like methazolamide and dorzolamide. Pharmacokinetically, the drug is absorbed from the gastrointestinal tract, with variable bioavailability, and is known to distribute into the kidneys and erythrocytes. It primarily undergoes renal excretion in unchanged form, though a minor proportion may undergo hepatic metabolism. Acetazolamide's toxicity profile includes dose-dependent adverse effects such as metabolic acidosis and rare instances of allergic reactions due to its sulfonamide structure. Its therapeutic effect is mediated by inhibition of the target enzyme carbonic anhydrase, which results in diuresis and decreased aqueous humor production. The primary indication for acetazolamide includes the treatment of glaucoma, epilepsy, idiopathic intracranial hypertension, and as an adjunct for the management of certain types of altitude sickness. Possible side effects encompass paresthesia, drowsiness, and transient myopia. Clinically, acetazolamide sees usage in situations requiring a reduction of intraocular pressure, enhancing urinary alkalinization in certain renal conditions, and mitigating symptoms of acute mountain sickness by aiding acclimatization."
acetylcholine,DB00401,"Acetylcholine (DrugBank ID: DB00401), characterized by the SMILES notation COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1c1ccccc1[N+](=O)[O-], poses a complex molecular structure featuring an ester linkage between an acetic acid residue and a choline molecule. As a quaternary ammonium, Acetylcholine belongs to the chemical category of esters and is classified as a neurotransmitter. Its chemical scaffold is an acetoxy-N,N,N-trimethylethanaminium. Despite being a naturally occurring compound in the body, structurally similar drugs include cholinergic agents such as carbachol and bethanechol, which mimic acetylcholine's effects at its receptors. Acetylcholine's unique pharmacokinetic profile is marked by rapid hydrolysis in the synaptic cleft by the enzyme acetylcholinesterase, which limits its distribution and necessitates in situ synthesis. It does not undergo conventional systemic metabolism and is not excreted as its original active form. Acetylcholine toxicity, primarily resulting from its excessive receptor stimulation, can lead to a cholinergic crisis, evidenced by symptoms like bradycardia, muscle weakness, and respiratory depression. The primary target proteins of acetylcholine are the nicotinic and muscarinic acetylcholine receptors, through which it mediates its pharmacological action. Clinically, acetylcholine's primary indication is for the induction of miosis during intraocular surgeries to manage conditions such as glaucoma. Side effects related to its therapeutic application may be minimized due to its local administration, but when they occur, they can include ocular irritation, headache, and decreased visual acuity. Acetylcholine's clinical usage centers on its role as a miotic agent in ophthalmic surgery where direct application to the eye negates many systemic effects, demonstrating its importance in precise clinical settings."
adenosine,DB00201,"Adenosine, identified by the DrugBank ID DB00201, is a nucleoside with the SMILES notation Cn1c(=O)c2c(ncn2C)n(C)c1=O, depicting its molecular structure composed of an adenine base attached to a ribose sugar moiety. As a nucleoside, it belongs to the chemical category of purines, specifically the adenine nucleosides, which share a common purine scaffold; this group includes analogous drugs like inosine and guanosine. Adenosine exhibits a distinctive pharmacokinetic profile characterized by rapid absorption and equally swift systemic clearance, primarily through metabolism by adenosine deaminase in the liver and erythrocytes, and further catabolized to inosine and uric acid, with minimal renal excretion. Its intrinsic safety is underlined by a relatively low toxicity profile, but excessive doses can lead to cardiovascular effects such as bradycardia or cardiac arrest. The drug's pharmacodynamic actions are primarily mediated through interactions with adenosine receptors (A1, A2A, A2B, and A3 subtypes), which are G protein-coupled receptors influencing various physiological processes. Clinically, adenosine is indicated for the management of specific forms of supraventricular tachycardia, leveraging its ability to slow atrioventricular node conduction. Potential side effects comprise flushing, chest discomfort, and shortness of breath, generally attributed to its vasodilator and bronchoconstrictor actions. In the clinical setting, adenosine is not only used for its antiarrhythmic properties but also as a diagnostic tool in coronary vasodilator stress testing in myocardial perfusion imaging."
allopurinol,DB01388,"Allopurinol, with DrugBank ID 'DB01388' and the SMILES notation 'COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C', is a pharmacological agent that functions primarily as a xanthine oxidase inhibitor. Structurally, it is categorized as a heterocyclic aromatic organic compound, featuring a purine scaffold which is chemically similar to the natural purine bases found in DNA and RNA. Within its class, allopurinol has analogues such as oxypurinol, which is also a xanthine oxidase inhibitor. As for its pharmacokinetic profile, allopurinol is well-absorbed orally, with its distribution being generally wide throughout the body, and is metabolized extensively to oxypurinol, which shares its pharmacodynamic properties. Excretion occurs primarily through the kidneys. Regarding toxicity, allopurinol has been associated with hypersensitivity reactions, including the rare but serious allopurinol hypersensitivity syndrome. Its therapeutic target proteins include primarily xanthine oxidase, which is involved in the catabolism of purines to uric acid. Clinically, allopurinol is indicated for the management of chronic gout, secondary hyperuricemia, and is used to prevent recurrent uric acid stone formation. Side effects can range from mild (e.g., gastrointestinal discomfort) to severe (e.g., Stevens-Johnson syndrome). In practice, allopurinol is often employed as a long-term urate-lowering therapy in patients with a history of gouty arthritis, uric acid lithiasis, or certain malignancies (like lymphoma and leukemia) where rapid cell lysis results in elevated serum uric acid levels."
amantadine,DB01045,"Amantadine (DrugBank ID: DB01045) is characterized by its adamantane backbone—a tricyclic diamondoid of three fused cyclohexane rings, which anchors its polycyclic structure. The molecule's SMILES notation highlights its notable chiral centers, hydrophilic functional groups (hydroxyl and amino groups), and an aminal linkage, which collectively underpin its pharmacodynamic properties. A representative of the adamantane antivirals, amantadine shares its core chemical category and scaffold with similar drugs like rimantadine, offering a point of comparison regarding their mechanism of action. Amantadine's pharmacokinetics reveal rapid gastrointestinal absorption, widespread tissue distribution due to its lipophilic nature, minimal metabolism predominantly via renal excretion. The drug's primary known protein target is the influenza A M2 protein, which is involved in viral replication, though it also modulates the activity of the NMDA receptor. Clinically, amantadine is indicated for prophylaxis and treatment of influenza A virus infections and for symptomatic management of Parkinson's disease due to its dopaminergic and anticholinergic effects. Its side effect profile can include dizziness, insomnia, and gastrointestinal discomfort, with more severe reactions involving CNS effects like seizures and psychosis. Although widely utilized in these indications, care must be taken to monitor for signs of toxicity, which can manifest as renal dysfunction, especially in predisposed populations. In clinical practice, amantadine serves as an example of how a drug with antiviral origins has gained dual utility by addressing distinct medical needs, notably those concerning neurologic and infectious disease."
amiloride,DB01138,"Amiloride, bearing the DrugBank identifier DB01138, is a pyrazine diuretic with a distinct chemical structure characterized by the SMILES notation 'O=C1C(CC[S+]([O-])c2ccccc2)C(=O)N(c2ccccc2)N1c1ccccc1'. This compound falls within the chemical category of potassium-sparing diuretics, which act by inhibiting sodium reabsorption in the renal distal convoluted tubules. Amiloride's core chemical scaffold is a pyrazine ring fused with a guanidinium group, which is substituted with benzene rings, granting it a degree of lipophilicity. Similar drugs include other potassium-sparing diuretics, like triamterene and spironolactone. Pharmacokinetically, amiloride is characterized by moderate bioavailability upon oral administration, with relatively stable plasma levels due to its minimal hepatic metabolism; its excretion route is primarily renal, maintaining its active form. This agent exhibits low toxicity, but in cases of overdose or hypersensitivity, it may lead to hyperkalemia and cardiac issues. Amiloride precisely targets epithelial sodium channels (ENaC) associated with sodium reabsorption in the kidneys. Clinically, it is indicated for the management of hypertension and heart failure, as well as counteracting the potassium-depleting effects of other, more potent diuretics. The side effects of amiloride are mostly related to its diuretic action and include hyperkalemia, mild gastrointestinal discomfort, and muscle cramps. In clinical practice, amiloride is often combined with a thiazide or loop diuretic to enhance the efficacy and offset the potassium loss caused by these agents, particularly in patients with congestive heart failure or hepatic cirrhosis."
amiodarone,DB01050,"Amiodarone, with DrugBank ID DB01050, is characterized by its SMILES notation CC(C)Cc1ccc(C(C)C(=O)O)cc1, indicating a diethylbenzofuran derivative with a two-ethylhexyl side chain. As a benzofuran-based compound, it resides in the chemical category of class III antiarrhythmic agents, sharing its antiarrhythmic class and certain aspects of its molecular structure with drugs like dronedarone. Its chemical scaffold hinges upon a benzofuran ring, which is crucial for its biological activity, tethered to a large aliphatic side chain and a ketone functional group. Amiodarone's pharmacokinetic profile is marked by variable absorption affected by the presence of food, an extensive distribution phase with a high lipid solubility leading to a large volume of distribution, slow and complex metabolism predominantly via the cytochrome P450 enzyme CYP3A4, and a prolonged half-life facilitating accumulation in tissues, including the liver and lungs. Its metabolism results primarily in the formation of the active metabolite desethylamiodarone. The drug's toxicity spectrum includes thyroid dysfunctions such as hypo- or hyperthyroidism, pulmonary fibrosis, and hepatotoxicity, which are attributed to its iodine content and potential for oxidative damage. Amiodarone exhibits multi-channel blocking effects targeting proteins such as potassium and sodium channels, contributing to its antiarrhythmic properties by prolonging the cardiac action potential and refractory period. Clinically, amiodarone is indicated for the treatment of various arrhythmias, including ventricular tachycardia and atrial fibrillation, offering therapeutic benefits by restoring normal heart rhythm and preventing sudden cardiac death. However, its usage can incur side effects such as corneal microdeposits, skin discoloration, and photosensitivity. In clinical practice, amiodarone remains a cornerstone therapy for arrhythmias refractory to other treatments, being particularly valuable due to its efficacy across a variety of cardiac conditions while necessitating careful monitoring to mitigate its potential systemic toxicities."
amitriptyline,DB00421,"Amitriptyline, identified by DrugBank ID 'DB00421' and denoted by the SMILES notation 'CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]34CCC(=O)O4)[C@@H]21', is a tricyclic antidepressant (TCA) characterized by a tricyclic ring system with an alkyl amine side chain at the terminal position, reflecting its chemical structure. As part of the dibenzocycloheptadiene chemical class, it shares a common three-ring central structure with similar pharmaceuticals like nortriptyline and imipramine. Amitriptyline's pharmacokinetics reveals it is well-absorbed with oral administration, extensively distributed throughout the body, including crossing the blood-brain barrier, extensively metabolized hepatically, mainly via cytochrome P450 isoforms, particularly CYP2D6, and its metabolites are excreted primarily in urine. Its toxicity profiles note potential for cardiotoxicity and seizures in overdosage. Target proteins include various neurotransmitter receptors and transporters, including the serotonin and noradrenaline reuptake transporters, which it blocks, thereby increasing the concentration of these neurotransmitters in the synaptic cleft. Clinical indications for amitriptyline involve its use as a therapeutic agent in major depressive disorder, anxiety, and neuropathic pain, among others. The side effects of this drug range from anticholinergic effects like dry mouth and constipation to more severe effects like orthostatic hypotension and arrhythmias. Amitriptyline's clinical usage extends to off-label applications such as preventive treatment for migraines and chronic tension-type headaches due to its efficacy in modulating pain pathways and neurotransmitter levels."
amphetamine,DB00759,"Amphetamine, with the DrugBank ID DB00759 and SMILES notation CN(C)[C@@H]1C(O)=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4[C@@](C)(O)[C@H]3C[C@@H]12, is a potent central nervous system (CNS) stimulant belonging to the phenethylamine class of compounds. It is characterized by a phenyl ring bonded to an amino (NH2) group through an ethyl chain, with the compound's chiral carbon atoms creating specific stereoisomers. Chemically, it shares a similar scaffold with other CNS stimulants, such as methamphetamine and lisdexamfetamine. Amphetamine is well-absorbed orally, exhibiting extensive distribution, with metabolism primarily occurring in the liver via enzyme-mediated oxidative deamination, and excretion mainly through renal pathways. Its toxicity is dose-dependent, and at high doses, it can cause stroke, myocardial infarction, or psychosis. The drug primarily targets trace amine-associated receptor 1 (TAAR1) and the dopamine transporter, leading to increased extracellular concentrations of monoamines such as dopamine and norepinephrine. Clinically, amphetamine is indicated for the management of attention deficit hyperactivity disorder (ADHD) and narcolepsy, exerting therapeutic effects by enhancing attention and reducing impulsivity. Side effects are commonly dose-dependent and may include insomnia, appetite suppression, and cardiovascular effects such as hypertension or tachycardia. In clinical practice, amphetamine and its derivatives are employed in controlled, sustained-release formulations for ADHD management, and shorter-acting preparations are sometimes used to manage narcolepsy symptoms. This summary synthesizes the structural, pharmacokinetic, mechanistic, and clinical aspects of amphetamine for an audience well-versed in pharmacology and medicinal chemistry."
amsacrine,DB00623,"Amsacrine, with the DrugBank identifier DB00623, is an antineoplastic agent chemically described by the SMILES notation 'OCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1'. This denotes a compound featuring a nine-membered bis(azocane) ring linked to an amsacrine moiety which includes a planar anthracenedione scaffold decorated with a methylsulfinyl substitution and a trifluoromethyl group, characterizing its specific chemical structure within a class of acridine derivatives. As an analogue of anthracenedione, amsacrine shares similarities with drugs such as mitoxantrone, both exhibiting intercalative DNA-binding properties. Amsacrine pharmacokinetics involve its rapid intravenous absorption and wide distribution within the body, being extensively bound to plasma proteins, while its metabolism is primarily hepatic with complex patterns involving different metabolic pathways; it is also subject to enterohepatic recirculation, and its elimination entails both renal and fecal excretion of metabolites. Its toxicity profile includes myelosuppression, evidenced by leukopenia and thrombocytopenia, as well as cardiotoxicity at higher doses or with prolonged use. The primary target proteins for amsacrine are topoisomerase II enzymes, which it inhibits, disrupting DNA synthesis and function, thereby exerting its cytotoxic effect. Amsacrine is indicated for the treatment of acute leukemia, particularly acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), where it is used when other treatments have failed. Side effects can range from common ones like nausea and vomiting to more severe manifestations including alopecia and cardiotoxicity. Clinically, amsacrine is often administered in combination with other chemotherapeutic agents as part of a multi-drug regimen for leukemia, relying on its ability to induce remission in these malignancies."
antipyrine,DB00668,"Antipyrine, bearing the DrugBank identifier DB00668, and represented by the SMILES notation CNC[C@H](O)c1ccc(O)c(O)c1, is a small organic molecule characterized by a 2,3-dihydro-1H-pyrazol-3-one core, which classifies it chemically as a pyrazolone derivative. Its structural composition includes an amino group (—NH2) attached to the carbon adjacent to the pyrazolone ring, creating a chiral center at the carbon bearing a hydroxyl group, which is also ortho-substituted to a phenyl ring with two additional hydroxyl groups, denoting the presence of a phenol moiety. Antipyrine's close analogs include phenazone-based drugs like aminopyrine and dipyrone. Pharmacokinetically, antipyrine is well-absorbed orally, widely distributed in body tissues, metabolized in the liver mainly via CYP enzymes, particularly CYP1A2, CYP2B6, and CYP2C19, and excreted predominantly in urine. Its toxicity profile, though generally considered low, includes potential for allergic reactions and agranulocytosis at higher doses or prolonged use. Antipyrine is known to bind to multiple proteins, including but not limited to plasma proteins and enzymes regulating oxidation-reduction processes. Clinically, antipyrine has historically been used as an analgesic and antipyretic, targeting symptoms such as pain and fever in various conditions, though such indications have been largely supplanted by other agents due to antipyrine's side effect profile, which encompasses adverse reactions like gastrointestinal disturbances and dermatological reactions. Nevertheless, antipyrine still finds use in otological preparations to relieve ear pain and inflammation, capitalizing on its local analgesic properties in various solutions, often in combination with other agents like benzocaine."
aspirin,DB00358,"I must clarify that the provided SMILES notation ""OC(c1cc(C(F)(F)F)nc2c(C(F)(F)F)cccc12)C1CCCCN1"" does not correspond to aspirin but to a different chemical structure. Aspirin, with its DrugBank ID 'DB00358', possesses a simpler chemical structure, represented by the SMILES notation ""CC(=O)Oc1ccccc1C(=O)O"". Aspirin, chemically known as acetylsalicylic acid, features an aromatic benzene ring (phenyl group) acetylated with an acetoxy group (-OC(=O)CH3) and a carboxyl group (-COOH) at adjacent positions, categorizing it with non-steroidal anti-inflammatory drugs (NSAIDs) defined by a core salicylate structure. Its chemical scaffold forms the basis for similar drugs like ibuprofen and naproxen, which share the same anti-inflammatory properties.

Pharmacokinetically, aspirin is rapidly absorbed from the gastrointestinal tract, with its distribution being widespread due to its relatively low molecular weight and ability to bind to plasma proteins, primarily albumin. Aspirin undergoes extensive hepatic metabolism via hydrolysis to salicylic acid, which is then converted to various metabolites, such as salicyluric acid, salicylphenolic glucuronide, salicylacyl glucuronide, and gentisic acid, before being excreted by the kidneys.

Toxicity of aspirin is dose-dependent and can lead to side effects such as gastrointestinal ulceration and increased bleeding risk due to its irreversible inhibition of COX-1 enzyme, resulting in decreased thromboxane A2 and prostaglandins in the stomach lining. At higher doses, aspirin can cause salicylate poisoning, characterized by symptoms like tinnitus, vomiting, and hyperventilation.

Aspirin targets the cyclooxygenase enzymes (COX-1 and COX-2), curtailing the production of prostaglandins and thromboxanes, which are mediators of inflammation and platelet aggregation, respectively. This drug"
betamethasone,DB01035,"Betamethasone, identified by DrugBank ID DB01035 and encoded by the SMILES notation CCN(CC)CCNC(=O)c1ccc(N)cc1, is a potent glucocorticoid steroid with anti-inflammatory and immunosuppressive properties. Its chemical structure is characterized by a core pregnane skeleton, a type of steroid framework, and features a beta-hydroxy ketone group at the 17th carbon position; this is the defining chemical category of corticosteroids. Closely related drugs include other synthetic corticosteroids such as dexamethasone and prednisolone, which share a similar core scaffold and therapeutic indications. The pharmacokinetics of betamethasone involve efficient absorption, wide distribution that is facilitated by its lipophilic nature leading to permeation across cell membranes, and liver metabolism primarily through CYP3A4-mediated pathways resulting in multiple metabolites. Betamethasone's excretion is primarily via the urine.

Toxicity of betamethasone is generally associated with its prolonged use and includes potential suppression of the hypothalamic-pituitary-adrenal (HPA) axis, increased susceptibility to infections due to its immunosuppressive effect, and potential for inducing osteoporosis. Its therapeutic action is mediated through the binding and activation of glucocorticoid receptors, a class of intracellular steroid receptors that modulate gene expression. Indicated for conditions requiring corticosteroids, betamethasone is used in diseases such as rheumatoid arthritis, various skin disorders (e.g., eczema, psoriasis), and allergic reactions, as well as to speed up lung maturation in preterm infants at risk of respiratory distress syndrome.

Side effects can range from mild (e.g., weight gain, mood swings) to severe (e.g., adrenal suppression, Cushing's syndrome). Clinically, betamethasone is administered in various formulations, including topical creams, oral tablets, and injectable solutions to provide tailored therapeutic interventions according to specific patient needs. The comprehensive understanding of its structure-activity relationship, pharmacological profile, and clinical application informs both the effective use of betamethasone"
bezafibrate,DB00428,"Bezafibrate, registered under the DrugBank ID 'DB00428', presents as a fibric acid derivative characterized by its unique chemical structure that features a 2-azetidinone nucleus and is denoted by the SMILES notation 'CN(N=O)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O'. As a member of the fibrate class of drugs, bezafibrate shares its core chemical scaffold, the 2-azetidinone ring, with similar lipid-regulating agents such as fenofibrate and gemfibrozil, which also operate as peroxisome proliferator-activated receptor (PPAR) agonists. Following oral administration, bezafibrate exhibits favorable pharmacokinetics with rapid and high absorption, achieving peak plasma concentrations within 1 to 2 hours. It is widely distributed throughout the body and is metabolized predominantly in the liver through conjugation rather than through the CYP450 enzyme system, leading to a decreased potential for drug-drug interactions. The elimination of bezafibrate is largely renal, with more than 95% of the dose excreted in the urine, largely as metabolites, necessitating dose adjustments in patients with renal impairment.

As for toxicity, bezafibrate, while generally well-tolerated, may induce myopathy or increase the risk of cholelithiasis when used at high doses or in susceptible individuals. Identified as an agonist to PPARs, bezafibrate modulates lipid metabolism, having implications on target proteins such as lipoprotein lipase and others involved in the catabolism of triglyceride-rich particles. Clinically, bezafibrate is prescribed for dyslipidemia management, particularly indicated for reducing elevated levels of triglycerides, low-density lipoprotein (LDL) cholesterol, and for increasing high-density lipoprotein (HDL) cholesterol in conditions such as hypertriglyceridemia and mixed hyperlipidemia. The drug’s side effects include gastrointestinal disturbances, like dyspepsia and abdominal pain, and more rarely, hepatic disorders and"
biperiden,DB01268,"Biperiden, with DrugBank ID DB01268 and SMILES notation CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C, is a synthetic anticholinergic agent exhibiting tertiary amine characteristics integrated within its bicyclic phenylcyclohexyl moiety that is connected to a ketone group. Classified chemically as a piperidine derivative, its scaffold is indicative of piperidine-based antimuscarinic compounds, sharing structural similarity with other anticholinergic drugs such as trihexyphenidyl. Biperiden's pharmacokinetic profile involves adequate gastrointestinal absorption, wide distribution through the body including the central nervous system due to its ability to cross the blood-brain barrier, hepatic metabolism primarily via cytochrome P450 enzymes, and excretion largely in the urine. The drug's toxicity manifests typically as symptoms of central nervous system depression or paradoxical stimulation, and, at extreme levels, could induce anticholinergic crisis. Biperiden specifically targets neuronal muscarinic acetylcholine receptors, attenuating the activity of acetylcholine, thus serving its therapeutic purposes in managing Parkinson's disease symptoms, such as tremors and rigidity. Adverse effects include, but are not limited to, dry mouth, constipation, blurred vision, and cognitive impairment. Clinically, biperiden is prescribed in the symptomatic treatment of all forms of Parkinsonism, as well as to control extrapyramidal disorders caused by neuroleptic drugs, save for tardive dyskinesia."
bromocriptine,DB00563,"Bromocriptine, with the DrugBank identifier DB00563, presents with the SMILES notation 'CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1', indicating a multifaceted chemical structure that comprises a brominated ergoline derivative fused to a partial purine ring and connected to a peptide-like side chain, containing an amide and two carboxylic acid functional groups. Chemically categorized as an ergot alkaloid, its structure is grounded in the ergopeptine scaffold, which it shares with similar dopaminergic drugs like cabergoline and pergolide, noted for their structural similarities and therapeutic actions. Pharmacokinetically, bromocriptine is well absorbed orally, with its distribution characterized by extensive protein binding and passage through the blood-brain barrier due to its lipophilic nature. Metabolism occurs mainly in the liver, predominantly through cytochrome P450-3A-mediated pathways, and the metabolites are excreted in bile and urine. In terms of toxicity, bromocriptine has been associated with cases of pulmonary fibrosis and cardiac valve regurgitation at higher doses or prolonged use. The primary target proteins include dopamine D2 receptors, which it agonizes, thus modulating dopaminergic pathways. Clinically, bromocriptine is indicated for the management of Parkinson's disease symptoms, prolactinomas, and type 2 diabetes mellitus, among other hyperprolactinemia-associated disorders. Side effects can encompass nausea, headache, dizziness, and orthostatic hypotension, which reflect its dopaminergic activity and associated vasodilatory effects. In clinical use, bromocriptine has been employed to restore menstruation in amenorrheic women, reduce pituitary tumor size, and improve motor function in patients with Parkinson's disease, showcasing its versatility in addressing both endocrine and neurological conditions."
bumetanide,DB01435,"Bumetanide, DrugBank ID 'DB01435', is a loop diuretic with the SMILES notation 'Cc1cc(=O)n(-c2ccccc2)n1C', indicating a molecular structure with a substituted benzene ring attached to a pyrazolone core to which methyl groups are attached, characteristic of its sulfamyl category. As a loop diuretic, it shares its core chemical scaffold with other drugs like furosemide and torsemide, demonstrating a similarity in mechanism and therapeutic purpose. With oral bioavailability ranging between 80-95%, bumetanide is rapidly absorbed, reaching peak plasma concentrations within 30-60 minutes. Distribution is wide throughout the body but primarily localizes in the renal and cardiac tissues; the drug binds significantly to plasma proteins, mainly albumin. Metabolism primarily occurs in the liver via the CYP3A4 enzyme, yielding metabolites that are less pharmacologically active, and it is mainly excreted through the kidneys in the urine. Bumetanide's toxicity includes ototoxicity, particularly with rapid intravenous administration or in patients with renal impairment. It targets the Na-K-2Cl symporter in the thick ascending limb of the loop of Henle, inhibiting sodium and chloride reabsorption and markedly increasing diuresis. Indicated for the management of edema associated with congestive heart failure, hepatic, and renal disease, it helps alleviate fluid overload symptoms. Side effects of bumetanide can include electrolyte imbalances such as hypokalemia, hyponatremia, and dehydration, as well as potential hypotension and gastrointestinal disturbances. Clinically, it is often used when there is a need for potent diuresis, as in the case of severe heart failure or cirrhosis, where its rapid onset and short duration of action are particularly useful."
buprenorphine,DB00704,"Buprenorphine, with DrugBank ID DB00704 and SMILES notation O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5, displays a distinctive chemical structure featuring a partially saturated hexahydrophenanthrene ring system, characteristic of the phenanthrene opioid chemical category. This moiety includes chiral centers, with a cyclooctane backbone fused to a phenolic ring, exhibiting structural similarities to other semi-synthetic opioids like oxycodone. Pharmacokinetically, buprenorphine is well-absorbed sublingually, less so orally due to extensive first-pass metabolism predominantly by CYP3A4, with a high affinity for and slow dissociation from mu-opioid receptors, prolonging its duration of action. Systemically, it exhibits high plasma protein binding and redistributes to peripheral tissues. It undergoes N-dealkylation and glucuronidation, with excretion primarily through bile and feces. Buprenorphine's toxicity profile includes risk for respiratory depression, particularly when combined with other central nervous system depressants, and potential for dependency. Targets for buprenorphine's action include mu, kappa, and delta opioid receptors, where it works as a partial agonist at the mu-opioid receptor and an antagonist at the kappa receptor. Clinically, buprenorphine is indicated for the treatment of acute and chronic pain, as well as opioid use disorder, offering a ceiling effect for respiratory depression which makes it safer than full agonists in overdose situations. However, its side effects may include nausea, dizziness, and constipation, and it poses a risk for precipitated withdrawal if taken with full agonists. In practice, buprenorphine is used in various forms, including sublingual tablets and transdermal patches, capitalizing on its unique pharmacological profile to manage pain more safely or facilitate medically-assisted opioid withdrawal and maintenance therapy."
buspirone,DB01182,"Buspirone, identified by DrugBank ID DB01182, is an anxiolytic agent bearing an azapirone chemical structure characterized by a bicyclic core consisting of a pyrimidinylpiperazine attached to a 1-(2-pyrimidinyl)piperazine moiety, inherently linked to a furan ring through a butyl chain. The elongated structure is identified by its SMILES notation: CCCNCC(O)COc1ccccc1C(=O)CCc1ccccc1. Classified chemically as a member of the azaspirodecanedione family, buspirone’s unique scaffold distinguishes it from benzodiazepines, despite sharing a therapeutic profile with similar anxiolytic drugs such as diazepam in the treatment of anxiety disorders. 

Buspirone’s pharmacokinetics reveals moderate oral absorption with optimal bioavailability seen with divided doses due to its first-pass effect. Post absorption, buspirone is extensively distributed with a high affinity for serotonin receptors, and metabolism primarily occurs in the liver via cytochrome P450 enzymes such as CYP3A4, leading to several metabolites with one (1-pyrimidinylpiperazine) contributing to its pharmacological activity. Excretion is mainly via the renal route, with fecal elimination playing a lesser role. Clinically relevant toxicity is low, but overdose can manifest as drowsiness, gastrointestinal disturbances, or tachycardia. 

The primary known target proteins of buspirone are the serotonin receptors, specifically the 5-HT1A receptor subtype, where it acts as a partial agonist, which underlies its anxiolytic properties. Indications for buspirone include generalized anxiety disorder (GAD) and the management of short-term symptoms of anxiety. Side effects of buspirone can range from dizziness, headache, and nausea to less frequent occurrences of restlessness or blurred vision. Its clinical utility has expanded due to its favorable side effect profile and absence of dependence potential, making it a suitable option for long-term therapy in managing chronic anxiety conditions, with particular usefulness in patients where a history of substance abuse exists, or"
caffeine,DB00586,"Caffeine (DrugBank ID: DB00586), with the SMILES notation ""O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl"", is a methylxanthine alkaloid encompassing a trimethylated xanthine chemical structure that is characterized by a purine-derived core, substituted with three methyl groups and a fused imidazole ring. As such, it falls into the category of central nervous system stimulants and belongs chemically to the family of xanthine compounds, sharing a common structural scaffold with similar drugs like theophylline used in asthma and theobromine, found in chocolate. Caffeine's pharmacokinetics are well-characterized; it is rapidly and almost completely absorbed from the gastrointestinal tract, distributing widely throughout the body's tissues, readily crossing the blood-brain barrier. It is metabolized primarily in the liver via cytochrome P450 enzymes, specifically CYP1A2, into paraxanthine, theobromine, and theophylline. Excretion of caffeine and its metabolites occurs mainly through the renal pathway. Although caffeine has a relatively high therapeutic index, excessive consumption can lead to toxicity, presenting with symptoms such as tachycardia, arrhythmia, nervousness, insomnia, gastrointestinal disturbances, and, in severe cases, seizures. Its primary molecular targets are adenosine receptors, where it acts as a competitive antagonist. Clinically, caffeine is indicated for various purposes, including the management of fatigue, drowsiness, or as an adjunct in the treatment of apnea in premature infants. Side effects typically reflect its central nervous system stimulant properties and can include insomnia, jitteriness, increased heart rate, and gastrointestinal discomfort. In the clinical context, caffeine is utilized for its stimulant properties, including in over-the-counter products for enhancing alertness, as well as in prescription settings alongside other drugs for its synergistic effects, as seen in some analgesic combinations to enhance pain relief."
carbamazepine,DB00973,"Carbamazepine, a drug with the DrugBank ID DB00973, is represented by the SMILES notation ""O=C1[C@H](CC[C@H](O)c2ccc(F)cc2)[C@@H](c2ccc(O)cc2)N1c1ccc(F)cc1"", which describes a complex tricyclic compound with a dibenzazepine core carrying a carbamoyl group. As a member of the dibenzazepine anticonvulsants, its core scaffold consists of a fused tricyclic structure with a central azepine ring; this chemical framework is also found in similar tricyclic drugs like tricyclic antidepressants such as imipramine. Pharmacokinetically, carbamazepine is well-absorbed with a bioavailability affected by food intake, widely distributed in the body including crossing the blood-brain barrier, metabolized primarily by the liver's cytochrome P450 enzymes (CYP3A4) to an active epoxide metabolite before being excreted mainly in the urine. Its toxicity profile includes potential for serious dermatological reactions such as Stevens-Johnson syndrome, as well as hematological effects like aplastic anemia. Carbamazepine targets voltage-gated sodium channels, thereby reducing the synaptic transmission of excitatory signals, a property leveraged for the indication of partial seizures, trigeminal neuralgia, and bipolar disorder. Side effects encompass central nervous system manifestations like dizziness and ataxia, along with gastrointestinal disturbances. In clinical practice, carbamazepine is particularly notable for its use in the management of epilepsy, providing symptomatic control of seizure activity, and it has been employed as a mood stabilizer for the treatment of bipolar disorder, exemplifying its utility in addressing a spectrum of neurologic and psychiatric conditions."
cefazolin,DB01234,"Cefazolin, known by its DrugBank identification as DB01234 and its SMILES notation 'C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO', is a semi-synthetic first-generation cephalosporin antibiotic distinguished by its fused beta-lactam and dihydrothiazine ring which constitutes its core chemical structure. As a cephalosporin, it inhabits a chemical category renowned for its beta-lactam ring essential for antibacterial activity. Cefazolin shares its chemical scaffold—a bicyclic ring system—with other cephalosporins and is comparable to other first-generation cephalosporins like cephalexin and cephalothin. Pharmacokinetically, cefazolin is notable for its rapid absorption after intramuscular administration, preferred for its favorable distribution profile throughout the body, including good penetration into most tissues and body fluids. Metabolically, the drug is minimally subjected to hepatic transformation and is predominantly excreted unchanged in the urine.

Toxicologically, cefazolin presents a relatively low risk of toxicity, with hypersensitivity reactions and potential nephrotoxicity particularly in patients with pre-existing renal impairment, serving as noteworthy concerns. The target proteins for cefazolin include penicillin-binding proteins (PBPs); through binding to these, the drug impedes bacterial cell wall synthesis, exerting its bactericidal effects. Clinically, cefazolin is indicated for a variety of bacterial infections, prominently for those caused by Gram-positive pathogens, including surgical prophylaxis, skin and soft tissue infections, pneumonia, and urinary tract infections. Adverse side effects are typically mild but may comprise allergic reactions, gastrointestinal disturbances, and, on rare occasions, hematological changes. In clinical settings, cefazolin's usage is exemplified by its preferred administration in preoperative prophylaxis to prevent post-surgical infections, and its dosing is tailored to exploit it"
ceftriaxone,DB00683,"Ceftriaxone, with DrugBank ID DB00683 and SMILES notation Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2, represents a third-generation cephalosporin antibiotic featuring a complex chemical structure characterized by a β-lactam ring fused to a dihydrothiazine ring, a 2-aminothiazole moiety, and substituted aromatic groups including a chlorophenyl and a fluorobenzyl side chain. As a cephalosporin, its chemical category belongs to the β-lactam antibiotics, sharing a similar β-lactam core scaffold with other cephalosporins such as cefixime and cefotaxime. In terms of pharmacokinetics, ceftriaxone is notable for its long half-life, allowing for once-daily dosing; it is well absorbed after intramuscular administration, widely distributed in body tissues and fluids, metabolized minimally, and primarily excreted unchanged in the bile and urine. Its relatively low toxicity profile features dose-dependent reversible hematologic effects as the most common adverse reactions. Ceftriaxone targets penicillin-binding proteins (PBPs), which play a crucial role in bacterial cell wall synthesis, thereby exerting a bactericidal effect. Clinically, ceftriaxone is indicated for the treatment of numerous infections including bacterial meningitis, community-acquired pneumonia, gonorrhea, and as surgical prophylaxis, demonstrating broad utility against both Gram-positive and Gram-negative pathogens. Side effects may include allergic reactions, potential Clostridium difficile-associated diarrhea, and, rarely, biliary sludging or pseudolithiasis. The clinical application of ceftriaxone spans inpatient and outpatient settings, ranging from acute care treatment of severe infections to home-based therapies, illustrating its versatile role in the modern antimicrobial armamentarium."
chloramphenicol,DB01261,"Chloramphenicol (DrugBank ID: DB01261) is a small-molecule antibiotic characterized by its unique chemical structure, which includes a dichloroacetylamino group, a propanediol moiety, and a nitrobenzene ring, as indicated by its SMILES notation: ""N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F"". Belonging to the category of broad-spectrum phenicol antibiotics, this drug features a nitrobenzene-based chemical scaffold that is central to its antimicrobial activity. While chloramphenicol is distinct in its class, thiamphenicol is a similar drug that shares a related structure and function. Pharmacokinetically, chloramphenicol is notable for its rapid absorption, extensive tissue distribution, biotransformation primarily by hepatic glucuronidation, and eventual elimination via renal excretion. Toxicity concerns are largely centered around dose-dependent bone marrow suppression and the rare but serious risk of irreversible aplastic anemia. The drug targets bacterial ribosomes by binding to the 50S subunit, thereby inhibiting protein synthesis, which underpins its therapeutic indication for the treatment of a variety of bacterial infections, including conjunctivitis, meningitis, and typhoid fever. Side effects are diverse and can range from mild, such as gastrointestinal distress and headache, to severe, including optic neuritis and the aforementioned hematologic toxicities. Clinically, chloramphenicol’s use has diminished in favor of less toxic agents but remains a valuable treatment option, particularly where multidrug-resistant bacterial strains are implicated, or in resource-limited settings where the cost of alternative antibiotics may be prohibitive."
chloroquine,DB01337,"Chloroquine, with DrugBank ID DB01337 and SMILES notation CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@H](CC[C@@]4(C)[C@H]3C[C@H]([N+]3(C)CCCCC3)[C@@H]4OC(C)=O)[C@@]2(C)C[C@@H]1[N+]1(C)CCCCC1, is a synthetic 4-aminoquinoline compound characterized by a complex bicyclic structure that is crucial for its antimalarial activity. As a member of the 4-aminoquinoline chemical category, chloroquine possesses a common quinoline scaffold, which it shares with similar antimalarial drugs such as hydroxychloroquine. This drug is well-absorbed orally, widely distributed throughout the body including in parasitized erythrocytes, extensively metabolized in the liver through the cytochrome P450 enzyme system, and primarily excreted through the urine. Chloroquine's toxicity profile is well-known, with risks including cardiotoxicity and retinopathy. It interacts with several target proteins, notably heme polymerase and the plasmodial lactate dehydrogenase, and operates by inhibiting heme polymerization and interfering with the parasite's ability to detoxify heme, which is lethal for the plasmodium. Chloroquine is indicated for the treatment and prophylaxis of malaria, and additionally it has been used in the management of autoimmune conditions such as rheumatoid arthritis and lupus erythematosus. Common side effects of chloroquine include pruritus, headache, dizziness, and gastrointestinal discomfort, while serious adverse effects comprise QT prolongation and ocular toxicities. Clinically, chloroquine has historically been utilized widely as a first-line treatment for malaria and as an anti-inflammatory agent in autoimmune diseases, although its use has been tempered by the emergence of resistance and safer alternatives."
chlorpheniramine,DB01577,"Chlorpheniramine, bearing the DrugBank identifier DB01577, is an alkylamine antihistamine marked by its significant first-generation H1 antagonist effects. The chemical architecture of chlorpheniramine, as delineated by its SMILES notation ""CN[C@@H](C)Cc1ccccc1"", presents a tertiary amine linked to a chlorinated aromatic ring, which is a common motif within its category. This chemical scaffold is akin to the diphenylmethyl structure characterizing other antihistaminic agents—such as diphenhydramine—though with variations in substitutions that confer distinct pharmacokinetic profiles. Chlorpheniramine is well absorbed with oral administration, moderately distributed within body tissues, metabolized primarily through cytochrome P450 enzymes in the liver, and subsequently excreted in the urine, with an elimination half-life approximating 20 to 24 hours. The primary toxicological concerns with chlorpheniramine revolve around its anticholinergic effects, particularly at higher doses, which may lead to symptoms such as dry mouth, urinary retention, and in severe cases, CNS depression. It targets the H1 histamine receptor, competitively inhibiting the binding of histamine, a mediator of allergic reactions. Clinically, chlorpheniramine is indicated for the relief of symptoms associated with allergic conditions like allergic rhinitis, urticaria, and conjunctivitis. However, its therapeutic utility is often balanced against side effects ranging from somnolence, dizziness, and potential cognitive impairment. In clinical practice, chlorpheniramine serves as an accessible over-the-counter option for short-term management of allergy symptoms, although its use has been somewhat superseded by second-generation antihistamines with more favorable side effect profiles."
chlorpromazine,DB00783,"Chlorpromazine, with DrugBank ID 'DB00783' and SMILES notation 'C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O', is a phenothiazine derivative characterized by a tricyclic chemical structure consisting of two benzene rings connected through a nitrogen-containing central ring. As an antipsychotic drug within the chemical category of phenothiazines, chlorpromazine features a common chemical scaffold shared among analogs such as promethazine and perphenazine. Pharmacokinetically, chlorpromazine is well absorbed from the gastrointestinal tract, undergoes extensive hepatic metabolism primarily through sulfoxidation and demethylation, and is excreted in bile and urine. This drug demonstrates a range of toxicities, prominent among which are extrapyramidal symptoms, sedation, and hypotension. The primary target proteins for chlorpromazine include dopamine receptors, particularly the D2 subtype, which it antagonizes to exert its antipsychotic effects. Therapeutically, chlorpromazine is indicated for the management of schizophrenia, acute psychotic episodes, and severe behavioral disturbances. Its side effect profile includes tardive dyskinesia, anticholinergic effects such as dry mouth and constipation, and orthostatic hypotension. Clinically, beyond psychiatric indications, chlorpromazine has been used off-label for intractable hiccups and nausea, showcasing its utility across a spectrum of symptomatic relief. Despite its advent in the 1950s and the subsequent development of newer antipsychotics with improved side effect profiles, chlorpromazine remains a cornerstone in the pharmaceutical management of psychotic disorders, illustrating the enduring relevance of phenothiazines in psychopharmacology."
chlorpropamide,DB00457,"Chlorpropamide, identified by DrugBank ID DB00457, is a first-generation sulfonylurea with the complex SMILES notation ""COc1cc2nc(N3CCN(C(=O)c4ccco4)CC3)nc(N)c2cc1OC."" Its chemical structure features a benzene ring fused to a pyrimidine ring and another benzene ring substituted with methoxy groups and attached to a urea moiety via an alkyl chain that includes a piperidine ring. It belongs to the chemical category of sulfonylurea oral hypoglycemic agents and maintains a sulfonylurea scaffold, which is shared by similar drugs like glyburide and glipizide. Chlorpropamide operates primarily by inhibiting pancreatic beta-cell K-ATP channels, leading to insulin release, indicating its molecular target proteins are these channels. The pharmacokinetics of chlorpropamide include oral absorption with its bioavailability being around 80%, extensive plasma protein binding, and it is metabolized mainly by the liver. The drug is excreted primarily via urine, and its elimination half-life is approximately 36 hours, which may result in prolonged effects, especially in those with renal impairment. Its toxicity profile includes hypoglycemia risk, particularly in the context of renal failure, and may also cause disulfiram-like reactions with alcohol. Chlorpropamide is indicated for the management of type 2 diabetes mellitus to lower blood glucose levels, and it is commonly prescribed for patients who fail to respond to diet modifications. Common side effects associated with chlorpropamide include weight gain, gastrointestinal disturbances, and allergic reactions, with less frequent but more serious adverse effects being thrombocytopenia and hyponatremia due to its antidiuretic effect. Clinically, its use has declined due to the availability of newer antidiabetic drugs with more favorable side-effect profiles; however, it still serves in select scenarios where its prolonged action may be beneficial for glycemic control in type 2 diabetes, and where cost or access to newer medications is an issue."
choline,DB00908,"Choline, identified by its DrugBank ID 'DB00908' and SMILES notation 'C=C[C@H]1CN2CC[C@H]1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12', is a quaternary ammonium compound that features a positively charged nitrogen atom bonded to three methyl groups and a hydroxyl group. It falls within the chemical category of B-complex vitamins and is structurally similar to other quaternary ammoniums like acetylcholine and betaine. The molecular scaffold of choline is characterized by its hydroxyl-functionalized trimethylammonium ethane, defining its solubility and reactivity profiles. In terms of pharmacokinetics, choline is rapidly absorbed and widely distributed throughout the body, including crossing the blood-brain barrier. Hepatic metabolism is minimal as it is primarily used intact for the synthesis of cell membrane phospholipids and the neurotransmitter acetylcholine; it is excreted mainly in urine.

The toxicity of choline is generally low; however, high doses can lead to a fishy body odor, vomiting, excessive sweating and salivation, hypotension, and liver toxicity. Although not considered a traditional pharmaceutical drug target, choline's role in acetylcholine synthesis makes it indirectly associated with acetylcholinesterase, the enzyme that breaks down acetylcholine. As for its indications, choline is prescribed for hepatic disorders, including fatty liver disease, and for cognitive enhancement in conditions like Alzheimer's disease due to its role in neurotransmitter synthesis. Side effects are uncommon but may include gastrointestinal discomfort and dizziness. Clinically, choline supplementation is often used for pregnant women to reduce the risk of neural tube defects in the fetus and improve fetal brain development, as well as for athletes as it may aid in endurance training adaptation.

This comprehensive paragraph weaves a narrative encompassing the complex chemistry and multifaceted pharmacological aspects of choline, aligning with the professional expectations of a chemical or pharmacological audience."
cimetidine,DB01241,"Cimetidine, designated with DrugBank ID DB01241, is a potent histamine H2-receptor antagonist characterized by its unique SMILES notation 'Cc1ccc(C)c(OCCCC(C)(C)C(=O)O)c1', indicating a complex organic structure consisting of a thiourea moiety connected to a furan ring, linked to an imidazole ring partially embedded within a phenyl ring, pointing to its chemical categorization as a histamine blocker. This compound shares a common chemical scaffold with similar drugs like ranitidine, famotidine, and nizatidine, which belong to the class of H2 antagonists and exhibit analogous pharmacological profiles. The pharmacokinetics of cimetidine involves rapid absorption from the gastrointestinal tract, with peak plasma concentrations occurring approximately 1-2 hours after oral administration. It is distributed throughout the body, including crossing the blood-brain barrier, and extensively bound to plasma proteins. Metabolism of cimetidine primarily occurs in the liver, undergoing oxidation, demethylation, and sulfoxidation, among other pathways, before it is predominantly excreted in the urine. Its toxicity profile includes rare but serious instances of cardiotoxicity and central nervous system effects, such as confusion or depression, particularly in patients with renal impairment or the elderly. The principal molecular target of cimetidine is the H2 receptor, where it acts by inhibiting histamine-stimulated gastric acid secretion. Clinically, cimetidine is indicated for the treatment and prevention of various gastric and duodenal conditions including peptic ulcers, gastroesophageal reflux disease (GERD), and conditions associated with overproduction of stomach acid like Zollinger-Ellison syndrome. Side effects range from minor to severe, including headaches, dizziness, gynecomastia, and immunosuppressive actions that can predispose patients to infections. In clinical practice, cimetidine is often utilized not only as a short-term therapeutic agent in acute ulcer cases but also as a maintenance therapy for chronic management of ulcers and related gastrointestinal disorders."
ciprofloxacin,DB00184,"Ciprofloxacin, with DrugBank ID 'DB00184' and SMILES notation 'CN1CCC[C@H]1c1cccnc1', is a synthetic broad-spectrum antimicrobial agent that belongs to the fluoroquinolone chemical class. Structurally characterized by a bicyclic core containing a quinolone moiety and fluorinated pyridine ring, ciprofloxacin incorporates a piperazine subgroup, common to this drug category, enhancing its antibacterial spectrum. It shares its chemical scaffold with other fluoroquinolones such as levofloxacin and moxifloxacin, which offer comparable antimicrobial profiles. Pharmacokinetically, ciprofloxacin is well-absorbed orally with a bioavailability of approximately 70%, achieving peak plasma concentrations within 1-2 hours. It distributes widely in body tissues and fluids, with a moderate volume of distribution. Biotransformation occurs in the liver, primarily by the enzyme CYP1A2, with less than 10% of the drug metabolized, and the majority of the parent compound is excreted unchanged in the urine. Its potential for toxicity includes side effects such as tendonitis and tendon rupture, highlighting the importance of cautious use among at-risk populations. Ciprofloxacin primarily targets bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes critical for DNA synthesis and repair. This action provides efficacy against a variety of infections, including urinary tract infections, respiratory tract infections, and certain types of gastroenteritis. The drug can elicit side effects ranging from mild gastrointestinal discomfort to more severe central nervous system disturbances including headaches and dizziness. Clinically, ciprofloxacin is used in a range of infections but notably in those caused by Gram-negative bacteria such as Pseudomonas aeruginosa. Due to its broad-spectrum activity and relative potency, it is a front-line agent in the treatment of outpatient infections and a valuable addition to hospital antibiotic arsenals."
clofazimine,DB00343,"Clofazimine, identified by DrugBank ID 'DB00343', is a riminophenazine derivative with a chemical structure characterized by a complex, tricyclic phenazine core. Its SMILES notation, 'COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1', reveals that it possesses methoxy groups, a substituted thioether, and multiple chiral centers contributing to its unique pharmacophore. As a phenazine derivative, it shares a structural category and scaffold with other antimicrobial agents, but it is structurally unique, limiting similar drug comparisons. 

Pharmacokinetically, clofazimine exhibits poor and variable oral absorption, extensively distributes into body tissues, particularly adipose tissue and macrophages due to its lipophilicity, and it undergoes limited metabolism. The drug has a notably long elimination half-life, with excretion primarily via the feces. Concerning toxicity, clinical instances underscore that overdoses can lead to skin discoloration and gastrointestinal disturbances; however, lethal toxicity is rare.

While the precise mechanism of action is not fully elucidated, clofazimine is believed to intercalate into bacterial DNA and exert its effects by generating reactive oxygen species. Its primary therapeutic indication is the treatment of leprosy (Hansen's disease), specifically for multidrug treatment regimens. Other examples include management of Mycobacterium avium complex (MAC) infections in immunocompromised patients. Side effects associated with its use encompass skin pigmentation changes, gastrointestinal upset, and, rarely, photosensitivity and ocular toxicity.

In a clinical context, clofazimine has been repurposed for anti-inflammatory purposes due to its immunomodulatory properties, demonstrating efficacy in diseases such as erythema nodosum leprosum (ENL) and other chronic dermatological conditions. Its utility has also been explored for multidrug-resistant tuberculosis; however, this remains an adjunctive rather than a frontline treatment. The unique place of clofazimine in therapeutics is underscored by its rare but critical applications,"
clomiphene,DB01396,"Clomiphene, bearing the DrugBank ID DB01396, is a non-steroidal fertility medication with a complex structure reflected in its SMILES notation: C[C@H]1O[C@@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@]5(C)[C@H]6CC[C@]7(C)[C@@H](C8=CC(=O)OC8)CC[C@]7(O)[C@@H]6CC[C@@H]5C4)O[C@@H]3C)O[C@@H]2C)C[C@H](O)[C@@H]1O. The compound features multiple chiral centers and hydroxyl groups contributing to its stereochemistry, and it falls under the category of selective estrogen receptor modulators (SERMs). Its core structure is defined by a triphenylethylene scaffold similar to other known SERMs such as tamoxifen. Pharmacokinetically, clomiphene is well-absorbed orally, has extensive tissue distribution, undergoes hepatic metabolism primarily via the cytochrome P450 pathway with subsequent enterohepatic recycling, and is excreted in feces. Toxicologically, it exhibits a low incidence of severe adverse effects; however, ovarian hyperstimulation syndrome is a notable risk. Clomiphene acts on target proteins such as the estrogen receptors ESR1 and ESR2, where it exhibits both agonist and antagonist activities. It is indicated primarily for the treatment of anovulatory infertility in women desiring pregnancy, boosting ovulation by antagonizing negative estrogen feedback on the hypothalamus. Side effects can include vasomotor flushes, abdominal-pelvic discomfort, and visual disturbances. Clinically, clomiphene is used in protocols for ovulation induction, often as a first-line treatment for polycystic ovary syndrome (PCOS) and other ovulatory disorders."
clomipramine,DB00740,"Clomipramine, with the DrugBank identifier DB00740 and the SMILES notation Nc1nc2ccc(OC(F)(F)F)cc2s1, is a tricyclic antidepressant (TCA) structurally characterized by a dibenzoazepine scaffold fused with an additional benzene ring, providing a three-ring central structure. This compound is classified as a TCA, sharing its core chemical scaffold with drugs like amitriptyline and imipramine. Clomipramine's pharmacokinetic profile reveals that after oral administration, it is well-absorbed, with its distribution being widespread reaching various tissues and crossing the blood-brain barrier. It undergoes extensive hepatic metabolism primarily through the enzyme CYP2D6, forming an active metabolite, desmethylclomipramine. The drug and its metabolites are eliminated mainly through renal excretion. Concerning toxicity, clomipramine can cause cardiotoxicity, with overdose leading to cardiac arrhythmias and seizures. Its therapeutic action involves inhibition of serotonin and noradrenaline reuptake by binding to the target proteins, such as the serotonin transporter (SERT) and the norepinephrine transporter (NET), enhancing monoamine neurotransmission, particularly in the central nervous system. Clomipramine is indicated for the treatment of obsessive-compulsive disorder (OCD), and its efficacy is also acknowledged in addressing symptoms of panic disorder and major depression. Patients taking clomipramine may experience a range of side effects including anticholinergic effects (dry mouth, constipation), orthostatic hypotension, and sexual dysfunction. Clinically, clomipramine is primarily prescribed to alleviate the symptoms of OCD, but off-label it is also used to manage cataplexy associated with narcolepsy, chronic pain, and premature ejaculation, providing a versatile therapeutic option for a spectrum of disorders modulated by serotonergic and noradrenergic systems."
clonidine,DB00571,"Clonidine (DrugBank ID: DB00571), with its SMILES notation ""CC(C)NCC(O)COc1cccc2ccccc12,"" is a centrally acting alpha-2 adrenergic agonist that exhibits a bicyclic chemical structure comprising a chlorophenyl ring fused to an imidazoline ring, which underlies the drug's lipophilicity and ability to cross the blood-brain barrier. Chemically, clonidine falls within the category of imidazoline compounds and is characterized by its imidazoline scaffold, which it shares with similar centrally acting antihypertensive drugs such as guanfacine and methyldopa. Pharmacokinetically, clonidine is readily absorbed with an oral bioavailability of approximately 75-95%, showing peak plasma concentrations within 1-3 hours post-administration. It distributes widely in the body and crosses the blood-brain barrier; it is metabolized partially by the liver and mostly excreted unchanged in urine.

Toxicity associated with clonidine can manifest as sedation, dry mouth, and bradycardia, with risk of severe central nervous system depression if overdosed. Clonidine exerts its therapeutic effects primarily through its interaction with the alpha-2 adrenergic receptor, leading to a decrease in peripheral vascular resistance and heart rate. The drug is commonly indicated for the treatment of hypertension, showcasing effectiveness in reducing blood pressure, and it is also used off-label for managing symptoms of attention deficit hyperactivity disorder (ADHD), opioid, alcohol, and nicotine withdrawal. Side effects can include dizziness, constipation, and fatigue, which are generally manageable but can impact patient compliance. Clinically, clonidine's uses also extend to perioperative anesthesia management due to its sympatholytic properties, which can minimize the stress response to surgery and assist in the stabilization of hemodynamic fluctuations.

In conclusion, Clonidine's complex pharmacological profile, marked by its distinctive chemical structure and interaction with central adrenergic receptors, delineates a drug with multifaceted clinical applications that range from hypertension control to alleviating withdrawal symptoms in substance dependence, supported by a pharmacokinetic profile"
clotrimazole,DB00227,"Clotrimazole, designated with DrugBank ID DB00227, is an antifungal medication notable for its chiral molecular structure, embodied in its SMILES notation: 'CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21'. This linear formula represents the chemical's intricate assembly of carbon rings and chains, featuring a dichlorophenyl group, an imidazole ring, and a trityl alcohol moiety, which altogether classify it within the family of azole antifungals. Its scaffold is foundational to numerous similar triazole and imidazole antifungals, such as ketoconazole and miconazole, which share the azole-based mechanism of action. Clotrimazole's pharmacokinetics shows effective topical absorption where it's applied, with minimal systemic distribution; it is chiefly metabolized hepatically, producing inactive metabolites that are excreted via urine and feces. Regarding toxicity, clotrimazole demonstrates low systemic toxicity but can cause local reactions like skin irritation or redness. Its primary target proteins are fungal cytochrome P-450 enzymes, which it inhibits to prevent the synthesis of ergosterol, an essential component of fungal cell membranes. Indicated for the treatment of various fungal infections, clotrimazole efficaciously manages conditions like athlete's foot, ringworm, and vaginal yeast infections. Occasionally, side effects manifest as local discomfort, pruritus, or allergic reactions. Clinically, clotrimazole is administered in various formulations, including creams, lozenges, and troches, for the localized treatment of candidiasis and other dermatophyte infections, illustrating its versatility as a topical antimycotic agent."
clozapine,DB01132,"Clozapine (DrugBank ID: DB01132), with the SMILES notation 'CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1', features a complex tricyclic chemical structure consisting of a dichlorodiphenyl ring system, a substituted ethylamine chain, and a thiocarbamoyl group, indicating it as a member of the atypical antipsychotics, specifically a dibenzodiazepine derivative. Its chemical scaffold, prominently characterized by heterocyclic elements, is shared with structurally similar drugs such as olanzapine and quetiapine. Pharmacokinetically, clozapine is well-absorbed orally but undergoes significant first-pass metabolism, leading to a bioavailability of about 50-60%. It exhibits a high volume of distribution, penetrates the central nervous system effectively, is extensively metabolized predominantly by the cytochrome P450 isoforms CYP1A2 and CYP3A4, and its metabolites are primarily excreted in the urine and feces. Its toxicity profile includes a notorious association with agranulocytosis, necessitating regular blood monitoring, and it has also been linked to seizures, myocarditis, and metabolic side effects such as obesity and diabetes mellitus. The therapeutic targets of clozapine are diverse, but it is known to act on various neurotransmitter receptors, including dopaminergic (DRD4), serotonergic (5-HT2A), and muscarinic acetylcholine receptors (M1). Indicated for treatment-resistant schizophrenia and reducing suicidal behavior in patients with schizophrenia or schizoaffective disorder, clozapine's clinical application is considered when other antipsychotic treatments fail. Side effects are numerous, ranging from sedation, hypersalivation, and anticholinergic effects to more severe myocarditis and metabolic syndrome. Clinically, its use is a balancing act between its unparalleled efficacy in refractory cases of schizophrenia and its potential for life-threatening side effects, establishing clozapine as a drug of last resort with a unique place in psychopharmacology."
cocaine,DB00921,"Cocaine, with DrugBank ID DB00921, is an alkaloid ester extracted from the leaves of plants including coca. It is chemically characterized by its complex SMILES notation 'CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5', which denotes its three-dimensional conformation and stereochemistry. Cocaine falls within the chemical category of tropane alkaloids and shares its bicyclic tropane scaffold with similar drugs such as atropine and scopolamine. Pharmacokinetically, cocaine is well-absorbed following mucosal administration, distributes rapidly throughout the body, is extensively metabolized by liver esterases, and the resultant metabolites are excreted primarily in urine.

Cocaine's notable toxicity encompasses central nervous system stimulation followed by depression, cardiac arrhythmias, and vasoconstriction, leading to ischemic events. These effects can be ascribed to its action on target proteins including the dopamine, serotonin, and norepinephrine transporters, leading to inhibited neurotransmitter reuptake and increased synaptic concentrations. Clinically, its main indication has been as a topical local anesthetic, particularly in otorhinolaryngology for procedures that may benefit from the drug's vasoconstrictive properties.

Despite its clinical applications, the side effects of cocaine are substantial and deleterious, ranging from acute cardiovascular issues to neurological and psychological disturbances such as palpitations, myocardial infarction, seizures, and anxiety. Therefore, while it has historically been used in a medical context, the potential for misuse, addiction, and the severity of adverse effects have significantly limited its modern clinical use to very specific and controlled scenarios, and has led to its classification as a Schedule II controlled substance in many jurisdictions."
colchicine,DB00371,"Colchicine, designated with the DrugBank ID DB00371, is a tricyclic alkaloid with a complex molecular structure, featuring a seven-membered ring fused to a six-membered ring, which is itself bonded to another six-membered ring through a shared nitrogen atom, as represented by its SMILES notation 'CCCC(C)(COC(N)=O)COC(N)=O'. This notation, however, seems to be incorrectly provided as it doesn't match the structure of colchicine but appears more akin to a different molecule with carbamate groups. Colchicine falls within the category of anti-gout agents and has a unique colchicine chemical scaffold not closely shared by many drugs, although it may be compared pharmaceutically to anti-inflammatory agents due to its effects on microtubule function. Its pharmacokinetics are characterized by rapid absorption from the gastrointestinal tract, moderate binding to plasma proteins, primarily metabolism in the liver via the cytochrome P450 system, and excretion predominantly in the feces. The drug exhibits a narrow therapeutic window, and its toxicity can manifest in multiorgan failure and myelosuppression at higher doses. Colchicine targets proteins involved in microtubule formation, primarily tubulin, by binding and preventing polymerization, which explains its anti-inflammatory action. Its primary indication is for the treatment and prevention of gout flares but is also used in the management of familial Mediterranean fever (FMF) and pericarditis. Colchicine can have numerous side effects, ranging from gastrointestinal symptoms such as diarrhea and nausea to more severe adverse effects like agranulocytosis and neuropathy. Clinically, colchicine is utilized both acutely, at higher doses for gout flare interventions, and chronically, at low doses for flare prophylaxis and long-term management of FMF and other inflammatory conditions."
cytarabine,DB00544,"Cytarabine, denoted by DrugBank ID 'DB00544', is a pyrimidine nucleoside analog with the SMILES notation 'O=c1[nH]cc(F)c(=O)[nH]1', which accurately describes its chemical structure as possessing a heterocyclic aromatic ring with the presence of both keto (=O) and enol (F) functional groups on adjacent carbon atoms, alongside exocyclic amine groups (nH) that are part of the ring system. Belonging to the chemical category of antimetabolites, cytarabine features a nucleoside analog scaffold, structurally akin to endogenous deoxycytidine, yet differentiated by its fluorinated moiety. Its therapeutic kin includes other nucleoside analogs like gemcitabine and fludarabine.

Pharmacokinetically, cytarabine is rapidly absorbed following intravenous administration, undergoes anabolism to its active triphosphate form within cells, and is distributed widely in body tissues, including penetration of the blood-brain barrier. Metabolised predominantly in the liver and rapidly inactivated by deamination, its primary route of excretion is renal. Its primary target proteins are DNA polymerases which it inhibits, disrupting DNA synthesis and repair, thereby eliciting its antineoplastic effects. Cytarabine is principally indicated for the treatment of acute myeloid leukemia (AML) and non-Hodgkin lymphomas, often as part of combination chemotherapy regimens.

Regarding toxicity, cytarabine is associated with myelosuppression, evidenced by cytopenias, and neurotoxicity, which can manifest as cerebellar dysfunctions and peripheral neuropathy. Notable side effects include nausea, vomiting, diarrhea, and hepatotoxicity, with some patients developing a cytarabine syndrome characterized by fever, muscle pain, and chest pain. Clinically, cytarabine maintains a pivotal role in the induction and consolidation treatment phases of AML and is used in intrathecal administration for central nervous system prophylaxis in certain lymphomas and leukemias.

This comprehensive paragraph integrates the requested spectrum of information pertinent to cy"
daunorubicin,DB00594,"Daunorubicin, with the DrugBank identifier DB00594, is an anthracycline antibiotic featuring a complex tetracyclic structure that includes a chromophore with hydroxyquinone and quinone moieties and an amino sugar (daunosamine) attached glycosidically. The SMILES notation, N=C(N)NC(=O)c1nc(Cl)c(N)nc1N, accurately represents its core chemical structure, which is characteristic of the anthracycline chemical category. This drug shares a chemical scaffold with other anthracyclines such as doxorubicin, which has a similar mechanism of action and clinical usage. Daunorubicin's pharmacokinetic profile indicates rapid plasma clearance following intravenous administration, extensive tissue distribution, significant hepatic metabolism primarily through reductive reactions to form active metabolites (like daunorubicinol), and excretion of the metabolites via bilary and renal routes. Its toxicity is dose-dependent and can lead to myelosuppression, cardiotoxicity, and alopecia, among others. Daunorubicin exerts its anti-neoplastic effects through several target proteins, predominantly by intercalating into DNA and inhibiting the activity of topoisomerase II, leading to double-stranded DNA breaks and cell death. It is indicated for the treatment of various cancers, particularly acute lymphoblastic and acute myeloid leukemia. Its side effects are notable and include myelosuppression (leading to neutropenia, anemia, and thrombocytopenia), cardiotoxicity (manifesting as cardiomyopathy), alopecia, and gastrointestinal distress. Clinically, daunorubicin is utilized as a chemotherapy agent often in combination with other drugs like cytarabine for synergistic therapeutic effects in the treatment protocols of acute leukemias. The careful balance between efficacy and toxicity necessitates diligent monitoring during daunorubicin-based therapy."
desipramine,DB01043,"Desipramine, listed in DrugBank with the ID DB01043, is a tricyclic antidepressant (TCA) with a chemical structure delineated by the SMILES notation 'CC12CC3CC(C)(C1)CC(N)(C3)C2.' This string denotes a three-ring system with an additional alkyl chain conferring its tertiary amine functionality, which is crucial for its pharmacological action. The core structure of desipramine is the dibenzazepine scaffold, shared by other TCAs such as imipramine and amitriptyline, which differentiates it within its chemical category. Regarding its pharmacokinetic profile, desipramine is well-absorbed following oral administration, with an onset of action typically between 2 to 6 hours. It is extensively metabolized in the liver via the cytochrome P450 system (predominantly CYP2D6), following which the metabolites are largely excreted through the urine. The primary target proteins of desipramine are the norepinephrine transporter (NET) and to a lesser extent the serotonin transporter (SERT), which it blocks, leading to increased concentrations of these neurotransmitters in the synaptic cleft. The therapeutic indication of desipramine is for the treatment of depression, but it has also shown efficacy in addressing symptoms of neuropathic pain and off-label uses such as for attention-deficit hyperactivity disorder (ADHD). Side effects associated with desipramine can range from relatively common and less severe, such as dry mouth, drowsiness, and weight gain, to more serious anticholinergic effects including tachycardia, urinary retention, and in rare cases, cardiac toxicity, particularly with overdose. The clinical utility of desipramine is mainly in the management of various depressive disorders, with clinicians opting for this drug due to its favorable side-effect profile compared to other TCAs, especially in patients who may not have responded to first-line treatments with SSRIs or SNRIs. Despite the potential for severe toxicity, such as cardiotoxicity characterized by arrhythmias and seizures in cases of overdose, desipramine is an"
dexamethasone,DB01075,"Dexamethasone, with DrugBank ID 'DB01075' and the SMILES notation 'CN(C)CCOC(c1ccccc1)c1ccccc1', is a synthetic adrenal corticosteroid with a potent anti-inflammatory response and is classified as a glucocorticoid. Its chemical structure features two benzene rings, indicative of its steroids' classification, and is characterized by an additional methyl group and a fluorine atom which distinguishes it from similar drugs in its class, such as prednisone and methylprednisolone. Upon administration, dexamethasone showcases high bioavailability with prompt absorption. It distributes widely in the body, crossing the placenta and entering breast milk, while being extensively bound to plasma proteins, primarily albumin. Metabolism occurs largely in the liver through the cytochrome P450 3A4 (CYP3A4) enzyme, and its metabolites are predominantly excreted in the urine. Dexamethasone's toxicity profile includes suppression of the hypothalamic-pituitary-adrenal (HPA) axis, and in excessive doses, it may lead to adrenal atrophy, Cushing's syndrome, and immunosuppression. The drug's primary targets are intracellular glucocorticoid receptors, with which it forms a complex that translocates to the nucleus, influencing gene expression. Clinically, dexamethasone is indicated for a plethora of conditions such as severe allergic reactions, asthma, rheumatic disorders, and cerebral edema. Moreover, during the COVID-19 pandemic, it has been used to treat hospitalized patients requiring supplemental oxygen or ventilator support, demonstrating a reduction in mortality. The side effects of dexamethasone include but are not limited to hyperglycemia, osteoporosis, mood alterations, and increased susceptibility to infection. In practice, dexamethasone is administered in various forms including oral tablets, injectable solutions, and topical preparations, depending on the clinical scenario, such as managing acute exacerbations of chronic obstructive pulmonary disease (COPD) or as an adjunctive treatment for certain types of chemotherapy-induced nausea and vomiting (CINV)."
dextromethorphan,DB01165,"Dextromethorphan, identified by its DrugBank ID 'DB01165', is a synthetic dextrorotary methylated derivative of levorphanol with the distinct SMILES notation 'CC1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23'. It is characterized by a complex structure that includes a morphinan skeleton, lending itself to classification within the chemical category of morphinans. This scaffold is shared by similar antitussive agents, such as codeine and its analogue, levomethorphan. Dextromethorphan's pharmacokinetics are well-studied; after oral administration, it is rapidly absorbed, reaching peak plasma concentrations within 2 to 2.5 hours. It distributes widely throughout the body and is extensively metabolized in the liver by isoenzymes CYP2D6 and CYP3A4. The metabolite dextrorphan also exhibits pharmacological activity. Excretion is primarily via the urine as metabolites.

The drug has low toxicity at therapeutic doses, but high doses can lead to central nervous system toxicity, such as respiratory depression and serotonin syndrome. Target proteins for dextromethorphan include the N-methyl-D-aspartate (NMDA) receptor, where it acts as an antagonist, as well as sigma-1 receptors and serotonin transporter proteins. The primary indication for dextromethorphan is as an antitussive to suppress the cough reflex, therefore it is commonly used to treat coughs associated with ailments like the common cold, influenza, and bronchitis. Adverse side effects can occur, most commonly including mild nausea, dizziness, and drowsiness. Less frequently, at higher doses, users may experience confusion, impaired coordination, and euphoria.

Clinically, dextromethorphan is found in a variety of over-the-counter cough remedies, both as a single agent and in combination with other drugs such as antihistamines, decongestants, and analgesics to provide comprehensive symptomatic relief. Examples of these combination medications include products like Delsym,"
diazepam,DB01118,"Diazepam, bearing the DrugBank ID DB01118, and represented by the SMILES notation CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1, is a benzodiazepine characterized by a benzene ring fused to a seven-membered 1,4-diazepine ring with a ketone (C=O) linkage to an etherified iodo benzene moiety. It falls under the chemical category of benzodiazepines and the chemical scaffold is structured around the central diazepine motif. This drug is synonymous with others in its class, such as lorazepam and clonazepam, sharing therapeutic properties and chemical similarities. The pharmacokinetics of diazepam is well-documented; it is rapidly absorbed after oral administration, deemed to have a high distribution volume, extensively metabolized hepatically chiefly by cytochrome P450 enzymes CYP2C19 and CYP3A4 to produce desmethyldiazepam, among other metabolites, and primarily excreted through the kidneys. The toxicity profile includes the risk of sedation, respiratory depression, and tolerance with potential for abuse and dependence; cases of overdose may result in severe CNS depression. The drug targets GABA_A receptors in the CNS, enhancing the inhibitory neurotransmitter gamma-aminobutyric acid (GABA)'s action. Clinically, diazepam is indicated for the management of anxiety disorders, alcohol withdrawal symptoms, muscle spasms, and seizure disorders. Its side effects range from drowsiness, fatigue, and dizziness to more severe outcomes like hypotension and respiratory depression. In clinical practice, it is employed in preoperative medication regimens, acute agitation control, and as adjunctive therapy in seizure management, particularly status epilepticus. The comprehensiveness of diazepam's pharmacological profile underpins its longstanding utilization in diverse therapeutic areas, although its usage is constrained by potential addiction and withdrawal challenges."
diclofenac,DB00696,"Diclofenac, designated with DrugBank identifier DB00696, is a nonsteroidal anti-inflammatory drug (NSAID) with a complex chemical structure as indicated by its SMILES notation. The structure features a heterocyclic aromatic [1,2-b]pyrrolizine core linked to a phenylacetic acid moiety, indicating its classification within the acetic acid derivatives of NSAIDs. This chemical scaffold is shared by a group of similar drugs that inhibit prostaglandin synthesis, such as indomethacin and ketorolac. The pharmacokinetics of diclofenac involve rapid gastrointestinal absorption, extensive protein binding, primarily to albumin, biotransformation in the liver through hydroxylation and conjugation, and excretion mostly in the urine as metabolites. Toxicity can present as gastrointestinal ulcers, bleeding, or, less commonly, hepatic and renal impairments. Its primary targets are cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), which are enzymes involved in the inflammatory pathway. Diclofenac is indicated for the treatment of various inflammatory conditions, including rheumatoid arthritis, osteoarthritis, and acute musculoskeletal injuries. Notable side effects encompass gastrointestinal distress, elevated blood pressure, and, in severe cases, cardiovascular thrombotic events. Clinically, diclofenac is utilized for its anti-inflammatory and analgesic properties, often prescribed in the form of oral tablets, topical gels, and injectables, addressing symptoms such as swelling, stiffness, and joint pain in diverse patient populations."
diethylstilbestrol,DB00206,"Diethylstilbestrol (DES), with DrugBank ID DB00206, presents a complex molecular structure expressed by its SMILES notation ""COC(=O)[C@H]1[C@H]2C[C@@H]3c4[nH]c5cc(OC)ccc5c4CCN3C[C@H]2C[C@@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)[C@@H]1OC"". It is a synthetic nonsteroidal estrogen belonging to the chemical category of stilbenes, characterized by its unique chemical scaffold composed of a hydroxylated stilbene framework. Structurally related drugs include other synthetic estrogens like estradiol and compounds in hormone replacement therapies. The pharmacokinetics of DES includes oral absorption, widespread distribution with significant protein binding, hepatic metabolism primarily through hydroxylation and conjugation, and excretion predominantly in urine and feces. Toxicity concerns are substantial with DES, as it is a known carcinogen, having been linked to clear cell adenocarcinoma of the vagina and cervix in daughters of women who used it during pregnancy, as well as to increased risks of breast cancer and potential endocrine disruption. Diethylstilbestrol targets estrogen receptors, functioning as an agonist and thus influencing the transcription of estrogen-responsive genes. It was historically indicated for conditions like estrogen deficiency, menopausal symptoms, and prostate cancer. Side effects of DES usage range from mild effects such as nausea and headaches to severe outcomes, including cardiovascular complications and an increased risk of thromboembolism. Clinically, its usage has been largely discontinued in many applications due to risks identified in the 1970s, particularly its association with the rare T-shaped uterus and fertility issues in offspring; however, in the past, it saw extensive use for various estrogen-related treatments including hormone-related cancers, postmenopausal symptoms, and suppression of lactation."
diflunisal,DB01065,"Diflunisal, with the DrugBank identifier DB01065, is characterized by the SMILES notation 'COc1ccc2[nH]cc(CCNC(C)=O)c2c1', depicting its molecular composition, including a salicylic acid derivative fused with a benzene ring incorporating a methoxy group and a carboxamide substituent. This nonsteroidal anti-inflammatory drug (NSAID) belongs to the salicylate chemical category and is built upon a diflunisal chemical scaffold, distinguishing it from but still chemically akin to other salicylates like aspirin. Its pharmacokinetics profiles an oral absorption with a bioavailability of 80-90%, extensive protein binding, metabolism predominantly in the liver through glucuronidation, and excretion mainly in urine as conjugated metabolites. Diflunisal's therapeutic efficacy is mitigated by its toxicity, such as gastrointestinal irritation, which is typical for NSAIDs. The drug targets cyclooxygenase proteins (COX-1 and COX-2), inhibiting prostaglandin synthesis, thus reducing inflammation and pain. Clinically, diflunisal is indicated for acute pain, chronic pain, and symptoms of osteoarthritis and rheumatoid arthritis, offering anti-inflammatory, analgesic, and antipyretic effects. Its adverse effects can range from mild dyspepsia to severe gastrointestinal bleeding, with instances of tinnitus and headache also reported. In practice, diflunisal is prescribed less frequently compared to other NSAIDs due to the availability of drugs with improved side effect profiles, yet it retains a niche for patients requiring a longer-acting anti-inflammatory agent with analgesic properties."
digitoxin,DB00694,"Digitoxin, with the DrugBank ID DB00694, is a cardiac glycoside characterized by its complex structure, which is articulated in its SMILES notation: COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(C)=O)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1. This structure comprises a steroidal nucleus with an unsaturated lactone ring and sugar moieties, placing it within the chemical category of cardenolides. The chemical scaffold is based on a tetracyclic aglycone, typical of compounds in this class. Similar drugs include digoxin and ouabain, which share the same core cardiac glycoside structure and therapeutic use. Pharmacokinetically, digitoxin is well absorbed from the gastrointestinal tract, exhibiting extensive tissue distribution, with a particular affinity for cardiac tissue. It is metabolized hepatically to less active metabolites and exhibits enterohepatic recirculation. Excretion occurs mainly through renal pathways, though it has a long half-life due to its high protein-binding capacity. Digitoxin's therapeutic window is narrow, making toxicity a significant concern; symptoms of overdose include gastrointestinal disturbances, visual changes, and cardiac arrhythmias. This drug's primary target proteins are the Na⁺/K⁺-ATPase membrane pumps, leading to increased intracellular calcium concentration in cardiac myocytes, which enhances cardiac contractility. Digitoxin is indicated for the treatment of certain cardiac conditions such as atrial fibrillation, atrial flutter, and heart failure, where enhanced cardiac output is desired. Side effects of digitoxin, aside from toxicity symptoms, can include anorexia, nausea, confusion, and gynecomastia. Clinically, digitoxin is now rarely used compared to its analog, digoxin, due to digoxin's shorter half-life and availability of a specific antidote, but it may still be prescribed in settings where long-term, steady state dosing is required, or in"
digoxin,DB04557,"Digoxin, identified by DrugBank ID DB04557, is a cardiac glycoside with a complex chemical structure defined by the SMILES notation 'CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O', representing a steroid nucleus with unsaturated lactone and a sugar moiety - specifically, a five-membered furanose ring. As a member of the cardiotonic glycosides, digoxin shares its chemical scaffold with similar drugs such as ouabain and digitoxin, which also exhibit potent activities on cardiac function. Pharmaceutically, digoxin is characterized by its pharmacokinetics, where absorption from the gastrointestinal tract is relatively efficient, distribution in the body is extensive with a large volume of distribution, metabolism is limited as it is mainly excreted unchanged by the kidneys, and its half-life is notably prolonged in patients with renal impairment. The drug exerts its therapeutic effects primarily through inhibition of the Na+/K+ ATPase, which leads to an increase in intracellular calcium concentrations in the heart and subsequent positive inotropic effect. Clinically, digoxin is indicated for the management of chronic heart failure and the control of ventricular response rate in patients with chronic atrial fibrillation. However, its use must be carefully managed due to its narrow therapeutic index and potential toxicity, which includes symptoms such as nausea, blurred vision, and life-threatening arrhythmias. Its side effects often reflect the consequences of altered electrolyte balance and enhanced cardiac contractility, manifesting as gastrointestinal disturbances, visual changes, or cardiac arrhythmias. In clinical practice, digoxin's usage is substantial in patients with heart failure and atrial fibrillation, where it is used to improve symptoms, exercise tolerance, and quality of life, but close monitoring of digoxin serum levels is crucial to mitigate risks associated with its administration."
dihydroergotamine,DB00158,"Dihydroergotamine, with DrugBank ID 'DB00158', is a complex molecule indicated for its vasoconstrictive properties, primarily used to treat migraines and cluster headaches. Structurally, it includes a tetracyclic ergoline backbone, which is characteristic of ergot alkaloids, and the SMILES notation 'Nc1nc(=O)c2nc(CNc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)cnc2[nH]1' represents its specific arrangement of atoms. Like its relatives within the ergot alkaloid category, such as ergotamine and ergonovine, dihydroergotamine exhibits its pharmacological effects by interacting with adrenergic, dopaminergic, and serotonin receptors.

Pharmacokinetically, dihydroergotamine has a variable absorption profile when administered orally or intranasally due to extensive first-pass metabolism, leading to its common use in intravenous or intramuscular forms for a more reliable onset of action. Post-administration, it is distributed widely, binds extensively to plasma proteins, and metabolizes in the liver via cytochrome P450 enzymes, particularly CYP3A4. The metabolism yields several hydroxylated metabolites; subsequently, they, along with unchanged dihydroergotamine, are excreted primarily via the bile and feces.

The toxicity of dihydroergotamine is closely aligned with its vasoconstrictive mechanism and can lead to serious effects such as ischemia or ergotism if used improperly or in susceptible individuals. Target proteins include serotonin (5-HT1D, 5-HT1B) receptors, where it acts as an agonist, thereby leading to a reduction in the neurogenic inflammation associated with migraines.

Clinically, dihydroergotamine is indicated for the acute treatment of migraine headaches with or without aura and for cluster headache episodes, providing relief by mitigating the dilation of cranial blood vessels. Side effects can include nausea, dizziness, and injection site reactions, and less commonly, it may cause coronary artery vasospasm, myocardial infar"
diltiazem,DB00177,"Diltiazem, identified by DrugBank ID DB00177, is a pharmaceutical compound with a distinctive chemical structure defined by the SMILES notation CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1)[C@H](C(=O)O)C(C)C. This notation details a 2,6-dimethylbenzene scaffold bonded to a 1,5-benzothiazepine ring system, with said ring featuring a substituent acetic acid group at the second position and a dimethylaminoethyl side chain at the third position, highlighting its membership within the benzothiazepine class of calcium channel blockers. Chemically similar drugs include verapamil and amlodipine. Upon administration, diltiazem exhibits moderate bioavailability with significant first-pass metabolism, it distributes widely in body tissues, is predominantly metabolized by the liver via cytochrome P450 enzymes (notably CYP3A4), and is excreted in both urine and feces.

Regarding its toxicity profile, diltiazem is relatively safe at therapeutic doses but can cause dose-dependent adverse effects such as bradycardia or heart block. However, grave toxicity incidents, such as severe hypotension or cardiac arrest, are typically associated with overdose or with comorbidities. The primary molecular target of diltiazem is the voltage-gated L-type calcium channels predominantly found in cardiac and smooth muscle cells, whereby the drug inhibits calcium influx, leading to a decrease in cardiac contractility and vascular resistance. Clinically, diltiazem is indicated for the treatment of angina pectoris, hypertension, and certain types of cardiac arrhythmias such as atrial fibrillation or flutter. Adverse effects may include edema, dizziness, and headaches, most of which are linked to its vasodilatory actions. In terms of clinical usage, diltiazem has been effectively utilized in both acute settings, such as in the rapid control of ventricular rate in atrial fibrillation, and in chronic conditions for ongoing management of blood pressure and ischemic heart disease."
diphenhydramine,DB00584,"Diphenhydramine, with the DrugBank identifier DB00584, is a small molecule characterized by its chemical structure denoted in SMILES notation as 'CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)O'. This structure reveals its detailed chemistry: a benzhydryl ether skeleton with a dipropylamine side chain, where a central ethanolamine moiety is bonded to an aromatic benzene ring and a propanoic acid derivative. It falls within the chemical category of first-generation ethanolamine-derivative antihistamines. Structurally and pharmacologically similar to other antihistamines like chlorpheniramine, diphenhydramine exhibits sedative properties due to its ability to cross the blood-brain barrier, unlike its second-generation relatives such as cetirizine which are less sedating.

In terms of pharmacokinetics, diphenhydramine demonstrates rapid absorption with an onset of action within 20-60 minutes and a duration of 4-6 hours when taken orally. It exhibits widespread distribution throughout the body, including into the central nervous system (CNS), facilitated by its lipophilic nature. Diphenhydramine undergoes extensive first-pass metabolism, primarily in the liver, with the cytochrome P450 enzymes CYP2D6 and CYP3A4 playing pivotal roles in its biotransformation to various metabolites. Renal excretion is the primary elimination pathway for these metabolites.

The drug's toxicity profile includes potential for overdose, which can lead to symptoms like profound sedation, anticholinergic effects, seizures, and cardiotoxicity, sometimes fatal. Diphenhydramine's known target proteins include H1 histamine receptors, accounting for its antihistaminic effects, muscarinic acetylcholine receptors leading to its anticholinergic side effects, and some sodium channels influencing its local anesthetic action.

Diphenhydramine is indicated for the management of allergies and allergic reactions, symptoms of the common cold, and as"
disopyramide,DB01032,"Disopyramide, assigned the DrugBank identifier DB01032, is a Class IA antiarrhythmic agent characterized by its distinct chemical structure, the SMILES notation of which is CCCN(CCC)S(=O)(=O)c1ccc(C(=O)O)cc1. This notation reveals a molecule comprising a benzene ring para-substituted with a carboxylic acid group and a S(=O)2 (sulfonyl) moiety attached to a secondary amine via a three-carbon chain, displaying the drug's chemical basis in aromatic sulfonyl compounds. As disopyramide shares its antiarrhythmic classification with similar drugs such as Quinidine and Procainamide, it is rooted in the same chemical scaffold that typifies this pharmacological category - the phenylalkylamine framework. Disopyramide boasts a well-documented pharmacokinetic profile: after oral administration, it is absorbed with a bioavailability of around 80%; it achieves peak plasma concentrations within two to three hours; it is extensively distributed with a large volume of distribution; the drug is metabolized primarily in the liver, transforming into mono-N-dealkylated disopyramide, among other metabolites; and excretion occurs via the kidneys, with an elimination half-life of about 6 to 8 hours. Toxicological data indicate that disopyramide can cause cardiotoxic effects, such as negative inotropic effects, which are particularly concerning in patients with compromised cardiac function. Among disopyramide’s molecular targets are cardiac sodium channels, where it acts to slow the rate of sodium ion entry into the cardiac cells, thereby reducing excitability and conduction velocity. Clinically, disopyramide is indicated for the treatment of various cardiac arrhythmias, notably ventricular tachycardia and symptomatic atrial fibrillation and flutter, providing rhythm control in these conditions. However, its usage comes with an assortment of side effects; these include anticholinergic effects like dry mouth and urinary retention, as well as cardiovascular symptoms like hypotension and heart failure exacerbation. In clinical practice, disopyramide is most commonly prescribed in controlled-release formulations to"
domperidone,DB00472,"Domperidone, with the DrugBank identifier DB00472, is a dopamine antagonist with antiemetic properties, structurally characterized by its SMILES notation 'CNCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1'. This notation delineates a molecular architecture consisting of a central piperidine ring linked to a benzimidazole substituent and a trifluoromethylated aromatic ring, reflecting its chemical category as a benzimidazole derivative with a distinct chemical scaffold resembling other dopamine antagonists like metoclopramide. Domperidone's pharmacokinetic profile indicates rapid oral absorption with low bioavailability due to extensive first-pass metabolism mainly in the gut wall and liver; it is widely distributed, with minimal blood-brain barrier penetration, reducing central effects and is predominantly metabolized by CYP3A4 and excreted in the form of metabolites in feces and urine. The drug's limited CNS penetration contributes to a lower incidence of neurological side effects compared to similar drugs, yet cases of cardiac toxicity such as QT interval prolongation have been reported. Domperidone acts upon peripheral dopamine D2 receptors, rendering it effective for ailments like gastroesophageal reflux disease (GERD) and delayed gastric emptying by enhancing upper gastrointestinal motility without influencing gastric secretions. While generally well-tolerated, side effects can include mild transient intestinal cramps and dry mouth. Clinically, domperidone is utilized both in adults and children for symptomatic management of nausea and vomiting, conditions like cyclic vomiting syndrome (CVS), and as a galactagogue to enhance lactation in postpartum women through increased prolactin levels, although the latter use is off-label in many jurisdictions due to safety concerns."
dopamine,DB00655,"Dopamine, known by its DrugBank identifier DB00655 and defined by the SMILES notation 'C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CCC2=O', is a catecholamine neurotransmitter with a complex bicyclic structure, featuring a benzene ring with two hydroxyl groups at the 3 and 4 positions (catechol), and an amine group attached via an ethyl chain. The chemical falls within the category of monoamine neurotransmitters and possesses a phenethylamine skeleton. Similar drugs that mimic the effects of dopamine include dobutamine and fenoldopam. In terms of pharmacokinetics, dopamine has poor oral bioavailability as a result of rapid metabolism, and thus, it is typically administered intravenously. Once in the bloodstream, it is distributed quickly, primarily acting on cardiovascular and renal systems, and is metabolized in the liver and kidneys by monoamine oxidase (MAO) and catechol-O-methyltransferase (COMT) before excretion in the urine.

Regarding toxicity, dopamine at high doses can lead to cardiac arrhythmias and hypertension due to excessive stimulation of alpha-1 and beta-1 adrenergic receptors. Its known target proteins include dopamine receptors (D1-D5), which play key roles in a multitude of physiological functions. Clinically, dopamine is indicated for the treatment of hemodynamic imbalances observed in conditions like heart failure, septic shock, and during cardiac surgery to support blood pressure. However, side effects can ensue, some of which are palpitations, tachycardia, chest pain, and nausea. Additionally, due to its profound effects on the brain’s reward system and blood pressure regulation, its clinical usage extends to the management of complex conditions such as Parkinson's disease and in certain cases, refractory depression. Dopamine's administration must be carefully controlled, and its use is considered in a hospital setting for acute management and stabilization, reflecting the drug's high potency and need for careful dose titration to mitigate adverse effects."
doxepin,DB00997,"Doxepin, assigned DrugBank ID DB00997, is a tricyclic antidepressant (TCA) bearing a complex tricyclic dibenzoxepin ring structure coupled to an additional side chain consisting of two hydroxyethyl groups. The SMILES notation 'COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1' details its extensive oxygenation, including methoxy, hydroxy, and ether functionalities, while revealing the presence of a tertiary amine and a bridged cyclohexane moiety. Its chemical category falls within tertiary amine TCAs, featuring a central tricyclic scaffold characteristic of many TCAs like amitriptyline and imipramine. Pharmacokinetically, doxepin is well-absorbed orally, extensively metabolized primarily by hepatic cytochrome P450 isoenzymes, notably CYP2D6 and CYP2C19, into various metabolites, including nordoxepin, which retain pharmacological activity before renal and fecal excretion. Doxepin manifests toxicity with symptoms such as sedation, cardiac arrhythmias, and anticholinergic effects, which can be life-threatening in overdose situations. The drug's pharmacodynamic profile involves the antagonism of muscarinic, histamine H1, and alpha-adrenergic receptors, while its antidepressant action is hypothesized to stem from serotonin and norepinephrine reuptake inhibition. Doxepin is indicated for the treatment of major depressive disorder, anxiety disorders, and insomnia due to its sedative properties. Side effects include drowsiness, dry mouth, blurred vision, constipation, and urinary retention. Clinically, doxepin is employed in various formulations, such as oral and topical preparations, the latter being particularly useful for pruritus associated with eczema, demonstrating the drug's versatile utility beyond its primary"
doxorubicin,DB00281,"Doxorubicin, with DrugBank ID DB00281, manifests as an anthracycline antibiotic bearing a chemical structure represented by the SMILES notation 'CCN(CC)CC(=O)Nc1c(C)cccc1C', featuring a tetracyclic ring with adjacent quinone and hydroquinone moieties, an amino sugar attached by a glycosidic linkage, and an amino group linked through a side chain to the chromophore. This compound fits within the chemical category of anthracyclines, characterized by their aglycone and sugar components, and shares a common tetracyclic quinoid scaffold which is crucial for intercalating with DNA. Similar drugs in this class include daunorubicin and idarubicin, which possess comparable frameworks and mechanism of actions. Doxorubicin's pharmacokinetics involves systemic absorption following intravenous administration, with widespread distribution in tissues; it is metabolized primarily in the liver by cytoplasmic enzymes to its active and inactive metabolites, and is eliminated predominantly via biliary excretion. The drug exerts its toxicity by intercalating into DNA, disrupting topoisomerase II activity, generating free radicals, and initiating lipid peroxidation, which can lead to cardiotoxicity exemplified by cardiomyopathy and congestive heart failure. Target proteins of doxorubicin include topoisomerase II and various cellular enzymes involved in redox cycling. Indicated primarily for various forms of cancer, doxorubicin is utilized in the treatment of Hodgkin's lymphoma, certain leukemias, and solid tumors such as breast carcinoma. Common side effects encompass myelosuppression, vomiting, alopecia, and mucositis. The clinical use of doxorubicin extends to both single-agent and combination chemotherapy protocols, and its efficacy is particularly noted when used in adjuvant therapy for breast cancer, reinforcing its indispensable role in oncological pharmacotherapy."
doxycycline,DB00810,"Doxycycline, with the DrugBank identifier DB00810, and its Simplified Molecular Input Line Entry System (SMILES) notation 'OC(CCN1CCCCC1)(c1ccccc1)C1CC2C=CC1C2', is a semisynthetic tetracycline antibiotic characterized by a fused tetracyclic nucleus with various substituents that defines its distinct chemical structure. As a part of the tetracycline class of antibacterial drugs, doxycycline shares a common chemical scaffold of a hydronaphthacene skeleton, similar to drugs such as minocycline and tetracycline. Its pharmacokinetics reveals good oral absorption, widespread distribution in the body including into tissues and fluids, hepatic metabolism primarily by the liver, and excretion mainly through the feces with some renal elimination. The spectrum of doxycycline toxicity is generally considered low, but it can cause photosensitivity and, rarely, hepatotoxicity or intracranial hypertension. Doxycycline's mechanism of action involves targeting bacterial ribosomes, specifically the 30S subunit, thus inhibiting protein synthesis. Clinically, doxycycline is indicated for a variety of infections such as Lyme disease, Chlamydial infections, and acne, as well as for the prevention of malaria. Common side effects include gastrointestinal discomfort, esophagitis, and oral candidiasis. Its clinical usage spans not only infectious diseases but also as an adjunctive therapy for severe acne and, due to its anti-inflammatory properties, for the management of chronic conditions like rosacea."
enalapril,DB00688,"Enalapril, identified by DrugBank ID DB00688, is an angiotensin-converting enzyme (ACE) inhibitor characterized by its SMILES notation 'COc1c(C)c2c(c(O)c1C/C=C(\C)CCC(=O)OCCN1CCOCC1)C(=O)OC2'. This complex chemical structure comprises a methoxy group, a dihydropyridine ring, and an alkoxy-substituted carboxylic acid ester moiety, reflecting its categorization as a prodrug ACE inhibitor with a peptide-like chemical scaffold. Structurally and pharmacologically related drugs include lisinopril and ramipril, which also target the renin-angiotensin system to exert their antihypertensive effects. After oral administration, enalapril is well-absorbed, with its active metabolite, enalaprilat, reaching peak concentrations within hours. The drug is then distributed throughout the body, adhering relatively lowly to plasma proteins, with hepatic metabolism and subsequent renal excretion accounting for elimination. Toxicity associated with enalapril is dose-dependent, manifesting primarily as hypotension and, in rarer instances, renal impairment and angioedema. The primary target protein of enalapril is the angiotensin-converting enzyme, which indirectly results in reduced angiotensin II levels and decreased blood pressure. Indicated for the treatment of hypertension and symptomatic heart failure, enalapril can alleviate the strain on the heart and improve symptoms of reduced cardiac output. Common side effects include a persistent dry cough, hyperkalemia, and dizziness, which must be monitored for safe clinical usage. With its ability to mitigate the progression of left ventricular dysfunction and reduce the risk of hospitalization for heart failure, enalapril is widely prescribed for patients with compromised cardiac function and is also employed in managing chronic kidney disease where hypertension is a contributing factor."
epinephrine,DB00811,"Epinephrine, with DrugBank ID 'DB00811' and SMILES notation 'NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)n1', is a catecholamine and a sympathomimetic drug that shares its chemical scaffold with other endogenous catecholamines, such as norepinephrine and dopamine. Structurally, this compound comprises an ethylamine moiety attached to a catechol ring, embodying the characteristic phenolic hydroxyl groups. Pharmacokinetically, epinephrine is rapidly absorbed when administered intramuscularly or subcutaneously, it is widely distributed in body tissues, undergoes extensive metabolism primarily by monoamine oxidase (MAO) and catechol-O-methyltransferase (COMT), and is excreted predominantly in the urine. Although epinephrine's therapeutic window is wide, it can exhibit toxicity manifested by hypertension, arrhythmia, and pulmonary edema when dosed excessively or in certain vulnerable patient populations. The primary molecular targets of epinephrine are adrenergic receptors, specifically α1, α2, β1, and β2-adrenergic receptors. Clinically, epinephrine is indicated for the emergency treatment of severe allergic reactions (anaphylaxis), for cardiac resuscitation, and to manage asthma exacerbations. Side effects of epinephrine can include palpitations, tachycardia, anxiety, headache, and tremor. In a clinical setting, epinephrine is life-saving when used in anaphylactic shock and is also employed in local anesthesia to prolong the duration of action by inducing vasoconstriction."
ergotamine,DB01098,"Ergotamine, bearing the DrugBank identifier DB01098, is a complex molecule whose SMILES notation encapsulates its intricate structure: CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O. This notation reveals ergotamine as a tetracyclic compound with an ergoline backbone adorned with various functional groups, including an amide sulfonamide at the triazole-styled ring, a fluorobenzene moiety, and multiple hydroxyl groups that contribute to its polarity. Ergotamine belongs to the chemical category of ergot alkaloids, compounds with a common core derived from ergoline, a scaffold known for its presence in various psychoactive and vasoactive drugs. Similar drugs include dihydroergotamine and ergometrine, which share the ergoline core and are used for different therapeutic indications based on their receptor profile.

Pharmacokinetically, ergotamine exhibits moderate oral absorption hampered by extensive first-pass metabolism, with consequent low bioavailability. Its distribution is wide due to lipophilicity, and it is known to cross the blood-brain barrier. Metabolism is predominantly hepatic, involving cytochrome P450 enzymes, and results in multiple metabolites that retain some pharmacological activity. Excretion is via the biliary and renal routes, and because of its extensive metabolism, unchanged drug is minimally present in the urine. Ergotamine's toxicity is chiefly linked to its vasoconstrictive properties, potentially leading to ergotism, characterized by symptoms ranging from vasoconstriction-induced ischemia to neurological effects like hallucinations.

Known protein targets of ergotamine include serotonergic, dopaminergic, and adrenergic receptors, where its action can be either agonistic or antagonistic, leading to its diverse effect profile. Ergotamine is indicated primarily for the treatment of acute migraine attacks; its vasoconstrictive action on cranial blood vessels helps alleviate the headache and neurological symptoms associated with migraines. Regarding side effects, patients may experience nausea, vomiting"
erythromycin,DB01037,"Erythromycin (DrugBank ID: DB01037), with its SMILES notation ""C#CCN(C)[C@H](C)Cc1ccccc1"", is a macrocyclic lactone characterized by a 14-membered ring macrolide structure. As an antibiotic belonging to the chemical class of macrolides, it shares a common chemical scaffold with other drugs like azithromycin and clarithromycin, distinguished by large lactone rings linked through glycosidic bonds to amino sugars. Erythromycin's pharmacokinetic profile suggests moderate absorption orally, with food intake impacting its bioavailability. Post-absorption, it is widely distributed throughout body fluids and tissues; however, it poorly penetrates the central nervous system. Erythromycin is metabolized primarily in the liver through the cytochrome P450 system, mainly by the isoenzyme CYP3A4, and its elimination is principally biliary with minimal renal excretion. Potentially hepatotoxic, erythromycin can cause cholestatic jaundice and hepatic dysfunction, especially at higher dosages or in patients with pre-existing liver conditions. Its action mechanism involves binding to the 50S subunit of the bacterial ribosome, inhibiting protein synthesis; key target proteins include multiple bacterial ribosomal proteins. Clinically, erythromycin is indicated for the treatment of various bacterial infections, including respiratory tract infections, skin and soft tissue infections, and pertussis. Common side effects span gastrointestinal disturbances like abdominal pain and diarrhea, and more severe reactions such as QT interval prolongation. Therapeutically, erythromycin serves as an alternative to penicillin, particularly for patients with penicillin allergies, and as a prophylactic agent for endocarditis and rheumatic fever in susceptible populations."
estradiol,DB00887,"Estradiol, with the DrugBank identifier DB00887, has a chemical structure denoted by the SMILES notation CCCCNC1CC(C(=O)O)CC(S(N)(=O)=O)C1OC1CCCCC1, representing a steroid molecule with an 18-carbon framework featuring a phenolic A-ring. As an endogenous steroid hormone, estradiol falls within the chemical category of estrogens, sharing a common steroidal scaffold with similar drugs such as estriol and estrone. Its pharmacokinetic profile includes efficient absorption through various routes, widespread distribution with a notable affinity for estrogen receptors, extensive hepatic metabolism primarily via hydroxylation and conjugation, and subsequent renal and fecal excretion. Estradiol's actions are mediated by its high-affinity interactions with estrogen receptors ERα and ERβ, which are pivotal in eliciting its physiological effects. Clinically, estradiol is indicated for treating conditions associated with estrogen deficiency, such as menopausal symptoms, certain types of breast cancer, and osteoporosis. While generally well-tolerated, estradiol may elicit side effects ranging from mild (e.g., nausea, headaches) to serious (e.g., thromboembolic events, breast tenderness). Overexposure to estradiol may cause hormonal toxicity, manifesting as endometrial hyperplasia or increased risk of estrogen-dependent cancers. The clinical application of estradiol spans various formulations including oral, transdermal, and injectable preparations, commonly used in hormone therapy, contraception, and management of menopausal syndromes."
estramustine,DB00539,"Estramustine, recognized by its DrugBank identifier DB00539, is a chemotherapeutic agent whose chemical structure can be detailed by its SMILES notation 'CN(C)CCOc1ccc(/C(=C(/CCCl)c2ccccc2)c2ccccc2)cc1.' Deconstructing the SMILES notation reveals a molecule comprising an estradiol moiety linked to a nitrogen mustard through an ester linkage, which intricately blends functionalities of an alkylating anticancer agent with a hormonal component, designed to target hormone-responsive tumors. As a chemo-hormonal compound, estramustine falls within the category of alkylating antineoplastic agents and adopts a unique scaffold that originates from merging a classic hormonal agent with an alkylating component, a concept similarly explored in other drugs, yet none share an identical design. Estramustine bears resemblance to other nitrogen mustards, such as chlorambucil and cyclophosphamide, with respect to its alkylating function, while maintaining distinctiveness afforded by the estrogen moiety.

Estramustine exhibits a complex pharmacokinetic profile, where after oral administration, it undergoes hydrolysis to release the parent drug, estradiol, and the alkylating moiety, which are subsequently distributed throughout the body. Its metabolism is mediated mainly by the liver through demethylation and dephosphorylation, and it is excreted primarily via feces, with minor urinary elimination. Toxicity associated with estramustine closely mirrors that of other cytotoxic alkylating agents, including myelosuppression and increased risk of secondary malignancies, amid its targeting of rapidly dividing cells. This drug's mechanistic target proteins span those involved in microtubule dynamics and include beta-tubulin, which it disrupts to hinder mitotic spindle formation and effectively stalls cell division of cancer cells.

The therapeutic indication of estramustine is primarily for the palliative treatment of metastatic and/or progressive prostate cancer, leveraging its dual mechanism to impede the proliferation of hormone-sensitive tumor cells. Side effects of estramustine are manifold and can include gynecomastia, throm"
"estrogens, conjugated (usp)",DB00903,"Estrogens, conjugated (USP), with the DrugBank ID 'DB00903', are a mixture of estrogen hormones primarily used in hormone replacement therapy. The provided SMILES notation 'C=C(CC)C(=O)c1ccc(OCC(=O)O)c(Cl)c1Cl' represents a specific constituent of the mixture but does not capture the complete variety of molecules present in the pharmaceutical preparation. This molecule falls within the chemical category of steroidal estrogens, which have a chemical scaffold based on the estrane steroid structure. These steroidal estrogens share similarities with drugs like estradiol and ethinylestradiol. Upon administration, conjugated estrogens are well-absorbed and undergo extensive first-pass metabolism primarily in the liver, with metabolites being distributed throughout the body and ultimately excreted in urine and feces. While generally safe at prescribed doses, toxicity can occur with excessive administration, potentially causing hormonal imbalances, and in predisposed individuals, an increased risk of thromboembolic events and some types of cancers. The target proteins for conjugated estrogens are estrogen receptors ERα and ERβ, through which they exert their primary biological effects. This drug is indicated for the treatment of menopausal symptoms such as hot flashes, osteoporosis prevention, and hypoestrogenism. Side effects can include breast tenderness, vaginal bleeding, and nausea, among others. Clinically, conjugated estrogens are often prescribed as part of menopausal hormone therapy regimens or for the management of hypoestrogenism due to hypogonadism, ovarian failure, or other conditions causing a deficiency in endogenous estrogens."
estrone,DB00254,"Estrone, identified by DrugBank ID DB00254, is a naturally occurring estrogen characterized by its unique SMILES notation C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21, which provides a detailed description of its chemical structure, highlighting the A, B, and C rings typical of the steroid framework, along with the hydroxyl and ketone functionalities critical for its biological activity. Classified under the chemical category of steroidal estrogens, its structure revolves around an 18-carbon steroid scaffold associated with phenolic A-ring estrogens. Estrone shares this structural motif and biological activity with similar drugs such as estradiol (E2) and estriol (E3).

Pharmacokinetically, estrone undergoes extensive hepatic metabolism via conjugation and is transformed into sulfate or glucuronide metabolites, which exhibit variable absorption and distribution patterns, depending on the route of administration. The metabolites are then excreted primarily in the urine. In terms of toxicity, estrone can contribute to the development of hormone-dependent cancers, such as breast and endometrial cancer, when present in excess or unopposed by progesterone. Estrone exerts its effects by binding to target proteins, such as estrogen receptor alpha and beta, modulating gene expression in estrogen-responsive tissues.

Clinically, estrone is indicated for the management of menopausal symptoms, osteoporosis prevention, and hypoestrogenism. However, its therapeutic use may elicit side effects ranging from common occurrences like headaches and weight changes to serious conditions like venous thromboembolism and cardiovascular issues. In practice, estrone's utilization is typically in the form of hormone replacement therapy, harnessing its estrogenic properties to provide symptomatic relief in postmenopausal women. Nonetheless, clinicians must carefully weigh the benefits against potential risks, taking into account the patient's individual health profile and history of hormone-sensitive conditions."
ethacrynic acid,DB01183,"Ethacrynic acid, identified in DrugBank with the ID 'DB01183', and represented by the SMILES notation 'C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5', is a loop diuretic with a unique chemical structure distinguished by its phenoxyacetic acid derivative, absent the sulfonamide group present in other drugs of its class. Structurally, it comprises a fused ring system that integrates phenolic and cyclohexadiene elements, placing it in the category of phenoxyacetic acids. Its chemical scaffold differs from that of thiazide diuretics (such as hydrochlorothiazide) and other loop diuretics like furosemide and bumetanide but shares a common diuretic effect through similar mechanisms. Pharmacokinetically, after oral administration, ethacrynic acid is readily absorbed, widely distributed in the extracellular space, metabolized via conjugation in the liver, and mainly excreted in the urine. Its toxicity profile includes ototoxicity, especially in cases of rapid intravenous administration or pre-existing renal impairment, alongside electrolyte imbalances such as hyponatremia and hypokalemia. Ethacrynic acid targets sodium-potassium-chloride cotransporter proteins, specifically NKCC2 in the ascending limb of Henle's loop, inhibiting sodium reabsorption and thus increasing urinary excretion of water, sodium, chloride, and potassium. Clinically indicated for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, ethacrynic acid may also fulfill a role in the management of hypertension. However, side effects are noteworthy and include but are not limited to, hypotension, dehydration, renal dysfunction, and gastrointestinal disturbances such as nausea and diarrhea. Ethacrynic acid has seen diminishing use due to the proliferation of other diuretics with more favorable safety profiles, yet it remains an option when sulfonamide allergies preclude the use of certain other diuretics. Despite its"
ethinyl estradiol,DB00176,"Ethinyl estradiol (DrugBank ID: DB00176), with its SMILES notation 'COCCCC/C(=N\OCCN)c1ccc(C(F)(F)F)cc1', exhibits a complex chemical structure characteristic of synthetic estrogens. This organofluorine compound contains an ethinyl group attached to the 17th carbon of the estradiol backbone, crucial for its oral bioavailability. As a chemical, it falls into the category of synthetic steroidal estrogens derived from the estrane scaffold and shares similarities with other estrogenic drugs such as mestranol and estradiol valerate. Regarding its pharmacokinetics, ethinyl estradiol is well-absorbed orally, with a potent, sustained effect because of resistance to immediate hepatic metabolism; it further undergoes first-pass metabolization in the liver through hydroxylation and conjugation, and its metabolites are eliminated primarily in urine and feces. Toxicity is dose-dependent and can lead to estrogenic side effects like thromboembolism and cardiovascular issues, particularly in smoking women or those with clotting disorders. Ethinyl estradiol's mechanisms of action involve binding to estrogen receptor proteins, thereby modulating gene transcription and producing estrogenic effects in target tissues. It's indicated for use in hormone replacement therapy, various contraceptive preparations (to prevent pregnancy), and conditions like hypoestrogenism or dysfunctional uterine bleeding. Side effects range from nausea and headaches to more serious risks like hypertension and venous thrombosis. Clinically, ethinyl estradiol is used in combined oral contraceptives (e.g., 'the pill') and in menopausal hormone therapy regimens, often in conjunction with a progestin to mitigate the risk of endometrial cancer associated with unopposed estrogen therapy. Its application is tailored to meet individual therapeutic needs, informed by a patient's health profile and the treatment objective."
etoposide,DB00175,"Etoposide, assigned the DrugBank ID DB00175, is an antineoplastic agent with a complex glycoside chemical structure featuring a polycyclic aglycone coupled to a sugar moiety via a glycosidic bond. Its SMILES notation, CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(=O)O)[C@H]21, describes a chirally rich framework, underlining four stereocenters within a fused ring system typical of podophyllotoxin derivatives, situating it in the chemical category of epipodophyllotoxin. This particular scaffold is shared by drugs such as teniposide, which like etoposide acts as a topoisomerase inhibitor, used in the treatment of various malignancies. Etoposide exhibits its pharmacokinetic profile through adequate absorption upon administration, extensive distribution as evidenced by its volume of distribution, metabolism mainly in the liver via the cytochrome P450 enzyme CYP3A4, and it is primarily excreted through renal pathways with a fraction undergoing biliary excretion.

Toxicity of etoposide includes dose-limiting myelosuppression leading to neutropenia and thrombocytopenia, and a risk of secondary malignancies such as acute myelogenous leukemia. Etoposide targets the DNA topoisomerase II enzyme, inducing DNA strand breaks and leading to apoptosis in rapidly dividing cancer cells. Its therapeutic indications encompass a variety of neoplastic disorders, including small cell lung cancer and testicular tumors, among others. Side effects can encompass both hematologic toxicities like anemia and non-hematologic events such as alopecia, gastrointestinal disturbances, and hypersensitivity reactions. Clinically, etoposide is used both as a single agent and in combination regimens, particularly in the case of refractory testicular tumors and small cell lung cancer where it is part of the standard chemotherapeutic protocols, often combined with drugs like"
fentanyl,DB00344,"Fentanyl, identified with the DrugBank ID DB00344 and encoded by the SMILES notation ""CNCCCC1c2ccccc2C=Cc2ccccc21"", is a potent synthetic opioid analgesic with a rapid onset and short duration of action, noted for its highly lipophilic nature owing to an aromatic and aliphatic structure, which significantly contributes to its central nervous system penetrance. It falls within the chemical category of phenylpiperidines, sharing a core structural similarity to other opioid analgesics such as alfentanil and sufentanil, characterized by a 4-anilidopiperidine scaffold. Pharmacokinetically, fentanyl is well-absorbed, especially when given intravenously or transdermally, and it exhibits a high volume of distribution, with extensive protein binding and rapid redistribution to tissues. Biotransformation occurs primarily in the liver via the cytochrome P450 3A4 enzyme system, and it is predominantly excreted through urine as metabolites, with minimal unchanged drug. Fentanyl’s toxicity profile includes respiratory depression, a common but serious adverse effect which can lead to fatal outcomes if not properly managed, underscoring the need for cautious dose titration. The drug exerts its pharmacological effects mainly through the μ-opioid receptor, mediating analgesic responses. It is indicated for managing severe pain, such as that experienced in cancer, as well as in anesthesia protocols. Side effects, in addition to respiratory depression, include but are not limited to, nausea, sedation, and constipation. Clinically, fentanyl is employed across various settings, incorporating its use in both acute pain management via injection or transdermal patches in chronic pain management, exemplified in its role in palliative care for cancer-associated pain relief. The profile of fentanyl necessitates a judicious balance of its therapeutic efficacy against potential risks, mandating stringent monitoring and compliance with recommended practice guidelines."
fluorouracil,DB01103,"Fluorouracil, with DrugBank ID 'DB01103', is an antimetabolite chemotherapy drug characterized by its distinct chemical structure represented by the SMILES notation 'CCN(CC)CCCC(C)Nc1c2ccc(Cl)cc2nc2ccc(OC)cc12', which indicates a complex bicyclic ring system featuring a pyrimidine ring fused to an imidazole ring, including chloride and methoxy substituents. As a member of the pyrimidine analogue class of chemotherapy agents, it shares a common chemical scaffold with other similar drugs, such as capecitabine and gemcitabine. Fluorouracil's pharmacokinetics involve rapid absorption following administration, extensive distribution due to its low molecular weight, metabolism primarily in the liver through the enzyme dihydropyrimidine dehydrogenase (DPD), and excretion via the kidneys. Its toxicity profile includes myelosuppression exemplified by leukopenia and thrombocytopenia, gastrointestinal disturbances like mucositis, and dermatological reactions such as hand-foot syndrome. One of the key target proteins for fluorouracil is thymidylate synthase, which is pivotal in DNA synthesis. Indicated for treating various solid tumors, fluorouracil's applications include treatment for colorectal cancer and head and neck carcinomas. Notable side effects encompass a range from mild (e.g., nausea, diarrhea) to severe (e.g., cardiotoxicity, neurotoxicity). Clinically, fluorouracil is used both as a sole agent and in combination with other cytotoxic drugs in chemotherapeutic regimens, exemplified by the FOLFOX regimen for colorectal cancer."
fluoxetine,DB00882,"Fluoxetine, with the DrugBank ID DB00882, is a structurally complex phenylpropylamine featuring a substituted phenyl ring, linked to a propylamine side chain with the SMILES representation 'CCN(CC)CCOc1ccc(C(=C(Cl)c2ccccc2)c2ccccc2)cc1'. It falls under the chemical category of selective serotonin reuptake inhibitors (SSRIs), sharing its chemical scaffold with similar antidepressant drugs like sertraline and paroxetine. A prominent pharmacokinetic profile of fluoxetine includes oral absorption with a relatively slow onset of action, widespread distribution, being extensively metabolized primarily in the liver through the cytochrome P450 system, specifically CYP2D6, and elimination chiefly via the kidneys with a long elimination half-life. The toxicity of fluoxetine is generally well-characterized, presenting a low acute toxicity profile; however, overdose can lead to serotonin syndrome and, in severe cases, seizures or cardiac arrhythmias. Fluoxetine exerts its therapeutic effects through target proteins such as the serotonin transporter (SERT), inhibiting the reuptake of serotonin into presynaptic nerves, thereby increasing the levels of serotonin available in the synaptic cleft. Fluoxetine is indicated for the treatment of major depressive disorder, obsessive-compulsive disorder, and panic attacks, among others. Common side effects include nausea, headache, and sexual dysfunction, while more severe reactions can involve suicidal ideation particularly in young adults. Clinically, fluoxetine is used not only for its antidepressant qualities but is also employed in managing bulimia nervosa and is occasionally used off-label for anxiety disorders, showcasing its versatile application in psychiatric conditions."
flupenthixol,DB00285,"Flupenthixol, designated with the DrugBank identifier DB00285 and represented by the SMILES notation COc1ccc(C(CN(C)C)C2(O)CCCCC2)cc1, is a thioxanthene derivative characterized by its tricyclic structure fused with a piperazine ring and a side chain featuring a methoxy group at the phenothiazine nucleus. As a member of the thioxanthene class of antipsychotic agents, flupenthixol shares structural similarities and pharmacological properties with other thioxanthenes, such as zuclopenthixol. The pharmacokinetics of flupenthixol includes moderate oral absorption, extensive distribution with high protein binding, hepatic metabolism predominantly by cytochrome P450 enzymes with CYP2D6 involvement, and elimination through both renal and fecal pathways. Flupenthixol exhibits its antipsychotic effect through antagonism of dopamine D1 and D2 receptors, and may act on serotonergic and adrenergic systems, leading to its therapeutic use against schizophrenia and other psychoses. However, its dopamine antagonist activity can contribute to its toxicity profile, which includes extrapyramidal side effects, tardive dyskinesia, and neuroleptic malignant syndrome with potential for serious outcomes. The side effects encompass sedation, weight gain, and anticholinergic effects such as dry mouth and constipation. Clinically, flupenthixol is employed in both acute and chronic management of schizophrenia and is administered in various forms including oral tablets and depot injections, enabling both rapid control of acute symptoms and maintenance therapy to prevent relapse."
fluphenazine,DB00829,"Fluphenazine, with DrugBank ID DB00829 and SMILES notation CN1C(=O)CN=C(c2ccccc2)c2cc(Cl)ccc21, is a phenothiazine antipsychotic featuring a tricyclic dibenzothiazepine structure with a chlorine atom at the 2-position and a piperazine substituent at N10. This chemical category is known for its neuroleptic properties, with the phenothiazine scaffold providing the basis for several other psychotropic agents such as chlorpromazine and perphenazine. Fluphenazine's pharmacokinetics exhibits typical characteristics: after administration, it is well-absorbed, extensively distributed across tissues including the brain, heavily metabolized by hepatic enzymes (primarily CYP2D6), and ultimately excreted in urine and feces. Its toxicity can manifest in various forms, such as extrapyramidal symptoms, tardive dyskinesia, and neuroleptic malignant syndrome, particularly at higher doses or with long-term use. The drug mainly targets dopamine D2 receptors in the central nervous system, which elucidates its primary indication for managing symptoms of schizophrenia and other psychotic disorders. Side effects of fluphenazine can range from mild (drowsiness, dry mouth) to severe (akathisia, QT prolongation), necessitating careful monitoring. Clinically, fluphenazine is employed both for acute psychotic episodes and for maintenance therapy, showcasing its utility as a long-acting typical antipsychotic in the management of chronic psychiatric conditions."
flurazepam,DB00622,"Flurazepam, known by its DrugBank identifier DB00622, is characterized by a complex chemical structure featuring a methyl ester group (COC(=O)), an amidine, and a substituted diphenylmethane moiety within its framework, as delineated by its SMILES notation: COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)Cc2ccccc2)C1c1cccc([N+](=O)[O-])c1. As a member of the benzodiazepine chemical category, flurazepam exhibits a classic benzodiazepine scaffold, sharing structural similarities with other benzodiazepines, such as diazepam and lorazepam. Its pharmacokinetics reveal rapid absorption, with extensive distribution throughout the body's tissues; metabolism primarily occurs hepatically via cytochrome P450 enzymes leading to active metabolites, and elimination is predominantly renal. The drug's toxicity is generally dose-dependent, with excessive sedation and respiratory depression as notable examples of overdose manifestations. GABA(A) receptors are the primary target proteins, where flurazepam exerts its therapeutic effects by enhancing the inhibitory neurotransmitter GABA's action. Indicated for the short-term treatment of insomnia, flurazepam alleviates symptoms of sleep disturbances. Notwithstanding its efficacy, side effects include drowsiness, dizziness, and sometimes more severe cognitive impairments. Clinically, flurazepam's usage is primarily intended for patients who require initial insomniac symptom relief, with careful consideration given to its dependency potential and the patient's overall medication regimen to mitigate risks of adverse effects or potentiation of toxicity."
flurbiprofen,DB00758,"Flurbiprofen, designated by DrugBank ID DB00758, is a nonsteroidal anti-inflammatory drug (NSAID) and its unique SMILES string, ""COC(=O)[C@H](c1ccccc1Cl)N1CCc2sccc2C1"", delineates the drug's chemical structure revealing a substituted phenyl group combined with a chiral carbon center linked to a propionic acid moiety that is further conjugated to a tetrahydropyran ring, integrating sulfur into its heterocyclic system. This chemical framework categorizes flurbiprofen as a member of the profens, with a chemical scaffold characterized by a propionic acid derivative incorporate within an aromatic ring, similar to drugs like ibuprofen and ketoprofen which feature variations in their aromatic or heterocyclic rings. Flurbiprofen's pharmacokinetics involves rapid absorption after oral administration, with peak plasma concentrations reached within 1.5 to 2 hours, and an appreciable volume of distribution; it is extensively metabolized in the liver predominantly via hydroxylation and glucuronidation, with excretion mainly through the urine. Toxicity profiles indicate that overconsumption or sensitivity to flurbiprofen can lead to gastrointestinal ulcers or renal toxicity, exemplified by cases of gastritis or nephritis respectively. It primarily targets cyclooxygenase-1 and cyclooxygenase-2 proteins, inhibiting the synthesis of prostaglandins that contribute to inflammation. Flurbiprofen is indicated for the treatment of conditions such as rheumatoid arthritis and osteoarthritis, alleviating symptoms like inflammation and pain. Some common side effects include, but are not limited to, gastrointestinal discomfort, headache, and dizziness. In clinical practice, flurbiprofen is administered to manage mild to moderate pain, control arthritic flare-ups, and in some instances used in ophthalmic solutions for pupil dilation during eye surgery."
folic acid,DB01054,"Folic acid, with DrugBank ID DB01054, is characterized by its SMILES notation CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1cccc([N+](=O)[O-])c1, revealing a complex structure with a pteridine ring conjugated to a para-aminobenzoate and glutamate. Classified chemically as a form of vitamin B9, its structure is built on a pterin scaffold, sharing similarities with other folate derivatives such as methotrexate and leucovorin. Folic acid's pharmacokinetic profile includes good oral absorption, wide distribution across body tissues, metabolism into active tetrahydrofolate derivatives primarily in the liver, and excretion through urine. Though considered to have a high margin of safety, folic acid toxicity can emerge at high doses, leading to symptoms such as nausea, abdominal cramps, and, rarely, neurological issues. Its primary biological target is the enzyme dihydrofolate reductase, involved in the synthesis of thymidylate and purine, which are essential for DNA synthesis. Clinically, folic acid is indicated for conditions like megaloblastic anemia and is also employed to prevent neural tube defects in pregnancy, such as spina bifida. Side effects are generally mild but can include gastrointestinal discomfort and allergic reactions. In clinical practice, folic acid is routinely used in prenatal vitamins, for folate deficiency, and as an adjunct in specific chemotherapy regimens to mitigate methotrexate toxicity, exemplifying its crucial role in human health."
furosemide,DB01200,"Furosemide, with DrugBank ID DB01200 and SMILES notation CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]c(Br)c(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12, is a potent loop diuretic featuring a complex chemical structure that includes a sulfonamide moiety, indicative of its chemical category as a sulfonamide derivative. Its chemical scaffold is based on a furanose ring, central to its pharmacophoric properties. Furosemide is structurally similar to other diuretics such as bumetanide and torsemide, which share its loop diuretic classification. Pharmacokinetically, furosemide is characterized by rapid absorption from the gastrointestinal tract, widespread distribution including passage into the renal tubular fluid, hepatic metabolism via glucuronidation, and eventual renal excretion. Furosemide's toxicity profile includes the potential for ototoxicity, especially when used in high doses or in combination with other ototoxic drugs like aminoglycoside antibiotics. The drug exerts its pharmacological action primarily through inhibition of the Na-K-2Cl symporter in the ascending limb of the loop of Henle, one of its known target proteins. Clinically, furosemide is indicated for the management of edema associated with congestive heart failure, cirrhosis, and renal disease, as well as for the treatment of hypertension. Common side effects can include electrolyte imbalance, dehydration, hypotension, and, in some cases, metabolic alkalosis. In the clinical setting, furosemide is often used for its rapid onset of diuresis, making it a drug of choice in acute settings requiring quick fluid removal, such as pulmonary edema."
glyburide,DB00925,"Glyburide, with the DrugBank ID DB00925, is characterized by its SMILES notation CC(COc1ccccc1)N(CCCl)Cc1ccccc1, which denotes a complex organic molecule composed of a central urea linked to a cyclohexyl group on one end and an ethylbenzene moiety on the other, further substituted with a chloro propyl and a methoxy phenyl group. Classified as a sulfonylurea, glyburide shares its chemical scaffold—a sulfonylurea bridge connecting an aryl group with a cyclic substituent—with similar antidiabetic drugs such as glipizide and glimepiride. As a sulfonylurea, glyburide functions by stimulating insulin release from pancreatic beta cells. Regarding pharmacokinetics, glyburide exhibits rapid oral absorption, extensive plasma protein binding, hepatic metabolism primarily through the CYP2C9 enzyme, and urinary excretion of its metabolites.

Glyburide's toxicity profile includes the risk of hypoglycemia, particularly in cases of overdose or in combination with other glucose-lowering agents, and contraindications in patients with hepatic or renal impairment. Sulfonylurea medications such as glyburide act on ATP-sensitive potassium channels in pancreatic beta cells; these channels have the protein SUR1 (sulfonylurea receptor 1) as a key component which is essential to their insulinotropic effect. Glyburide is indicated for the control of blood glucose levels in type 2 diabetes mellitus, especially in cases where diet, exercise, and weight reduction alone have not led to adequate glycemic control.

Common side effects can include weight gain, nausea, and dizziness, while more severe adverse effects are jaundice and thrombocytopenia, although these are less common. Clinically, glyburide is typically part of a larger diabetes management plan and is preferred for patients who can still produce insulin. Its long action allows for once or twice daily dosing, assisting in the improvement of patient adherence. The integration of glyburide into therapeutic regimens should always be contingent upon a comprehensive evaluation of patient-specific factors"
glycerol,DB00790,"Glycerol, represented by DrugBank ID DB00790 and SMILES notation CCC[C@H](N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@@H]2CCCC[C@@H]21)C(=O)OCC, has a chemical structure characterized by a central glycerol backbone with attached carbamate and cyclic carbonate ester groups, hinting at its classification as a carbamate ester. This compound consists of a unique chemical scaffold which does not broadly fall into a category of drugs with numerous similar analogs; however, its structural motifs may draw parallels with other carbamate-containing compounds such as meprobamate. In terms of pharmacokinetics, glycerol could potentially exhibit pharmacokinetic properties such as rapid absorption due to its small size and significant hydrophilicity, a wide distribution given its aqueous solubility, metabolism by various esterases, and excretion likely chiefly via the renal route.

However, glycerol's chemical structure as provided does not align with the typical understanding of glycerol as a simple trihydroxy alcohol, and instead, this appears to be a complex derivative with additional reactive groups. This can lead to a misalignment with the conventional toxicity profile of simple glycerol, which is generally regarded as safe but can cause osmotic diuresis and electrolyte imbalance in excessive doses. The provided structure suggests a more complex toxicity profile due to the presence of lactam and ester functionalities that could be hydrolyzed in vivo, requiring consideration of metabolites in toxicity assessments. Known target proteins of conventional glycerol could involve various pathways such as osmoregulation, although with the given structure, it might engage additional specific enzymes or receptors dues to its altered chemical scaffold.

The typical indication of common glycerol is for conditions requiring osmotic diuresis or as a hyperosmolar agent in the reduction of cerebral edema and intraocular pressure. Side effects of simple glycerol usage can include headache, dehydration, and gastrointestinal discomfort, although the structure in question might elicit side effects related to its ester and lactam components. In a clinical context"
haloperidol,DB03783,"Haloperidol, a high-potency, typical antipsychotic drug associated with DrugBank ID DB0037883 and represented by the SMILES notation ""CCOc1ccc(NC(C)=O)cc1"", is characterized by its butyrophenone chemical structure, which features a ketone functional group attached to an amino group through a tertiary carbon within a benzene ring conjugated to a piperidine and a tetrahydrofuran moiety. This butyrophenone scaffold is integral to its activity and is shared by other antipsychotics, such as droperidol. Pharmacokinetically, haloperidol is well-absorbed orally, with hepatic metabolism predominantly via the cytochrome P450 isozymes CYP3A4 and CYP2D6; it has a high volume of distribution, indicating substantial tissue uptake, and is excreted primarily through the biliary route. In terms of toxicity, haloperidol can induce extrapyramidal symptoms and, occasionally, rare but serious side effects like neuroleptic malignant syndrome and QT interval prolongation. The drug exerts its therapeutic effects by antagonizing dopamine D2 receptors in the brain, among other targets, making it particularly suitable for treating schizophrenia, acute psychosis, and Tourette syndrome. Side effects, including sedation, akathisia, and tardive dyskinesia, have been well-documented. Clinically, haloperidol is also employed in off-label uses, such as for symptomatic control in delirium and as an adjunctive treatment for severe behavioral problems in children, highlighting its versatility in neuropsychiatric management."
hydrocortisone,DB00537,"Hydrocortisone, with the DrugBank identifier DB00537, is a glucocorticoid medication whose core chemical structure is depicted by the SMILES notation ""O=C(O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O"". This notation outlines a compound with a pregnane backbone, featuring a ketone at the 3 position and a hydroxyl at the 17 position, which classifies it chemically as a corticosteroid—a category known for its anti-inflammatory and immunosuppressive effects. Structurally related drugs within this category include prednisone and dexamethasone. Pharmacokinetically, hydrocortisone is well-absorbed following topical, oral, or parenteral administration, with significant hepatic metabolism predominantly via the cytochrome P450 enzyme pathway, subsequent conjugation with glucuronic acid or sulfate, and renal excretion. Its safety profile indicates a relatively low toxicity at therapeutic doses, but potential adrenal suppression or Cushing's syndrome can develop with prolonged high-dose therapy. The drug acts on glucocorticoid receptors, entering the nucleus and modulating gene expression to exert its pharmacological effects. Clinically, it is indicated for conditions such as adrenal insufficiency, inflammation from rheumatic or skin diseases, and allergies. Side effects can range from mild, such as weight gain and mood alterations, to more severe, such as osteoporosis and immune compromise with long-term use. Hydrocortisone's clinical use extends across various formulations, including oral, topical, and injectable preparations, for acute and chronic management of adrenal disorders like Addison's disease, inflammatory conditions like dermatitis, and as adjunctive treatment in certain cases of cancer-related edema."
ibuprofen,DB01023,"Ibuprofen (DB01023) is a nonsteroidal anti-inflammatory drug (NSAID) with a chemical structure characterized by a propionic acid derivative consisting of a benzene ring substituted with two chlorine atoms (4-chlorophenyl) and a methyl group (2-methylpropyl), connected to a central hexane ring that encompasses both ketone and isobutyl functionalities. The SMILES notation 'CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1cccc(Cl)c1Cl' encapsulates this molecular architecture, indicating the presence of two ester groups derived from ethanoic acid (acetic ester) and additional functionalities that confer its pharmacodynamic properties. As a representative chemical entity in the NSAID category, ibuprofen's core chemical scaffold is comparable to other propionic acid derivatives, including naproxen and ketoprofen, which share the anti-inflammatory, analgesic, and antipyretic effects attributed to the inhibition of cyclooxygenase (COX) enzymes.

Pharmacokinetically, ibuprofen is well absorbed from the gastrointestinal tract, achieving peak plasma concentrations within 1 to 2 hours. It is widely distributed throughout the body, with a volume of distribution typically around 0.1 L/kg and a plasma protein binding of approximately 99%. The metabolism of ibuprofen primarily occurs in the liver via oxidation and hydroxylation, facilitated by cytochrome P450 enzymes, followed by conjugation with glucuronic acid. The resulting metabolites are primarily excreted through the urine, with a minor extent of unchanged drug also detected.

In terms of toxicity, ibuprofen exhibits a relatively safe profile at prescribed dosages, though overdose can lead to symptoms such as nausea, abdominal pain, dizziness, and, in severe cases, renal failure or gastrointestinal bleeding. Its primary target proteins are the COX-1 and COX-2 enzymes, which are pivotal in the biosynthesis of prostanoids, including prostaglandins, prostacyclin, and thromboxanes, compounds involved in mediating inflammation, pain, and fever.

Clinically, ibuprofen"
imipramine,DB00443,"Imipramine, assigned the DrugBank ID DB00443, is a tricyclic antidepressant (TCA) that possesses a dibenzazepine moiety as its core chemical scaffold. Its intricate chemical structure is depicted through the SMILES notation ""C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,"" which reveals a tricyclic core with a propylamine side chain, and includes stereocenters illustrating the drug's chiral nature. Imipramine is chemically related to other TCAs such as amitriptyline and desipramine. Pharmacokinetically, imipramine undergoes extensive first-pass metabolism, is well-absorbed from the gastrointestinal tract, is highly protein-bound, and is metabolized primarily by the liver, with subsequent excretion in the urine and feces. Its drugs' metabolism predominantly involves hepatic cytochrome P450 isozymes, leading to various metabolites including the active desipramine. Imipramine's toxicity profile includes cardiotoxicity and seizures, especially in overdose situations. As for its pharmacological targets, imipramine primarily inhibits the reuptake of neurotransmitters serotonin and norepinephrine, thereby modulating mood and affect. Indications for imipramine encompass major depressive disorder and enuresis in children, providing relief from depressive symptoms and nocturnal bedwetting. Notable side effects span from anticholinergic effects such as dry mouth and constipation to cardiovascular disturbances like orthostatic hypotension. Clinically, imipramine has seen extensive use for depressive states, sometimes extending to off-label applications including anxiety disorders and chronic pain management. Despite its efficacy, the drug's side effect profile and toxicity risk call for careful patient monitoring and consideration of newer, safer antidepressants as first-line therapy."
indomethacin,DB00197,"Indomethacin, with DrugBank ID DB00197, is a nonsteroidal anti-inflammatory drug (NSAID) that exhibits a complex chemical structure denoted by the SMILES notation Cc1c(C)c2c(c(C)c1O)CCC(C)(COc1ccc(CC3SC(=O)NC3=O)cc1)O2. Its chemical structure features a benzoylindole scaffold and is characterized by an indole ring substituted at position 1 with a chlorobenzoyl group and at position 2 with a methoxyethyl group. This class of drugs shares this scaffold, with closely related NSAIDs including ibuprofen, naproxen, and diclofenac, among others. Indomethacin is well absorbed after oral administration, with peak plasma concentrations occurring typically within 2 hours. It is widely distributed in the body, with plasma protein binding over 98%, chiefly to albumin. Metabolism occurs largely in the liver through processes such as demethylation and deacetylation, with the metabolites primarily excreted via urine and, to a lesser extent, in feces. The toxicity profile of indomethacin includes gastrointestinal ulcers and bleeding, renal dysfunction, and, rarely, cardiovascular thrombotic events, reflecting its action on prostaglandin synthesis by inhibition of the COX (cyclooxygenase) enzymes, which are the primary drug targets. Indomethacin is indicated for a variety of conditions, most notably for treating pain and inflammation associated with diseases such as rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, and acute gouty arthritis. Side effects often encountered include headaches, dizziness, gastrointestinal distress, and nausea, aligning with its widespread effects on prostaglandin-mediated processes. Clinically, indomethacin is also used off-label for conditions such as patent ductus arteriosus in neonates, highlighting its vasoactive properties that have practical applications beyond anti-inflammatory purposes. Its clinical use is generally considered when other NSAIDs are either ineffective or contraindicated, with therapeutic decisions being guided by a risk-benefit assessment owing to its"
ivermectin,DB00641,"Ivermectin is a macrocyclic lactone with a complex chemical structure, designated by the SMILES notation CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21, which reveals its multiple chiral centers and a condensed bicyclic system embedded within a tricyclic framework. As a member of the avermectin class, it shares its chemical category with other avermectins, though ivermectin is unique in its substitution pattern and is widely recognized for its use in treating parasitic infections compared to its analogs like selamectin, commonly used in veterinary medicine. Ivermectin's pharmacokinetics exhibit moderate absorption following oral administration, wide distribution in body tissues due to its lipophilic nature, metabolism primarily by the liver enzyme CYP3A4, and excretion mainly in feces, with minimal renal clearance. Its toxicity profile includes neurotoxicity, attributable to its ability to potentiate inhibitory neurotransmission through glutamate-gated chloride channels, which are among its target proteins, specifically affecting parasites more so than mammalian counterparts due to differences in the blood-brain barrier. Clinically, ivermectin is indicated for the treatment of various parasitic diseases, such as onchocerciasis and strongyloidiasis, and is sometimes used in managing scabies and filariasis. Side effects are generally mild but can include dermatological reactions (like pruritus) and gastro-intestinal symptoms, with serious adverse effects being rare and often associated with the disease being treated, particularly the die-off of parasites. The clinical usage of ivermectin is broad, with significant impact on global health, exemplified by its inclusion in efforts to control river blindness in endemic regions, thus underscoring its reputation as a ""wonder drug"" in parasitology."
ketamine,DB00441,"Ketamine, with DrugBank ID DB00441, is a cyclohexanone derivative with a notable chemical structure characterized by the SMILES notation 'Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1', indicating a chiral compound with two enantiomers due to the [C@@H] stereocenters. As a member of the arylcyclohexylamine chemical class, ketamine possesses a phenyl ring bound to a cyclohexane ring, akin to its scaffold, which is shared by similar dissociative anesthetics like phencyclidine (PCP). It exhibits a complex pharmacokinetics profile: rapid absorption, extensive distribution with a high lipid solubility, predominantly hepatic metabolism via N-demethylation to norketamine, and finally renal excretion. Ketamine's known toxicity includes the potential for neurocognitive deficits and urinary tract dysfunction at high or prolonged doses. It modulates neuronal activity primarily through noncompetitive antagonism of the N-methyl-D-aspartate (NMDA) receptor; however, it also influences opioid receptors and monoamine transporters. Clinically, ketamine is utilized for induction and maintenance of anesthesia, as well as a rapid-acting antidepressant, particularly in treatment-resistant major depressive disorder (MDD) cases. Adverse effects range from psychotomimetic symptoms, such as hallucinations, to cardiovascular stimulation. In clinical practice, off-label use of ketamine has grown for chronic pain management, while emergency medicine exploits its dual properties of sedation and analgesia, exemplified in procedural sedation and acute pain control."
ketoconazole,DB00502,"Ketoconazole, registered under DrugBank ID 'DB00502', is an antifungal agent possessing a complex chemical structure delineated by the SMILES notation 'O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1'. Its structure features a bisphenyl moiety bearing a chloro-substituted and a fluoro-substituted phenyl ring, joined by a saturated three-carbon side chain to an imidazole ring, indicative of its classification within the imidazole chemical category. This structure is emblematic of the azole chemical scaffold, known for its utility in various antifungal drugs, such as fluconazole and itraconazole, which share the azole-containing core that is crucial for inhibiting ergosterol synthesis in fungi. Ketoconazole's pharmacokinetic profile illustrates moderate absorption from the gastrointestinal tract, extensive distribution including high lipophilicity enabling penetration into various tissues, metabolism primarily in the liver via the cytochrome P450 (CYP3A4) enzyme, and excretion predominantly in the bile and feces.

Toxicity concerns for Ketoconazole include hepatotoxicity, QT prolongation, and potentially fatal adrenal insufficiency, with instances of severe liver injury warranting its cautious use. Its principal mechanism of action involves the inhibition of fungal cytochrome P450 enzymes, especially the 14α-demethylase crucial for ergosterol synthesis, a component of the fungal cell membrane. This drug is indicated for systemic fungal infections such as candidiasis, chronic mucocutaneous candidiasis, oral thrush, and dermatophytosis when topical therapy is impractical. Side effects of ketoconazole may encompass gastro-intestinal distress, such as nausea and vomiting, hepatic dysfunction, and more rarely, alopecia and gynecomastia due to its antiandrogenic effects.

Clinically, ketoconazole was extensively used in both oral and topical formulations; however, due to concerns over adverse effects and the availability of safer alternatives, its use has declined, particularly for systemic infections. The topical formulation, nevertheless, remains in use for conditions like seborrheic dermat"
ketoprofen,DB01595,"Ketoprofen, with the DrugBank identifier DB01595, is a nonsteroidal anti-inflammatory drug (NSAID) characterized by its SMILES notation 'O=C1CN=C(c2ccccc2)c2cc([N+](=O)[O-])ccc2N1', which reveals a benzoyl ring fused to a pyrrole ring, incorporating an oxo functional group and a nitro phenyl moiety at distinct positions. This chemical composition belongs to the broader category of propionic acid derivatives, sharing its core structure with other NSAIDs like ibuprofen and naproxen. Its pharmacokinetic profile is well understood, with rapid and high absorption from the gastrointestinal tract, extensive protein binding, primarily albumin, and a relatively short half-life necessitating multiple doses per day for sustained effect. Metabolism primarily occurs through the cytochrome P450 enzyme system, specifically CYP2C9, converting it into various metabolites, followed by renal and biliary excretion. Toxicity concerns revolve mainly around gastrointestinal, renal, and cardiovascular risks, similar to other NSAIDs. The primary target of ketoprofen is cyclooxygenase (COX-1 and COX-2) enzymes, inhibiting prostaglandin synthesis, thereby exerting its anti-inflammatory, analgesic, and antipyretic effects. Clinically, ketoprofen is indicated for the management of acute pain, the signs and symptoms of rheumatoid arthritis, and osteoarthritis. However, its utility must be balanced against potential side effects, including but not limited to gastrointestinal ulcers, bleeding, kidney dysfunction, and hypersensitivity reactions. Nonetheless, when used judiciously following medical guidance, ketoprofen has proven to be an effective component in the therapeutic arsenal against inflammation and pain."
levodopa,DB00342,"Levodopa, with DrugBank ID DB00342 and SMILES notation CC(C)(C)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1, is a prodrug that undergoes enzymatic decarboxylation to become dopamine. This aromatic amino acid is categorized within the chemical class of dopa derivatives. Its structure features a benzene ring connected to a propyl side chain that terminates in a carboxylic acid and amino group, which is characteristic of its phenethylamine scaffold. Similar drugs that mimic levodopa's function or are used in conjunction to treat the same conditions include carbidopa and entacapone. Pharmacokinetically, levodopa is rapidly absorbed from the gastrointestinal tract, crosses the blood-brain barrier via an amino acid transport system, is extensively metabolized primarily by the enzyme aromatic L-amino acid decarboxylase, and finally, is excreted in the urine. Toxicity can manifest as dyskinesias and cardiovascular disturbances in sensitive individuals. Levodopa's therapeutic effects derive mainly from its ability to replenish dopamine in the brain by targeting and being converted by DOPA decarboxylase. Its primary indication is for the treatment of Parkinson's disease and dopamine-responsive dystonia, as it mitigates symptoms such as bradykinesia, rigidity, and tremors. Side effects include nausea, orthostatic hypotension, and behavioral changes. Clinically, levodopa is often used in combination with a DOPA decarboxylase inhibitor like carbidopa to prevent peripheral metabolism and thus increase its availability to the central nervous system, enhancing its effectiveness for the symptomatic management of Parkinsonian syndromes."
lidocaine,DB00458,"Lidocaine, with the DrugBank ID DB00458, is a local anesthetic and antiarrhythmic drug featuring a diethylamine group attached to an amide linker and a secondary amine incorporated into a xylidine moiety, as reflected in its SMILES notation 'CN(C)CCCN1c2ccccc2CCc2ccccc21'. Chemically categorized as an amide local anesthetic, its structure is built upon the xylidine scaffold, which it shares with analogous drugs such as mepivacaine and bupivacaine. Lidocaine's pharmacokinetics profile reveals rapid absorption when administered intravenously or topically with anesthetic effect onset within minutes, extensive distribution being highly lipid-soluble, hepatic metabolism primarily via CYP3A4 with formation of several metabolites including the pharmacologically active monoethylglycinexylidide (MEGX), and renal excretion of metabolites. Its toxicity is characterized by dose-dependent CNS and cardiovascular effects, and, in high doses, can lead to seizures, cardiac arrhythmias, or even cardiac arrest. Lidocaine acts upon voltage-gated sodium channels, specifically Na_v1.7, Na_v1.8, and Na_v1.9, inhibiting ion conduction and membrane depolarization. Clinically indicated for the treatment of ventricular arrhythmias and as a local anesthetic for various procedures, including dental work and minor surgeries, it is effective in alleviating pain, itching, or burning by blocking nerve signal transmission. Notwithstanding its therapeutic benefits, potential side effects encompass numbness, tingling, dizziness, and in rare cases, anaphylactic reactions. In medical practice, lidocaine may be administered in several formulations, such as intravenous infusions for acute arrhythmias, topical gels or creams for surface anesthesia, or via infiltration and nerve block techniques for regional anesthesia during invasive procedures."
loperamide,DB00471,"Loperamide, with DrugBank ID 'DB00471' and SMILES notation 'CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1', is a synthetic opioid derivative with a detailed chemical structure that includes a piperidine ring bonded to a phenyl group and an aromatic system containing a chlorinated diphenyl moiety, characterized by a conjugated double bond. It belongs to the chemical category of opioids, more specifically to the peripheral opioid receptor agonists. Its chemical scaffold is based on a tetrahydropyrimidine system, sharing similarities with other antidiarrheal opioids like diphenoxylate.

Pharmacokinetically, after oral administration, loperamide is well absorbed from the gastrointestinal tract, but its bioavailability is reduced due to significant first-pass metabolism in the liver, mainly by the CYP450 isoenzyme CYP3A4 and to a lesser extent CYP2C8. The drug is extensively distributed, binds to tissues and proteins like albumin, and metabolically transformed into inactive metabolites, which are mainly excreted in the feces, with minimal renal clearance.

Loperamide's toxicity is typically low due to its poor central nervous system penetration; however, at higher doses or in cases of misuse, it can lead to cardiac toxicity, including QT interval prolongation and Torsades de Pointes. Its known pharmacological target proteins are the mu-opioid receptors (MOR) in the myenteric plexus of the large intestine, which mediate the drug's antiperistaltic and antisecretory effects, reducing fecal volume and increasing water and electrolyte absorption.

Loperamide is indicated for the symptomatic treatment of acute nonspecific diarrhea and chronic diarrhea associated with inflammatory bowel disease. Side effects of loperamide are typically mild and can include constipation, dizziness, and nausea. Clinically, loperamide's usage extends to managing diarrhea resulting from gastroenteritis and as a component in reducing ileostomy output. However, it is not recommended"
lovastatin,DB00715,"Lovastatin, designated by DrugBank ID DB00715, is a molecule with a complex chemical structure that incorporates a fluorophenyl group linked to a hexahydronaphthalene ring system through a tetrahydropyran ether, as illustrated by its SMILES notation Fc1ccc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)cc1. This compound falls under the chemical category of statins, which are typically characterized by their lactone or hydroxy acid forms and are synthesized by fungi. Lovastatin's chemical scaffold is based on a dihydromonacolin K structure, similar to other statins like simvastatin and pravastatin, which share a common HMG-CoA reductase inhibitory activity. Pharmacokinetically, lovastatin is well-absorbed in the gastrointestinal tract, undergoes substantial first-pass metabolism in the liver primarily by Cytochrome P450 3A4, is highly protein-bound in circulation, and is excreted via the bile. Its toxicity profile includes the potential for myopathy and rare instances of rhabdomyolysis, primarily when interacted with drugs that inhibit its primary metabolic pathway. Lovastatin specifically targets the HMG-CoA (3-hydroxy-3-methyl-glutaryl-CoA) reductase protein, which is critical in the biosynthetic pathway for cholesterol, thus making it particularly effective in the treatment of hypercholesterolemia. Side effects may include muscle pain, constipation, and headache. Clinically, lovastatin has been used to manage dyslipidemias and to prevent cardiovascular events in patients with risk factors for coronary artery disease. It serves as an example of a lipid-lowering agent that has changed the landscape of cardiovascular risk management by significantly lowering low-density lipoprotein (LDL) cholesterol levels in patients."
maprotiline,DB00199,"Maprotiline, bearing the DrugBank ID DB00199, is characterized by a complex and extensive chemical structure as delineated by its SMILES notation. As a tetracyclic antidepressant (TeCA), maprotiline structurally resembles other tricyclic antidepressants (TCAs) but incorporates an additional fourth ring, establishing its chemical category within the realm of heterocyclic chemical compounds. Its scaffold is characterized by a central seven-membered ring fused to additional ring systems—a structure it shares with similar antidepressants such as amitriptyline and imipramine, though with distinct pharmacokinetic profiles. Maprotiline is well-absorbed orally and exhibits extensive tissue distribution, binding significantly to plasma proteins. The hepatic metabolism of maprotiline involves demethylation and hydroxylation, primarily via the cytochrome P450 isoenzymes CYP2D6 and CYP1A2, before conjugation and renal excretion. Its toxicity profile includes cardiotoxicity such as arrhythmias, which is consistent with other TCAs, and central nervous system effects like convulsions at high doses. It acts primarily by inhibiting the reuptake of norepinephrine, with its main target protein being the norepinephrine transporter (NET). Clinically, maprotiline is indicated for the treatment of depressive disorders, benefiting patients with major depression by mitigating symptoms such as pervasive sadness and anhedonia. Its side effects are typical of TCAs, including but not limited to, anticholinergic effects like dry mouth and constipation, sedation, and weight gain. In clinical practice, maprotiline is considered particularly for patients who do not respond to or cannot tolerate other antidepressants, often serving as an alternative when patients have comorbid insomnia due to its sedating properties."
mebendazole,DB00115,"Mebendazole, bearing the DrugBank identifier DB00115, is a synthetic benzimidazole derivate with a complex chemical structure outlined by the SMILES notation ""C/C1=C2/N=C(/C=C3\N=C(/C(C)=C4\[N-][C@@](C)([C@@H]5N=C1[C@](C)(CCC(=O)NC[C@@H](C)OP(=O)([O-])O[C@@H]1[C@@H](CO)O[C@H](n6cnc7cc(C)c(C)cc76)[C@@H]1O)[C@H]5CC(N)=O)[C@@](C)(CC(N)=O)[C@@H]4CCC(N)=O)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]2CCC(N)=O.[C-]#N.[Co+3]"". This notation incorporates a cobalt-coordinated complex, but it's important to note that mebendazole does not typically contain this metal ion in its therapeutic form. As an anthelmintic agent, mebendazole falls within the scope of anti-parasitic medication, withholding a chemical scaffold characteristic of the benzimidazole class. Closely-related compounds such as albendazole and thiabendazole exhibit similar anthelmintic properties. Mebendazole's pharmacokinetic profile shows limited oral absorption, a considerable hepatic first-pass effect with metabolism chiefly occurring in the liver, yielding multiple metabolites. It is poorly systemically distributed, lending to its efficacy in the digestive tract, and is primarily excreted in the feces. The compound exhibits relatively low human toxicity, yet long-term, high-dose therapy may potentially lead to liver dysfunction and neutropenia. Specific protein targets include parasite-specific β-tubulin, which the drug binds to, disrupting microtubule synthesis and thus impeding glucose uptake, effectively starvating and ultimately killing the susceptible helminths. Mebendazole is predominantly indicated for the treatment of a variety of worm infest"
melatonin,DB00373,"Melatonin (DrugBank ID: DB00373) is a naturally-occurring hormone with a chemical structure delineated by the SMILES notation 'CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1', which reveals its position as a tryptophan derivative, bearing an indole ring connected to an ethylamine side-chain. As a member of the chemical category of indoleamines, melatonin's structure features a heterocyclic scaffold characteristic of indoles, specifically modified by the attachment of a methoxy group and an acetyl side group at distinct points on the indole framework. This structural makeup shares similarities with other indole-based compounds such as serotonin and various synthetic indoleamine analogs developed for research or therapeutic purposes.

Pharmacokinetically, melatonin is rapidly absorbed with high bioavailability, it then undergoes distribution throughout body tissues with a significant proportion bound to plasma proteins. Metabolism predominantly occurs in the liver via cytochrome P450 enzymes, specifically CYP1A2, resulting in 6-hydroxymelatonin as a primary metabolite, which is further conjugated and prepared for renal excretion. The majority of an administered dose of melatonin is excreted in the urine as sulfate and glucuronide metabolites. Regarding toxicity, melatonin is generally regarded as having a high safety profile, but excessive dosages can lead to elevated blood levels, which might cause various symptoms ranging from dizziness to hormonal imbalances.

Melatonin's primary target proteins include the melatonin receptors MT1 and MT2, which belong to the G protein-coupled receptor (GPCR) family, involved in regulating circadian rhythms and reproductive hormones. Clinically, melatonin is indicated primarily for the management of sleep disorders such as insomnia, delayed sleep phase disorder, and to alleviate circadian rhythm disturbances like those experienced during shift work or jet lag. It has also shown some promise in treating seasonal affective disorder (SAD) and for preoperative anxiety.

While melatonin is generally well-tolerated, potential side-effects can include drowsiness, headache, dizziness, and nausea. In some cases, melatonin can"
memantine,DB00490,"Memantine, bearing the DrugBank ID DB00490, is defined by the SMILES notation O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(c2ncccn2)CC1, which reveals its unique bicyclo[3.3.1]nonan-9-one chemical structure, highlighting a tricyclic amine pharmacophore. It falls under the chemical category of adamantanes—an alicyclic chemical compound characterized by its rigid bicyclic framework which provides structural analogy to the diamond crystal lattice. As a chemical scaffold, Memantine is distinctive in its adamantane core fused with an aminoalkyl chain that links to a terminal adamantyl moiety. This structure is not widely replicated in pharmacology, however, related drugs such as Amantadine share some structural traits, mainly the adamantane pharmacophore. 

Memantine's pharmacokinetics are characterized by moderate bioavailability, a relatively slow absorption rate, a volume of distribution signifying substantial distribution into body tissues, minimal metabolism—largely without involvement of the cytochrome P450 system, and primary renal excretion as unchanged drug. Its toxicity profile includes neurological effects, such as dizziness and confusion, largely attributed to its action on the central nervous system. The drug’s primary target protein is the N-methyl-D-aspartate (NMDA) receptor, where it acts as a noncompetitive antagonist, thus modulating the glutamatergic system. Memantine is indicated for the treatment of moderate to severe Alzheimer's disease, where it can help to alleviate symptoms related to cognition and behavior. Adverse effects associated with memantine are usually mild to moderate and can include headache, constipation, and dizziness. In clinical practice, memantine is employed in symptomatic management to slow the progression of Alzheimer’s-related dementia, often in combination with acetylcholinesterase inhibitors for a more comprehensive approach to the management of neurodegenerative disorders."
meprobamate,DB00968,"Meprobamate, with the DrugBank identifier DB00968, is a central nervous system depressant featuring a 2-methyl-2-propyltrimethylene dicarbamate structure and can be denoted by the SMILES notation C[C@](N)(Cc1ccc(O)c(O)c1)C(=O)O. Chemically, it belongs to the carbamate class, based on a carbamate ester functional scaffold, and is structurally similar to other anxiolytic drugs such as carisoprodol, from which it can be metabolically derived. Pharmacokinetically, meprobamate is well absorbed orally, widely distributed throughout the body tissues, metabolized primarily in the liver via the cytochrome P450 enzyme system, and eliminated primarily through renal excretion. The drug's toxicity profile includes potential for abuse and overdose, which may lead to respiratory depression, coma, and shock. Its mechanism of action involves potentiating GABAergic neurotransmission by binding to GABA-A receptors, although the precise target proteins are not fully delineated. Meprobamate is indicated for the short-term relief of anxiety symptoms, though its use has decreased due to the risks of dependence and the availability of safer alternatives. Side effects may include drowsiness, dizziness, headache, and, in severe cases, impairment of motor function and ataxia. Clinically, the use of meprobamate has been largely supplanted by benzodiazepines and other anxiolytics, but it still may be encountered in the management of acute episodes of anxiety or tension in specified patients, as part of a tailored therapeutic regimen."
methadone,DB00559,"Methadone, with the DrugBank ID 'DB00559', is a synthetic opioid with a complex chemical structure, as indicated by its SMILES notation ""COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(C(C)(C)C)cc2)nc(-c2ncccn2)nc1OCCO."" The structure features a diphenyl ether framework with a phenyl ring at one end and a dioxolane ring linked to a benzamido group at the other. It falls under the chemical category of synthetic opioids, sharing its scaffold with other opioids but distinguished by its unique substitution pattern compared to drugs like morphine. Regarding pharmacokinetics, methadone is well-absorbed orally, has a high volume of distribution, is extensively metabolized in the liver primarily via N-demethylation by CYP3A4, CYP2B6, and CYP2D6 enzymes, with renal and fecal excretion of its metabolites. Its toxicity can include respiratory depression and QT interval prolongation leading to torsades de pointes. The primary target proteins for methadone are the mu-opioid receptors, where it functions as an agonist to produce analgesia. Methadone is indicated for the management of chronic pain and as a part of opioid maintenance therapy in individuals with opioid use disorder, aiming to reduce withdrawal symptoms and opioid cravings. Common side effects encompass sedation, constipation, and sweating, with more severe effects potentially including life-threatening respiratory depression. Clinically, methadone is utilized in various settings such as pain clinics for its analgesic properties and in substance abuse treatment programs, where it is provided via a methadone maintenance program to aid in the recovery process for individuals struggling with opioid dependence."
methamphetamine,DB00451,"Methamphetamine, with DrugBank ID DB00451 and the incorrect SMILES notation 'N[C@@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(=O)O', is a psychostimulant of the phenethylamine and amphetamine chemical classes that belong to a broader category of psychoactive compounds. The correct SMILES notation for methamphetamine is 'CC(CC1=CC=CC=C1)NC', which reflects its structure consisting of a phenethylamine core with a methyl group attached to the amine nitrogen (N-alkylated), indicative of its placement in the amphetamine subclass. Similar stimulant drugs include dextroamphetamine and lisdexamfetamine, which share the phenethylamine scaffold and have comparable central nervous system (CNS) stimulant effects.

Pharmacokinetically, methamphetamine is well absorbed from the gastrointestinal tract, crossing the blood-brain barrier to exert its effects centrally. It is distributed widely in the body and is known for its high lipid solubility, which contributes to its addictive potential. Methamphetamine is metabolized primarily in the liver by oxidative deamination, followed by p-hydroxylation and N-demethylation, with the involvement of various cytochrome P450 isoforms. The drug and its metabolites are excreted mainly in the urine, with renal clearance rates influenced by urine pH.

The toxicity of methamphetamine is well-documented, including neurotoxicity and cardiotoxicity, potentially leading to long-term cognitive deficits, psychosis, and cardiovascular complications. Acute overdoses can result in hyperthermia, seizures, and fatal arrhythmias.

Methamphetamine's primary pharmacological targets are the transport proteins for dopamine, norepinephrine, and serotonin, which it influences by promoting the release of these neurotransmitters into the synaptic cleft, thereby amplifying their signaling and eliciting potent CNS stimulation.

Clinically, methamphetamine is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) and certain cases of treatment-resistant obesity. However, its use is limited due to high abuse potential and severe side effects, including insomnia, agitation, anore"
methionine,DB00950,"Methionine, with the DrugBank identifier DB00950, is an essential amino acid with a complex molecular structure denoted by the SMILES notation 'CC(C)(C(=O)O)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1'. This notation reveals a thioether-containing side chain, underscoring its classification as a sulfur-containing amino acid and a member of the alpha-amino acids chemical category. The compound is built around an aliphatic chemical scaffold that is key to its role in biological systems alongside similar sulfur-containing amino acids, such as cysteine. Methionine's pharmacokinetic profile includes gastrointestinal absorption, distribution through bodily fluids, metabolism mainly in the liver via the transsulfuration pathway, and excretion predominantly via urine. The amino acid exhibits low toxicity; however, excessive dosages could lead to hypermethioninemia and its associated symptoms. Target proteins for methionine's biological activity are largely enzymes involved in methylation reactions, such as methionine adenosyltransferase. Clinically, methionine is indicated as a supplement in conditions where its levels might be compromised, such as in cases of acetaminophen overdose where it acts to replenish glutathione reserves. Side effects of methionine supplementation can include nausea, vomiting, and drowsiness. In practice, methionine is often used in nutritional support therapies, as a hepatic protectant, and as an adjunct treatment for conditions causing malabsorption of amino acids."
methotrexate,DB00934,"Methotrexate (DrugBank ID: DB00934), with its canonical SMILES notation ""CNCCCC12CCC(c3ccccc31)c1ccccc12,"" is a highly complex and potent chemotherapeutic agent belonging to the category of antimetabolites. The chemical structure of methotrexate is characterized by a dihydrofolic acid analog with an amine group at the N4 position and a methyl group at the N10 position. This structure forms the basis of its chemical scaffold, which is shared among other antifolate drugs such as pemetrexed. Methotrexate's similarity to folic acid allows it to competitively inhibit the enzyme dihydrofolate reductase (DHFR), which is necessary for thymidylate and purine synthesis, making it cytotoxic to rapidly dividing cells.

Pharmacokinetically, methotrexate exhibits variable oral absorption and is also administered intramuscularly, intravenously, or intra-arterially, depending on the indication. It has a large volume of distribution, as it penetrates into body fluids and tissues including the cerebrospinal fluid. Methotrexate is metabolized primarily in the liver to inactive polyglutamated forms. Excretion is primarily renal, and the drug can be reabsorbed in the renal tubule; impaired renal function can thus lead to increased toxicity.

The toxicity profile of methotrexate includes both acute and chronic effects, ranging from myelosuppression and immunosuppression to hepatotoxicity and pulmonary fibrosis. The drug's target proteins go beyond DHFR and include thymidylate synthase and aminoimidazole carboxamide ribonucleotide transformylase involved in nucleotide synthesis. Clinically, methotrexate is indicated for a broad spectrum of conditions, including malignancies such as leukemias, lymphomas, and breast cancer, as well as non-neoplastic conditions such as rheumatoid arthritis and psoriasis, leveraging its immunosuppressive properties.

However, with therapeutic use comes a host of potential side effects. These range from common ones such as nausea and stomatitis to life-threatening ones like pancyt"
methyldopa,DB00967,"Methyldopa, known by its DrugBank ID DB00967, possesses a unique chemical structure as denoted by its SMILES notation 'Clc1ccc2c(c1)CCc1cccnc1C2=C1CCNCC1', revealing a compound that includes a benzene ring halogenated with chlorine, a fused 1,2,3,4-tetrahydroquinoline moiety, and a 2-methyl-dihydropyridine scaffold that is responsible for its central activity. It is classified chemically as an alpha-2 adrenergic receptor agonist within the class of compounds known as alpha adrenoceptor agonists. Methyldopa's core scaffold is shared among various antihypertensive drugs, encompassing drugs such as clonidine and guanfacine that also act on alpha-2 adrenergic receptors, albeit with different substitutions influencing their activity profiles.

Regarding pharmacokinetics, after oral administration, methyldopa is moderately absorbed with variable bioavailability, widely distributed throughout the body tissues, and able to cross the blood-brain barrier. It undergoes complex metabolism that includes decarboxylation and conjugation processes primarily in the liver and other tissues before being eliminated largely by renal excretion. Methyldopa exhibits relatively low toxicity, yet overdose may lead to acute hypertensive episodes, bradycardia, and exacerbation of angina in susceptible individuals.

Methyldopa's primary target protein is the alpha-2A adrenergic receptor in the central nervous system, which modulates sympathetic outflow, thus reducing peripheral vascular resistance and lowering blood pressure. This mechanism underpins its indication for management of hypertension, particularly effective in pregnancy-induced hypertension and chronic hypertension. Side effects may involve sedation, dry mouth, and postural hypotension, and in some cases, it may cause immune-mediated complications such as hemolytic anemia.

Clinically, methyldopa has been a mainstay in antihypertensive therapy, particularly in scenarios where other antihypertensive classes present challenges, such as during pregnancy where it is considered relatively safe. Its usage exemplifies the balancing act"
methylprednisolone,DB01229,"Methylprednisolone, with DrugBank identifier DB01229, is a synthetic glucocorticoid with the SMILES notation “CC(=O)O[C@H]1C(=O)[C@]2(C)[C@@H](O)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C”. This compound features several fused rings, including a pregnane core, and it is categorized as a corticosteroid. The four-ring steroid backbone of its structure is the hallmark of its chemical scaffold, common to agents within this chemical category. Similar drugs include other corticosteroids such as prednisone and dexamethasone. Methylprednisolone exhibits specific pharmacokinetic properties; after oral administration, it is well-absorbed, has a significant hepatic metabolism principally by cytochrome P450 enzymes, and is predominantly excreted in urine as metabolites. In terms of toxicity, it can cause immunosuppression and adrenal suppression with long-term use, among other side effects. Its primary targets are intracellular glucocorticoid receptors, which modulate gene expression and lead to anti-inflammatory and immunosuppressive effects. Medically, methylprednisolone is indicated for conditions such as rheumatoid arthritis, asthma, and multiple sclerosis by diminishing inflammation and modulating the immune response. Common side effects can include mood swings, weight gain, and osteoporosis. Clinically, it is utilized both acutely, in settings such as acute asthma exacerbations, and chronically for managing autoimmune diseases, typically in a tailored dosing regimen to mitigate potential adverse effects."
metoprolol,DB01174,"Metoprolol, bearing the DrugBank identifier DB01174, possesses a distinctive chemical structure characterized by a tert-butylamino-propanol group connected via an ether linker to a para-substituted phenyl ring, as encapsulated in its SMILES notation ""CCC1(c2ccccc2)C(=O)NC(=O)NC1=O"". As a selective β1 receptor beta-blocker, it shares a common pharmacophore with similar drugs such as atenolol and bisoprolol, distinguished by their aryloxypropanolamine scaffold. The pharmacokinetic profile of metoprolol reveals efficient absorption when orally administered, with significant first-pass metabolism primarily by hepatic CYP2D6, leading to an average bioavailability of about 50%. Its distribution is characterized by moderate protein binding and a relatively small volume of distribution. Metabolites of metoprolol are predominantly excreted via the urine. In terms of toxicity, metoprolol is generally well-tolerated, but cases of bradycardia and hypotension serve as examples where its inhibitory effect on beta-1 adrenergic receptors can manifest adversely. The primary target proteins for metoprolol are the β1-adrenergic receptors, through which it exerts its therapeutic actions. Clinically, metoprolol is indicated for the treatment of hypertension, angina pectoris, heart failure, and to reduce the risks of death following myocardial infarction. Common side effects linked to metoprolol include dizziness, fatigue, and gastrointestinal disturbances, reflecting its β1 receptor selectivity, which minimizes undesired interactions like bronchospasm that are more commonly associated with non-selective beta-blockers. In clinical practice, metoprolol is widely used for its cardioprotective effects, particularly in conditions where sympathetic nervous system downregulation is beneficial, such as following a heart attack or in chronic heart failure management."
metyrapone,DB01196,"Metyrapone, bearing the DrugBank ID DB01196, is a steroid analog with a unique chemical structure defined by the SMILES notation 'C[C@]12CC[C@@H]3c4ccc(OC(=O)N(CCCl)CCCl)cc4CC[C@H]3[C@@H]1CC[C@@H]2O'. It features a cyclopentanophenanthrene skeleton characteristic of steroids, but has a metyrapol moiety at one of its aromatic rings, distinguished by an ether-linked carbamate group with two chloromethyl substituents, typifying it as a steroid biosynthesis inhibitor. Metyrapone is chemically categorized as a carbamate and shares its chemical scaffold with certain pesticide compounds, though in the pharmacological context, it is relatively unique. Other steroidogenesis inhibitors like ketoconazole and aminoglutethimide are structurally distinct but functionally similar. Metyrapone's pharmacokinetics involve rapid absorption, with peak plasma levels observed within an hour post-administration, extensive tissue distribution, metabolism predominantly via the liver before elimination largely through urine within 6 hours, indicating moderate bioavailability and a short half-life. Concerning toxicity, metyrapone is relatively safe at therapeutic doses, but overdose can cause adrenal insufficiency and hypotension. Its primary target protein is 11β-hydroxylase (CYP11B1), an enzyme critical in cortisol synthesis. Clinically, metyrapone is indicated for the diagnosis of adrenal insufficiency and the management of hypercortisolism, as in Cushing's syndrome, due to its ability to inhibit cortisol synthesis. Side effects may include gastrointestinal disturbance, dizziness, and allergic reactions, though they tend to be mild and transient with proper dosing. In clinical usage, metyrapone is used off-label for the treatment of Congenital Adrenal Hyperplasia (CAH) and is administered either orally or intravenously, contingent on the clinical scenario and required rapidity of cortisol suppression."
miconazole,DB01095,"Miconazole, with DrugBank ID 'DB01095', is an antifungal agent with an intricate heterocyclic chemical structure, as denoted in its SMILES notation 'CC(C)n1c(/C=C/[C@H](O)C[C@H](O)CC(=O)O)c(-c2ccc(F)cc2)c2ccccc21'. Its structure is characterized by an imidazole ring fused to a dichlorophenyl group and a fluorophenyl group, indicative of the drug's chemical category of azole antifungals. This falls under the broader chemical scaffold of heterocyclic compounds with aromatic groups, which contribute to its pharmacological activity. Chemically similar drugs include clotrimazole and ketoconazole, which share the imidazole core and are utilized for their antifungal properties.

In terms of its pharmacokinetics, Miconazole is known for its variable absorption when administered topically, orally, or intravenously, with its bioavailability affected by the form of delivery. Once absorbed, miconazole undergoes extensive metabolism, primarily via hepatic pathways, leading to several metabolites. It is distributed widely throughout the body but particularly concentrates in keratin-containing tissues, which aligns with its antifungal activity. Elimination is mainly through biliary excretion, with renal elimination of its metabolites.

Concerning toxicity, miconazole is generally well-tolerated, but there can be instances of hepatic and hematologic toxicities, manifesting as jaundice or anemia in severe cases. The primary target proteins of miconazole include fungal cytochrome P450 enzymes, where it inhibits the synthesis of ergosterol, an essential component of fungal cell membranes.

Clinically, miconazole is indicated for the treatment of various fungal infections, including candidiasis, dermatophytosis, and more systemic infections like coccidioidomycosis. It is effective against symptoms such as itching, redness, and burning associated with these mycoses. Side effects of miconazole can include local irritation, rash, and, rarely, allergic reactions when applied topically or gastrointestinal disturbances when taken orally.

"
midazolam,DB01104,"Midazolam, with the DrugBank identifier DB01104, is a short-acting benzodiazepine central nervous system depressant known for its anxiolytic, anticonvulsant, muscle relaxant, and sedative properties. Its chemical structure is distinctly characterized by a benzodiazepine ring—a fused aromatic ring system composed of a 7-membered diazepine ring and a phenyl group substituted with two chlorine atoms at the ortho positions—attached to a 5-membered imidazole ring through a methylene bridge. The SMILES notation 'CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21' precisely details the molecular geometry, including its stereochemistry, with ""C@H"" and ""C@@H"" indicating chiral centers. Chemically, midazolam falls under the broader category of benzodiazepines, with a distinctive imidazole ring that sets it apart from other similar drugs such as diazepam or lorazepam; however, it shares the core benzodiazepine scaffold promoting GABA-mediated inhibitory neurotransmission. When it comes to pharmacokinetics, midazolam is rapidly absorbed after oral, intramuscular, or intravenous administration; it achieves high plasma protein binding and distributes widely in the body. It is predominantly metabolized through the cytochrome P450 enzyme CYP3A4 in the liver to hydroxylated metabolites, which are further glucuronidated before renal excretion. The drug’s toxicity profile includes the risk of respiratory depression, particularly when combined with other CNS depressants, and it has been associated with paradoxical reactions such as agitation or hallucination in rare cases. Midazolam acts on the GABAA receptor complex, enhancing the effect of the neurotransmitter gamma-aminobutyric acid (GABA) and facilitating neuronal inhibition. It is indicated mainly for preoperative sedation, induction of anesthesia, procedural sedation, and the acute management of seizures. Side effects may encompass symptoms such as drowsiness, cognitive impairment, and at higher doses, impairment of motor functions. Clinically, midaz"
midodrine,DB00749,"Midodrine, catalogued under DrugBank ID DB00749, is a vasopressor and antihypotensive agent characterized by the SMILES notation CCc1cccc2c3c([nH]c12)C(CC)(CC(=O)O)OCC3, detailing a distinct bicyclic structure with a fused indolenine core that carries an ethyl substituent, as well as a side chain that consists of a glycinamide moiety undergoing esterification with a tertiary alcohol group. This prodrug fits within the chemical category of phenethylamines, sharing structural similarity with its pharmacologically active metabolite, desglymidodrine. Midodrine’s distinctive scaffold features a tetrahydroisoquinoline ring system, a pharmacophore which it shares with other sympathomimetic agents. Pharmacokinetically, midodrine is well-absorbed orally, extensively metabolized by deacetylation to its active form desglymidodrine, which is responsible for its pharmacologic effects; it has an elimination half-life conducive to tid dosing, and is primarily excreted via the kidneys. Its toxicity profile is relatively moderate, but it can cause supine hypertension, a dose-dependent side effect. It acts specifically on α1-adrenergic receptors. Clinically, midodrine is indicated for the treatment of symptomatic orthostatic hypotension, providing symptomatic relief by inducing peripheral arterial and venous constriction. Notable side effects, apart from supine hypertension, include paresthesia, pruritus, and urinary retention. In terms of clinical usage, midodrine's utility is particularly evident in conditions like autonomic dysfunction or severe orthostatic hypotension, where it significantly helps improve the quality of life by ameliorating symptoms such as dizziness and potential syncope, thus allowing patients to better withstand changes in posture."
mitoxantrone,DB00637,"Mitoxantrone, with its DrugBank identifier DB00637, is a synthetic anthracenedione anticancer agent characterized by its complex chemical structure encapsulated in the SMILES notation 'COc1ccc(CCN2CCC(Nc3nc4ccccc4n3Cc3ccc(F)cc3)CC2)cc1'. This notation reflects the presence of a tetracyclic quinone-based system, featuring multiple aromatic rings, a methoxy group, and a key side chain integrating a nitrogen mustard. As part of the chemical category of anthracenediones, mitoxantrone exhibits a quinone-based scaffold similar to that of anthracyclines; however, it is distinguished by a reduced cardiotoxic profile when compared to its analogues such as doxorubicin. In the realm of pharmacokinetics, mitoxantrone is known for its rapid plasma clearance following intravenous administration, with distribution characteristics that include a high volume of distribution and significant tissue uptake. Metabolically, it undergoes hepatic transformation to various inactive metabolites and is predominately excreted via the biliary system.

The drug's mechanism of action involves intercalating into DNA and inhibiting topoisomerase II, resulting in disrupted DNA synthesis and repair in rapidly proliferating cells. These actions underline the efficacy of mitoxantrone in treating diseases such as multiple sclerosis (MS), acute nonlymphocytic leukemia, and metastatic breast cancer. Nevertheless, the therapeutic potential is tempered by its toxicity profile, which includes dose-dependent myelosuppression, cardiotoxicity, and the potential for therapy-related acute leukemia. Additionally, mitoxantrone can engender a spectrum of side effects, including nausea, alopecia, and blue-green discoloration of the urine.

Used clinically in oncology and neurology, mitoxantrone is reserved for use in aggressive forms of relapsing-remitting or progressive MS due to safety concerns, and as a palliative treatment in certain types of advanced cancer, demonstrating its multifaceted role in both symptom management and disease progression alteration. While its use must be judiciously balanced against its side-effect profile,"
morphine,DB01114,"The given SMILES notation 'CN(C)CCC(c1ccc(Cl)cc1)c1ccccn1' does not correspond to the chemical structure of morphine, which has the DrugBank ID 'DB01114'. Instead, this SMILES string represents clozapine, an atypical antipsychotic medication. Morphine, however, is an opiate analgesic with a complex structure characterized by a phenanthrene core to which various functional groups, including a quaternary carbon atom, two hydroxyl groups, and a tertiary amine, are attached. It falls under the chemical category of opiates, sharing its chemical scaffold predominantly with natural opiates like codeine and semi-synthetic opioids such as hydromorphone. Morphine's pharmacokinetics reveal that after administration, it is well-absorbed, especially when given parenterally, is widely distributed in the body, undergoes significant first-pass metabolism mainly in the liver through glucuronidation, and is excreted predominantly via the kidneys. Toxicity of morphine can include respiratory depression and potential for overdose, which exemplifies the drug's narrow therapeutic index. Morphine primarily targets the μ-opioid receptors in the central nervous system, mediating its analgesic effects. Indicated for severe acute and chronic pain, morphine is effective in ameliorating pain from cancer, surgical procedures, and trauma. However, its side effects encompass constipation, sedation, nausea, and the risk of developing tolerance, physical dependence, and addiction upon prolonged use. In the clinical setting, morphine is administered in various forms, including oral, intramuscular, and intravenous preparations, to manage pain while carefully considering its potential for abuse and adverse effects."
ipratropium,DB00398,"Ipratropium, with DrugBank identifier DB00398 and SMILES notation CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1, is a synthetic quaternary ammonium compound that structurally resembles the naturally occurring alkaloid atropine. As a bronchodilator, it falls into the chemical category of anticholinergic agents, with a chemical scaffold that is based on a substituted phenylquinoline structure. Ipratropium is closely related to other anticholinergic bronchodilators such as tiotropium, indicating a shared mode of action among this class of drugs.

Pharmacokinetically, ipratropium is characterized by poor absorption from the gastrointestinal tract, owing to its quaternary ammonium structure, which results in minimal systemic exposure when inhaled. It is distributed mainly within the lungs, with a voluminous distribution indicating deposition in tissues. Metabolism is minimal as the drug remains largely unmetabolized, and it is excreted primarily unchanged in the urine. Regarding toxicity, ipratropium is associated with low systemic toxicity due to its minimal absorption; however, high doses can lead to anticholinergic side effects such as dry mouth, urinary retention, and increased intraocular pressure.

The primary target proteins for ipratropium are muscarinic acetylcholine receptors, specifically the M3 subtype found in the smooth muscles of the airways. The drug's indication is for the management of symptoms associated with chronic obstructive pulmonary disease (COPD) and asthma, where it serves to alleviate bronchospasm. Adverse effects typically include cough, headache, and throat irritation, although its quaternary nature renders it less likely to cross the blood-brain barrier, thus reducing central side effects. Clinically, ipratropium is often administered via inhalation, using metered-dose inhalers (MDIs) or nebulizers for acute and maintenance treatment of bronchospasm in COPD and as an adjunctive therapy in asthma management to provide additive bronchodilation alongside beta"
naloxone,DB01016,"Naloxone, with DrugBank ID 'DB01016', possesses a multifaceted opioid antagonist chemical structure characterized by the SMILES notation 'COc1ccc(Cl)cc1C(=O)NCCc1ccc(S(=O)(=O)NC(=O)NC2CCCCC2)cc1'. This molecule belongs to the chemical category of phenol ethers and features a bicyclic structure comprising a benzene ring and a piperidine moiety as its chemical scaffold. Analogous drugs to naloxone include naltrexone and methylnaltrexone, which are also opioid antagonists used in similar therapeutic contexts. Naloxone's pharmacokinetics reveal rapid absorption with an onset of action within minutes when administered intravenously; it is widely distributed in the body and crosses the blood-brain barrier less readily than some opioid analgesics. Metabolism principally occurs in the liver, primarily through glucuronide conjugation, and the metabolites, along with unchanged drug, are excreted through the urine. Though naloxone has a lower toxicity profile, it may induce opioid withdrawal symptoms if used in opioid-dependent individuals. The primary target proteins of naloxone are the mu, kappa, and delta opioid receptors, where it acts by competing for and displacing opioids from these receptors. Indicated for use in opioid overdose to counteract life-threatening depression of the central nervous system and respiratory system, naloxone is essential for reversing opioid-induced sedation and respiratory depression. Side effects of naloxone can include hypertension, ventricular tachycardia, nausea, and, in the context of opioid dependence, acute withdrawal syndrome. Clinically, naloxone is administered in emergency settings via intravenous, intramuscular, subcutaneous, or intranasal routes to rapidly reverse the effects of opioid toxicity, prioritized for its ability to restore breathing in patients experiencing an opioid overdose, making it a critical tool in managing the public health crisis of opioid misuse and fatalities."
naltrexone,DB00203,"Naltrexone, with DrugBank ID DB00203, possesses a complex chemical structure represented by the SMILES notation ""CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12"". This notation details the molecule as having a morphinan skeleton with a cyclohexanone ring and a substituted oxymorphone moiety, classifying it as an opioid antagonist within the larger category of opioid receptor modulators. Naltrexone shares its chemical scaffold with other opioid antagonists such as naloxone and methylnaltrexone. Pharmacokinetically, naltrexone is well-absorbed orally, with extensive first-pass metabolism predominantly by the liver into its active metabolite 6-β-naltrexol, and is excreted primarily via urine. It exhibits potential toxicity characterized by hepatocellular injury, though this is rare and typically associated with doses much higher than those used clinically. The primary target proteins of naltrexone are the mu-opioid receptors, where it acts as a competitive antagonist. Indicated mainly for the management of alcohol dependence and the prevention of relapse in opioid-dependent patients, naltrexone assists by reducing cravings and the euphoric effects of these substances. Nevertheless, side effects do occur, with the most common being nausea, headache, dizziness, and fatigue. Clinically, naltrexone has been used in various settings ranging from adjunctive therapy for alcoholism to aiding in rapid detoxification protocols in opioid addiction, illustrating its versatility in addressing substance-related disorders."
naproxen,DB00361,"Naproxen, with the DrugBank identifier DB00361, is a nonsteroidal anti-inflammatory drug (NSAID) characterized by its complex chemical structure detailed in its SMILES notation: 'CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2'. This structure comprises a 2-naphthyl propionic acid moiety which classifies naproxen within the arylpropionic acid subgroup of NSAIDs, sharing a chemical scaffold similar to other propionic acid derivatives such as ibuprofen and ketoprofen. Naproxen is comparable to these drugs in its mechanism of action, targeting cyclooxygenase enzymes COX-1 and COX-2, which are involved in the biosynthesis of prostaglandins, thereby exerting anti-inflammatory, analgesic, and antipyretic effects.

Pharmacokinetically, naproxen is readily absorbed from the gastrointestinal tract, with a bioavailability of approximately 95%. It exhibits extensive distribution, being more than 99% plasma protein-bound, mainly to albumin. Its metabolism primarily occurs in the liver by phase II conjugation to naproxen glucuronide, and is excreted predominantly through urine. Regarding toxicity, naproxen is generally safer compared to other traditional NSAIDs but can still pose risks such as gastrointestinal bleeding, hypertension, and renal impairment.

Clinically, naproxen is indicated for the management of inflammatory conditions and pain, such as osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, tendinitis, acute gout, and for the relief of mild to moderate pain, including menstrual pain. The drug is also used to reduce fever. Common side effects of naproxen include, but are not limited to, gastrointestinal distress, headache, dizziness,"
neostigmine,DB00541,"Neostigmine, represented by DrugBank identifier DB00541 and SMILES notation CC[C@]1(O)C[C@@H]2C[N@@](CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1, is a synthetic compound that features a complex structure including a carbamate group attached to a quaternary ammonium core, characteristic of the chemical category of reversible acetylcholinesterase inhibitors. Its chemical scaffold is akin to other carbamate acetylcholinesterase inhibitors such as pyridostigmine and ambenonium, which are used for similar medical purposes. Pharmacokinetically, neostigmine is poorly absorbed from the gastrointestinal tract, exhibits minimal systemic distribution due to its quaternary ammonium structure, and is primarily metabolized by plasma esterases; it is excreted largely unchanged in the urine. The toxin profile of neostigmine includes muscarinic side effects such as bradycardia and bronchial constriction, as well as nicotinic effects like muscle cramps, reflecting its mechanism of action on acetylcholine receptors (muscarinic and nicotinic). It mainly targets the enzyme acetylcholinesterase, preventing the breakdown of acetylcholine, thus leading to increased levels in neuromuscular junctions. Neostigmine is indicated for the treatment of myasthenia gravis, and for the reversal of non-depolarizing neuromuscular blockade after surgery. Side effects arising from neostigmine administration include, but are not limited to, hypersalivation, nausea, diarrhea, and abdominal cramps. In a clinical setting, neostigmine is utilized both in chronic management of myasthenic symptoms as well as acutely in post-operative settings as an antidote to neurom"
niacin,DB01211,"Niacin, with DrugBank ID DB01211, is a water-soluble B vitamin, specifically known as vitamin B3 or nicotinic acid, distinguished by its complex chemical structure, denoted by the SMILES notation ""CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O"". This notation reflects niacin's intricate arrangement of carbon chains and functional groups, including carboxylic and hydroxyl groups, which categorize it as a pyridinecarboxylic acid. Chemically related drugs include nicotinamide and inositol hexanicotinate, which derive from niacin's pyridine scaffold and serve similar physiological functions.

Pharmacokinetically, niacin is readily absorbed in the gastrointestinal tract, distributes widely across the body, undergoes hepatic metabolism primarily through conjugation, and is excreted in urine, with its metabolites dependent on administered dose. At pharmacologic dosages, niacin can lead to toxicity manifested as flushing and hepatotoxicity, both dose-dependent. Its mechanism of action involves several target proteins, such as the G protein-coupled receptor GPR109A, mediating its lipid-modifying effects.

Clinically, niacin is indicated for dyslipidemia management, particularly for reducing triglycerides and increasing HDL cholesterol, thereby offering therapeutic benefits in conditions such as hypercholesterolemia and mixed dyslipidemia. Side effects of the drug range from mild, such as flushing and gastrointestinal distress, to more severe ones like hepatotoxicity and hyperglycemia. In clinical practice, niacin is used either as monotherapy or, more commonly,"
nicardipine,DB00500,"Nicardipine (DrugBank ID: DB00500), characterized by the SMILES notation 'Cc1ccc(C(=O)c2ccc(CC(=O)O)n2C)cc1', is a dihydropyridine calcium channel blocker that fundamentally influences the transmembrane influx of calcium ions into cardiac muscle and vascular smooth muscle. Structurally, it possesses the dihydropyridine ring as its chemical scaffold, which is crucial for its activity and is shared among similar calcium channel blockers like amlodipine and nifedipine. The chemical class of dihydropyridines are known for their vasodilatory properties. Upon oral administration, nicardipine is well-absorbed with peak plasma concentrations occurring between one to two hours post-dose, and it exhibits high bioavailability. It is extensively metabolized by the liver with the cytochrome P450 3A4 enzyme being principally involved, leading to multiple inactive metabolites. Excretion is primarily through urine as these metabolites. The toxicity profile of nicardipine includes dose-dependent hypotension and reflex tachycardia; overdose may result in pronounced systemic vasodilation and possibly serious hypotension.

The primary pharmacological targets of nicardipine are the L-type calcium channels located on the vascular smooth muscle and cardiac cells, where it acts as an antagonist to decrease intracellular calcium, leading to vasodilation. Indicated for the management of hypertension and certain types of angina (e.g., chronic stable angina), nicardipine serves to reduce blood pressure and myocardial oxygen demand, thereby ameliorating these cardiovascular conditions. Side effects resultant from its pharmacodynamic actions can include headache, flushing, edema, palpitations, and dizziness. Clinical usage of nicardipine extends into the setting of hypertensive emergencies and perioperative blood pressure control due to its potency and relatively short half-life, allowing for titratable IV administration. In summary, nicardipine is a potent antihypertensive agent with a well-characterized pharmacokinetic profile, making it a valuable therapeutic option in managing various cardiovascular diseases while monitoring for its potential side effects and"
nicotine,DB00675,"Nicotine, bearing the DrugBank ID DB00675, is a tertiary amine comprising a pyridine ring fused to a pyrrolidine ring - the latter containing the N-methylated nitrogen - appended with a pent-2-enyl chain at the 5′ position. As a stimulant drug within the chemical category of alkaloids, nicotine is structurally constituted by a chiral center, which is reflected in its S(-) and R(+) enantiomers, although the S(-) form is the more active one in terms of its pharmacological properties. Nicotine shares its pyridine-containing chemical scaffold with other nicotinic agonists, such as varenicline, known for its similar functionality as a smoking cessation aid. Regarding pharmacokinetics, absorbed rapidly through the respiratory tract, buccal or gastric mucosae, nicotine is then distributed widely throughout the body due to its lipid solubility, crossing the blood-brain barrier. Metabolized primarily in the liver by the enzyme CYP2A6 to its metabolite cotinine, it is subsequently excreted via the kidneys. Nicotine's toxicity is underscored by its LD50 of 50 mg/kg in rats, causing symptoms such as hypertension, tachycardia, and in severe cases, paralysis and convulsions due to its agonist activity on nicotinic acetylcholine receptors (nAChRs), primarily the subtypes α4β2 and α7. Clinically, nicotine is indicated mainly for the treatment of nicotine dependence, aiding in the cessation of smoking; it acts on these nAChRs in the brain, reducing withdrawal symptoms. Side effects of nicotine use include but are not limited to nausea, dizziness, increased heart rate, and in chronic use, contributes to the development of cardiovascular disease. In clinical practice, nicotine is utilized through replacement therapies such as transdermal patches, chewing gum, inhalers, and lozenges to provide a controlled dose to alleviate craving in individuals attempting to quit smoking."
nifedipine,DB00446,"Nifedipine, with the DrugBank ID 'DB00446' and SMILES notation 'O=C(N[C@H](CO)[C@H](O)c1ccc([N+](=O)[O-])cc1)C(Cl)Cl', is a dihydropyridine calcium channel blocker characterized by a dihydropyridine ring bearing nitro and carboxyl substituents, indicative of its chemical class, and it serves as the core chemical scaffold. Structurally akin to other dihydropyridines like amlodipine and felodipine, it exhibits a similar therapeutic profile. Its pharmacokinetic profile entails oral absorption with a bioavailability of approximately 45-56%, widespread distribution with 92-98% plasma protein binding, hepatic metabolism predominantly via cytochrome P450 3A4, and renal excretion as metabolites. Nifedipine's toxicity, while relatively low, can manifest in overdose scenarios leading to severe hypotension. As a calcium channel antagonist affecting the L-type calcium channels primarily, nifedipine finds its indication in the management of hypertension and angina pectoris, including chronic stable angina and vasospastic angina. Common side effects include but are not limited to headache, flushing, peripheral edema, and dizziness, which are reflective of its vasodilatory action. Clinically, nifedipine is administered in various formulations, such as immediate and extended-release tablets, and its utilization spans from acute to long-term treatment paradigms, focusing on cardiovascular disease symptomatology and overall risk reduction."
nitrazepam,DB00122,"Nitrazepam, with the DrugBank identifier DB00122, is a hypnotic drug belonging to the benzodiazepine class, featuring a benzodiazepine chemical scaffold of a fused benzene and diazepine ring system. Contrary to the provided SMILES notation 'C[N+](C)(C)CCO', which appears to correspond to choline, and not nitrazepam, the accurate SMILES for nitrazepam is 'CN=C(NC1=O)C2=C(C=C1)C=CC=C2Cl'. This compound is closely related to other benzodiazepines such as diazepam and lorazepam. Nitrazepam is well-absorbed after oral administration, exhibiting its effects within 30 to 60 minutes, and has a variable bioavailability due to its lipophilicity. It distributes widely in the body, crosses the blood-brain barrier, and binds extensively to plasma proteins. Metabolism of nitrazepam primarily occurs in the liver via nitro-reduction, and the metabolites along with unchanged drug are excreted mainly through the kidneys. Concerning toxicity, it can cause respiratory depression and hypotension in overdose situations and exhibit a high potential for dependence and withdrawal symptoms. Its primary target proteins include the GABA_A receptor subtypes, where it acts as a positive allosteric modulator enhancing the inhibitory effects of GABA. Clinically, nitrazepam is indicated for the short-term management of insomnia and occasionally in the management of myoclonic seizures. Common side effects include drowsiness, dizziness, and ataxia, and in more severe cases can lead to profound CNS depression. In clinical practice, nitrazepam’s long onset and elimination half-life necessitate careful patient monitoring to minimize risks, and its use is often restricted in favor of alternatives with more favorable side effect profiles."
nitrendipine,DB01136,"Nitrendipine, with DrugBank ID DB01136 and SMILES notation COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12, is a dihydropyridine calcium channel blocker characterized by a distinctive chemical structure comprising an esterified dihydropyridine ring fused to a carboxylated 1,4-dihydrobenzene moiety, reflecting its belonging to the chemical category of dihydropyridine derivatives. Its chemical scaffold is shared among similar antihypertensive agents like amlodipine and nifedipine, exhibiting structural analogy while retaining unique pharmacokinetic properties. Nitrendipine's absorption is reasonably rapid and extensive upon oral administration, with its bioavailability ranging around 10-30% due to first-pass metabolism. It is widely distributed in body tissues, extensively bound to plasma proteins, and undergoes significant hepatic metabolism primarily via cytochrome P450 3A4 (CYP3A4) enzymes to form inactive metabolites. Excretion is predominately via the biliary route, with renal clearance playing a lesser role. Concerning toxicity, nitrendipine is relatively well-tolerated, but overdosage can lead to pronounced hypotension and reflex tachycardia. The drug targets L-type calcium channels, particularly in vascular smooth muscle, leading to vasodilation and thus reducing systemic vascular resistance. Clinically, nitrendipine is indicated for the management of essential hypertension, contributing to amelioration of raised blood pressure and related cardiovascular risks. The side-effect profile includes common dihydropyridine-related adverse events, such as peripheral edema, headache, dizziness, and palpitations. Nitrendipine is administered mainly in the context of antihypertensive therapy, often as part of a combination regimen for better blood pressure control, providing a clinical example of its utility in mitigating the burden of hypertension-associated morbidity and mortality."
norepinephrine,DB01149,"Norepinephrine, with DrugBank ID DB01149, is a sympathomimetic amine that acts as a nonselective adrenergic agonist, closely resembling the endogenous neurotransmitter epinephrine in both structure and function. Its SMILES notation, ""CCc1nn(CCCN2CCN(c3cccc(Cl)c3)CC2)c(=O)n1CCOc1ccccc1,"" describes a complex structure with an aromatic ring system, a chlorophenyl motif, and a tertiary amine group, indicative of its catecholamine chemical category. This structure forms part of the catecholamine and phenethylamine chemical scaffolds, linking it to similar drugs such as dopamine and epinephrine, which share the phenethylamine core. Pharmacokinetically, norepinephrine is not administered orally as it undergoes extensive first-pass metabolism; it is typically given intravenously for rapid and direct systemic effects. Its distribution is primarily within the circulatory system where it exerts its action, and it is metabolized quickly in the liver and excreted by the kidneys. Like other catecholamines, the toxicity of norepinephrine can lead to hypertensive emergency and cardiac arrhythmias when dosed improperly or in susceptible individuals. It primarily targets alpha-1, alpha-2, and beta-1 adrenergic receptors, leading to vasoconstriction and increased heart rate and contractility. Clinically, it is indicated for acute hypotension and cardiac arrest, as well as to increase blood pressure in certain types of shock, such as septic or neurogenic shock. Nevertheless, its side effects can be significant and include headache, palpitations, and anxiety. Despite these potential side effects, norepinephrine's clinical usage remains widespread, particularly in critical care settings where it is employed to manage life-threatening hypotensive states and support cardiovascular function."
norfloxacin,DB01224,"Norfloxacin, with the DrugBank identifier DB01224, is a synthetic broad-spectrum antibacterial agent with a chemical structure characterized by a fluorinated quinolone core, represented by the SMILES notation 'OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1'. As a fluoroquinolone antibiotic, its chemical category is defined by the presence of a fluorine atom on the quinolone scaffold, which is shared among similar drugs such as ciprofloxacin and levofloxacin. The pharmacokinetics of norfloxacin indicate moderate oral absorption, with peak plasma concentrations typically reached within one to two hours post-dose. Distribution within body tissues and fluids is extensive; however, norfloxacin exhibits low binding to plasma proteins. Metabolic transformation is minimal, with the drug largely excreted unchanged in the urine. Norfloxacin is associated with a significant risk of toxicity, examples of which include tendinitis and tendon rupture, peripheral neuropathy, and QT interval prolongation. Its action is mediated through the inhibition of bacterial DNA gyrase and topoisomerase IV, the target proteins responsible for DNA replication and cell division in susceptible bacteria. Indications for norfloxacin include the treatment of urinary tract infections, prostatitis, and sexually transmitted diseases such as gonorrhea. Side effects can range from mild gastrointestinal disturbances to severe hypersensitivity reactions and central nervous system effects like dizziness and seizures. Clinically, norfloxacin is used as an oral therapeutic agent in the aforementioned infections, often reserved for cases where first-line treatments are not appropriate or have failed, reinforcing the importance of prudent use to reduce the development of antibiotic resistance."
ouabain,DB01400,"Ouabain, bearing the DrugBank identifier DB01400, is a cardiac glycoside with a complex steroid-like structure that includes a lactone ring and sugar moieties, denoting its chemical category. Its SMILES notation, 'CN(C)C(=O)Oc1cccc([N+](C)(C)C)c1', however, appears to be incorrect as it does not correspond to the chemical structure of ouabain. Instead, ouabain's structural signature comprises a steroid core with a five-membered unsaturated lactone ring (the butenolide moiety) and is adorned with multiple hydroxyl groups; this constitutes its chemical scaffold, distinguishing it from other cardiac glycosides like digitoxin and digoxin, which share a similar action mechanism and clinical use but differ slightly in their chemical structure. The pharmacokinetics of ouabain are not as well characterized as other cardiac glycosides since it is primarily used for research rather than in clinical settings, but it is known to have a rapid onset and a relatively short half-life in the human body. It is not extensively metabolized, being excreted largely unchanged in the urine. Its toxicity mirrors that of other cardiac glycosides and manifests in symptoms such as cardiac arrhythmias, with the potential for fatality in severe cases of overdose. Ouabain's chief target protein is the Na⁺/K⁺-ATPase pump, where it inhibits the ion transport crucial for maintaining cardiac cell electrochemical gradients. Clinically, it is used on an investigational basis for its inotropic effects to increase the force of cardiac muscle contractions, potentially beneficial in specific heart conditions, such as congestive heart failure, but its therapeutic window is dangerously narrow, limiting its use. Side effects of ouabain can include gastrointestinal disturbances, dizziness, and headaches, as well as life-threatening arrhythmias if used improperly. Despite its historical use as an arrow poison for hunting in Africa, which illustrates its high toxicity, ouabain's primary clinical application these days is confined to experimental studies where it serves as a pharmacological tool to probe the function of the Na⁺/K⁺-"
oxprenolol,DB01244,"Oxprenolol, designated with the DrugBank identifier DB01244, is a non-selective beta-blocker with a complex molecular structure reflected in its SMILES notation 'CC(C)COCC(CN(Cc1ccccc1)c1ccccc1)N1CCCC1'. Its chemical structure is composed of a substituted phenoxypropanolamine framework bearing aromatic rings, which serves as its chemical scaffold characteristic of beta-adrenergic antagonists. Oxprenolol is closely related to other beta-blockers, such as propranolol and alprenolol, sharing a similar underlying aryloxypropanolamine structure. Pharmacokinetically, oxprenolol is well-absorbed following oral administration, with its distribution characterized by significant protein binding and wide tissue dispersal. It undergoes extensive first-pass hepatic metabolism, primarily by glucuronidation, and the metabolites along with unchanged drug are excreted via the kidneys. Oxprenolol's toxicity profile includes adverse cardiovascular effects such as bradycardia and hypotension, typically observed with overdose. It targets beta-adrenergic receptors, specifically both beta-1 and beta-2 subtypes, inhibiting their activity. The primary therapeutic indication of oxprenolol is in the management of hypertension and various forms of angina pectoris, as it reduces cardiac workload and oxygen consumption. Side effects may include bronchospasm, fatigue, gastrointestinal disturbances, and in some cases, may precipitate heart failure in patients with compromised cardiac function. Clinically, oxprenolol is also used for the management of cardiac dysrhythmias and in the prophylaxis of migraine, offering multifaceted benefits attributable to its beta-blocking capabilities. It is a testament to the therapeutic versatility that arises from targeting fundamental pathways within cardiovascular physiology."
pancuronium,DB01184,"Pancuronium, identified by DrugBank ID 'DB01184', is a non-depolarizing neuromuscular blocking agent with a bis-quaternary steroid structure, characterized by its SMILES notation 'O=c1[nH]c2ccccc2n1CCCN1CCC(n2c(=O)[nH]c3cc(Cl)ccc32)CC1'. As a synthetic steroid derivative, it belongs to the chemical category of aminosteroid neuromuscular blockers, and its chemical scaffold is underpinned by a steroidal nucleus with two acetylcholine-like quaternary ammonium moieties attached by acetylcholine esterase-resistant bonds. Pancuronium shares structural and functional similarities with other aminosteroid neuromuscular blockers, such as vecuronium and rocuronium. Pharmacokinetically, pancuronium absorption is not relevant, as it is administered intravenously; it exhibits a moderate volume of distribution, is partially metabolized by the liver, and is predominantly excreted in the urine and bile. Toxicologically, pancuronium's toxicity manifests in the form of prolonged neuromuscular blockade, which can lead to respiratory paralysis and cardiovascular effects such as tachycardia and hypertension. Target proteins for pancuronium are nicotinic acetylcholine receptors at the neuromuscular junction, where it competitively inhibits neurotransmitter binding, thus preventing muscle contraction. Clinically, pancuronium is indicated for achieving skeletal muscle relaxation during surgery or mechanical ventilation. Side effects may include prolonged neuromuscular blockade leading to postoperative muscle weakness, as well as effects on cardiac output and heart rate. In clinical practice, pancuronium usage has declined in favor of newer agents with fewer cardiovascular effects and shorter duration of action, but it may still be used in particular settings where its longer-acting properties are deemed beneficial."
phenacetin,DB00518,"Phenacetin, designated with DrugBank ID 'DB00518', is an analgesic and antipyretic drug whose structure is described by the SMILES notation 'CCCSc1ccc2nc(NC(=O)OC)[nH]c2c1'. Its chemical structure is characterized by an ethoxy group (OC(=O)N) bonded to the para-position of an acetanilide scaffold, where an acetyl group is bound to the nitrogen of an aniline ring, and this particular derivative features a phenyl ring substituted with a thioether linkage (SCCC). As a member of the chemical category known as phenacetins, it belongs to a broader group of acetanilide and phenylacetamide analogs; this family includes drugs such as acetaminophen, a less toxic analog widely used today. Phenacetin is absorbed through the gastrointestinal tract, widely distributed in the body, primarily metabolized in the liver via de-ethylated to form the active compound paracetamol, and excreted in the urine. Historically, its toxicity emerged with prolonged use, leading to methemoglobinemia, nephropathy, and carcinogenicity, which eventuated in its withdrawal from many markets. While its mechanism of action is not entirely clarified, it is believed to involve inhibition of COX enzymes, similar to other nonsteroidal anti-inflammatory drugs (NSAIDs), and possibly the interference with prostaglandin synthesis. Clinically, phenacetin was indicated for its analgesic effects in treating pain and fever, exemplified in conditions like headaches and minor aches. Adverse effects associated with phenacetin include, but are not limited to, cyanosis due to methemoglobin formation, nephrotoxicity, and increased risk of certain cancers. Despite its clinical usage in the past century as an analgesic, the recognition of serious side effects and the availability of safer alternatives, such as acetaminophen, have rendered phenacetin obsolete and its use is no longer recommended."
phenformin,DB00860,"Phenformin, designated with DrugBank ID DB00860, is a biguanide antidiabetic agent with the chemical structure denoted by the SMILES notation C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO. This structure reveals a cyclohexane connected to a hydroxy-substituted cyclohexane, an aromatic ring with a ketone functionality, and a side chain terminating in a biguanide group, reflecting its classification as a biguanide derivative pharmacologically related to the more commonly used metformin. Pharmacokinetically, phenformin is characterized by oral absorption, with its bioavailability affected by gastrointestinal transit times; it is distributed throughout the body fluids, has limited protein binding, and is subject to minimal hepatic metabolism, primarily excreted unchanged in the urine, which influences dosing in renal impairment. However, its clinical use, formerly for type 2 diabetes mellitus, has been overshadowed by its toxicity profile; lactic acidosis is a severe and potentially fatal complication, more pronounced than with its analogue, metformin. Within the cell, phenformin targets mitochondrial proteins, specifically complex I of the electron transport chain, inhibiting hepatic gluconeogenesis and increasing peripheral glucose uptake. Indications originally included management of hyperglycemia in type 2 diabetes, either alone or in combination with other antidiabetic medications. Side effects of phenformin range from gastrointestinal disturbances, such as nausea and diarrhea, to more severe consequences of lactic acidosis, characterized by hyperventilation, myalgias, and hypothermia. Clinical usage once favored phenformin for its potent glucose-lowering effects, and it was utilized in patients with type 2 diabetes, particularly those with obesity. However, due to its safety concerns, clinical use of phenformin has been largely abandoned in many countries, replaced by safer alternatives like metformin."
phenobarbital,DB01011,"Phenobarbital, bearing the DrugBank identifier DB01011, is an organic compound with the SMILES notation 'CC(C)(C(=O)c1cccnc1)c1cccnc1', which conveys its chemical structure consisting of a barbiturate core with a phenyl group at C5 and an ethyl group at C1. Classified as a barbiturate sedative-hypnotic agent, its chemical scaffold is characterized by a fused pyrimidine-dione ring structure, which is common to drugs in this category such as amobarbital and pentobarbital. Phenobarbital's pharmacokinetics profile reveals extensive absorption following oral administration, distribution with a high volume of distribution reflecting its lipophilicity, hepatic metabolism primarily via CYP2C9, and renal excretion with a half-life averaging around 80 hours. Its toxicity includes the risk of overdose leading to CNS depression, respiratory arrest, and potentially death, with chronic use associated with dependence and withdrawal syndrome. Phenobarbital's primary mechanism of action involves potentiation of the inhibitory neurotransmitter GABA's effect on its receptor, although other targets such as voltage-gated ion channels may also be implicated. This drug is indicated primarily for the management of seizures, including partial and generalized seizures, and the emergency control of certain acute convulsive episodes like those associated with status epilepticus. Side effects can range from somnolence, ataxia, and nystagmus to more severe cognitive and behavioral changes. Clinically, its utilization extends beyond anticonvulsant therapy to include its role in sedation and as an adjunct in the acute management of certain types of drug withdrawal, exemplifying its diverse therapeutic applications in the medical field."
phenoxybenzamine,DB00280,"Phenoxybenzamine, with the DrugBank identifier DB00280, is a potent α-adrenergic antagonist characterized by its distinct chemical structure represented by the SMILES notation ""CC(C)N(CCC(C(N)=O)(c1ccccc1)c1ccccn1)C(C)C"". This compound belongs to the chemical category of haloalkylamines and features a biphenyl moiety as its chemical scaffold, which is crucial for its antagonistic activity against adrenergic receptors. Phenoxybenzamine bears structural similarities to other non-selective alpha blockers, such as dibenamine, although it is distinguished by its irreversible binding to the receptor. Pharmacokinetically, phenoxybenzamine is absorbed after oral administration, distributed widely in tissues, is hepatically metabolized, and its conjugated metabolites are predominantly excreted in the urine. Its toxicity profile indicates that it can cause orthostatic hypotension and reflex tachycardia, among other cardiovascular effects. Phenoxybenzamine's therapeutic action is primarily mediated through its binding and inhibition of alpha-1 and alpha-2 adrenergic receptors. Clinically, the drug is indicated for the management of conditions like pheochromocytoma, where it mitigates hypertensive crises by blocking the effects of excess catecholamines. Common side effects include nasal stuffiness, nausea, and fatigue, which reflect its widespread inhibition of sympathetic nervous system activity. In clinical practice, phenoxybenzamine is also used off-label to treat conditions such as Raynaud's phenomenon and complex regional pain syndrome due to its vasodilatory properties, demonstrating its versatility in modulating vascular tone."
phenylbutazone,DB00439,"Phenylbutazone, assigned DrugBank ID DB00439, is a nonsteroidal anti-inflammatory drug (NSAID) with a complex chemical structure elucidated by its SMILES notation 'COCc1c(C(C)C)nc(C(C)C)c(/C=C/[C@@H](O)C[C@@H](O)CC(=O)O)c1-c1ccc(F)cc1'. This notation signifies a molecule comprising a butazolidine ring - a central chemical scaffold attributed to pyrazolidine derivatives - with an oxyethyl phenyl side chain and a florinated benzene ring, indicating its categorization as an organofluorine compound. Phenylbutazone shares structural similarities with other NSAIDs such as oxyphenbutazone, its active metabolite. Regarding pharmacokinetics, phenylbutazone is well absorbed following oral administration, is extensively distributed in the body with a high plasma protein binding, is metabolized principally in the liver via hydroxylation, and is excreted primarily in the urine. The drug exhibits toxicity in cases of overdose or chronic use, presenting risks such as bone marrow suppression which can lead to blood dyscrasias like aplastic anemia. Target proteins for phenylbutazone include cyclooxygenase (COX) enzymes, particularly COX-1 and COX-2, which are key players in the biosynthesis of prostanoids. Clinically, phenylbutazone is indicated for the relief of pain and inflammation associated with conditions like ankylosing spondylitis and rheumatoid arthritis. While effective, its use can be accompanied by various side effects, including gastrointestinal ulceration, renal impairment, and hypersensitivity reactions. Due to its risk profile and the availability of safer alternatives, the clinical usage of phenylbutazone has markedly declined, now being mostly limited to veterinary medicine, especially in equine practice to manage lameness and musculoskeletal pain."
phenytoin,DB00477,"Phenytoin, identified by DrugBank ID DB00477 and represented by the SMILES notation 'CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21', is a hydantoin derivative characterized by a bicyclic structure consisting of a hydantoin ring fused with a benzyl group substituted with a chlorine atom and linked to a phenyl group through a sulfur atom. It falls within the chemical category of hydantoin anticonvulsants and shares a common chemical scaffold with other hydantoins, such as ethotoin and mephenytoin. As a structural analog of the neurotransmitter GABA, phenytoin inhibits high-frequency firing of neurons by modulating voltage-gated sodium channels, which aligns with the functions of similar anticonvulsants like carbamazepine. The pharmacokinetic profile of phenytoin includes variable oral absorption, extensive protein binding (primarily to albumin), and a large volume of distribution, resulting in erratic plasma levels. It is metabolized predominantly in the liver by cytochrome P450 enzymes, mainly CYP2C9 and to a lesser extent CYP2C19, with subsequent renal excretion of metabolites. The drug's toxicity includes dose-dependent effects such as nystagmus, ataxia, and diplopia, and, less commonly, idiosyncratic hypersensitivity reactions like the Steven-Johnson syndrome. Phenytoin primarily targets voltage-gated sodium channels, with additional interactions that may contribute to its pharmacodynamic profile. It is indicated mainly for the prevention and control of seizures, particularly in epilepsy, and for the treatment of trigeminal neuralgia. Side effects can range from mild, e.g., gum hypertrophy and hirsutism, to severe, including hepatotoxicity and hematologic disorders such as megaloblastic anemia. In a clinical setting, phenytoin is frequently used in the management of status epilepticus and in the prophylaxis of seizures following neurosurgery."
pimozide,DB00788,"Pimozide (DrugBank ID: DB00788) is an antipsychotic drug belonging to the diphenylbutylpiperidine class, characterized by its notable chemical structure, which can be represented by the SMILES notation 'COc1ccc2cc([C@H](C)C(=O)O)ccc2c1'. This notation elucidates the presence of a methoxyphenyl ring and a keto carboxylic acid moiety linked to a chiral carbon in the piperidine ring, a hallmark of its chemical scaffold. Pimozide shares structural and pharmacological properties with similar drugs like fluspirilene and penfluridol. Pharmacokinetically, pimozide is known for its extensive hepatic metabolism predominately through the CYP3A4 enzyme, with a minor contribution from CYP1A2 and CYP2D6, leading to various metabolites which are then excreted mainly in the feces; absorption is modest, with a bioavailability of approximately 50%, and it is highly bound to plasma proteins, hence showing a wide distribution. Its toxicity profile includes QT prolongation and risk of arrhythmia exemplified by Torsades de Pointes. Pimozide targets primarily dopamine D2 receptors, inhibiting dopaminergic neurotransmission, which accounts for its antipsychotic effects. Indicated for use in conditions such as chronic schizophrenia where standard treatment has failed, pimozide also finds utility in treating the motor and phonic tics associated with Tourette's Syndrome. The side effects of pimozide encompass extrapyramidal symptoms such as tardive dyskinesia and parkinsonism, as well as less common adverse effects like hyperprolactinemia and weight gain. In clinical practice, pimozide is a second-line treatment for schizophrenia and is particularly invoked for treatment-resistant cases or specific symptoms like delusions of parasitosis, where its use is circumscribed by careful cardiac monitoring due to its association with significant cardiac events."
piroxicam,DB00412,"Piroxicam, identified by DrugBank ID 'DB00412', with the SMILES notation 'CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1', presents a complex chemical structure with thiazine and pyridine components. As a nonsteroidal anti-inflammatory drug (NSAID) of the oxicam class, it possesses an enolic acid moiety as its chemical scaffold, which is a common feature among oxicams. This class includes similar drugs such as meloxicam and tenoxicam. Regarding pharmacokinetics, piroxicam is well-absorbed following oral administration, widely distributed throughout the body, metabolized predominantly by the liver, mainly through hydroxylation, and excreted both in urine and feces. Its toxicity profile includes gastrointestinal disturbances, which can range from mild discomfort to severe gastritis and ulceration, as well as renal and hepatic toxicity in more serious instances. Piroxicam exerts its therapeutic effects by targeting and reversibly inhibiting cyclooxygenase (COX) enzymes, specifically COX-1 and COX-2, which are instrumental in the biosynthesis of prostaglandins and thromboxanes, thus mitigating inflammation and pain. Clinically, piroxicam is indicated for the treatment of various inflammatory conditions and symptoms such as rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis. Its side effects are reflective of its COX-inhibition mechanism, ranging from mild symptoms like dizziness and headache to severe reactions including gastrointestinal bleeding and cardiovascular events. In clinical practice, piroxicam is often utilized for its analgesic, antipyretic, and anti-inflammatory properties, making it a versatile agent in the symptomatic relief of chronic musculoskeletal and joint disorders."
prazosin,DB01212,"Prazosin, identified by DrugBank ID DB01212 and represented by the SMILES notation ""CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(CSc3nc(=O)c(=O)[nH]n3C)CS[C@H]12)c1csc(N)n1,"" is a quinazoline derivative that exhibits a complex chemical structure marked by a fused quinazoline ring system connected to a piperazine ring and a thiadiazine ring with a characteristic thiazinane dioxide motif. As a member of the chemical class of quinazolines, prazosin shares a chemical scaffold with other antihypertensive agents like doxazosin and terazosin but distinguishes itself with its unique substitutions and functional groups that contribute to its biological activity. Pharmacokinetically, prazosin is well-absorbed orally, widely distributed across tissues, extensively metabolized hepatically primarily by demethylation and conjugation, and excreted largely in the bile and feces, with lesser amounts in the urine. The therapeutic target of prazosin is the alpha-1 adrenergic receptor, which upon antagonism, leads to vasodilation and a subsequent decrease in blood pressure. Clinically indicated for the treatment of hypertension, prazosin effectively ameliorates high blood pressure and has been employed in managing symptoms associated with benign prostatic hyperplasia and post-traumatic stress disorder (PTSD)-related nightmares. Notwithstanding its therapeutic benefits, prazosin can engender side effects such as dizziness, headache, drowsiness, lack of energy, weakness, palpitations, and nausea. In severe cases, it may cause orthostatic hypotension, particularly after the first dose, a phenomenon characterized as the ""first-dose effect."" Its clinical usage spans several decades, earning a reputation as a well-tolerated antihypertensive that can be used alone or in combination with other agents, making it a versatile drug in the management of cardiovascular diseases."
prednisolone,DB00523,"Prednisolone, with DrugBank ID 'DB00523' and SMILES notation 'CC1=C(/C=C/C(C)=C\C=C\C(C)=C\C(=O)O)C(C)(C)CCC1', is a synthetic corticosteroid drug that mirrors the structure and function of cortisol, a natural hormone produced by the adrenal glands. It possesses a pregnane skeleton, which is a common chemical scaffold among steroids, and features a 1,4-diene-3-one structure, indicative of its anti-inflammatory and immunosuppressive properties. Chemically, prednisolone is categorized as a glucocorticoid, similar to drugs like dexamethasone and hydrocortisone, which share the core cyclopentanoperhydrophenanthrene structure inherent to steroids. Upon oral administration, prednisolone is well-absorbed and extensively distributed in the body. It is metabolized primarily in the liver via hydroxylation, with subsequent sulfate and glucuronide conjugation. Prednisolone and its metabolites are mostly excreted via the urine.

The primary mechanism of action of prednisolone involves its interaction with glucocorticoid receptors, leading to modulation of gene expression and suppression of pro-inflammatory pathways. Prednisolone is indicated for a variety of conditions due to its potent anti-inflammatory and immunosuppressive effects, including autoimmune diseases such as rheumatoid arthritis, inflammatory bowel diseases like ulcerative colitis, and asthma, among others. Despite its therapeutic efficacy, prednisolone's toxicity profile warrants attention; it can induce side effects such as osteoporosis, adrenal suppression, and increased susceptibility to infections. These adverse effects are dose-dependent and become more pronounced with prolonged use. Clinically, prednisolone is used in both acute settings, for instance, to manage acute asthma exacerbations, and in long-term treatment plans, as part of maintenance therapy for chronic conditions like systemic lupus erythematosus (SLE). The judicious use of prednisolone is essential to balance clinical efficacy against the potential for significant adverse effects."
prednisone,DB00690,"Prednisone, with DrugBank ID 'DB00690' and SMILES notation 'CCN(CC)CCN1C(=O)CN=C(c2ccccc2F)c2cc(Cl)ccc21', is a synthetic glucocorticoid with anti-inflammatory and immunosuppressive properties. Structurally, it contains a pregnane backbone with a 17,21-dihydroxypregna-1,4-diene-3,11,20-trione moiety, fluorine substitution at one phenyl ring, and a chlorine substitution at another, denoting a complex, multi-substituted chemical architecture. It belongs to the chemical category of glucocorticoids and shares a common steroid scaffold with similar drugs such as prednisolone and dexamethasone. Prednisone is well-absorbed after oral administration, it is widely distributed in body tissues, metabolized primarily in the liver to its active form, prednisolone, and excretion occurs via the urine. The drug’s toxicity is typically dose-dependent, with long-term use linked to adverse effects such as osteoporosis, adrenal suppression, and peptic ulcers. Prednisone exerts its effects by binding to cytoplasmic glucocorticoid receptors, influencing the transcription of target genes, which leads to its physiological actions. Clinically, prednisone is indicated for a variety of conditions, including autoimmune disorders like rheumatoid arthritis, allergic reactions, asthma, and chronic obstructive pulmonary disease (COPD), due to its potent anti-inflammatory and immunosuppressive effects. Common side effects of prednisone can range from mood changes and insomnia to more serious outcomes like hypertension and hyperglycemia. In clinical settings, prednisone is used in tapering doses to mitigate adrenal insufficiency and is a key drug in managing acute exacerbations of chronic diseases and in immunosuppressive regimens post-transplantation."
probenecid,DB00277,"Probenecid, with DrugBank ID DB00277 and SMILES notation Cn1c(=O)c2[nH]cnc2n(C)c1=O, exhibits a chemical structure characterized by a pyrazolidine scaffold bearing two amide groups, with its formula indicating the presence of a diazotized urea derivative. It falls under the chemical category of uricosuric agents, which modulate uric acid levels in the body. Structurally related drugs include sulfinpyrazone and benzbromarone, both of which also act to decrease plasma urate levels. Probenecid's pharmacokinetic profile reveals absorption in the gastrointestinal tract with peak plasma levels attained within 2 to 4 hours. It exhibits a volume of distribution reflective of extensive tissue binding, negligible metabolism, and is primarily excreted unchanged via the renal route. The risk of toxicity is associated with gastrointestinal disturbances and hypersensitivity reactions, such as anaphylaxis. The drug's primary target proteins are the renal organic anion transporters (OATs), particularly OAT1 and OAT3, which it inhibits to decrease renal uric acid reabsorption. Indicated primarily for the treatment of gout and hyperuricemia, Probenecid reduces the frequency of acute gout attacks and is often used in conjunction with other gout medications. However, the therapeutic utility of Probenecid extends beyond gout management; it's also employed to prolong the half-life of certain antibiotics like penicillin. Adverse effects range from mild, such as headaches and dizziness, to more serious conditions like nephrotic syndrome or blood dyscrasias. In clinical scenarios, aside from gout, Probenecid may be utilized off-label for enhancing antibiotic serum levels in infections where bacterial resistance is a concern, thus providing an important strategy in antimicrobial therapy."
procainamide,DB00321,"Procainamide (DrugBank ID: DB00321), with the SMILES notation CN(C)CCC=C1c2ccccc2CCc2ccccc21, is an antiarrhythmic agent with a complex biphenylmethane structure composed of a benzene ring linked to a diethylaminoethyl side chain through an amide functionality. As a member of the class Ia antiarrhythmics, it shares its core chemical scaffold with similar drugs like quinidine and disopyramide, characterized by their ability to block voltage-gated sodium channels. Procainamide exhibits a pharmacokinetic profile with moderate oral absorption and wide distribution, including crossing the blood-brain barrier. It is predominantly metabolized hepatically through N-acetylation via NAT2 isozyme and CYP450-mediated hydroxylation, and excreted renally; genetic polymorphisms in NAT2 can influence its metabolic rate and consequently, its plasma levels, affecting both efficacy and toxicity. Procainamide's toxicity is dose-related, with potential for causing agranulocytosis and a lupus-like syndrome among other adverse effects. It targets the cardiac sodium channels primarily and the potassium channels secondarily, stabilizing the cardiac membrane and suppressing arrhythmias. Clinically, procainamide is indicated for the management of acute ventricular arrhythmias post-myocardial infarction and for arrhythmias that are refractory to other interventions. Its side effects can include gastrointestinal disturbances, hypotension, and QT interval prolongation, which may predispose patients to torsades de pointes. Despite its side effects, procainamide maintains a clinical niche in the acute treatment of certain life-threatening arrhythmias, particularly when used in controlled settings with careful monitoring."
progesterone,DB00317,"Progesterone, with the DrugBank identifier DB00317, is a steroid hormone with a complex chemical structure characterized by its Simplified Molecular Input Line Entry System (SMILES) notation as 'COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1'. This notation describes a molecular framework that includes an assortment of functional groups such as methyl ethers, aromatic rings, halogens (specifically chlorine and fluorine), and a piperidine moiety, all contributing to its unique structure. Progesterone is a member of the progestins chemical category, which are synthetic or natural compounds that mimic the action of the endogenous hormone. The chemical scaffold of progesterone is based on a pregnane skeleton, a characteristic feature shared among several steroidal hormones.

Progesterone shares its chemical scaffold with similar steroidal drugs like corticosteroids and androgens, for example, hydrocortisone and testosterone. The pharmacokinetic profile of progesterone includes oral and parenteral (e.g., intramuscular) absorption with high variability in bioavailability due to the first-pass metabolism in the liver. Its distribution is widespread due to lipid solubility, and it binds to plasma proteins, such as serum albumin and corticosteroid-binding globulin. Metabolism occurs primarily in the liver through reduction and conjugation, leading to urinary and biliary excretion of metabolites.

Toxicity of progesterone is relatively low, but can induce dose-related side effects such as sedation or mood changes at higher doses. Known target proteins for progesterone include nuclear hormone receptors, namely the progesterone receptor, to which it binds and initiates gene transcription for various physiological effects. Clinically, progesterone is indicated for multiple conditions, including hormone replacement therapy in post-menopausal women, amenorrhea, and as part of assisted reproductive technology protocols. Side effects may include menstrual irregularities, headache, breast tenderness, mood swings, and an increased risk of thromboembolism.

Progesterone's clinical usage extends to the management of preterm labor and as a component of hormonal contraceptives,"
promethazine,DB00320,"Promethazine, with DrugBank ID DB00320 and SMILES notation CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21, is a phenothiazine derivative characterized by a tricyclic core containing two benzene rings linked through a nitrogen atom forming a diazepine ring, with additional aliphatic and aromatic substituents conferring its unique properties. It falls within the chemical category of histamine H1 antagonists and phenothiazines, sharing its chemical scaffold with other similar drugs such as chlorpromazine and trifluoperazine. Promethazine exhibits comprehensive pharmacokinetics; after oral administration, it is well-absorbed, widely distributed throughout the body, metabolized primarily in the liver by the cytochrome P450 enzyme system, and excreted largely in the urine with some components appearing in the feces. Its toxicity profile includes potential for central nervous system depression, anticholinergic effects, and, rarely, neuroleptic malignant syndrome. The drug targets the histamine H1 receptor, among others, effectively decreasing its action. Clinically, promethazine is indicated for conditions such as allergic reactions, sedation, nausea, and vomiting, exemplified by its use in anaphylaxis, preoperative sedation, and motion sickness. Its side effects may include drowsiness, dry mouth, and blurred vision, as well as more severe effects such as respiratory depression in excessive dosages. In a clinical setting, promethazine is often administered orally or via injection for its antihistaminic, antiemetic, and sedative properties, also serving as an adjunct in analgesic regimens for pain control."
propafenone,DB00669,"Propafenone, with the DrugBank identifier DB00669, is a class 1C antiarrhythmic agent characterized by the SMILES notation CNS(=O)(=O)Cc1ccc2[nH]cc(CCN(C)C)c2c1, displaying its complex chemical structure. This structure delineates a molecule containing a phenyl group connected to a dihydropyridine moiety through an ethyl chain, which additionally carries a sulfonamide group, reflecting its chemical category as a sulfonamide and its belonging to the diphenylpropylamine chemical scaffold. Propafenone shares mechanistic properties with similar drugs such as flecainide and encainide in inhibiting voltage-gated sodium channels. Its pharmacokinetic profile reveals oral absorption, extensive hepatic metabolism primarily through CYP2D6 to active metabolites like 5-hydroxypropafenone, and elimination substantially via renal excretion. Propafenone toxicity includes proarrhythmic effects and the potential for cardiac depression at high concentrations, necessitating careful monitoring. Target proteins for Propafenone encompass voltage-gated sodium channels and, to a lesser extent, beta-adrenergic receptors. Clinically, propafenone is indicated for use in the treatment of supraventricular and ventricular arrhythmias, such as atrial fibrillation and ventricular tachycardia. Notable side effects range from dizziness and taste disturbances to more serious cardiac events like bradycardia and heart failure exacerbation. In clinical practice, this drug is administered for rhythm control in patients with atrial fibrillation, where maintaining sinus rhythm is beneficial, and as secondary prophylaxis in individuals post-myocardial infarction with documented ventricular arrhythmias, to avoid sudden cardiac death. The comprehensive understanding of propafenone's chemistry, pharmacology, and clinical application aligns with its specialized use in cardiology, governed by the need for precise therapeutic regulation and individualized patient care strategies."
propranolol,DB01242,"Propranolol, with DrugBank ID DB01242, is a non-selective beta-adrenergic receptor-blocking agent manifesting its activity by its SMILES notation 'CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc21', which elucidates its chemical structure comprising a naphthalene ring with substituted ethylamine and chlorophenyl groups, reflecting its belonging to the class of beta blockers. Structurally characterized by the presence of a naphthylmethylamine scaffold, propranolol shares pharmacological properties with similar drugs such as metoprolol and atenolol. Propranolol's pharmacokinetic profile is marked by rapid absorption, wide distribution including crossing the blood-brain barrier, hepatic metabolism predominantly via oxidation through the enzyme CYP2D6, and subsequent renal excretion. The drug may exhibit toxicity, such as cardiogenic shock and bronchospasm, particularly in predisposed populations. Propranolol's therapeutic actions are mainly attributed to its antagonistic effects on target proteins, specifically the beta-1 and beta-2 adrenergic receptors. Clinically, it is indicated for a plethora of cardiovascular disorders including hypertension, angina, and tachyarrhythmias, and for symptomatic control in conditions like essential tremor and performance anxiety. Notwithstanding its versatility in clinical use, propranolol's administration can be accompanied by side effects ranging from mild, such as fatigue and dizziness, to severe, including bradycardia and hypotension. In clinical practice, propranolol is extensively employed for its antihypertensive, antianginal, and antiarrhythmic benefits, besides having off-label uses for migraine prophylaxis and mitigating the physiological symptoms associated with anxiety."
protriptyline,DB01394,"Protriptyline, with the DrugBank ID DB01394, is a tricyclic antidepressant characterized by its distinct chemical structure represented by the SMILES notation 'COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1C(NC(C)=O)CC2'. This notation specifies a tricyclic system with methoxy groups at various positions and an amide side chain, indicating a complex polycyclic molecule with an additional aromatic ketone conjugation. Protriptyline belongs to the chemical category of dibenzocycloheptenes, which serves as its chemical scaffold, closely related to other tricyclic antidepressants such as amitriptyline and nortriptyline. Pharmacokinetically, protriptyline is known for its good oral absorption, extensive tissue distribution due to its lipophilicity, hepatic metabolism primarily through CYP2D6 isoenzyme, and eventual renal and fecal excretion. The toxicity profile of protriptyline includes cardiac toxicity, such as tachycardia and arrhythmias, CNS effects like seizures and toxicity resulting in confusion or agitation, which is relatively common in overdosage scenarios. This drug's primary known target proteins are the monoamine transporters, including the serotonin transporter (SERT) and the norepinephrine transporter (NET), which it inhibits, thereby enhancing monoaminergic signaling. Protriptyline is indicated for the treatment of depressive disorders, particularly where an energizing antidepressant effect is desired, like in cases of psychomotor retardation. Side effects associated with protriptyline can include anticholinergic effects such as dry mouth, blurred vision, constipation, and urinary retention, as well as adrenergic effects like hypertension and tachycardia. Clinically, protriptyline is utilized as a second-line therapy for major depressive episodes when patients fail to respond to first-line drug treatments, but it may also be used off-label for conditions like ADHD or neuropathic pain based on its pharmacological profile."
quercetin,DB00333,"Quercetin (DrugBank ID: DB00333) with the SMILES notation CCC(=O)C(CC(C)N(C)C)(c1ccccc1)c1ccccc1 is a bioflavonoid compound that occurs widely in nature. Its chemical structure reveals two aromatic rings connected through a three-carbon chain that possesses a ketone function, fitting within the broader chemical category of flavonols, which are a class of flavonoids. The compound features a diphenylpropane skeleton, which is characteristic of the flavonoid chemical scaffold. Quercetin is structurally similar to other flavonoids, such as kaempferol and myricetin, which also display a range of biological activities. 

The pharmacokinetics of quercetin involves moderate absorption from the gastrointestinal tract with subsequent extensive phase II metabolism, resulting in methylated, glucuronidated, and sulfated metabolites. Distribution is widespread due to its solubility in lipids, but the bioavailability is limited due to rapid metabolism and elimination, primarily through the renal pathway. Quercetin's toxicity profile is relatively low, but it can cause adverse effects, especially at higher doses, such as headache and nephrotoxicity in animal studies.

Quercetin is known to interact with a range of target proteins including enzymes such as tyrosine kinases, and several transcription factors, which confer its multiple pharmacological effects. Therapeutically, quercetin is indicated for its antioxidant properties and as a supplemental treatment for conditions involving oxidative stress, such as cardiovascular diseases. However, as a supplement, it is important to note that rigorous clinical studies are limited. Potential side effects of quercetin, particularly when consumed in high doses, include mild dyspepsia and headaches, though these are relatively uncommon. Clinically, quercetin has seen usage in trials exploring interventions for allergies, hypertension, and inflammatory conditions due to its anti-inflammatory and antihypertensive effects, yet its use as a conventional pharmaceutical agent is not extensively established. This narrative compiles key insights into quercetin's structure, functionality, and potential in clinical applications, aligning"
quinacrine,DB00624,"Quinacrine, with DrugBank ID 'DB00624', is an acridine-derived compound expressed by the SMILES notation 'C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O'. Its detailed chemical structure includes a tricyclic system consisting of a quinoline moiety fused to a bicyclic decalin system, exemplifying its chemical category of acridine dyes. The chemical scaffold is characterized by a planar, heteroaromatic acridine nucleus responsible for intercalation into nucleic acids, a structural feature it shares with similar drugs like chloroquine and amodiaquine, used as antimalarial and anti-inflammatory agents. Quinacrine exhibits a complex pharmacokinetic profile, with rapid intestinal absorption, wide distribution including high affinity for tissues rich in mitochondria and lysosomes, hepatic metabolism primarily via cytochrome P450 enzymes, and excretion predominantly in the form of metabolites in urine and bile. The toxicity of quinacrine can manifest as gastrointestinal disturbances, dermatological reactions, and, in rare cases, central nervous system effects like psychosis. Quinacrine targets various proteins, including but not limited to those involved in protozoal DNA synthesis and certain prion proteins. Indicated primarily for its antiprotozoal activity, it is used in the treatment of diseases such as giardiasis and, historically, malaria. Notable side effects can include nausea, vomiting, headache, and yellowing of the skin or eyes due to its intense yellow color. Clinically, quinacrine has been employed in the chemoprophylaxis and therapy of malaria, although its use has declined due to the emergence of drug-resistant strains of Plasmodium. Additionally, it has seen application in the management of non-infectious conditions like rheumatoid arthritis and lupus, demonstrating the broad utility of this pharmacological agent."
quinidine,DB00845,"Quinidine, with DrugBank ID 'DB00845', is a stereoisomer of the antimalarial drug quinine, and its chemical structure is denoted by the SMILES notation 'CC(C)N=c1cc2n(-c3ccc(Cl)cc3)c3ccccc3nc-2cc1Nc1ccc(Cl)cc1'. This notation reflects its complex chemical structure, which includes multiple aromatic rings, nitrogen-containing moieties, and chlorine substituents, making it an alkaloidal molecule and a class 1a antiarrhythmic agent. Quinidine belongs to the cinchona alkaloids chemical category and features a quinoline-based scaffold, which it shares with related anti-malarial drugs such as chloroquine. Pharmacokinetically, quinidine is well-absorbed from the gastrointestinal tract, extensively metabolized in the liver primarily via CYP3A4, and excreted mainly by the kidneys. Therapeutically, it is used for the treatment of various cardiac arrhythmias, such as atrial fibrillation and ventricular tachycardia, by blocking voltage-gated sodium channels, which in turn prolong the refractory period of the heart. The known protein targets of quinidine include the voltage-gated sodium channels and potassium channels. Quinidine's use is also limited by its potential toxicity, manifesting in cinchonism, characterized by symptoms such as tinnitus, headache, and thrombocytopenia, and it poses a risk of Torsades de Pointes due to QT interval prolongation. Side effects associated with quinidine include gastrointestinal disturbances, such as diarrhea, and cardiovascular issues, such as hypotension. In clinical settings, quinidine is sometimes utilized in the treatment of malaria, albeit infrequently due to resistance, and is administered orally or intravenously depending on the indication and desired therapeutic effect."
quinine,DB00602,"Quinine, with DrugBank ID DB00602, is an alkaloid with a complex chemical structure characterized by its rigid tricyclic quinuclidine nucleus fused to a quinoline moiety and a variety of functional groups including ethers, alcohols, and olefins, as represented by its intricate SMILES notation. As a natural product, quinine belongs to the chemical category of cinchona alkaloids, and its chemical scaffold is akin to other quinoline derivatives used as antimalarial agents, such as chloroquine and mefloquine. Pharmacokinetically, quinine is well absorbed after oral administration, widely distributed including crossing the blood-brain barrier, extensively metabolized primarily by cytochrome P450 enzymes in the liver (CYP3A4) into inactive metabolites, and excreted mainly via the urine. Its toxicity profile includes symptoms like cinchonism, characterized by tinnitus, headache, nausea, and visual disturbances, and at higher doses, it can cause severe cardiac toxicity, hypoglycemia, and hypersensitivity reactions. Quinine's therapeutic action is attributed to its target protein, the Plasmodium falciparum chloroquine resistance transporter (PfCRT), which is involved in the protozoan's resistance mechanism to chloroquine. Indicated chiefly for the treatment of uncomplicated Plasmodium falciparum malaria, quinine is also used off-label for nocturnal leg cramps. Side effects can range from mild (nausea, dizziness) to severe (hemolysis in individuals with glucose-6-phosphate dehydrogenase deficiency), impacting its risk-benefit profile in clinical use. Despite the development of newer antimalarials, quinine's long-standing historical use is still notable, particularly in areas of chloroquine-resistant malaria, underscoring its relevance in contemporary medical therapy as both a first-line and a second-line treatment option."
ranitidine,DB00570,"Ranitidine, known by its DrugBank ID DB00570, is characterized by its intricate chemical structure denoted by the SMILES notation CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1, which reveals a framework displaying a fused ring system incorporating a benzimidazole linked to a dimethylaminomethylfuranyl moiety. As a member of the H2 receptor antagonist class, ranitidine acts by inhibiting histamine action at H2 receptors of the gastric parietal cells, consequently reducing gastric acid secretion and aiding in the treatment of peptic ulcers and gastroesophageal reflux disease (GERD). Chemically, ranitidine is embodied by a substituted furan, representative of its unique methoxy indole scaffold that distinguishes it from similar drugs such as cimetidine and famotidine.

Regarding its pharmacokinetics, ranitidine is well-absorbed from the gastrointestinal tract, with a bioavailability of about 50%, subject to first-pass metabolism. Post-absorption, the drug is distributed throughout the body's tissues, with a volume of distribution of 1.4 L/kg, and metabolized predominantly in the liver to the N-oxide, S-oxide, and desmethyl ranitidine. Most of the drug (about 30-70%) is excreted unchanged in urine. The drug's safety profile shows a relatively low toxicity, but it has been associated with rare instances of cardiac arrhythmias, hepatotoxicity, and, in more recent findings, potential contamination with N-Nitrosodimethylamine (NDMA), a recognized carcinogen.

The primary target protein of ranitidine is the histamine H2 receptor, through which it exerts its anti-secretory effect on gastric acid."
reserpine,DB00608,"Reserpine, assigned the DrugBank identifier DB00608 and represented by the SMILES notation CCN(CC)CCCC(C)Nc1ccnc2cc(Cl)ccc12, is an indole alkaloid bearing a distinctive fusion of a benzocarbazole system with a 2-chlorophenyl substitution, forming the core of its chemical structure. Classified as an antihypertensive and an antipsychotic, reserpine belongs to a category of alkaloids known as ""reserpine alkaloids"" and shares its chemical scaffold with closely related indole alkaloids like yohimbine and ajmaline. Its pharmacokinetics involve limited absorption with peak plasma levels reached within hours, wide distribution with a tendency to accumulate in tissues, extensive metabolism primarily in the liver, and renal excretion of metabolites. Toxicity of reserpine is documented, with serious adverse effects such as depression and Parkinson's-like symptoms at high doses, evidencing its profound impact on the central nervous system. It targets various proteins including the vesicular monoamine transporter 2 (VMAT2), which is integral to its mechanism of depleting catecholamines and serotonin from neuronal stores. Clinically, reserpine is indicated primarily for the management of hypertension and its secondary use in certain cases of psychosis; however, it has been largely supplanted by drugs with fewer side effects. Side effects are notable, ranging from mild gastrointestinal issues to severe mental depression and bradycardia. The clinical usage of reserpine has waned over recent years due to the availability of safer pharmacological alternatives, yet it remains a model compound in neuropharmacological research and has been used historically to control high blood pressure and alleviate the symptoms of agitated psychoses."
ribavirin,DB00575,"Ribavirin, with DrugBank ID DB00575 and SMILES notation Clc1cccc(Cl)c1NC1=NCCN1, is a synthetic nucleoside analogue with a complex chemical structure featuring a triazole ring fused to a ribose sugar moiety, which is substituted with two chlorine atoms on its benzene ring. Ribavirin belongs to the chemical category of antiviral agents and employs a purine nucleoside analog scaffold, which is shared by other analogous antiviral drugs such as inosine pranobex. The pharmacokinetics of ribavirin is characterized by rapid oral absorption, widespread distribution with a high volume of distribution, intracellular metabolism via phosphorylation into its active triphosphate form, and renal excretion, where the drug's half-life is prolonged in renal impairment. Ribavirin's toxicity profile includes dose-dependent hemolytic anemia and cardiac and teratogenic effects as notable examples, mandating caution during treatment. Known target proteins for ribavirin include viral RNA-dependent RNA polymerase along with host enzymes like inosine monophosphate dehydrogenase, contributing to its antiviral activity. Ribavirin is indicated primarily for the treatment of viral infections such as Hepatitis C (in combination with other drugs) and some types of viral hemorrhagic fevers. Side effects, apart from anemia, can include fatigue, cough, and irritation at the site of injection, which can influence treatment compliance. Clinically, ribavirin is utilized in several therapeutic regimens, often in combination therapy with pegylated interferon for the management of chronic Hepatitis C, and has been investigated for use against other viral infections, demonstrating its versatility and essential role in antiviral pharmacotherapy."
riboflavin,DB00590,"Riboflavin, known by its DrugBank identifier DB00590 and represented by the SMILES notation COc1cc2nc(N3CCN(C(=O)C4COc5ccccc5O4)CC3)nc(N)c2cc1OC, is a water-soluble B vitamin that presents a complex chemical structure prominently featuring an isoalloxazine ring - a three-ring structure containing nitrogen atoms at 1,3,7, and 9 positions. This isoalloxazine is adjoined to a ribityl side chain, classifying riboflavin as a flavin, which is a subset of the larger pteridine chemical family due to the presence of the heterocyclic pteridine moiety within its structure. As a flavin compound, riboflavin shares structural similarities with other flavins like FMN (flavin mononucleotide) and FAD (flavin adenine dinucleotide), which are derived from it and serve as cofactors in biological systems.

Pharmacokinetically, riboflavin is well-absorbed orally and gets distributed throughout the body's tissues; however, its bioavailability is limited, necessitating regular replenishment through diet or supplementation. It undergoes negligible metabolism and is excreted primarily in the urine, often imparting a distinct yellow coloration due to the body's limited retention capabilities. Riboflavin is generally associated with low toxicity, and adverse effects are rare, but high doses might lead to harmless, bright yellow discoloration of the urine. Target proteins for riboflavin include various flavoproteins which play key roles in the electron transport chain and metabolic pathways.

Medically, riboflavin is indicated for the treatment of riboflavin deficiency, which can lead to symptoms such as ariboflavinosis, characterized by cracks at the corners of the mouth, high sensitivity to sunlight, and a sore throat. It's also implicated in the prophylaxis of migraines and certain conditions like preeclampsia in pregnant women. While adverse effects are uncommon, they can include an increase in urine output, diarrhea, and, in some cases, allergic reactions"
rifampin,DB00936,"Rifampin, designated by DrugBank ID DB00936 and represented by the SMILES notation O=C(O)c1ccccc1O, embodies a macrocyclic antibiotic compound with a complex chemical structure that includes a naphthohydroquinone linked to a naphthoquinone by a bridged aliphatic chain. Classified chemically as a rifamycin derivative, rifampin's chemical scaffold is characteristic of its antibiotic class, sharing structural similarities with other rifamycins such as rifabutin and rifapentine, which exhibit comparable mechanisms of action. Rifampin is renowned for its pharmacokinetic properties, being well-absorbed after oral administration, subject to extensive hepatic metabolism primarily via deacetylation, with subsequent biliary and renal excretion of metabolites. Notably, it acts as an inducer of several cytochrome P450 enzymes, which can lead to significant drug-drug interactions. The toxicity of rifampin is generally well-characterized, with hepatotoxicity being one of the most severe potential side effects, along with interstitial nephritis and hypersensitivity reactions in rare cases. Rifampin exerts its bactericidal action through the inhibition of DNA-dependent RNA polymerase in susceptible microorganisms, particularly targeting the beta-subunit encoded by the rpoB gene. Clinically, rifampin is indicated for the treatment of several bacterial infections, including tuberculosis and leprosy, and as part of a prophylactic regimen against Neisseria meningitidis. However, its side effect profile, which includes hepatotoxicity, discoloration of bodily fluids, and gastrointestinal disturbances, must be considered when prescribing. In clinical practice, rifampin is utilized in conjunction with other antibacterials to prevent or delay the emergence of resistance, with its role in combination therapy for tuberculosis being one of its most critical usages."
sulfasalazine,DB00678,"Sulfasalazine, identifiable by its DrugBank ID DB00678 and characterized by its SMILES notation CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1, is a synthetic compound that exhibits a mesoionic structure comprising a sulfonamide group attached to a salicylate moiety through an azo linkage. This places it within the chemical category of aminosalicylates, with a core chemical scaffold that distinguishes it as an azo compound. As a prodrug, sulfasalazine shares therapeutic profiles with similar anti-inflammatory drugs such as mesalamine and olsalazine. Following oral administration, its absorption is relatively poor with the majority of the drug reaching the colon where it is metabolized by gut bacteria into sulfapyridine and 5-aminosalicylic acid (5-ASA), the active components. Distribution is largely local to the intestinal tract, while systemic metabolism involves acetylation and conjugation, with renal excretion playing a major role in the elimination of its metabolites.

Sulfasalazine's toxicity is generally considered to be low, but may include hypersensitivity reactions, hepatotoxicity, and in rare cases, blood disorders such as agranulocytosis. Its primary targets include pro-inflammatory cytokines and mediators, adding to its role in downregulating immune responses. Therapeutically, sulfasalazine is indicated for the treatment of inflammatory bowel diseases, such as ulcerative colitis and Crohn's disease, by reducing inflammation and maintaining remission. Side effects, ranging from mild to severe, may include gastrointestinal disturbances, headache, and a reversible oligospermia. From a clinical standpoint, sulfasalazine has stood the test of time since its initial use in the 1940s for rheumatoid arthritis, and continues to be a cost-effective treatment option in a variety of inflammatory and autoimmune conditions, where clinicians balance its beneficial outcomes with its known side effect profile and monitor patients for adverse reactions."
selegiline,DB00564,"Selegiline, assigned DrugBank ID DB00564 and represented by the SMILES notation NC(=O)N1c2ccccc2C=Cc2ccccc21, is a propargylamine derivative with a multifaceted chemical structure characterized by an indan ring system attached to a nitrogen atom which forms an amide bond with a carbonyl group. As a member of the phenethylamine class, it shares its core chemical scaffold with other monoamine oxidase inhibitors (MAOIs), similar to drugs like rasagiline and phenelzine, but stands out for its selectivity towards the MAO-B isoenzyme. Pharmacokinetically, selegiline is well absorbed orally, widely distributed throughout the body, and extensively metabolized by cytochrome P450 enzymes in the liver, primarily CYP2B6, before excretion largely in the urine. Its toxicity profile indicates a relatively safe therapeutic window, but at higher doses, it may manifest similar toxicities to other MAOIs, such as hypertensive crises when combined with tyramine-rich foods or other sympathomimetics. The principal target proteins of selegiline are the MAO-A and MAO-B enzymes, with a higher affinity for the latter, thus inhibiting the breakdown of dopaminergic neurotransmitters. Selegiline's clinical indications primarily include the treatment of Parkinson's disease and, as an adjunct therapy, major depressive disorder, aiming to alleviate motor and affective symptoms, respectively. Sidebar effects associated with selegiline range from mild, such as nausea and dizziness, to more severe, including orthostatic hypotension and serotonin syndrome when used in conjuncture with serotonergic agents. In a clinical setting, selegiline is utilized both in monotherapy for early-stage Parkinson's disease to delay the need for levodopa therapy and as an adjuvant to potentiate the effects of levodopa in more advanced disease stages, thus demonstrating its versatile role in the management of neurodegenerative diseases."
spironolactone,DB00134,"Spironolactone, with the DrugBank identifier DB00134, is a potassium-sparing diuretic that features a unique 7-alpha-acetylthio-17-alpha-hydroxy-3-oxopregn-4-ene-21-carboxylic acid gamma-lactone structure, as encoded in its SMILES notation 'CSCC[C@H](N)C(=O)O'. Structurally, spironolactone is a steroidal compound, deriving its core chemical scaffold from a spiro-fused gamma lactone and a thioacetate, reminiscent of other steroidal agents such as eplerenone. Spironolactone's pharmacokinetics are characterized by rapid oral absorption, a wide tissue distribution, and an extensive hepatic metabolism, primarily via the cytochrome P450 enzyme CYP3A4, to active metabolites such as canrenone; it's ultimately excreted predominantly in the urine. Its toxicity profile is generally low, but can include hyperkalemia, especially in the setting of renal impairment. Spironolactone's therapeutic mechanism mainly involves antagonism of the mineralocorticoid receptor (MR), responsible for the modulation of sodium and water balance. Clinically, this drug is indicated for conditions like congestive heart failure, cirrhotic ascites, nephrotic syndrome, and hypertension, due to its diuretic effects. Additionally, spironolactone possesses anti-androgenic properties, which makes it useful in the treatment of acne, hirsutism, and as part of hormone therapy for transgender women. Side effects can be diverse, ranging from gynecomastia and menstrual irregularities to gastrointestinal disturbances and dizziness. The clinical utility of spironolactone has been solidified through its use as an adjuvant in heart failure to improve symptoms and potentially increase survival, as well as in resistant hypertension, and for its protective effects in preventing hypokalemia in patients on thiazide or loop diuretics."
streptozocin,DB00396,"Streptozocin (DrugBank ID: DB00396), with the SMILES notation CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C, is a chemotherapeutic agent known for its intricate chemical structure featuring a methylnitrosourea moiety attached to a glucopyranose ring. This places it within the chemical category of nitrosoureas, a class of alkylating agents that target DNA. Streptozocin’s unique chemical scaffold links the alkylating nitrosourea group to a sugar, differentiating it from other similar alkylating agents such as carmustine and lomustine. Pharmacokinetically, streptozocin is not completely characterized, but it is known to exhibit rapid renal clearance and to decompose into a reactive methyldiazonium species that alkylates DNA. Its toxicity profile includes potential nephrotoxicity and hepatotoxicity evidenced by elevated serum creatinine and liver enzymes, respectively. The primary target proteins for its mechanism of action are DNA and RNA due to its alkylating properties, leading to DNA strand breaks and apoptosis. Streptozocin is specifically indicated for the treatment of pancreatic islet cell carcinoma, as it has a predilection for the beta cells of the pancreas. Its side effects can range from nausea and vomiting to more severe myelosuppression and renal toxicity, with thrombocytopenia and proteinuria as notable examples. Clinically, streptozocin has seen use in the context of managing symptomatic metastatic cancers related to neuroendocrine tumors and in combination protocols with other chemotherapeutic agents, exemplified by its pairing with doxorubicin for enhanced efficacy. In summary, streptozocin's utility in oncology, derived from its distinct nitrosourea-sugar molecule, positions it as a valuable, though potentially toxic, pharmacotherapeutic option for specific neoplastic disorders."
sulfinpyrazone,DB00382,"Sulfinpyrazone, identified by DrugBank ID DB00382 and represented by the SMILES notation Nc1c2c(nc3ccccc13)CCCC2, is a uricosuric agent characterized by an aromatic heterocycle structure with a pyrazolidinedione scaffold. As a chemical entity, it falls within the class of organic compounds known as pyrazolidines, relating chemically to other uricosuric drugs like probenecid. Structurally, sulfinpyrazone possesses a fused bicyclic core that integrates a pyrazole ring with both nitrogen and sulfur substituents, contributing to its pharmacological activity. The drug undergoes appreciable gastrointestinal absorption upon oral administration and is extensively distributed throughout the body, with a high plasma protein binding affinity. Metabolism takes place primarily in the liver, where it is transformed into less active metabolites, which, along with the unchanged drug, are then eliminated through the kidneys. Although generally well-tolerated, sulfinpyrazone's toxicity profile includes gastrointestinal disturbances and risk of peptic ulcers as notable adverse effects. Its pharmacodynamic action involves inhibition of renal tubular reabsorption of urate, consequently reducing serum uric acid levels by targeting proteins embedded in the tubular membrane. Indicated for the management of chronic gout, sulfinpyrazone aids in preventing attacks by mitigating hyperuricemia. Side effects, although typically mild, can encompass rashes, gastrointestinal discomfort, and renal impairment. In clinical practice, sulfinpyrazone is prescribed less frequently due to the availability of newer uricosuric drugs, but it is still used for patients with gout where first-line treatments are contraindicated or ineffective."
sulindac,DB00656,"Sulindac, with the DrugBank ID DB00656, has a distinct chemical structure represented by the SMILES notation ""O=c1n(CCCN2CCN(c3cccc(Cl)c3)CC2)nc2ccccn12,"" which denotes a sulfoxide that is a prodrug, metabolized in vivo to an active sulfide form. Chemically categorized as a nonsteroidal anti-inflammatory drug (NSAID), it possesses an indene moiety as its chemical scaffold, which is essential for its anti-inflammatory properties. Sulindac is structurally akin to other NSAIDs, such as indomethacin, sharing therapeutic effects and side-effect profiles due to similarities in the structural core and mechanism of action.

Pharmacokinetically, sulindac exhibits good oral absorption, wide tissue distribution, substantial hepatic metabolism via cytochrome P450 oxidases (principally CYP2C9) generating an active sulfide metabolite and inactive sulfone metabolite, followed by renal and biliary excretion. The drug's metabolism is significant for its pharmacological profile, as the sulfide metabolite is primarily responsible for its therapeutic effects.

Toxicity associated with sulindac includes gastrointestinal complications like ulcers, renal impairment, and hypersensitivity reactions, which are in line with adverse effects observed in other NSAIDs. COX-1 and COX-2 enzymes are known target proteins of sulindac, contributing to its anti-inflammatory, analgesic, and antipyretic effects due to the inhibition of prostaglandin synthesis.

Sulindac is indicated for the treatment of inflammatory conditions such as rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis. Side effects may include, but are not limited to, gastrointestinal irritation, dizziness, and rash, which often influence the benefit-risk assessment in its clinical application.

In clinical practice, sulindac is employed for its efficacy in reducing pain and inflammation associated with chronic arthritic conditions. It is also used off-label for the adjuvant treatment of certain neoplastic conditions, given its potential to interfere with tumor cell proliferation. The carefully balanced administration of sulindac, considering"
tacrine,DB00907,"Tacrine, known by its DrugBank ID DB00907, possesses a complex chemical structure articulated by the SMILES notation COC(=O)[C@H]1[C@@H](OC(=O)c2ccccc2)C[C@@H]2CC[C@H]1N2C. This molecule is characterized by a tricyclic framework incorporating an acridine scaffold, a class of compounds traditionally noted for their intercalative DNA-binding properties. Chemically, it can be placed in the category of acetylcholinesterase inhibitors, a group that includes similar drugs such as donepezil and rivastigmine. Regarding pharmacokinetics, tacrine undergoes rapid absorption, manifests with moderate bioavailability influenced by first-pass metabolism, is widely distributed in various tissues, metabolized extensively in the liver via CYP1A2 and CYP2D6 isoenzymes, and is primarily excreted in the urine. Tacrine's therapeutic effect, unfortunately, is accompanied by a toxicity profile that includes hepatotoxicity and increased liver enzymes, manifesting in some patients as jaundice or hepatic failure. Tacrine's primary pharmacological target is acetylcholinesterase, the enzyme responsible for acetylcholine degradation, and its inhibition leads to increased levels of acetylcholine in the brain. The primary indication for its use is in the palliative treatment of mild to moderate Alzheimer's disease, aimed at improving cognitive function or slowing the decline thereof. Side effects associated with tacrine are cholinergically mediated and can include nausea, diarrhea, vomiting, and muscle cramps. Clinically, its usage has fallen out of favor due to the availability of newer agents with improved safety profiles and once-daily dosing, yet its contribution to the symptomatic management in Alzheimer's patients has been a significant step in the chronicle of dementia pharmacotherapy."
tamoxifen,DB00390,"Tamoxifen, known by its DrugBank identifier DB00390, is a nonsteroidal agent with a complex chemical structure characterized by its SMILES notation 'C[C@H]1O[C@@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@]5(C)[C@H]6C[C@@H](O)[C@]7(C)[C@@H](C8=CC(=O)OC8)CC[C@]7(O)[C@@H]6CC[C@@H]5C4)O[C@@H]3C)O[C@@H]2C)C[C@H](O)[C@@H]1O'. This notation unveils its complex array of hydroxyl groups, ethylene bridges, and a phenyl group with a methoxy substituent, falling into the chemical category of selective estrogen receptor modulators (SERMs). Its chemical scaffold comprises a triphenylethylene structure, a characteristic it shares with similar drugs like clomiphene and toremifene. The pharmacokinetics of tamoxifen shows good oral absorption, extensive distribution with high lipid solubility, and it is metabolized predominantly in the liver through the cytochrome P450 enzyme system, giving rise to several active metabolites. Following metabolism, excretion occurs mainly through fecal matter.

The drug's toxicity profile includes risks such as endometrial cancer and thromboembolic events. Tamoxifen exerts its therapeutic effect primarily by targeting estrogen receptors, thereby exerting a tissue-selective effect on estrogenic activity. It indicates primarily for the treatment of estrogen receptor-positive (ER+) breast cancer, in both early and advanced stages, as well as for the prevention of breast cancer in high-risk populations. The side effects associated with tamoxifen can range from hot flashes and vaginal dryness to more serious conditions such as endometrial changes and visual disturbances. Clinically, tamoxifen is extensively used in the management of hormone-responsive breast cancer, serving as an adjuvant therapy post"
testosterone,DB00363,"Testosterone, with the DrugBank identifier DB00363, is structurally defined by its SMILES notation 'CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1', which incorrectly represents a nonsteroidal compound rather than the actual steroidal structure of testosterone. As testosterone is an endogenous steroid hormone, its chemical category is an androgen and anabolic steroid, with a structure that includes the typical four fused cycloalkane rings forming the steroid scaffold. Although the provided SMILES notation does not correspond to testosterone but appears to describe a different chemical entity, testosterone itself can be compared to similar steroidal drugs such as dihydrotestosterone (DHT) and synthetic analogs like oxandrolone. Regarding pharmacokinetics, testosterone is well-absorbed when administered via intramuscular injection and can also be administered transdermally. Its distribution includes being bound to sex hormone-binding globulin and albumin in the blood, and it is metabolized hepatically via the cytochrome P450 enzyme system into various metabolites including estradiol and DHT. Testosterone and its metabolites are excreted primarily in the urine. Concerning toxicity, high doses of testosterone can lead to adverse effects such as liver dysfunction or cardiovascular issues, exemplified by increased risk of developing a myocardial infarction. Testosterone's target proteins include androgen receptors, through which it exerts its physiological effects. Medically, testosterone is indicated for the treatment of hypogonadism in men, characterized by low testosterone levels leading to symptoms such as reduced libido, fatigue, and muscle weakness. Side effects of testosterone administration can range from acne and mood swings to more serious events such as polycythemia and venous thromboembolism. Clinically, testosterone is used not only for male hypogonadism but also off-label for conditions such as gender dysphoria in transgender men and as part of hormone therapy for postmenopausal symptoms in women, showcasing its versatile therapeutic applications. 

**Please note that the provided SMILES notation in the prompt is incorrect for testosterone, and it represents a different chemical substance. As a result, the above information pert"
tetracycline,DB01009,"Tetracycline, with the DrugBank identifier DB01009, epitomizes a broad-spectrum antibiotic that possesses a complex chemical structure delineated by the SMILES notation 'CC(C(=O)O)c1cccc(C(=O)c2ccccc2)c1'. This reveals a molecular composition with an amphenicol backbone, denoting it as a member of the tetracycline chemical category - a class of polyketide antibiotics. It shares its distinctive four-ring tetracyclic chemical scaffold, the naphthacene core, with analogous drugs such as doxycycline and minocycline, reflecting structural and functional commonality within the class. Pharmacokinetically, tetracycline is characterized by adequate oral absorption, wide tissue distribution including into bone and teeth, a metabolism that is less prominent compared to its contemporaries, and excretion primarily via renal pathways. Tetracycline toxicity, although seldom, can manifest as nephrotoxicity and hepatotoxicity, with photosensitivity being a generally noticed adverse effect. The primary targets of tetracycline are the 30S subunit of bacterial ribosomes, where it impedes protein synthesis, marking its utility against a plethora of microorganisms. Indications for tetracycline coverage include, but are not limited to, infections like acne vulgaris, Lyme disease, and chlamydia. Notable side effects range from gastrointestinal disturbances, such as nausea and diarrhea, to the more severe, albeit rare, instances of hepatotoxicity and drug-induced lupus erythematosus. Clinically, its versatility extends to treating bacterial infections like Helicobacter pylori-associated ulcers and respiratory tract infections. The encapsulation of these attributes underscores the vital role tetracycline plays in current therapeutic strategies, while continuing research and surveillance of its usage inform ongoing clinical practice."
dronabinol,DB01069,"Dronabinol, with the DrugBank identifier DB01069, is an analog of delta-9-tetrahydrocannabinol (Δ9-THC), the principal psychoactive constituent of cannabis. Its SMILES notation CC(CN1c2ccccc2Sc2ccccc21)N(C)C reveals a bicyclic structure consisting of a benzene ring fused to a pyran ring with an alkyl side chain. This synthetic cannabinoid falls under the chemical category of cannabinoids and shares its chemical scaffold with naturally occurring Δ9-THC. Chemically similar drugs include nabilone, a synthetic cannabinoid with a distinct therapeutic profile. Pharmacokinetically, dronabinol exhibits variable oral absorption with peak plasma concentrations occurring after 0.5 to 4 hours post-administration. Its distribution is characterized by high lipid solubility, which allows it to cross the blood-brain barrier effectively. Dronabinol is metabolized primarily in the liver, facilitated by the cytochrome P450 enzyme system, particularly CYP2C9 and CYP3A4 isoenzymes, and its metabolites are primarily excreted in the feces, with minor renal elimination. Toxicity of dronabinol can manifest as dizziness, confusion, and disorientation, particularly in overdose or in sensitive populations. The target proteins of dronabinol are the cannabinoid receptors, CB1, and CB2, with the former being primarily involved in its psychoactive effects. Clinically, dronabinol is indicated for the treatment of anorexia associated with weight loss in AIDS patients and for nausea and vomiting associated with cancer chemotherapy, in patients who have failed to respond adequately to conventional antiemetic treatments. Side effects include, but are not limited to, euphoria, dysphoria, sedation, abdominal pain, and tachycardia. Despite its side effect profile, dronabinol's utility in specific clinical scenarios, such as in chemotherapy-induced nausea and vomiting (CINV) and as an appetite stimulant in AIDS-related anorexia, demonstrates its valued role in therapeutic interventions where alternative treatments have been ineffective."
theophylline,DB00257,"Theophylline, with the DrugBank identifier DB00257, is a methylxanthine drug characterized by a complex aromatic chemical structure, featuring two benzene rings fused with a pyrimidinedione ring. Its SMILES notation, Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1, erroneously contains a chlorine group, which doesn't belong to theophylline. True theophylline would have the notation CN1C=NC2=C1C(=O)N(C(=O)N2C)C. The chemical category it belongs to is xanthines, which share a purine analog scaffold, placing theophylline in the same chemical class as caffeine and theobromine. Theophylline is absorbed rapidly and almost completely in the GI tract, having a bioavailability of about 100%. Circulating theophylline is widely distributed throughout body fluids and tissues and binds moderately to plasma proteins. It is hepatically metabolized via cytochrome P450 enzymes, mainly CYP1A2, into metabolites such as 1,3-dimethyluric acid. These metabolites are then excreted mainly in the urine. In terms of toxicity, theophylline has a narrow therapeutic window and can lead to cardiotoxicity and neurotoxicity at high plasma levels. Known target proteins of theophylline include adenosine receptors and phosphodiesterase enzymes, which underlie its bronchodilatory effects. The primary indication for theophylline use is in the treatment of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD), where it helps to relax constricted airways and reduce inflammation. Adverse effects can include insomnia, gastrointestinal discomfort, and, in severe cases, arrhythmias and seizures. Clinically, theophylline's use has decreased with the advent of safer and more effective therapies, but it still holds value in specific patient populations needing long-term management of chronic asthma or as an adjunct therapy in COPD, where its anti-inflammatory and bronchodilatory actions can be beneficial."
thiothixene,DB01110,"Thiothixene, with the DrugBank identifier DB01110, is a psychotropic agent characterized by the SMILES notation Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1, indicating a tricyclic structure containing a thiophene ring and substituted with chlorine atoms at specific phenyl positions. As a member of the thioxanthene chemical class, thiothixene possesses a dibenzothioxepine scaffold, structurally akin to typical antipsychotics such as chlorprothixene. Thiothixene's pharmacokinetic profile reveals oral absorption with variable bioavailability, widespread distribution in body tissues, hepatic metabolism involving cytochrome P450s, and renal alongside fecal excretion routes. Regarding toxicity, thiothixene can lead to extrapyramidal symptoms, tardive dyskinesia, and neuroleptic malignant syndrome in some patients. The primary target proteins for thiothixene encompass various dopamine receptors, whereby the drug exerts its antipsychotic effects. Clinically, thiothixene is indicated for the management of schizophrenia, where it mitigates symptoms such as hallucinations and delusions. However, its administration is often accompanied by side effects ranging from sedation, orthostatic hypotension, to anticholinergic effects like dry mouth and constipation. In the therapeutic landscape, thiothixene is utilized for its efficacy in addressing positive symptoms of psychosis, although careful patient monitoring is essential due to its side effect profile and the potential for severe reactions."
thyroxine,DB00726,"Thyroxine, with the DrugBank identifier DB00726, is characterized by its SMILES notation 'CC(CN(C)C)CN1c2ccccc2CCc2ccccc21', representing its complex aromatic heterocyclic structure containing a phenyl ether backbone and an alanine side chain. This structure classifies it chemically as a synthetic form of the thyroid hormone, specifically a thyroxine derivative. Thyroxine shares its chemical scaffold with other iodinated thyronine compounds, such as triiodothyronine (T3), both playing critical roles in regulating metabolic processes. Its pharmacokinetic profile demonstrates efficient absorption in the gastrointestinal tract, with a vast distribution into body tissues. Metabolism predominantly occurs in the liver through deiodination, conjugation, and decarboxylation, while excretion is managed primarily through the kidneys. Despite its essential nature, thyroxine can exhibit toxic effects at supratherapeutic doses, leading to thyrotoxicosis with symptoms such as palpitations and increased heart rate. Thyroxine targets various proteins, most notably thyroid hormone receptors (THR), to exert its physiological actions. It is indicated for the treatment of hypothyroidism, in which thyroid hormone levels are abnormally low, and for the suppression of thyroid-stimulating hormone (TSH) in the management of euthyroid goiters and thyroid cancer. Side effects may include cardiac effects, osteoporosis, and symptoms of hyperthyroidism in response to excessive dosages. Clinically, thyroxine usage involves careful dose titration to mimic endogenous hormone levels, optimizing it for the management of hypothyroid disorders such as Hashimoto’s thyroiditis, and as hormone replacement following thyroidectomy."
timolol,DB00182,"Timolol is a non-selective beta-adrenergic receptor antagonist with the DrugBank identifier DB00182 and the SMILES notation CC(N)Cc1ccccc1, which describes a molecule consisting of a tert-amino butyl chain attached to a phenyl group, indicative of its chemical structure as a beta-blocker with a tert-amino group. Timolol falls within the chemical category of beta-blockers and is built upon a propanolamine scaffold, typical of this class of compounds. It is chemically related to other non-selective beta-blockers such as propranolol and nadolol. The pharmacokinetics of timolol involve adequate absorption from the gastrointestinal tract when taken orally, moderate lipophilicity allowing for systemic distribution, hepatic metabolism primarily by cytochrome P450 enzymes (CYP2D6), and renal excretion of metabolites. Its toxicity profile includes bradycardia, hypotension, and bronchospasm in susceptible individuals, particularly those with pre-existing conditions such as asthma or cardiac disorders. Timolol targets both beta-1 and beta-2 adrenergic receptors, leading to reduced heart rate and decreased aqueous humour production in the eye. Its primary indications are the treatment of hypertension, prevention of myocardial infarction, and lowering of intraocular pressure in conditions like glaucoma. Common side effects reported with timolol use include fatigue, dizziness, and gastrointestinal disturbances, reflecting its systemic beta-adrenergic blockade. Clinically, timolol is widely used in the management of cardiovascular diseases like angina pectoris and arrhythmias, and as an ophthalmic solution for glaucoma, demonstrating its versatility and significance in medical practice."
tolbutamide,DB00542,"Tolbutamide, with the DrugBank ID DB00542 and the SMILES notation CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCc2ccccc2N(CC(=O)O)C1=O, is a first-generation sulfonylurea with a distinct chemical structure featuring an ethyl group linked to an etherified carboxylic acid, a secondary amine connected to a cyclohexyl group, and an N-linked sulfonylurea moiety. As a sulfonylurea, tolbutamide belongs to a chemical category of insulin secretagogues that work by inhibiting ATP-sensitive potassium channels in pancreatic beta cells, which is its chemical scaffold mechanism of action. Similar drugs in its class include glimepiride and glyburide. Tolbutamide is well-absorbed upon oral administration, exhibiting a half-life of approximately 5 to 7 hours, with metabolism primarily occurring in the liver through hydroxylation and carboxylation, and excretion mainly in the urine as metabolites. The primary known targets of tolbutamide are the sulfonylurea receptors (SUR) associated with the ATP-sensitive potassium channels in pancreatic beta cells. Clinically, tolbutamide is indicated for the management of Type 2 diabetes mellitus to lower blood glucose levels by stimulating endogenous insulin secretion. Noteworthy side effects of tolbutamide can include hypoglycemia, weight gain, and gastrointestinal disturbances. It also holds potential for drug-drug interactions, especially with other agents affecting blood glucose levels. Despite its efficacy, as a first-generation sulfonylurea, greater caution is required regarding its toxicity, which can include dose-related disulfiram-like reactions and cardiovascular risks compared to newer antidiabetic drugs. Tolbutamide's clinical usage has decreased over time, with patients with mild to moderate Type 2 diabetes often prescribed newer antidiabetic medications with a more favorable risk-benefit profile. However, its use persists in specific populations where other treatments are contraindicated or not tolerated."
tolmetin,DB00635,"Tolmetin, with DrugBank ID DB00635 and SMILES notation C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO, represents a non-steroidal anti-inflammatory drug (NSAID) characterized by a substituted indole acetic acid chemical structure with a distinct chiral tetra-cyclic scaffold, reminiscent of indomethacin and sulindac. Similar drugs within the NSAID category share pharmacophoric features such as a carboxylic acid moiety essential for anti-inflammatory activity. Tolmetin exhibits pharmacokinetics with rapid oral absorption, widespread tissue distribution, hepatic metabolism primarily via hydroxylation and conjugation, and renal excretion of its metabolites. Toxicological profile reveals potential gastrointestinal, renal, and cardiovascular toxicity, similar to other NSAIDs due to cyclooxygenase inhibition. Tolmetin targets proteins including COX-1 and COX-2, modulating prostaglandin synthesis, thereby reducing inflammation and pain. Indicated for the management of rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis, it mitigates symptoms such as joint pain and swelling. Side effects encompass gastrointestinal disturbances like dyspepsia and ulceration, hypersensitivity reactions, and effects on blood clotting. Clinically, tolmetin is prescribed in a regimen considering its therapeutic window and co-morbid conditions of patients, with adjunct gastroprotective agents in high-risk cases. This collective information underscores the drug’s comprehensive profile within its therapeutic class, guiding its careful utilization in medical practice."
trazodone,DB01151,"Trazodone, identified by DrugBank ID DB01151 and articulated by the SMILES notation 'CNCCCN1c2ccccc2CCc2ccccc21', is a triazolopyridine derivative, reflecting its chemical structure that combines a triazole ring with a pyridine moiety. This configuration places it within the broader chemical category of serotonin antagonist and reuptake inhibitors (SARIs), with its distinctive bicyclic chemical scaffold comprising a central core of fused triazolopyridine. Structurally and pharmacologically related drugs include nefazodone, though its use has been limited due to hepatotoxicity. Pharmacokinetically, trazodone is characterized by moderate absorption from the gastrointestinal tract, with its bioavailability being subject to a significant first-pass effect; it demonstrates widespread distribution, binding extensively to plasma proteins. Trazodone is metabolized in the liver primarily by CYP3A4 to several metabolites, including m-chlorophenylpiperazine (mCPP), and is excreted mainly in urine as metabolites. Its toxicity profile includes the potential for dose-dependent QT interval prolongation and, albeit rarely, the occurrence of priapism. The drug targets various proteins, most notably the serotonin type 2 (5-HT2) receptors and the serotonin reuptake transporters. Clinically, trazodone is indicated for the treatment of major depressive disorder, with additional off-label uses for insomnia and anxiety disorders due to its sedative properties. However, its therapeutic utility is sometimes limited by side effects such as drowsiness, dizziness, orthostatic hypotension, and nausea. Nonetheless, in a clinical setting, trazodone is often preferred due to its relatively favorable side effect profile compared to traditional tricyclic antidepressants, making it a viable option for patients, particularly when initiating therapy for depression or when treating depressed patients with insomnia."
tretinoin,DB00264,"Tretinoin, identified by DrugBank ID DB00264, is a retinoid medication, whose chemical structure is characterized by a fully conjugated cyclic polyene chain as part of its retinoic acid scaffold, distinguishing it from its parent compound vitamin A through oxidation of the terminal alcohol group to a carboxylic acid. As a derivative of retinoic acid, tretinoin belongs to the category of first-generation polyene retinoids, sharing a pharmacophore with similar drugs such as isotretinoin and acitretin. Its pharmacokinetic profile includes well-documented absorption following topical application, with systemic availability influenced by the formulation; distribution is presumed to occur through binding with plasma proteins, especially albumin. Tretinoin undergoes metabolism predominantly in the liver, involving isomerization and oxidation, and its metabolites as well as unmetabolised drug are excreted primarily through biliary mechanisms and to a lesser extent in the urine. The therapeutic activity of tretinoin centers on its modulation of gene expression through retinoic acid receptors (RARs), with RAR-β and RAR-γ being notable targets. Tretinoin is indicated principally for the treatment of acne vulgaris, promotion of skin peeling in conditions like photoaging, and in acute promyelocytic leukemia (APL) due to its differentiation-inducing effects on promyelocytes. Common side effects can include skin irritation manifested as erythema, peeling, and dryness, particularly in the dermatologic setting. Its clinical usage extends to mitigating fine wrinkles, mottled hyperpigmentation, and tactile roughness of the skin. Moreover, in oncology, the drug's ability to induce cellular differentiation and decrease proliferation provides a rationale for its inclusion in chemotherapeutic regimens for APL. The SMILES notation 'COCCc1ccc(OCC(O)CNC(C)C)cc1' provided does not correspond to tretinoin but appears to describe a different chemical entity, which suggests that either the notation or the associated context requires rectification."
trifluoperazine,DB00966,"Trifluoperazine, with DrugBank ID DB00966 and SMILES notation CCCc1nc2c(C)cc(-c3nc4ccccc4n3C)cc2n1Cc1ccc(-c2ccccc2C(=O)O)cc1, is a phenothiazine derivative exhibiting a tricyclic structure with substituents adding to its lipophilicity and therefore influencing its pharmacokinetic profile. As a chemical category, trifluoperazine falls under the typical antipsychotics, noted for its dopamine antagonist properties. It shares the common phenothiazine scaffold with other antipsychotic agents such as chlorpromazine and thioridazine. Its pharmacokinetics involves oral absorption, with the drug being widely distributed in the body. It undergoes hepatic metabolism via the cytochrome P450 system, particularly CYP2D6, and is excreted mainly in urine and feces. The toxicity of trifluoperazine is characterized by the risk of extrapyramidal symptoms, tardive dyskinesia, and neuroleptic malignant syndrome. Its primary target proteins include dopamine receptors, particularly D2 receptors, which it blocks to exert its antipsychotic effects. Trifluoperazine is indicated for the treatment of schizophrenia and for patients exhibiting severe anxiety or agitation. Common side effects range from drowsiness and dry mouth to ocular changes and cardiovascular effects. Clinically, trifluoperazine has been used efficaciously in controlling symptoms of schizophrenia, severe anxiety, and occasionally as an adjunct in short-term treatment of acute psychoses."
trimethoprim,DB00695,"Trimethoprim, designated with DrugBank ID DB00695, is a dihydrofolate reductase inhibitor characterized by its SMILES notation 'NS(=O)(=O)c1cc(C(=O)O)c(NCc2ccco2)cc1Cl'. This notation elucidates its chemical structure, highlighting a pyrimidine ring bearing an amino group and a sulfonamide moiety attached to a benzyl ring that is also substituted with a chlorine atom and a carboxyl group, describing a diaminopyrimidine scaffold. Trimethoprim is a member of the antibiotic class commonly referred to as dihydrofolate reductase inhibitors and is chemically similar to other antifolates like methotrexate and pyrimethamine. It exhibits a pharmacokinetic profile with good oral absorption, reaching peak plasma concentrations within 1-4 hours. Trimethoprim is distributed widely in body tissues and fluids, has a relatively small volume of distribution, and binds minimally to plasma proteins. It undergoes limited metabolism in the liver and is predominantly excreted unchanged in the urine, thus it is used cautiously in patients with renal impairment due to increased risk of toxicity.

Toxicity of trimethoprim can include hyperkalemia, thrombocytopenia, and megaloblastic anemia; such effects are dose-dependent and reversible upon the discontinuation of the drug. The primary target protein for trimethoprim is bacterial dihydrofolate reductase, which is essential for the synthesis of tetrahydrofolate and subsequent production of nucleotides and DNA. Indications for trimethoprim include the treatment of urinary tract infections, shigellosis, and pneumonia caused by Pneumocystis jirovecii, among other bacterial infections. Common side effects encompass gastrointestinal disturbances such as nausea and vomiting, and skin rashes. Clinically, trimethoprim's utility is particularly noted in its synergistic action with sulfamethoxazole in co-formulated drugs like co-trimoxazole, which is used to treat a variety of infections ranging from bronchitis to traveler's diarrhea. This collaboration between drugs enables"
trimipramine,DB00313,"Trimipramine, with the DrugBank identifier DB00313, is a tricyclic antidepressant (TCA) characterized by its complex chemical structure represented in the SMILES notation as 'CCCC(CCC)C(=O)O'. It features a tricyclic ring system attached to a side chain amine group, which is integral to its categorization within the dibenzazepine class of compounds. This chemical scaffold is shared by other TCAs like amitriptyline and imipramine, indicative of structural and pharmacological similarities. Pharmacokinetically, trimipramine undergoes considerable first-pass metabolism in the liver, leading to a bioavailability averaging approximately 40%. Its distribution is widespread in the body tissues and it is heavily protein-bound in plasma. The drug is metabolized primarily via demethylation and hydroxylation, facilitated by Cytochrome P450 enzymes, and is subsequently excreted in the urine and feces. In terms of toxicity, trimipramine may lead to cardiotoxicity typically characterized by arrhythmias, as well as CNS and respiratory depression in overdose scenarios. Trimipramine exerts its therapeutic effects through its action on multiple target proteins, including the serotonin transporter and various neuronal receptors, which accounts for its indication in the treatment of depression and, at times, off-label for insomnia due to its sedative properties. Side effects associated with trimipramine usage encompass a range of anticholinergic effects like dry mouth and blurred vision, cardiovascular effects such as orthostatic hypotension, and CNS effects including drowsiness or agitation. Clinically, trimipramine has been utilized primarily in the management of major depressive disorder, where it has been shown to alleviate symptoms by modulating monoamine neurotransmitter dynamics in the brain."
ursodeoxycholic acid,DB01221,"Ursodeoxycholic acid (UDCA), represented in the DrugBank database with the identifier DB01221, is chemically characterized by the SMILES notation ""CNC1(c2ccccc2Cl)CCCCC1=O"", which inaccurately describes its structure; the correct SMILES for UDCA should be ""C[C@H](CCC(=O)N[C@H](CS)C(=O)O)C(O)=O"". It is a bile acid and belongs to the category of secondary bile acids, which are metabolic byproducts in humans. Structurally, it is a hydrophilic compound featuring a steroid backbone that is distinguished from other bile acids by the presence of hydroxyl groups at positions 3, 7, and 12. Similar drugs include chenodeoxycholic acid and other bile acid analogues used in the treatment of cholestatic liver diseases.

Pharmacokinetically, UDCA is well-absorbed in the small intestine via passive and active mechanisms. Following absorption, it enters the enterohepatic circulation, becomes conjugated to glycine or taurine in the liver, and is then secreted into bile. Metabolism occurs primarily in the liver; the conjugated forms undergo dehydroxylation yielding lithocholic acid, which is poorly soluble and largely excreted in the feces; a small amount is detoxified by sulfation and excreted in bile. UDCA has a low toxicity profile since it's a naturally occurring bile acid in the human body; however, excessive doses may cause diarrhea.

UDCA primarily targets the bile acid receptors such as the farnesoid X receptor (FXR), which modulate bile acid synthesis and secretion. Clinically, it’s employed in the treatment of primary biliary cholangitis (formerly known as primary biliary cirrhosis), a chronic liver disease where it alleviates symptoms by reducing toxic concentrations of endogenous bile acids. Side effects of UDCA are typically mild but may include weight gain, abdominal discomfort, and allergic reactions.

Its clinical usage extends beyond cholestatic diseases to include the dissolution of gallstones, where it’s particularly useful for cholesterol stones in"
valproic acid,DB04216,"Valproic Acid (DrugBank ID: DB04216), represented by the SMILES notation O=c1c(O)c(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12, is a branched short-chain fatty acid that exhibits an intricate two-ringed chemical structure, composed of a pentanoic acid substituent attached to a bicyclic ring system which includes both ketone and hydroxyl functional groups. Chemically categorized as a carboxylic acid derivative, its structure is based on a valproate scaffold, shared by similar antiepileptic drugs such as sodium valproate and divalproex sodium. Valproic acid undergoes extensive hepatic metabolism primarily by glucuronide conjugation and β-oxidation, leading to a complex pharmacokinetic profile; it is well-absorbed after oral administration, with peak plasma levels reached within 1 to 4 hours, and has a high volume of distribution, being highly protein bound in the plasma. Its metabolites and unmetabolized drug are chiefly excreted via the kidneys. The risk of toxicity is heightened by its narrow therapeutic range, with hepatotoxicity and pancreatitis being notable examples. Target proteins of valproic acid include voltage-gated sodium channels and GABA transaminase, pathways central to its anticonvulsant action. It is indicated for the treatment of various seizure disorders, bipolar disorder, and as a prophylactic for migraine headaches. Side effects are dose-dependent and range from mild (e.g., gastrointestinal disturbances, weight gain) to severe (e.g., teratogenicity, thrombocytopenia). Clinically, valproic acid is utilized in both monotherapy and adjunctive therapy, providing symptomatic relief in epilepsy (e.g., absence seizures) and mood stabilization in bipolar disorder. The integration of these attributes confirms the role of valproic acid as a vital therapeutic agent, albeit accompanied by the necessity for careful monitoring due to its potential side effects and interactions."
verapamil,DB01248,"Verapamil, with the DrugBank ID 'DB01248', is a phenylalkylamine calcium channel blocker that features a complex fused-ring chemical structure, embodied by its SMILES notation ""CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C"". This compound is characterized by a fused bicyclic ring system that includes a tetrahydrofuran and a tetrahydropyran ring, as well as a diphenyl substituent and an amide linkage that is vital for its bioactivity. As a calcium channel blocker, it belongs to the chemical category of antiarrhythmic agents and to a broader class of cardiovascular drugs. Verapamil's scaffold shares similarities with other calcium channel blockers such as diltiazem and nifedipine, although they differ in their binding dynamics and selectivity.

Pharmacokinetically, verapamil undergoes first-pass metabolism in the liver, where it's extensively metabolized by the cytochrome P450 system, primarily CYP3A4, leading to the formation of norverapamil as the main active metabolite. Its absorption is moderate with peak plasma concentrations occurring within 1-2 hours post-oral administration, and it has a bioavailability of about 20-35%. Verapamil is widely distributed in the body, with high tissue uptake, especially in cardiac tissue, and approximately 90% bound to plasma proteins. It is excreted mainly via the kidneys, and to a lesser extent in the feces, with an elimination half-life ranging from 5 to 12 hours.

The drug's primary targets are the L-type calcium channels in the heart and vascular smooth muscle, which contribute to its vasodilatory and"
vinblastine,DB00619,"Vinblastine, with DrugBank ID DB00619 and SMILES notation Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1, is an alkaloid derived from the periwinkle plant (Catharanthus roseus) exhibiting a complex chemical structure including two multiring units: a catharanthine ring system and a vindoline ring system. The chemical intimately fits into the category of vinca alkaloids, a class that also includes closely related compounds such as vincristine, vindesine, and vinorelbine, which function similarly by inhibiting microtubule formation. Vinblastine's pharmacokinetics profile reveals moderate absorption, extensive tissue distribution with a high volume of distribution, significant hepatic metabolism primarily through CYP3A4/5 enzymes, and excretion largely in the bile and feces. Toxicity of vinblastine is considerable, commonly causing bone marrow suppression, manifested as neutropenia and thrombocytopenia, and peripheral neuropathy. Vinblastine targets tubulin, specifically inhibiting the assembly of microtubules, which impedes mitosis in rapidly dividing cells and is the basis for its antineoplastic effect. Indicated primarily for the management of a broad array of cancers, including Hodgkin's lymphoma, non-small cell lung cancer, and testicular carcinoma, vinblastine halts tumor growth. Side effects, however, are not insignificant, ranging from mild, such as alopecia and constipation, to more severe, such as autonomic neuropathy and SIADH (syndrome of inappropriate antidiuretic hormone secretion). In clinical practice, vinblastine is employed either as a single agent or in combination chemotherapy regimens, leveraging its cell cycle phase specificity, usually within a multidrug treatment plan tailored to the individual patient’s type and stage of cancer."
vincristine,DB01076,"Vincristine, with DrugBank ID DB01076 and SMILES notation CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O, is a complex indole alkaloid derived from the periwinkle plant, Catharanthus roseus. Structurally, vincristine is characterized by a dimeric structure combining a vindoline and catharanthine moiety, forming a central indole core linked to a dihydroindole containing a substituted phenyl ring and an additional six-membered lactam ring, contributing to its categorization as a vinca alkaloid. This chemical scaffold is responsible for its mechanism of action and underlies the pharmacophoric properties shared with similar drugs such as vinblastine. Pharmacokinetically, vincristine is known for poor absorption when administered orally, necessitating intravenous usage; it displays widespread distribution with substantial CNS exclusion due to poor blood-brain barrier penetration, undergoes hepatic metabolism primarily via CYP3A4/5 enzymes, and is predominantly excreted in bile. Toxicity is a critical concern with vincristine use, as it can cause peripheral neuropathy, and in more severe cases, potentially fatal autonomic dysfunction. Its mechanism of antineoplastic action targets tubulin proteins, whereby it inhibits tubulin polymerization, leading to mitotic arrest in the metaphase. Vincristine is indicated primarily for the treatment of acute lymphoblastic leukemia (ALL) and Hodgkin's lymphoma, among other malignancies. Common side effects are dose-dependent and include neuropathy, alopecia, constipation, and bone marrow suppression. Clinically, vincristine is a mainstay of combination chemotherapy protocols, often coupled with corticosteroids and other cytotoxic agents, as seen in the CHOP regimen for non-Hodgkin's lymphoma or the VAMP regimen for pediatric solid tumors."
vitamin b 12,DB00988,"Vitamin B12, with the DrugBank ID DB00988 and the SMILES notation NCCc1ccc(O)c(O)c1, is a structurally complex water-soluble compound categorized as a cobalamin due to its central cobalt atom. Its chemical scaffold includes a corrin ring, which distinguishes it from other tetrapyrrole-based compounds like porphyrins. Structurally related drugs include other cobalamin forms, such as hydroxocobalamin and cyanocobalamin, utilized for similar therapeutic purposes. Pharmacokinetically, vitamin B12 is uniquely absorbed via the intrinsic factor-mediated endocytosis in the ileum, with its distribution being reliant upon transport proteins, namely transcobalamin II; its metabolism involves conversion into metabolically active forms, methylcobalamin and 5-deoxyadenosylcobalamin, whereas excretion occurs through the bile and to a minimal extent, the urine. Its low toxicity profile is exemplified by the absence of upper intake level due to its water solubility, but in rare cases, hypersensitivity reactions may occur. The primary targets of vitamin B12 are methionine synthase and L-methylmalonyl-CoA mutase, enzymes crucial for homocysteine metabolism and fatty acid biosynthesis, respectively. Clinically, vitamin B12 is indicated for the treatment of pernicious anemia and other conditions characterized by vitamin B12 deficiency, such as malabsorption syndromes and certain neuropathies. While side effects are uncommon owing to its low toxicity, they can include allergic reactions and mild gastrointestinal distress. In clinical practice, it is administered both as a dietary supplement and parenterally in cases where oral absorption is compromised."
zidovudine,DB01167,"Zidovudine, with DrugBank ID 'DB01167', possesses a complex chemical structure delineated by its SMILES notation 'CCC(C)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@H]5CO[C@](Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O'. This notation reveals a molecule with a thymidine-based nucleoside analog backbone bearing an azido group at the 3' position of the ribose ring, categorized as an antiretroviral agent within the pharmacological class of reverse transcriptase inhibitors. Structurally, zidovudine is anchored by a pyrimidine analog scaffold and is structurally similar to other nucleoside reverse transcriptase inhibitors (NRTIs) like lamivudine and stavudine. Pharmacokinetically, zidovudine is well-absorbed orally with a bioavailability of approximately 60-70%, exhibits a volume of distribution of 1.6 L/kg, is metabolized primarily in the liver via glucuronide conjugation, and is excreted both renally and in the feces. Toxicological concerns associated with zidovudine include bone marrow suppression leading to anemia and neutropenia, along with potential lactic acidosis due to mitochondrial toxicity. Zidovudine targets the HIV-1 reverse transcriptase enzyme, inhibiting viral replication. Its primary indication is for the treatment of HIV infection, including its utilization in post-exposure prophylaxis and prevention of mother-to-child transmission of HIV. Side effects commonly seen with zidovudine therapy include headache, nausea, myopathy, and lipodystrophy. Clinically, zidovudine is utilized both as monotherapy and in combination with other antiretrovirals in highly active antiretroviral therapy (HAART) regimens, contributing to the management and suppression of HIV viral loads and the amelioration of associated progressive immunodeficiency."
dinoprostone,DB00555,"Dinoprostone (DrugBank ID: DB00555; SMILES: O=C1CC(O)C(=O)C1CCCCCCC(=O)O) is a naturally occurring prostaglandin, specifically a member of the prostanoid class of fatty acid derivatives which acts as a potent agent in inducing labor by softening the cervix and causing uterine contractions. Structurally, it is characterized by a unique cyclopentane ring, a hallmark of the prostanoid chemical category, as part of its core chemical scaffold. Dinoprostone is similar to other prostaglandins like misoprostol and carboprost in its mechanism and clinical application but differs in specific pharmacologic properties. Pharmacokinetically, dinoprostone is rapidly absorbed and distributed when administered vaginally or intracervically. It undergoes extensive first-pass metabolism in the lungs and is excreted primarily by the kidneys after metabolic transformation. Concerning toxicity, dinoprostone can precipitate excessive uterine contractions leading to uterine rupture or fetal distress. Its action is mediated through binding to the target proteins—prostanoid receptors, found on the surface of various tissues including the uterus. Clinically indicated for labor induction, dinoprostone is utilized when there are medical reasons to induce labor, such as in cases of term or near-term pregnancies, or in medical conditions like preeclampsia. Side effects of dinoprostone can include nausea, vomiting, diarrhea, and in certain cases, changes in fetal heart rate. In clinical practice, dinoprostone formulations such as vaginal gels, inserts, or suppositories are used to facilitate cervical ripening and labor induction under careful medical supervision, balancing its effective labor-inducing properties against potential maternal and fetal risks."
ofloxacin,DB01235,"Ofloxacin is a synthetic broad-spectrum antimicrobial agent with the DrugBank ID DB01235 and a SMILES notation of ""N[C@@H](Cc1ccc(O)c(O)c1)C(=O)O"", indicating a detailed chemical structure that consists of a racemic mixture of levorotatory and dextrorotatory isomers, with a fluorinated 4-oxoquinoline-3-carboxylic acid core representing its chemical scaffold. As part of the fluoroquinolone class of antibiotics, ofloxacin shares its core quinolone structure with similar drugs such as ciprofloxacin and levofloxacin. Its pharmacokinetics is characterized by good oral absorption, wide tissue distribution including adequate penetration into the cerebrospinal fluid, hepatic metabolism predominantly by the liver enzyme CYP1A2, and renal excretion as both unchanged drug and metabolites. Concerning toxicity, ofloxacin exhibits a safety profile similar to other fluoroquinolones, with potential risks including tendinitis and tendon rupture, QT interval prolongation, and seizures. It primarily targets bacterial enzymes DNA gyrase and topoisomerase IV, disrupting DNA replication and transcription. Clinically, ofloxacin is indicated for the treatment of a variety of bacterial infections, such as urinary tract infections, prostatitis, and certain types of pneumonia. Side effects may include gastrointestinal disturbances like nausea and diarrhea, central nervous system effects such as dizziness, and hypersensitivity reactions like rash. Its clinical usage spans across both acute and chronic infections, with specific examples including exacerbations of chronic bronchitis and skin and soft tissue infections, reflecting ofloxacin's utility in both inpatient and outpatient settings for its effective broad-spectrum antibacterial activity."
gemfibrozil,DB00875,"Gemfibrozil (DrugBank ID: DB00875), with the SMILES notation OCCN1CCN(CC/C=C2/c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1, represents a fibrate compound featuring a distinctive biphenyl moiety linked to a tetrahydrofuran ring via an alkenyl chain and a sulfur atom. Classified as a fibric acid derivative in terms of its chemical category, its scaffold is characterized by the fusion of aliphatic chains to aromatic rings, which is common among lipid-regulating agents. Structurally analogous to other fibrates such as fenofibrate, gemfibrozil acts to modulate lipid levels. Regarding its pharmacokinetics, gemfibrozil is well-absorbed following oral administration, widely distributed in tissues, extensively metabolized mainly by CYP3A4 in the liver, and primarily excreted in the urine. Its toxicity profile includes the potential for myopathy and increased risk of rhabdomyolysis, especially when co-administered with statins. Gemfibrozil targets proteins such as peroxisome proliferator-activated receptor-alpha (PPAR-α), modulating lipid metabolism. Clinically, gemfibrozil is indicated for the treatment of dyslipidemias, particularly hypertriglyceridemia, and can reduce the risk of developing coronary heart disease. Common side effects are gastrointestinal disturbances, including dyspepsia, abdominal pain, and diarrhea. The clinical usage extends to cases where statins are contraindicated or insufficient, often as part of a broader approach to cardiovascular risk management, exemplified in protocols for treating Type IIb hyperlipidemia."
epirubicin,DB00334,"Epirubicin, with DrugBank ID DB00334 and SMILES notation Cc1cc2c(s1)Nc1ccccc1N=C2N1CCN(C)CC1, is an anthracycline antibiotic featuring a tetracenequinone skeleton with an adjacent quinolone moiety and an amino sugar attached through a glycosidic linkage. As a chemotherapeutic agent, it belongs to the anthracycline chemical category, characterized by its planar four-ring anthraquinone scaffold that is pivotal for its activity. Epirubicin is structurally similar to other anthracycline drugs such as doxorubicin, differing only by the presence of a hydroxyl group at the C-4' position of the aminosugar. The pharmacokinetics of epirubicin involves rapid distribution following intravenous administration, extensive metabolism principally in the liver by enzymes such as cytochrome P450 isoenzymes into active metabolites like epirubicinol, and elimination primarily via the biliary route. Its toxicity profile includes dose-dependent cardiotoxicity and myelosuppression, manifesting as congestive heart failure and neutropenia, respectively. The principal targets of epirubicin are topoisomerase II and DNA, where it intercalates, causing DNA damage and apoptosis. Epirubicin is indicated for the treatment of various malignancies, particularly breast cancer and gastric cancer, often as part of a combination chemotherapy regimen. Adverse effects associated with epirubicin can range from nausea and vomiting to alopecia and cardiotoxicity. Clinically, the drug has seen extensive use in adjuvant therapy to improve survival outcomes post-surgery and as neoadjuvant therapy to reduce tumor size before surgical intervention, showing efficacy in increasing disease-free and overall survival rates in various cancer types."
idarubicin,DB00643,"Idarubicin, with the DrugBank identifier DB00643, is an anthracycline antibiotic featuring a chemical structure characterized by a planar anthraquinone moiety linked to an aminosugar, daunosamine, via a glycosidic bond. The SMILES notation COC(=O)Nc1nc2ccc(C(=O)c3ccccc3)cc2[nH]1 captures its detailed molecular structure, which includes an aromatic system, ketones, and a glycosidic linkage, underpinning its classification as an anthracycline antineoplastic agent within the chemical category of antitumor antibiotics. This chemical scaffold is also shared by similar drugs such as doxorubicin and daunorubicin, which possess analogous ring structures modified with different substituents and functional groups, often resulting in diverse pharmacokinetic and toxicological profiles.

Pharmacokinetically, idarubicin is well absorbed after intravenous administration, with distribution featuring high tissue penetration and binding to cellular components, particularly nuclear DNA. Metabolism occurs predominantly in the liver through reduction reactions and conjugation, resulting in metabolites, including the active idarubicinol. The parent compound and its metabolites are primarily excreted via biliary and, to a lesser degree, renal pathways. Toxicity associated with idarubicin includes dose-dependent myelosuppression, cardiotoxicity characterized by cardiomyopathy leading to congestive heart failure, and potential increased risk of secondary malignancies.

The primary target proteins for idarubicin are topoisomerase II and DNA, where the drug intercalates between base pairs, disrupting the function of this critical enzyme, leading to DNA strand breaks and ultimately inhibiting DNA and RNA synthesis. Indications for idarubicin use include the treatment of various cancers, notably acute myeloid leukemia (AML) and other leukemias, where it's integrated into chemotherapeutic regimens. Side effects encompass a range of adverse events such as alopecia, gastrointestinal disturbances (nausea, vomiting, diarrhea), and hematologic toxicities, particularly leukopenia and thrombocytopenia.

Clin"
citalopram,DB04077,"Citalopram, bearing the DrugBank identifier DB04077, is a selective serotonin reuptake inhibitor (SSRI) with a chemical structure characterized by a bicyclic phthalane skeleton attached to a fluorophenyl group. Its chemical category falls within the realm of antidepressants, featuring a tertiary amine function as part of its core scaffold that is common among SSRIs. Structurally related drugs include escitalopram, its enantiomer, and other SSRIs such as fluoxetine and sertraline. Upon administration, citalopram is well absorbed from the gastrointestinal tract, exhibiting a bioavailability of around 80%. It achieves peak plasma concentrations within 1-4 hours and distributes widely in the body with a volume of distribution around 12 L/kg. Metabolism occurs primarily in the liver via cytochrome P450 3A4 and 2C19 isoenzymes, resulting in demethylated metabolites that are less pharmacologically active. Excretion is through both urine and feces, primarily as metabolites, with a half-life of approximately 35 hours. Toxicity profiles indicate that citalopram can cause dose-dependent QT interval prolongation, which may lead to torsade de pointes or other ventricular arrhythmias. Target proteins for citalopram primarily include the serotonin transporter (SERT), where it functions to block reuptake, resulting in increased extracellular levels of serotonin. Clinically, citalopram is indicated for the treatment of major depressive disorder and can also be utilized in certain anxiety disorders, such as generalized anxiety disorder. Common side effects include nausea, dry mouth, increased sweating, and insomnia—though sexual dysfunction and weight changes are also noted. In clinical practice, citalopram is typically initiated at a lower dose and titrated based on therapeutic response and tolerability in both adult and geriatric populations, shaping its usage pattern to cautiously balance efficacy with safety concerns."
mifepristone,DB00495,"Mifepristone, with the DrugBank identifier DB00495, is a synthetic steroid with a distinctive chemical structure represented by the SMILES notation Cc1cn([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)c(=O)[nH]c1=O. Its molecular architecture includes a dimethylaminophenyl group with a terminal hydrazino moiety that is part of a larger steroidal framework. Classified chemically as a steroid, mifepristone's structure is based on a norpregnane scaffold, which it shares with other cortisol receptor antagonists. Mifepristone is closely related to other glucocorticoid receptor antagonists, such as ulipristal. Pharmacokinetically, mifepristone is absorbed orally, with its distribution being modulated by high plasma protein binding. Metabolism occurs in the liver predominantly via pathways involving CYP3A4, giving rise to mono-demethylated and hydroxylated forms. The drug and its metabolites are excreted primarily in the bile and feces. Its toxicity profile includes potential teratogenic effects and adrenal suppression at high doses, thus contraindicating its use during pregnancy. Mifepristone targets several proteins, including but not limited to, the progesterone receptor, glucocorticoid receptor, and the androgen receptor, antagonizing their effects. Clinically, it is indicated for medical termination of intrauterine pregnancies up to 70 days gestation, as an emergency contraceptive, in the management of high blood sugar levels associated with Cushing's syndrome, and for inducing labor in the case of fetal death. Side effects can include abdominal pain, uterine bleeding, fatigue, and nausea. In clinical practice, mifepristone is utilized in various protocols for medical abortion, often in combination with a prostaglandin analogue like misoprostol to increase its efficacy. It also forms part of the therapeutic approach in cases of ectopic pregnancies and in managing endometriosis and fibroids by exploiting its anti-progestational activity."
felodipine,DB00834,"Felodipine, with the DrugBank identification number DB00834, is a dihydropyridine derivative that structurally features an ethynyl group at the second position of its carbon chain and a distinctive dihydropyridine core with a substituent that contains an asymmetric carbon atom, as reflected in its SMILES notation ""CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C"". This medication falls under the category of calcium channel blockers and shares a common dihydropyridine scaffold with similar antihypertensive drugs such as amlodipine and nifedipine. Upon oral administration, felodipine is well-absorbed and exhibits a high degree of plasma protein binding; it undergoes extensive first-pass metabolism primarily via the cytochrome P450 3A4 (CYP3A4) isoenzymes and its metabolites, along with the parent drug, are eliminated mostly in the urine. The drug demonstrates low toxicity with reported adverse effects mainly related to its vasodilatory action. Felodipine targets the L-type calcium channels in vascular smooth muscle, leading to vasodilation. It is indicated primarily for the treatment of hypertension and may also be used in angina pectoris. Common side effects related to felodipine's mechanism of action include headache, flushing, and peripheral edema. Clinically, felodipine is prescribed as an extended-release formulation to provide a more stable plasma concentration, thus enhancing its therapeutic use and patient compliance in managing cardiovascular diseases."
nisoldipine,DB00470,"Nisoldipine, identified by DrugBank ID DB00470 and defined by the SMILES notation 'CCCCCc1cc(O)c2c(c1)OC(C)(C)[C@@H]1CCC(C)=C[C@@H]21', is a dihydropyridine calcium channel blocker with a distinct chemical structure characterized by a long alkyl side chain and a distinctive dihydropyridine core giving it selectivity for particular voltage-gated calcium channels. It belongs to the chemical category of dihydropyridine derivatives, sharing a common scaffold with similar drugs such as amlodipine and felodipine which are also used for their vasodilatory properties. The pharmacokinetics of nisoldipine involve oral administration with relatively good absorption, extensive distribution mainly in vascular smooth muscles, hepatic metabolism predominantly via the CYP3A4 isoenzyme, and renal as well as fecal excretion of its metabolites. The toxicity profile of nisoldipine includes dose-dependent hypotension and reflex tachycardia, with the propensity for exaggerated effects in cases of overdose. Nisoldipine targets L-type calcium channels, which it inhibits to reduce calcium influx in vascular smooth muscle leading to vasodilation. It is indicated primarily for the treatment of angina pectoris and hypertension, where it helps alleviate symptoms by decreasing cardiac afterload and myocardial oxygen demand. Common side effects of nisoldipine include dizziness, headache, peripheral edema, and occasionally gingival hyperplasia, which are related to its vasodilatory actions. Clinically, nisoldipine is used in the management of chronic stable angina and in the control of blood pressure in patients with essential hypertension, either as monotherapy or in combination with other antihypertensive agents."
famotidine,DB00252,"Famotidine, known by its DrugBank identifier DB00252, possesses a specific chemical structure indicated by its SMILES notation 'O=C1NC(=O)C(c2ccccc2)(c2ccccc2)N1', which reveals its dual ring system comprising a thiazole ring attached to a sulfamide group. This structure categorizes famotidine as a member of the histamine H2 receptor antagonists, which work primarily by inhibiting stomach acid production. Its chemical scaffold, featuring the fused ring system noted above, is characteristic of the H2 antagonist pharmacophore, with similar drugs including ranitidine and cimetidine. Famotidine exhibits a favorable pharmacokinetic profile, with rapid absorption from the gastrointestinal tract, moderate plasma protein binding, metabolism that is not extensively hepatic thus yielding a minimal first-pass effect, and renal excretion as the primary route of elimination. The compound's toxicity is low, but overdose can lead to effects such as tachycardia and gastrointestinal disturbances. Its pharmacodynamic targets are the histamine H2 receptors located on gastric parietal cells, blocking the action of histamine and thereby reducing gastric acid secretion. Famotidine is specifically indicated for the treatment of gastrointestinal disorders such as peptic ulcers, gastroesophageal reflux disease (GERD), and Zollinger-Ellison syndrome. While generally well-tolerated, it can cause side effects ranging from minor (headache, dizziness) to more severe although rare (QT prolongation, agranulocytosis). Clinically, famotidine is frequently used in both over-the-counter and prescription forms for the management and prevention of ulcer recurrence, for the relief of heartburn, and as part of a regimen for the eradication of Helicobacter pylori, in conjunction with antibiotics."
alfentanil,DB00286,"Alfentanil, with DrugBank ID 'DB00286', is a potent synthetic opioid analgesic, structurally characterized by its SMILES notation 'C[C@]12CC[C@@H]3c4ccc(OS(=O)(=O)[O-])cc4CC[C@H]3[C@@H]1CCC2=O.[Na+]', delineating its complex arrangement of cyclohexyl and phenyl rings along with a sulfonate ester group, indicating sodium salt form presence. As a chemical entity, it falls within the chemical category of phenylpiperidine opioids, sharing a common phenylpiperidine scaffold that is also present in related drugs such as fentanyl and sufentanil, which possess similar opioid analgesic properties. Alfentanil's pharmacokinetic profile is distinguished by rapid absorption and onset of action, with a relatively short duration due to its rapid distribution and metabolism predominantly by hepatic cytochrome P450 3A4 enzymes, leading to various inactive metabolites; it is primarily excreted via the kidneys. Its toxicity profile is in line with that of other potent opioids, with risks including respiratory depression, hypotension, and cardiac arrest at high doses or in sensitive individuals. Alfentanil's mechanism of action primarily involves agonism of the mu-opioid receptor, exerting its analgesic effects. Clinically, it is indicated for short-term analgesia, especially in the context of anesthesia for surgery and immediate postoperative pain due to its rapid onset and short duration of effect. However, administration of alfentanil carries the risk of typical opioid side effects such as nausea, vomiting, pruritus, and the potential for rapid tolerance and dependence with prolonged use. In a typical hospital or surgical setting, alfentanil is utilized for its excellent control of pain, with specific usage examples including induction of anesthesia and adjunctive use in general anesthesia to provide analgesia, known for its ease of titration and reversibility by naloxone in cases of overdose."
bepridil,DB00863,"Bepridil, bearing the DrugBank ID 'DB00863', is a unique multi-ion channel blocker with a complex chemical structure indicated by its SMILES notation ""CNC(=C[N+](=O)[O-])NCCSCc1ccc(CN(C)C)o1"". The molecule features a distinctive organic framework consisting of a benzopyridine core linked to a thiethylamine side chain, representing its chemical category as a calcium channel blocker with ancillary antiarrhythmic properties. As for its chemical scaffold, bepridil incorporates a hybrid structure that combines aspects of a phenylalkylamine backbone integrated with a nitrate ester group, setting it apart from other calcium antagonists such as verapamil or diltiazem. Bepridil's pharmacokinetics are characterized by variable absorption bioavailability, substantial volume of distribution due to its lipophilicity, extensive hepatic metabolism primarily by the CYP3A4 enzyme, and eventual renal and fecal excretion of its metabolites. Toxicity concerns have been noted, with examples including drug-induced long QT syndrome and torsade de pointes, necessitating careful clinical monitoring. Bepridil targets a variety of proteins, including voltage-dependent L-type calcium channels, and has also been reported to influence potassium and sodium channels, accounting for its broad spectrum of cardiac effects. It is indicated primarily for the treatment of angina pectoris, specifically exertional angina, acting to reduce myocardial oxygen demand and alleviate ischemic symptoms. Side effects of bepridil are varied and may range from common occurrences such as dizziness or nausea to more severe cardiac complications. Clinically, bepridil has seen use in various settings of chronic stable angina where other treatments have failed or are contraindicated, though its application is often limited by its potential for adverse cardiovascular events."
albendazole,DB00455,"Albendazole, identified by DrugBank ID DB00455 and represented by the SMILES notation ""CCOC(=O)N1CCC(=C2c3ccc(Cl)cc3CCc3cccnc32)CC1,"" is a benzimidazole derivative with a molecular scaffold consisting of a carbamate-linked cyclohexyl and benzene ring fused to an imidazole ring, which is substituted with a chlorine atom and a vinyl group. Chemically, albendazole belongs to the benzimidazole class of anthelmintic agents, which also include similar drugs such as mebendazole and thiabendazole. Its pharmacokinetic profile is characterized by poor absorption from the gastrointestinal tract, which is enhanced when taken with a fatty meal; extensive metabolism in the liver to its active metabolite, albendazole sulfoxide; and elimination primarily via the biliary route. The drug targets beta-tubulin proteins in parasitic worms, interfering with their microtubule formation, which leads to the depletion of their energy stores and eventual death. It is indicated for the treatment of a variety of parasitic worm infestations, including neurocysticercosis caused by Taenia solium and hydatid disease due to Echinococcus granulosus. Albendazole's side effects may include gastrointestinal distress, headache, dizziness, and in rare cases, hematologic toxicities such as leukopenia and agranulocytosis. Clinically, albendazole's versatility extends to the use in mass deworming campaigns, particularly in areas with a high prevalence of soil-transmitted helminth infections, showcasing its essential role in global antiparasitic strategies."
mefloquine,DB00914,"Mefloquine, bearing the DrugBank identifier DB00914, is a synthetic quinoline derivative characterized by its SMILES notation ""N=C(N)NC(=N)NCCc1ccccc1,"" indicating a complex structure with an ethanolamine chain linking a quinoline ring and a diamine substituent, embodying its chemical category as a 4-quinolinemethanol. Its chemical scaffold is shared by other antimalarial agents such as quinine, chloroquine, and amodiaquine, highlighting its place within a group of structurally related drugs. In terms of pharmacokinetics, mefloquine is well-absorbed orally, widely distributed with a relatively long elimination half-life, and primarily metabolized in the liver via the cytochrome P450 system with subsequent excretion mainly in the feces. The toxicity of mefloquine is dose-related and can involve neuropsychiatric effects, such as seizures and psychosis, in predisposed individuals. Its known mechanism of action involves targeting the intraerythrocytic stage of Plasmodium species, essentially proteins such as the Plasmodium falciparum chloroquine resistance transporter (PfCRT), contributing to its antimalarial activity. Indicated primarily for the prevention and treatment of malaria, mefloquine is particularly employed in regions with chloroquine-resistant Plasmodium falciparum. Adverse side effects associated with mefloquine include neuropsychiatric symptoms such as dizziness, headache, and sleep disturbances, along with gastrointestinal disturbances like nausea and vomiting. Clinically, mefloquine is used both as a prophylactic and a therapeutic agent for malaria, with the prophylactic dose generally taken once weekly and the therapeutic course administered as a single dose or split dose regimen depending upon the severity of the infection and the local malaria treatment guidelines."
astemizole,DB00482,"Astemizole, bearing the DrugBank identifier DB00482, is a non-sedating antihistamine structurally defined by its SMILES notation 'Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1', which describes a complex aromatic compound with a diphenylmethyl moiety, a trifluoromethyl group, and a sulfonamide-linked phenyl ring, indicating a distinctive chemical architecture with specific electronic and steric characteristics. As a member of the chemical category of histamine H1 antagonists, astemizole's chemical scaffold mimics that of other analogous H1 blockers such as terfenadine. The pharmacokinetics of astemizole describe its moderate absorption, extensive distribution including crossing the blood-brain barrier, metabolic transformation predominantly via hepatic cytochrome P450 enzymes, specifically CYP3A4, and its elimination is primarily biliary. Its toxicity, which garnered regulatory attention, is tied to its potential to cause QT interval prolongation and torsades de pointes; thus, its therapeutic window must be carefully observed. Astemizole's target proteins are histamine H1 receptors, which it binds to, preventing histamine-induced responses in allergic conditions. Clinically, it is indicated for the symptomatic relief of allergic symptoms such as rhinitis and urticaria. However, due to the risks of cardiac side effects, including tachycardia and palpitations, its use has been severely restricted. Initially used as a mainstay in the treatment of allergies, the identification of significant safety concerns has led to astemizole's replacement in clinical practice by newer antihistamines with more favorable safety profiles, relegating its use to less frequent circumstances where its risks are duly monitored and deemed acceptably mitigated."
terfenadine,DB00549,"Terfenadine, with DrugBank ID DB00549, is a potent second-generation antihistamine whose chemical structure is characterized by the presence of a diphenylmethyl group and a tertiary aminoethyl side chain attached to a central ethylbenzene moiety. This is succinctly captured by its SMILES notation: 'COc1cc(C(=O)NS(=O)(=O)c2ccccc2C)ccc1Cc1cn(C)c2ccc(NC(=O)OC3CCCC3)cc12'. This agent falls within the chemical category of antihistamines and features a piperidine-based scaffold—a common core that it shares with similar drugs such as loratadine and fexofenadine. Pharmacokinetically, terfenadine is well absorbed from the gastrointestinal tract but undergoes extensive first-pass metabolism primarily through CYP3A4 in the liver, transforming it into the active metabolite fexofenadine. Its excretion is through both renal and biliary pathways. Terfenadine's toxicity profile includes the rare but serious risk of QT interval prolongation and the potential for causing torsade de pointes, particularly at higher doses or when co-administered with CYP3A4 inhibitors. Histamine H1 receptors are its primary target proteins, and by antagonizing these receptors, terfenadine mitigates allergic symptoms such as rhinitis and urticaria. Notable side effects of terfenadine can include dizziness, headache, and gastrointestinal disturbances. Clinically, the drug was widely used for the treatment of allergic conditions, providing symptomatic relief of allergic reactions such as seasonal allergic rhinitis (hay fever) and chronic idiopathic urticaria before concerns over its safety profile led to its market withdrawal in most countries."
fluvoxamine,DB00178,"Fluvoxamine, with DrugBank ID DB00178, is a selective serotonin reuptake inhibitor (SSRI) characterized by its distinct chemical structure, denoted by the SMILES notation 'CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@@H]2CCC[C@@H]21'. This chiral molecule comprises a bicyclic hexahydrofuro[3,4-b]furan moiety fused with a 1-phenylbutan-2-amine scaffold, a structure that defines its chemical category as an SSRI and shares similarities with other drugs within this class, such as sertraline and paroxetine. Pharmacokinetically, fluvoxamine is well-absorbed orally, widely distributed throughout the body, extensively metabolized principally by the cytochrome P450 1A2 (CYP1A2) in the liver, and primarily excreted in the urine. Regarding toxicity, while generally well-tolerated, overdosage may lead to symptoms like nausea, tachycardia, seizures, and even coma. Its chief target proteins are the serotonin transporters (SERT), where it inhibits the reuptake of serotonin into presynaptic cells, thereby prolonging its action in the synaptic cleft. Clinically, fluvoxamine is indicated for the treatment of obsessive-compulsive disorder (OCD) and is also used to manage symptoms of anxiety disorders and depression. Side effects can include gastrointestinal disturbances, like nausea and diarrhea, central nervous system effects such as insomnia or drowsiness, and sexual dysfunction. It is imperative to monitor dosage and observe for adverse effects in clinical settings to maximize therapeutic benefits for conditions such as OCD, which entails not only pharmaceutical management but often a multimodal approach with psychotherapy."
arachidonic acid,DB01092,"Arachidonic acid (DrugBank ID: DB01092), with its SMILES notation C[C@@H]1O[C@@H](O[C@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@@H](C6=CC(=O)OC6)CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)[C@H](O)[C@H](O)[C@H]1O, is a polyunsaturated omega-6 fatty acid that serves as a significant structural component of cellular membranes and is involved in signal transduction. As a member of the fatty acid chemical group, its characteristic chemical scaffold is a 20-carbon chain with four cis-double bonds. Drugs with structures akin to arachidonic acid include other eicosanoids like prostaglandins and leukotrienes. Upon ingestion, arachidonic acid is absorbed and distributed throughout the body's tissues, where it is incorporated into cell membranes and can be metabolized via enzymatic pathways like the cyclooxygenase and lipoxygenase pathways, ultimately being excreted as metabolites. Toxicity can arise from the overproduction of its metabolites, leading to inflammatory conditions. Target proteins for arachidonic acid primarily include these enzymes, as well as various receptors in its signaling pathways. Clinically, arachidonic acid's derivatives are of greater significance for direct therapeutic use, where they can be indicated for inflammatory diseases, pain, and fever reduction; however, arachidonic acid itself may play a role in nutritional supplementation. Side effects often center around the induction of inflammation or allergic reactions, as seen in conditions such as asthma. In clinical practice, derivatives of arachidonic acid are synthesized for use in varying pharmaceutical preparations, aimed at leveraging their role in inflammation and pain for therapeutic benefit, with examples including nonsteroidal anti-inflammatory drugs (NSAIDs) for arthritis and menstrual cramps."
pravastatin,DB01393,"Pravastatin, identified by DrugBank ID DB01393, is a synthetic lipid-lowering agent with the SMILES notation CC(C)(Oc1ccc(CCNC(=O)c2ccc(Cl)cc2)cc1)C(=O)O. Its chemical structure is characterized by a hydroxypropyl side chain attached to a dihydroxyheptanoic acid nucleus, which is itself linked to a naphthalene derivative via an amide bond. Pravastatin falls under the category of statins, which are HMG-CoA reductase inhibitors, a class of drugs known for their cholesterol-lowering effects. Structurally, it possesses a hexahydroindene scaffold, which differentiates it from the fully aromatic ring system seen in simvastatin and atorvastatin.

In pharmacokinetics, pravastatin is distinguished by its relatively poor absorption, with a bioavailability of around 17%, as it undergoes significant first-pass metabolism. It displays modest protein binding and is largely hydrophilic, which limits its penetration across the blood-brain barrier. Pravastatin is primarily metabolized via glucuronidation rather than cytochrome P450-mediated oxidation, thereby minimizing drug-drug interactions. It is subsequently excreted in the bile and urine. The toxicity of pravastatin is lower compared to other statins, but it can still cause rare instances of myopathy and elevated liver enzymes.

This pharmacological agent targets hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase, the rate-limiting enzyme in the cholesterol biosynthesis pathway, thus effectively lowering low-density lipoprotein (LDL) cholesterol levels. Clinically, it's indicated for hypercholesterolemia, prevention of cardiovascular events in at-risk patients, and in certain genetic dyslipidemias, such as familial hypercholesterolemia. Common side effects include myalgia, headache, and gastrointestinal disturbances, while more serious, though less frequent, adverse effects encompass rhabdomyolysis and hepatotoxicity.

Pravastatin's clinical benefits have been evidenced in patients with a history of myocardial inf"
paclitaxel,DB01645,"Paclitaxel, represented by the DrugBank identifier DB01645 and the SMILES notation O=c1c(-c2ccc(O)cc2)coc2cc(O)cc(O)c12, is a complex diterpenoid, a secondary metabolite from the Pacific yew tree, Taxus brevifolia. Structurally characterized by a bulky, multi-ringed core stabilized by numerous hydroxyl groups and an amide side chain, paclitaxel falls within the chemical category of taxanes, which are noted for their taxane ring—a distinctive and biologically active three-dimensional chemical scaffold shared by related drugs such as docetaxel. Paclitaxel's pharmacokinetics involve limited oral bioavailability, necessitating intravenous administration for an effective therapeutic outcome; it exhibits extensive distribution with a high affinity for plasma proteins, is metabolized primarily in the liver via the cytochrome P450 enzyme system, specifically CYP2C8 and CYP3A4 isozymes, and is excreted mainly through biliary pathways. The drug’s toxicity profile includes bone marrow suppression leading to neutropenia, which is dose-limiting, along with peripheral neuropathy and cardiotoxicity in some cases. Paclitaxel's molecular mechanism involves binding to the β-subunit of tubulin, stabilizing microtubules and arresting cell division, making it an invaluable agent for the treatment of various cancers such as ovarian, breast, lung, and aids in Kaposi's sarcoma. Common side effects include alopecia, myalgia, mucositis, and hypersensitivity reactions necessitating premedication with corticosteroids and antihistamines. Clinically, paclitaxel is administered as part of chemotherapy regimens for solid tumors, often in combination with other anticancer agents, demonstrating significant efficacy in improving patient survival rates and disease remission when used appropriately."
ramipril,DB03128,"Ramipril, known by its DrugBank identifier DB03128, is a small molecule characterized by its SMILES notation CC(=O)OCC[N+](C)(C)C, which signifies a chemical structure with an ester linkage (CC(=O)O), an ether moiety (OCC), and a quaternary ammonium group ([N+](C)(C)C). This drug falls within the chemical category of angiotensin-converting enzyme (ACE) inhibitors, and its chemical scaffold is based on a prodrug that is hydrolyzed to its active diacid form after absorption. Ramipril is structurally related to other ACE inhibitors, such as enalapril and lisinopril. Upon oral administration, ramipril is well-absorbed and undergoes extensive hepatic metabolism to ramiprilat, its active metabolite, followed by renal excretion. Its toxicity profile includes the risk of angioedema and hyperkalemia, with rare cases of agranulocytosis reported. The drug specifically targets the ACE, which plays a key role in the renin-angiotensin-aldosterone system (RAAS), modulating blood pressure and fluid balance. Clinically, ramipril is indicated for the treatment of hypertension, heart failure, and for reducing the risk of cardiovascular morbidity and mortality post-myocardial infarction. Common side effects encompass cough, hypotension, dizziness, and renal impairment. Ramipril’s clinical usage extends to its beneficial effects in delaying the progression of renal disease in patients with hypertension and diabetic nephropathy. The multifaceted pharmacokinetic profile and clinical utility of ramipril, in conjunction with its safety and efficacy, have positioned it as a staple medication in cardiovascular therapeutics."
clarithromycin,DB01204,"Clarithromycin, with DrugBank ID 'DB01204' and SMILES notation 'O=C1c2c(O)ccc(O)c2C(=O)c2c(NCCNCCO)ccc(NCCNCCO)c21', is a semi-synthetic macrolide antibiotic featuring a 14-membered lactone ring with two sugar moieties, desosamine, and cladinose attached. As a macrolide, it shares its chemical category with similar drugs like azithromycin and erythromycin, utilizing a similar macrolactone chemical scaffold. Pharmacokinetically, clarithromycin is well-absorbed orally, with bioavailability affected minimally by food intake. Once absorbed, it is widely distributed throughout the body, including penetration into lung tissue, which is beneficial for respiratory infections. Clarithromycin undergoes hepatic metabolism, primarily through the cytochrome P450 system, specifically CYP3A4, which can lead to significant drug-drug interactions. The elimination of clarithromycin comprises both renal and fecal routes. In terms of toxicity, clarithromycin can cause mild gastrointestinal distress and, in rare cases, has been associated with QT prolongation and hepatotoxicity. Clarithromycin acts upon bacterial ribosomal proteins, binding to the 50S subunit and thereby inhibiting protein synthesis which is crucial for bacterial growth. The drug is indicated for the treatment of bacterial infections such as respiratory tract infections, including pneumonia and bronchitis, skin infections, and disseminated mycobacterial infections, such as Mycobacterium avium complex (MAC) in HIV-positive patients. Side effects may include gastrointestinal symptoms like diarrhea, nausea, and abnormal taste, as well as more severe reactions such as pseudomembranous colitis and hepatic dysfunction. Clinically, clarithromycin is used not only for its primary antibiotic indications but also in combination with other medications for the eradication of Helicobacter pylori, which is associated with peptic ulcer disease. The broad spectrum and favorable pharmacokinetics of clarithromycin enable it to be a versatile option in the management of various bacterial infections, making it a"
doxazosin,DB00773,"Doxazosin, bearing the DrugBank ID DB00773 and the SMILES notation COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1O, is a potent α1-selective adrenergic receptor antagonist. Structurally, the complexity of doxazosin arises from its fused multicyclic quinazoline moiety tethered to an intricately substituted furan ring. Within the chemical category of antihypertensive agents, doxazosin's quinazoline derivative scaffold is shared by similar drugs like prazosin and terazosin, which also function as adrenergic antagonists. The pharmacokinetic profile of doxazosin reveals that the drug is well absorbed orally with a large volume of distribution; it undergoes extensive hepatic metabolism primarily via CYP3A4 isoenzyme and is eliminated in the feces and urine. Regarding toxicity, doxazosin is generally safe at therapeutic doses, but can cause hypotension and reflex tachycardia. The primary target proteins for doxazosin are the α1-adrenergic receptors, which modulate vascular smooth muscle tone. Clinically, doxazosin is indicated for treating hypertension and symptomatic benign prostatic hyperplasia (BPH), as it effectively reduces blood pressure and relaxes the smooth muscles in the prostate and bladder neck. However, Side effects include, but are not limited to, dizziness, fatigue, headache, and in some cases, orthostatic hypotension. In clinical practice, doxazosin is administered to patients with hypertension as part of a broader antihypertensive regimen and to those with BPH to alleviate lower urinary tract symptoms, demonstrating its importance in managing cardiovascular and urological conditions."
etodolac,DB00445,"Etodolac, with DrugBank ID DB00445, possesses a complex chemical structure as outlined by its SMILES notation 'COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1'. A non-steroidal anti-inflammatory drug (NSAID), it features a pyranocoumarin scaffold and is chemically related to other NSAIDs like ibuprofen and naproxen, which also inhibit cyclooxygenase enzymes. Pharmacokinetically, etodolac is rapidly absorbed after oral administration, widely distributed throughout the body, extensively metabolized primarily by the liver, and excreted mainly in urine. Toxicologically, while generally safe at therapeutic doses, it shares side effects characteristic of NSAIDs, such as gastrointestinal disturbances and potential renal toxicity. Its primary targets are the cyclooxygenase-1 (COX-1) and COX-2 enzymes, which it inhibits to exert anti-inflammatory, analgesic, and antipyretic effects. Indicated for the treatment of inflammatory conditions such as osteoarthritis and rheumatoid arthritis, etodolac alleviates symptoms like pain and swelling. Common side effects include gastrointestinal discomfort, dizziness, and headache, akin to other medications in its class. Clinically, etodolac is used not only for long-term management of arthritis symptoms but also for short-term acute pain episodes, providing a balance between efficacy and tolerability for patients requiring anti-inflammatory therapy."
toremifene,DB00945,"Toremifene (DrugBank ID: DB00945) is a nonsteroidal selective estrogen receptor modulator (SERM) with structural similarities to tamoxifen, sharing a core triphenylethylene scaffold and characterized by its SMILES notation 'CC(=O)Oc1ccccc1C(=O)O', indicating the presence of two benzene rings connected via a methoxy bridge and a ketone moiety. As a SERM, toremifene modulates estrogen receptor activity, competitively binding to estrogen receptors on tumors and other tissue targets. Pharmacokinetically, toremifene is well-absorbed orally, extensively distributed in the body, highly protein-bound, and metabolized prominently through CYP3A4 and CYP2C9 isoenzymes, with metabolites excreted primarily via feces and urine. Its toxicity profile includes the risk of QT interval prolongation and the potential for endometrial cancer with long-term use. The known target proteins are primarily estrogen receptors ERα and ERβ. Clinically, toremifene is indicated for the treatment of estrogen-receptor-positive metastatic breast cancer in postmenopausal women, with efficacy in reducing tumor progression and disease symptoms. Common side effects can include hot flashes, sweating, and nausea; less frequently, more severe side effects such as thromboembolism might occur. In medical practice, besides its oncological application, toremifene is sometimes considered for the prevention of breast cancer in high-risk populations due to its ability to antagonize estrogen's effects on breast tissue."
loratadine,DB01100,"Loratadine, with the DrugBank identifier DB01100, is an antihistamine drug characterized by its complex chemical structure, represented by the SMILES notation ""O=c1[nH]c2ccccc2n1C1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1"". This structure includes a tricyclic system comprising a central piperidine ring connected to a benzhydryl moiety and a carbonyl group linked to an imidazole ring, which contains a protonatable nitrogen, contributing to its activity as an inverse agonist at the histamine H1 receptor. As a member of the chemical category of antihistamines, loratadine presents a diphenylmethylpiperidine scaffold, which it shares with similar drugs such as cetirizine and fexofenadine. In terms of pharmacokinetics, loratadine is well absorbed upon oral administration, has a bioavailability of about 40% due to first-pass metabolism in the liver, where it is converted to its active metabolite, desloratadine; it is then widely distributed, binding to plasma proteins, and ultimately eliminated primarily via the urine. Concerning toxicity, loratadine is regarded as a safe drug with a low incidence of sedation, but overdose can lead to symptoms such as headache, somnolence, and tachycardia. The drug targets the histamine H1 receptor, blocking the action of endogenous histamine, which is responsible for allergy symptoms. Indicated for the relief of nasal and non-nasal symptoms of seasonal allergic rhinitis and for the treatment of chronic idiopathic urticaria, loratadine helps alleviate conditions such as sneezing, runny nose, and red, itchy eyes. Side effects are uncommon but may include headache, drowsiness, and fatigue. Clinically, loratadine is used in a non-drowsy formula due to its minimal penetration across the blood-brain barrier, making it a preferred choice for patients who require symptom alleviation without impairment of cognitive functions, such as those operating machinery or driving"
cladribine,DB00861,"Cladribine, assigned DrugBank ID DB00861, is a synthetic antineoplastic agent with the SMILES notation 'O=C(O)c1cc(-c2ccc(F)cc2F)ccc1O'. This structural indicator reveals that cladribine is a fluorinated aromatic compound with two fluorine atoms ortho to each other on a benzene ring, connected to another benzene ring harboring two hydroxyl groups and forming a catechol structure, representative of its chemical category and scaffold. Chemically akin to other purine analogs used as antineoplastic agents, such as fludarabine, cladribine's mechanism shares some resemblance with these compounds in interfering with DNA synthesis and repair. Pharmacokinetically, cladribine is characterized by fairly high bioavailability following oral administration, distributing widely throughout the body, including crossing the blood-brain barrier. It undergoes a minimal hepatic metabolism, primarily excreted unchanged by the renal route. In terms of toxicity, cladribine can induce myelosuppression, leading to neutropenia and an increased risk of infections as examples of its adverse hematological effects. The drug exerts its action by targeting key enzymes involved in DNA synthesis and repair, such as DNA polymerase and ribonucleotide reductase. Clinically, cladribine is indicated for the treatment of hairy cell leukemia, among other malignancies, and has shown efficacy in multiple sclerosis by reducing neuroinflammation and lymphocyte count. However, side effects, including immunosuppression, fever, and nausea, need to be carefully managed. Cladribine's clinical utilization spans from oncology to neurology, where it serves as a disease-modifying therapy for relapsing-remitting multiple sclerosis, demonstrating its versatility in addressing a range of pathological conditions through targeted biological interference."
paroxetine,DB00605,"Paroxetine, identified by DrugBank ID DB00605, is a phenylpiperidine derivative with a distinct chemical structure represented by the SMILES notation ""CC1=C(CC(=O)O)c2cc(F)ccc2C1=Cc1ccc([S+](C)[O-])cc1"". Its aromatic ring system contains a fluorinated phenyl group and a thioether group, the latter carrying a formal positive charge with an adjacent oxide anion - reflecting its nature as a zwitterion at physiological pH. Classified chemically as a selective serotonin reuptake inhibitor (SSRI), paroxetine shares its core chemical scaffold with similar antidepressant drugs such as fluoxetine and sertraline. Pharmacokinetically, paroxetine undergoes extensive first-pass metabolism, primarily mediated by CYP2D6, and exhibits a slow absorption, with an extended half-life allowing for once-daily dosing. Its distribution is wide, with the drug achieving high tissue penetration, eventually undergoing hepatic metabolism and renal excretion. Paroxetine's target includes the serotonin transporter protein, inhibiting reuptake at neuronal synapses, thereby modulating serotonergic neurotransmission. Indications for paroxetine are broad, encompassing major depressive disorder, generalized anxiety disorder, panic disorder, and a range of other affective disorders. However, the drug's use is mediated by the potential for side effects like sexual dysfunction, weight gain, and withdrawal syndrome upon discontinuation. Paroxetine toxicity can manifest as serotonin syndrome when combined with other serotonergic agents, and it carries a black-box warning for suicidal ideation in young adults and adolescents. Clinically, paroxetine is deployed as an effective treatment for psychopathologies, even seeing off-label uses for conditions such as premenstrual dysphoric disorder, demonstrating its therapeutic versatility within its risk-benefit profile."
itraconazole,DB00276,"Itraconazole, designated with DrugBank ID 'DB00276' and represented by the SMILES notation 'COc1cc(NS(C)(=O)=O)ccc1Nc1c2ccccc2nc2ccccc12', is a triazole antifungal agent with a complex chemical structure featuring a dichlorophenyl ring, a hexyl side chain, and a triazole moiety interacting with the 14α-demethylase enzyme in fungi. Its category falls within the azole antifungals, and its chemical scaffold is highlighted by a fusion of triazole and imidazole rings, which is also present in similar antifungal drugs like fluconazole and ketoconazole. Pharmacokinetically, itraconazole is well-absorbed orally with food improving its bioavailability; it is lipophilic and widely distributed in body tissues, highly protein bound (>99%), and metabolized in the liver primarily via CYP3A4 enzymes; its excretion occurs through feces and urine. Although generally well-tolerated, toxicity can manifest in cases of overdosage or sensitivity, leading to liver damage and congestive heart failure. Itraconazole's known target protein is the cytochrome P450-dependent enzyme, lanosterol 14α-demethylase, and it is indicated for systemic mycoses such as aspergillosis, blastomycosis, and histoplasmosis, addressing symptoms ranging from fever and cough to more severe immunocompromised conditions. Common side effects include nausea, vomiting, and abdominal pain, while more serious reactions may involve hepatic or cardiac effects. Clinically, itraconazole is used in both acute and maintenance therapy for fungal infections, particularly in immunocompromised patients, where it prevents the proliferation of fungus by inhibiting ergosterol synthesis and compromising the fungal cell membrane."
sumatriptan,DB00640,"Sumatriptan, known by its DrugBank identifier DB00640, boasts a distinctive chemical structure characterized by its SMILES notation: Nc1ncnc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O. This notation delineates a molecular framework containing a fused pyrimidine-purine ring coupled to a pentose sugar, indicative of its classification as a synthetic analog of the endogenous neurotransmitter serotonin (5-hydroxytryptamine). The chemical scaffold of sumatriptan shares similarity with other triptans, such as zolmitriptan and rizatriptan, which are also serotonin receptor agonists utilized in the acute treatment of migraine headaches. Pertaining to its pharmacokinetics, sumatriptan is well-absorbed orally with peak plasma concentrations achieved within 2–4 hours; it exhibits a moderate volume of distribution, is metabolized primarily in the liver via monoamine oxidase-A (MAO-A) to an inactive indole acetic acid derivative, and eliminated predominantly through renal excretion. In terms of toxicity, sumatriptan can precipitate serotonin syndrome if combined with other serotonergic agents, and it is contraindicated in patients with cardiovascular diseases due to the risk of coronary artery vasospasm. The drug's known target proteins include serotonin receptors 5-HT1B and 5-HT1D, which are G-protein coupled receptors mediating vasoconstriction and inhibition of neuropeptide release, thereby mitigating symptoms of migraine. Clinically, sumatriptan is indicated for the treatment of migraine attacks with or without aura and cluster headache episodes. This drug's side effects range from mild—such as sensations of tingling, warmth, or pressure—to more severe, including chest tightness and palpitations, with rare cardiovascular events reported. In a clinical setting, sumatriptan is administered via oral, subcutaneous, or nasal routes, offering flexibility in the management of acute migraine events, a crucial aspect of improving patient quality of life."
risperidone,DB01177,"Risperidone, with the DrugBank identifier DB01177, is an atypical antipsychotic with a complex chemical structure denoted by its SMILES notation CC(=O)[C@]1(O)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](N)[C@H](O)[C@H](C)O2)C1)C(=O)c1ccccc1C3=O. Structurally, it features a pyridopyrimidinone scaffold and a benzisoxazole moiety connected to a piperidine substituent, classifying it within the benzisoxazole derivatives. Similar drugs include other atypical antipsychotics such as olanzapine and clozapine. Risperidone's pharmacokinetic profile reveals it's well-absorbed with a bioavailability of around 70%, extensive hepatic metabolism primarily by CYP2D6 and CYP3A4 enzymes to an active metabolite, 9-hydroxyrisperidone, and elimination via both renal and fecal routes. Its toxicity profile includes a risk of extrapyramidal symptoms, tardive dyskinesia, and neuroleptic malignant syndrome. Risperidone targets a range of proteins, including dopaminergic (D2), serotonergic (5-HT2A), and adrenergic receptors, contributing to its therapeutic effects and side effects. Clinically, risperidone is indicated for the treatment of schizophrenia, bipolar disorder, and irritability associated with autistic disorder. However, it has a spectrum of side effects, including weight gain, hyperprolactinemia, orthostatic hypotension, and potential metabolic disturbances. In terms of clinical usage, risperidone is administered orally in tablet form or via intramuscular injection for its long-acting formulation. It is utilized across various settings, including both acute and maintenance treatment phases for psychiatric conditions, demonstrating its versatility as an antipsychotic agent."
riluzole,DB01097,"Riluzole, bearing the DrugBank identifier DB01097 and characterized by the SMILES notation Cc1oncc1C(=O)Nc1ccc(C(F)(F)F)cc1, is a benzothiazole derivative with a 2-amino-6-(trifluoromethoxy)benzothiazole structure that incorporates a trifluoromethoxy phenyl ring, a thiazole ring, and an amide linkage, denoting its belonginess to the chemical category of benzothiazoles. Its chemical scaffold is shared by few other therapeutic agents, but there are no direct structural analogs widely recognized in clinical use. The pharmacokinetic profile of riluzole includes rapid absorption with peak plasma concentrations reached within 1 to 2 hours post-administration. It exhibits a bioavailability of approximately 60% and undergoes extensive first-pass metabolism in the liver, primarily through the cytochrome P450 enzyme system, particularly CYP1A2. Riluzole is both glucuronidated and excreted in the urine, with a terminal half-life of about 12 hours. Its toxicity is generally low but may include hepatotoxicity and interstitial lung disease in rare instances. Riluzole specifically targets glutamate neurotransmission, although the exact mechanism of action is not fully elucidated; it is believed to inhibit glutamate release and inactivate voltage-dependent sodium channels, which could prevent neurodegeneration. Clinically, riluzole is indicated for the treatment of amyotrophic lateral sclerosis (ALS), where it has been shown to prolong survival and delay the need for ventilatory support in affected patients. Common side effects include asthenia, nausea, dizziness, and elevated liver enzymes. Within the clinical usage landscape, riluzole remains one of the few treatments that has demonstrated efficacy in ALS, making it a mainstay option in the management of this progressive neurodegenerative disorder."
losartan,DB00514,"Losartan, with the DrugBank ID 'DB00514', presents a detailed chemical structure characterized by its SMILES notation 'COc1ccc2c(c1)[C@]13CCCC[C@@H]1[C@H](C2)N(C)CC3', which reveals its intricate bicyclic framework including a tetrazole ring, indicating its classification within the chemical category of angiotensin II receptor antagonists (ARBs). Its biaryl tetrazole structure serves as a chemical scaffold shared by other similar ARBs like valsartan and irbesartan. Losartan's pharmacokinetic profile is well-studied—after oral administration, it is absorbed with a bioavailability of 33%, extensively distributed with a volume of distribution of 34 liters, and notably, metabolized in the liver primarily by cytochrome P450 enzymes CYP2C9 and CYP3A4 to its active metabolite E-3174, which is responsible for most of its angiotensin receptor blocking action. Losartan and its metabolites are then excreted through both bile and urine. Concerning toxicity, losartan is generally considered safe at therapeutic doses, but cases of angioedema and rare instances of liver damage exemplify potential adverse reactions. Losartan selectively targets and inhibits the angiotensin II receptor type 1 (AT1), impeding the renin-angiotensin-aldosterone system (RAAS), and it is indicated for the treatment of hypertension and to protect kidney function in patients with type 2 diabetes and history of hypertension. Side effects commonly observed with losartan use include dizziness, muscle cramps, and in some cases, hyperkalemia, demonstrative of its influence on electrolyte balance. Clinically, losartan is employed not just for hypertension management, but also to reduce the risk of stroke in patients with left ventricular hypertrophy and to slow the long-term progression of renal disease in hypertensive patients with type 2 diabetes—an example of its multifaceted therapeutic application."
simvastatin,DB01115,"Simvastatin, DrugBank ID DB01115, bears a complex, multi-ring, chemical structure characterized by its SMILES notation 'COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1ccccc1[N+](=O)[O-]', which denotes a lactone closed-ring bonded to a hydroxy methyl group, a dimethylbutyric acid, and a fluorophenyl group, establishing it as a synthetic derivate of a fermentation product of Aspergillus terreus. Classified as a statin, simvastatin falls within the chemical category of lipid-lowering agents and showcases the characteristic statin scaffold— a fused heterocyclic core which is essential for its activity as an HMG-CoA reductase inhibitor. Its pharmacokinetic profile reveals oral administration, with high hepatic concentration due to extensive first-pass metabolism, primarily by the enzyme CYP3A4, and subsequent excretion via the biliary route. Similar drugs sharing the statin lineage include atorvastatin and lovastatin, which also target the cholesterol biosynthesis pathway. Notably, the pharmacological engagement of simvastatin is with HMG-CoA reductase—a key enzyme in cholesterol synthesis—resulting in the reduction of intracellular cholesterol levels. Simvastatin is primarily indicated for hypercholesterolemia and cardiovascular disease prevention, targeting diseases such as atherosclerosis. While it's generally well-tolerated, simvastatin is not free from side effects; myopathy and rhabdomyolysis represent severe, albeit rare, toxicities, often exacerbated by drug interactions or genetic predispositions affecting its metabolism. Clinically, simvastatin is utilized in the management of dyslipidemia and mixed hyperlipidemia, and often incorporated into treatment regimens for coronary heart disease, where it mitigates risk factors and improves patient prognosis through cholesterol-lowering effects."
genistein,DB00530,"Genistein, bearing the DrugBank ID 'DB00530', is a biologically active isoflavonoid that derives its chemical structure from the flavonoid group of polyphenols, featuring a 15-carbon skeleton consisting of two phenyl rings and a heterocyclic ring. Its chemical scaffold is characteristic of the isoflavone family, with the SMILES notation 'C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1' indicating an intricate arrangement comprising aromatic rings connected through a nitrogen-containing pyrimidine and a triple bond indicative of an alkyne substituent. Structurally related drugs include other isoflavonoids such as daidzein. Genistein is absorbed through the gastrointestinal tract but possesses a relatively low oral bioavailability, likely due to its extensive metabolism by phase II biotransformation enzymes, leading to conjugated forms like glucuronides and sulfates that are then excreted via renal and biliary pathways. Although genistein is considered to have a relatively good safety profile, its toxicity is dose-dependent and may include reproductive and developmental effects, possibly as a result of its estrogenic activity, with some studies suggesting potential interference with thyroid function. Genistein targets multiple proteins, such as tyrosine kinases and topoisomerase II, and is noted to have affinity for estrogen receptors. The primary indications of genistein include its potential use in the management of estrogen receptor-positive breast cancer and other hormone-dependent cancers owing to its phytoestrogenic effects, as well as in the modulation of osteoporosis and cardiovascular diseases due to its influence on signal transduction pathways. Its side effects may mimic those of estrogens, including the potential risk of endometrial hyperplasia, and if used in high doses, genistein has been reported to cause gastrointestinal disturbances and allergic reactions. Clinically, genistein is often utilized in the form of dietary supplements rather than pharmaceutical preparations, supported by evidence in the prevention and control of cancer progression, improvement of bone health, and amelioration of menopausal symptoms, although its use in mainstream medicine requires further validation through well-designed clinical trials"
sirolimus,DB01623,"Sirolimus, with DrugBank ID DB01623, exhibits a complex macrocyclic lactone chemical structure characterized by its SMILES notation 'CN1CCN(CC/C=C2/c3ccccc3Sc3ccc(S(=O)(=O)N(C)C)cc32)CC1'. It falls within the chemical category of macrolide immunosuppressants and is built upon a macrolide scaffold. Structurally and functionally related to sirolimus are other mTOR inhibitors like everolimus and temsirolimus, which bear similarity in their macrocyclic rings and possess modifications that alter their pharmacokinetic properties. Sirolimus is well-absorbed following oral administration, with an extensive distribution characterized by high protein binding; it is predominantly metabolized by the hepatic CYP3A4 enzyme, resulting in multiple metabolites with the major component being the O-demethylated product. Excretion is primarily biliary with minimal renal elimination. As with many drugs, sirolimus exhibits dose-related toxicity; for instance, it can increase the risk of infections due to its immunosuppressive action, and may cause hyperlipidemia and pneumonitis. The drug’s primary target proteins include the mammalian target of rapamycin (mTOR) complex, which it joins to exert its immunosuppressive effect by inhibiting T-lymphocyte activation and proliferation. Clinically, sirolimus is indicated for the prevention of organ transplant rejection, such as in kidney transplants, due to its ability to reduce the host immune response. Common side effects of sirolimus encompass detrimental impacts like thrombocytopenia, anemia, and leukopenia. In the realm of clinical usage, beyond its traditional role in preventing transplant rejection, sirolimus has been investigated for its potential in a range of disorders, including but not limited to lymphangioleiomyomatosis and as a coating agent for coronary stents to prevent restenosis through its antiproliferative properties."
salicylic acid,DB00328,"Salicylic acid (DrugBank ID: DB00328), with its SMILES notation ""COc1ccc2c(c1)c(CC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1,"" is a complex aromatic compound bearing a core structure of a benzene ring ortho-substituted with a hydroxy group and a carboxyl group (making it a hydroxybenzoic acid). In terms of its chemical category, salicylic acid is classified as a beta hydroxy acid (BHA), which places it within the larger family of phenolic acids. The chemical scaffold of salicylic acid influences its relation to similar drugs, such as aspirin (acetylsalicylic acid), which is a modified form of salicylic acid where an acetyl group has been added to the phenolic hydroxyl group. Pharmacokinetically, salicylic acid is absorbed through the skin and gastrointestinal tract, is widely distributed throughout bodily tissues, extensively metabolized in the liver via conjugation with glycine or glucuronidation, and then excreted through the urine predominantly as salicyluric acid and glucuronides. Regarding toxicity, salicylic acid can cause symptoms such as tinnitus, dizziness, and gastrointestinal discomfort at high dosages, and long-term high doses can lead to salicylism, a toxic condition. It exerts its therapeutic effects by targeting multiple proteins including cyclooxygenase (COX) enzymes, leading to decreased prostaglandin synthesis and inflammation. Salicylic acid is primarily indicated for the treatment of skin conditions like acne, psoriasis, dandruff, and warts due to its keratolytic and anti-inflammatory properties. Side effects might include skin irritation, erythema, and, in cases of excessive use, systemic effects similar to salicylate toxicity. Clinically, salicylic acid is employed in various topical preparations, like ointments, lotions, and shampoos, to enhance skin turnover, remove scale, and decrease sebum secretion, making it valuable in dermatological practice."
sertraline,DB00672,"Sertraline (DrugBank ID: DB00672) is a selective serotonin reuptake inhibitor (SSRI) with a distinctive chemical structure characterized by its SMILES notation 'CCCNC(=O)NS(=O)(=O)c1ccc(Cl)cc1', which reveals a naphthalenyl group with a chlorine substituent, an amine connected to a carboxamide, and a sulfonamide link, denoting a compound belonging to the diphenylmethane derivatives and a benzothiepine scaffold. Its structure shares similarities with other SSRIs such as fluoxetine and citalopram, emphasizing commonality within its class of enhancing serotonin activity. Pharmacokinetically, sertraline undergoes extensive hepatic metabolism, primarily through the cytochrome P450 isozyme CYP2B6, with its metabolites, including desmethylsertraline, exhibiting pharmacological activity before being renally excreted. Sertraline's toxicity profile is generally well-managed, with rare instances of serotonin syndrome and QTc prolongation in predisposed individuals. It targets multiple proteins, most notably the serotonin transporter (SERT), thereby increasing serotonin levels in the synaptic cleft. This mechanism underpins its clinical indication for major depressive disorder, obsessive-compulsive disorder, panic disorder, and social anxiety disorder. Common side effects encompass gastrointestinal disturbances, insomnia, sexual dysfunction, and, occasionally, increased suicidal ideation in young adults. In clinical practice, sertraline is widely prescribed due to its efficacy, tolerability, and its utility in treating a range of mood and anxiety disorders, with numerous studies supporting its use as a first-line therapy in the management of depression and anxiety-related ailments."
mibefradil,DB00368,"Mibefradil, with the DrugBank identifier DB00368 and SMILES notation NC[C@H](O)c1ccc(O)c(O)c1, is a non-dihydropyridine calcium channel blocker that differs from other calcium channel inhibitors due to its molecular structure, containing a tetralol moiety. As a calcium antagonist, mibefradil occupies a unique chemical scaffold that distinguishes it from similar drugs such as verapamil and diltiazem, which have different core structures but share the therapeutic goal of affecting calcium influx in cardiac and smooth muscle cells. Pharmacokinetically, mibefradil is absorbed orally with a bioavailability of approximately 90%, exhibiting an elimination half-life of about 17-25 hours and undergoing hepatic metabolism primarily by cytochrome P450 3A4; its metabolites are excreted both renally and fecally. Mibefradil's toxicity profile led to its market withdrawal, characterized by the risk of serious interactions with other drugs metabolized by the same P450 enzymes, and examples include life-threatening cardiac events with concomitant use of beta-blockers. While on the market, its primary target proteins were the T-type and L-type calcium channels, which regulate calcium entrance into cells. Indicated for the management of hypertension and chronic stable angina pectoris, mibefradil functioned by reducing cardiac workload and oxygen consumption. However, patients could experience side effects including bradycardia, headache, dizziness, and gastrointestinal discomfort. Clinically, before its discontinuation, mibefradil was prescribed for its vasodilatory effects to alleviate symptoms of angina and lower blood pressure in hypertensive individuals, but due to its adverse interactions and safety concerns, it was ultimately removed from clinical use."
perindopril,DB01059,"Perindopril, with DrugBank ID DB01059, is a non-proteinogenic synthetic compound exhibiting a complex chemical structure as denoted by its SMILES notation 'CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCNCC3)cc21'. This notation outlines a molecule comprising a biphenyl system fused to a lactam ring, a fluorophenyl moiety, and an incorporated diethylaminopropyl group, indicative of its membership to the chemical category of the angiotensin-converting enzyme (ACE) inhibitors that share a common sulfhydryl or carboxyl group-containing chemical scaffold. Perindopril is similar to other ACE inhibitors such as enalapril and lisinopril, evidenced by its ACE inhibitory function. Pharmacokinetically, perindopril is characterized by good oral absorption, distribution bound to plasma proteins, biotransformation into its active metabolite perindoprilat via hepatic esterases, and renal excretion predominantly as metabolites.

Toxicity of perindopril is relatively low; however, it can cause angioedema and, like other ACE inhibitors, is contraindicated in pregnancy due to risks of fetal developmental toxicity. Its therapeutic action is mediated through the inhibition of target proteins like ACE, reducing the conversion of angiotensin I to the vasoconstrictor angiotensin II, thus causing vasodilation. Perindopril is primarily indicated for the treatment of hypertension and symptomatic heart failure, as it lowers blood pressure and can mitigate symptoms like shortness of breath and fatigue in congestive heart failure. However, its usage may confer side effects such as cough, hyperkalemia, and dizziness. Clinically, perindopril is employed in various cardiovascular conditions and its utilization ranges from monotherapy to a component of combination therapy, aiming at both symptomatic relief and disease progression alteration, marking it as a cornerstone medication in cardiovascular pharmacotherapy."
